<?xml version='1.0' encoding='UTF-8' ?>
<Trials_downloaded_from_ICTRP>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13680448
    </Internal_Number>
    <TrialID>NCT06234995
    </TrialID>
    <Last_Refreshed_on>5 February 2024
    </Last_Refreshed_on>
    <Public_title>Cortical Electrophysiology of Response Inhibition in Parkinson's Disease
    </Public_title>
    <Scientific_title>Cortical Electrophysiology of Response Inhibition in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Emory University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20240123
    </Date_registration3>
    <Date_registration>23/01/2024
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06234995
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>45 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 9, 2021
    </Date_enrollement>
    <Target_size>80
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Svjetlana Miocinovic, MD, PhD;Jonna Seppa
    </Contact_Lastname>
    <Contact_Email>;jonna.k.seppa@emory.edu
    </Contact_Email>
    <Contact_Tel>;404-727-1509
    </Contact_Tel>
    <Contact_Affiliation>Emory University;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria for Persons with Parkinson's Disease for Aim 1:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosis of idiopathic Parkinson's disease (PD)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hoehn and Yahr (H&amp;Y) stage 2-4 (off medication)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria for Persons with Parkinson's Disease for Aim 1:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe tremor at rest or severe dyskinesia which would cause significant artifacts in&#x0D;&lt;br&gt;             electrophysiological signals&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  inability to hold antiparkinsonian medications for research recordings&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria for Persons with Parkinson's Disease for Aim 2:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosis of idiopathic PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  there is a clinical indication for DBS surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  normal preoperative MRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ability to tolerate microelectrode-guided neurosurgery in an awake state&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria for Persons with Parkinson's Disease for Aim 2:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  presence of a coagulopathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  uncontrolled hypertension&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  heart disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  other medical conditions considered to increase the patient's risk for surgical&#x0D;&lt;br&gt;             complications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria for Persons with Parkinson's Disease for Aim 3:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosis of idiopathic PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  functioning DBS system&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria for Persons with Parkinson's Disease for Aim 3:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe tremor at rest or severe dyskinesia which would cause significant artifacts in&#x0D;&lt;br&gt;             electrophysiological signals&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  inability to hold antiparkinsonian medications for research recordings&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  inability to tolerate temporary discontinuation of DBS therapy or alteration of&#x0D;&lt;br&gt;             stimulation settings for research purposes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  other medical conditions considered to increase the patient's risk for surgical&#x0D;&lt;br&gt;             complications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria for Healthy Controls:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age 45-75&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria for Healthy Controls:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  history of a neuropsychiatric disorder and/or treatment with psychotropic medications&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Drug: Levodopa;Device: Clinical DBS Setting;Device: Sham DBS;Device: DBS Setting Maximizing Prefrontal Activation;Device: DBS Setting Minimizing Prefrontal Activation
    </Intervention>
    <Primary_outcome>Response Time During Go/No-Go (GNG) Task for Participants in Aim 1;Percent of Errors During Go/No-Go (GNG) Task for Participants in Aim 1;Stopping Time During Modified Stop Signal (MSS) Task for Participants in Aim 1;Response Time During Go/No-Go (GNG) Task for Participants in Aim 3;Percent of Errors During Go/No-Go (GNG) Task for Participants in Aim 3;Stopping Time During Modified Stop Signal (MSS) Task for Participants in Aim 3
    </Primary_outcome>
    <Secondary_outcome>Electroencephalogram (EEG) Signals During GNG for Participants in Aim 1;Electroencephalogram (EEG) Signals During MSS for Participants in Aim 1;Electrocorticography (ECoG) Signals During GNG for Participants in Aim 2;Electroencephalogram (EEG) Signals During GNG for Participants in Aim 3;Electroencephalogram (EEG) Signals During MSS for Participants in Aim 3
    </Secondary_outcome>
    <Secondary_ID>P50NS123103;STUDY00007291
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institute of Neurological Disorders and Stroke (NINDS)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13560897
    </Internal_Number>
    <TrialID>NCT06127771
    </TrialID>
    <Last_Refreshed_on>27 November 2023
    </Last_Refreshed_on>
    <Public_title>Effects of Unblocking the Full Potential of Percept PC IPG
    </Public_title>
    <Scientific_title>Examining the Effects of Unblocking the Full Potential of Medtronic PerceptTM PC IPG on Symptoms of Individuals With Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Toronto
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20231106
    </Date_registration3>
    <Date_registration>06/11/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06127771
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 29, 2023
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Canada
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Alfonso Fasano, MD, PhD
    </Contact_Lastname>
    <Contact_Email>alfonso.fasano@uhn.ca
    </Contact_Email>
    <Contact_Tel>(416) 603-5800
    </Contact_Tel>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals with idiopathic Parkinson's disease who previously underwent DBS surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who had IPG replacement from Activa PC to Medtronic PerceptTM PC&#x0D;&lt;br&gt;             Neurostimulator as standard-of-care&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals should be able to provide their informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognition impairment (MoCA &lt; 20/30)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with severe PD symptoms who are unable to come to the clinic three times&#x0D;&lt;br&gt;             within three months (e.g. bedridden patients)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Programming DBS using Percept PC neurostimulator's full potential
    </Intervention>
    <Primary_outcome>Patients' Global Impression of Change (PGIC) scale
    </Primary_outcome>
    <Secondary_outcome>MDS-UPDRS-III;MDS-UPDRS-IV;The Parkinson's Disease Questionnaire (PDQ-39)
    </Secondary_outcome>
    <Secondary_ID>23-5697
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13698114
    </Internal_Number>
    <TrialID>NCT06122675
    </TrialID>
    <Last_Refreshed_on>19 February 2024
    </Last_Refreshed_on>
    <Public_title>Cerebellar Deep Brain Stimulation for Movement Disorders in Cerebral Palsy in Children and Young Adults
    </Public_title>
    <Scientific_title>Cerebellar Deep Brain Stimulation for Severe Combined Movement Disorders and Spasticity in Children and Young Adults With Cerebral Palsy
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of California, San Francisco
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20231102
    </Date_registration3>
    <Date_registration>02/11/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06122675
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>7 Years
    </Inclusion_agemin>
    <Inclusion_agemax>25 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 1, 2024
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 1/Phase 2
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Marta San Luciano Palenzuela, MD, MS;Marta San Luciano Palenzuela, MD, MS;Marta San Luciano Palenzuela, MD
    </Contact_Lastname>
    <Contact_Email>;Marta.SanLucianoPalenzuela@ucsf.edu;Marta.SanLucianoPalenzuela@ucsf.edu
    </Contact_Email>
    <Contact_Tel>;4153532311;
    </Contact_Tel>
    <Contact_Affiliation>University of California, San Francisco;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of DCP (dystonic and/or choreoathetotic cerebral palsy) with or without&#x0D;&lt;br&gt;             comorbid spasticity, with a clear history of hypoxic ischemic brain injury preceding&#x0D;&lt;br&gt;             motor symptoms made by a pediatric neurologist, with supporting MRI findings.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 7-25 at the time of surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Gross Motor Function Classification System (GMFCS) Levels II-V.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of appropriate therapy with oral medications with inadequate relief as&#x0D;&lt;br&gt;             determined by a movement disorders or pediatric neurologist. Prior history of&#x0D;&lt;br&gt;             selective dorsal rhizotomy is allowed.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient and family have requested surgical intervention with DBS for their movement&#x0D;&lt;br&gt;             disorder.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No gross cerebellar abnormalities observed and reported on structural MRI.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent and written/verbal assent for those younger than 18 years of&#x0D;&lt;br&gt;             age.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to comply with study follow-up visits for brain recordings, neuroimaging and&#x0D;&lt;br&gt;             testing of sham and effective stimulation and clinical assessments.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Coagulopathy, uncontrolled epilepsy, severe cardiopulmonary or gastrointestinal&#x0D;&lt;br&gt;             conditions, or other medical conditions considered to place the patient at elevated&#x0D;&lt;br&gt;             risk for surgical complications.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy: all women of child-bearing potential will be required to have a negative&#x0D;&lt;br&gt;             urine pregnancy test prior to undergoing their surgical procedure.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Exclusion of genetic mimics of cerebral palsy: exclusion of conditions that manifest&#x0D;&lt;br&gt;             with a clinical syndrome similar to CP, in the absence of documented risk factors or&#x0D;&lt;br&gt;             neuroimaging findings consistent with a history of brain injury or congenital cerebral&#x0D;&lt;br&gt;             malformation. Work up may include comparative genomic hybridization (CGH) microarray&#x0D;&lt;br&gt;             and multi-gene panel and/or whole genome or whole exome sequencing.)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe fixed contractions and skeletal deformities that would preclude determination&#x0D;&lt;br&gt;             of improvement.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Traumatic brain injury (i.e., non-accidental trauma) or history of infectious or&#x0D;&lt;br&gt;             autoimmune encephalitis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Requirement of diathermy, electroconvulsive therapy or transcranial magnetic&#x0D;&lt;br&gt;             stimulation.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Dyskinetic Cerebral Palsy;Dystonic Cerebral Palsy
    </Condition>
    <Intervention>Device: DBS
    </Intervention>
    <Primary_outcome>Average total (global index) MD-CRS 4-18-R scores;Average total standardized CPCHILD scores
    </Primary_outcome>
    <Secondary_ID>22-37182
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institutes of Health (NIH)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13650689
    </Internal_Number>
    <TrialID>DRKS00032906
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>How does deep brain stimulation affect tremor and motor learning in essential tremor patients?
    </Public_title>
    <Scientific_title>How does deep brain stimulation affect tremor and motor learning in essential tremor patients?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Universitätsklinik für Stereotaktische Neurochirurgie
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20231020
    </Date_registration3>
    <Date_registration>20/10/2023
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00032906
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>01/03/2018
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: basic science  
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Nanna
    </Contact_Firstname>
    <Contact_Lastname>Hartong
    </Contact_Lastname>
    <Contact_Address>Leipziger Str. 44
    </Contact_Address>
    <Contact_Email>nanna_hartong@hotmail.com
    </Contact_Email>
    <Contact_Tel>+49-761-270-95200 
    </Contact_Tel>
    <Contact_Affiliation>Universitätsklinik für Stereotaktische Neurochirurgie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: essential tremor patients at the university clinic
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: - History of epilepsy&#x0D;&lt;br&gt;- other previous neurological diseases&#x0D;&lt;br&gt;- significant alcohol, drug or medication abuse&#x0D;&lt;br&gt;- other clinical psychiatric disorders&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G25.0;Essential tremor;G25.0
    </Condition>
    <Intervention>Group 1: In SRTT, a series of spatial positions will be seen on a computer screen that correspond to buttons in front of the patient. The patient should press the corresponding button as quickly and accurately as possible each time the dot on the screen lights up red. To facilitate learning, the order will follow a predetermined pattern with a twelve-position sequence. The experiment consists of four blocks. Each of these blocks consists of eight sequences (four learned and four random sequences) and each block is followed by a short break. At the end of the experiment, the patient is asked whether he or she noticed a repeated sequence in order to identify a contribution of declarative memory in task performance.&lt;br&gt;The SRTT task lasts approximately 10 minutes and is performed twice in total: once without stimulation and once while the DBS is on. In total, the study time of the SRTT task is approximately 30 minutes. Tremor degree measurements using an accelerometer are carried out as part of clinical care to determine the optimal stimulation parameters. Both these data and the 3T MRI data, which are also measured for clinical reasons to determine electrode location, will be correlated with the results of the SRTT task.
    </Intervention>
    <Primary_outcome>Correlation of motor learning performance with tremor level
    </Primary_outcome>
    <Secondary_outcome>Dependence on the electrode position&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>U1111-1299-1501
    </Secondary_ID>
    <Source_Support>Universitätsklinik für Neurologie
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>12/02/2018
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ethikkommission@ovgu.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Otto-von-Guericke-Universität an der Medizinischen Fakultät und am Universitätsklinikum Magdeburg A.ö.R.
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-391-6714314
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ethikkommission@ovgu.de
    </Ethics_review_contact_email>
    <results_date_completed>30/09/2023
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00032906#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13503452
    </Internal_Number>
    <TrialID>NCT06090682
    </TrialID>
    <Last_Refreshed_on>23 October 2023
    </Last_Refreshed_on>
    <Public_title>Effect and Mechanism of Brain Stimulation for Parkinson's Disease With Cognitive Impairment
    </Public_title>
    <Scientific_title>Effect and Mechanism of Deep Brain Stimulation and Transcranial Magnetic Stimulation on Parkinson's Disease With Cognitive Impairment
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Tianjin Huanhu Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20231014
    </Date_registration3>
    <Date_registration>14/10/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06090682
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 1, 2023
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>China
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Zhao Guangrui, doctor;Yin Shaoya, doctor
    </Contact_Lastname>
    <Contact_Email>Guangrui-Zhao@hotmail.com;yinsya@hotmail.com
    </Contact_Email>
    <Contact_Tel>+86 18956405513;+86 18622139285
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        1. The clinical diagnosis of PD is consistent with the United Kingdom Parkinson's Disease&#x0D;&lt;br&gt;        Society Brain Bank criteria, with disease duration over 5 years, acute levodopa motor&#x0D;&lt;br&gt;        response =30%, and indication for STN-DBS.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria included patients with severe cognitive impairment, severe psychiatric&#x0D;&lt;br&gt;        disorders, acute levodopa motor response less than 30%, atypical parkinsonism, and&#x0D;&lt;br&gt;        contraindications to surgery.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Cognitive Impairment
    </Condition>
    <Intervention>Device: Deep Brain Stimulation(DBS) and Transcranial Magnetic Stimulation(TMS)
    </Intervention>
    <Primary_outcome>Montreal Cognitive Rating Scale(MoCA);verbal fluency test (VF)
    </Primary_outcome>
    <Secondary_outcome>the third part of the Unified Parkinson's Disease Rating Scale (UPDRS III)
    </Secondary_outcome>
    <Secondary_ID>TianjinHH-02
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13503471
    </Internal_Number>
    <TrialID>NCT06090929
    </TrialID>
    <Last_Refreshed_on>23 October 2023
    </Last_Refreshed_on>
    <Public_title>STN-DBS and the Risk of Sialorrhea
    </Public_title>
    <Scientific_title>STN-DBS is a Risk Factor of Sialorrhea in Patients With Advanced Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Qilu Hospital of Shandong University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20231007
    </Date_registration3>
    <Date_registration>07/10/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06090929
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2019
    </Date_enrollement>
    <Target_size>234
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Crossover Assignment. Primary purpose: Prevention. Masking: Single (Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical diagnosis of Alzheimer's Disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age between 20 and 80 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  without drooling&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  swallowing function &lt;5 on the Drooling Rate Scale (DRS).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medications affecting drooling had to have stopped medications at least 4 weeks before&#x0D;&lt;br&gt;             study entry.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Not he typical PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects on warfarin,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  with significant medical illnesses or neuromuscular transmission disorders&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  past use of BoNT&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  -cognitive impairment (&lt;23/30 on Mini Mental Status Exam) were excluded.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: STN-DBS
    </Intervention>
    <Primary_outcome>DRS score 36 months postoperatively
    </Primary_outcome>
    <Secondary_outcome>DSFS score 36 months postoperatively;BOTOX injection ratio 36 months postoperatively
    </Secondary_outcome>
    <Secondary_ID>DBS &amp; drooling in PD
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13650413
    </Internal_Number>
    <TrialID>DRKS00032470
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Frequency Associated Suppression of Tremor in Parkinson’s Disease and Essential Tremor
    </Public_title>
    <Scientific_title>Frequency Associated Suppression of Tremor in Parkinson’s Disease and Essential Tremor - FAST                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
    </Scientific_title>
    <Primary_sponsor>Universität zu Köln, Zentrum für Klinische Studien Köln
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230814
    </Date_registration3>
    <Date_registration>14/08/2023
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00032470
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>03/04/2023
    </Date_enrollement>
    <Target_size>45
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Randomized controlled study; Masking: Blinded (masking used); Control: active; Assignment: crossover; Study design purpose: treatment 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Christina
    </Contact_Firstname>
    <Contact_Lastname>Hennen
    </Contact_Lastname>
    <Contact_Address>Kerpener Str. 62
    </Contact_Address>
    <Contact_Email>christina.hennen1@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>+4922147877099
    </Contact_Tel>
    <Contact_Affiliation>Universitätsklinikum Köln, Klinik und Poliklinik für Neurologie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Uni- or bilateral implantation of DBS leads in the subthalamic nucleus (PD) or the ventral intermedius nucleus of the thalamus and the posterior subthalamic area (ET) at least 3 months prior to study inclusion and confirmed diagnosis of Parkinson's Disease or Essential Tremor. &#x0D;&lt;br&gt;Patients with Parkinson’s Disease must have a relevant tremor burden defined as =  2 of 4 points of the MDS-UPDRS item 3.17 (rest tremor) without medication, patients with Essential Tremor =2 of 4 points of item 5/6 of the Fahn Tolosa Marin Tremor Rating Scale (postural or intention tremor). &#x0D;&lt;br&gt;Patients must be able to consent to participate at the study and to give written informed consent prior to study inclusion. 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Non-fulfillment of all inclusion criteria
    </Exclusion_Criteria>
    <Condition>Parkinson's Disease,  Essential Tremor
    </Condition>
    <Intervention>Group 1: Clinical assessment of deep brain stimulation effects with a stimulation frequency of 130 Hz &lt;br&gt;Group 2: Clinical assessment of deep brain stimulation effects with a stimulation frequency of 185 Hz
    </Intervention>
    <Primary_outcome>Difference in tremor suppression, assessed by accelerometry, with energy-equivalent stimulation using two different stimulation frequencies (130 Hz vs 185 Hz)
    </Primary_outcome>
    <Secondary_outcome>-Amplitude-equivalent effects of the different frequencies on tremor&#x0D;&lt;br&gt;- effects on therapeutic window&#x0D;&lt;br&gt;- for PD, effects on rigidity and bradykinesia 
    </Secondary_outcome>
    <Source_Support>Universität zu Köln
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>31/03/2023
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ek-med@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ek-med@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00032470#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13736911
    </Internal_Number>
    <TrialID>NL-OMON54196
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation for MOtor symptoms in patients with Parkinson*s disease DEmentia (DBS- MODE)
    </Public_title>
    <Scientific_title>Deep Brain Stimulation for MOtor symptoms in patients with Parkinson*s disease DEmentia (DBS- MODE) - DBS-MODE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Academisch Medisch Centrum
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230809
    </Date_registration3>
    <Date_registration>2023-08-09
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/54196
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>64
    </Inclusion_agemax>
    <Inclusion_gender/>
    <Date_enrollement>2021-11-02
    </Date_enrollement>
    <Target_size>44
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized  controlled trial, Open (masking not used), Other, Treatment
    </Study_design>
    <Phase>2
    </Phase>
    <Countries>The Netherlands
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address>Meibergdreef 9
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Academisch Medisch Centrum
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;p&gt;• age 18 years and older; • diagnosis of PD according to the clinical &lt;br&gt;diagnostic criteria of the Movement Disorder Society (MDS); • despite optimal &lt;br&gt;pharmacological treatment, at least one of the following symptoms, that are &lt;br&gt;severe enough to impair functioning in daily life independent of dementia: o &lt;br&gt;motor response fluctuations; o dyskinesia; o painful dystonia; o &lt;br&gt;levodopa-responsive bradykinesia; • diagnosis of probable or possible &lt;br&gt;Parkinson*s disease dementia (PDD) according to the MDS clinical diagnostic &lt;br&gt;criteria (a.o. this encompasses the development of dementia a*fter established &lt;br&gt;diagnosis of PD). This will be based on a standardized neuropsychological &lt;br&gt;examination; i.e. presence of at least 3 abnormal (i.e. &lt; 2 standard &lt;br&gt;deviations) tests covering at least 2 cognitive domains. If a test cannot be &lt;br&gt;executed due to severe cognitive difficulties the test is regarded to be &lt;br&gt;abnormal; • an expected life expectancy of at least two years; • participant &lt;br&gt;has decision capacity to give informed consent, judgement of which is at the &lt;br&gt;discretion of an experienced neurologist from the study team; • participant &lt;br&gt;provides written informed consent; • regular contact with a caregiver, who has &lt;br&gt;approximately twice a week contact with the participant and also provides &lt;br&gt;written informed consent for their own participation.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;p&gt;• any neurodegenerative disorder other than PD; &lt;br&gt;• previous neurosurgery for PD (e.g., DBS, pallidotomy, thalamotomy). Nota &lt;br&gt;bene: intrajejunal levodopa infusion or subcutaneous apomorphine infusion are &lt;br&gt;not considered an exclusion criterion;&lt;br&gt;• contraindications for DBS-surgery, such as a physical disorder making surgery &lt;br&gt;hazardous;&lt;br&gt;• Hoehn and Yahr stage 4 or 5 at the best moment during the day;&lt;br&gt;• co*existence of another abnormality or disorder:&lt;br&gt;o that causes cognitive impairment that may improve with specific treatment; OR &lt;br&gt;o that besides PDD is judged to contribute significantly to the cognitive &lt;br&gt;impairment by the treating physician; &lt;br&gt;• current major depressive episode according to the fifth edition of the &lt;br&gt;Diagnostic and Statistical Manual of Mental Disorders (DSM-5); &lt;br&gt;• current psychosis (treatment with antipsychotics is allowed);&lt;br&gt;• other severely disabling condition; &lt;br&gt;• immobility during the greater part of the day not related to off-drug phase &lt;br&gt;(e.g., due to apathy);&lt;br&gt;• pregnancy, breastfeeding, and women of childbearing age not using a reliable &lt;br&gt;method of contraception.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Parkinson &lt;br&gt;shaking palsy;10028037;10009720;Parkinson;shaking palsy
    </Condition>
    <Intervention>&lt;p&gt;During the DBS surgery high frequency stimulation electrodes will be placed &lt;br&gt;bilaterally in the STN. Next a pulse generator will be implanted subcutaneously &lt;br&gt;under the clavicula, which can adjust current, pulse width and frequency. All &lt;br&gt;patients will receive BMT, consisting of PD-treatment according to current &lt;br&gt;guidelines and can be adjusted accordingly.&lt;/p&gt;&lt;br&gt;;Deep brain stimulation;Dementia;Motor symptoms;Parkinson's disease
    </Intervention>
    <Primary_outcome>&lt;p&gt;Patients will be assessed at baseline, 15 weeks, 30 weeks and 52 weeks after&lt;br /&gt;&lt;br&gt;randomization. The primary outcome measure is the change from baseline to 30&lt;br /&gt;&lt;br&gt;weeks follow-up of motor symptoms in off-drug phase measured with the Movement&lt;br /&gt;&lt;br&gt;Disorder Society - Unified Parkinson*s Disease Rating Scale (MDS-UPDRS) part&lt;br /&gt;&lt;br&gt;III.&lt;/p&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>&lt;p&gt;The secondary outcome measures include neuropsychological evaluation,&lt;br /&gt;&#x0D;&lt;br&gt;psychiatric assessment, additional motor evaluations during on-drug phase,&lt;br /&gt;&#x0D;&lt;br&gt;functional health status, falls, usage of medication, (S)AEs, treatment&lt;br /&gt;&#x0D;&lt;br&gt;satisfaction, caregiver burden, medical care consumption and recruitment and&lt;br /&gt;&#x0D;&lt;br&gt;retention rate.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>NL76772.018.21
    </Secondary_ID>
    <Source_Support>Stichting Bavalo
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>21/06/2021;04/11/2021;26/07/2023
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>;;&lt;p&gt;Kamer G4-214&lt;br /&gt;&#x0D;
Postbus 22660&lt;br /&gt;&#x0D;
1100 DD Amsterdam&lt;br /&gt;&#x0D;
020 566 7389&lt;br /&gt;&#x0D;
mecamc@amsterdamumc.nl&lt;/p&gt;&#x0D;

    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13306436
    </Internal_Number>
    <TrialID>NCT05997667
    </TrialID>
    <Last_Refreshed_on>28 August 2023
    </Last_Refreshed_on>
    <Public_title>Study on the Efficacy and Safety of Rechargeable Implantable DBS System in the Treatment of Parkinson's Disease
    </Public_title>
    <Scientific_title>A Prospective, Multicenter, Randomized Controlled Clinical Study Evaluating the Efficacy and Safety of Rechargeable Implantable Deep Brain Stimulation System for the Treatment of Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Lepu Medical Technology (Beijing) Co., Ltd.
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230807
    </Date_registration3>
    <Date_registration>07/08/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05997667
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 20, 2023
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Ting Zhang
    </Contact_Lastname>
    <Contact_Email>ting_zhang@lepumedical.com
    </Contact_Email>
    <Contact_Tel>+86-010-80120666
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. 18-75 years old, male or female;.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Primary PD (according to the UK Parkinson's Disease Society Brain Bank clinical&#x0D;&lt;br&gt;             diagnostic criteria for primary PD or Chinese diagnostic criteria for primary PD),&#x0D;&lt;br&gt;             with a duration of PD = 4 years, and the improvement rate after an acute levodopa&#x0D;&lt;br&gt;             challenge test = 30%; or primary PD, mainly characterized by tremor, the improvement&#x0D;&lt;br&gt;             of tremor by standardized drug treatment is not satisfactory and tremor is severe,&#x0D;&lt;br&gt;             which affects the patients' quality of life, after evaluation, duration can be relaxed&#x0D;&lt;br&gt;             to 3 years, the improvement rate of acute levodopa challenge test can be&lt;30%.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. The use of levodopa once had good effects, but currently cannot satisfactorily control&#x0D;&lt;br&gt;             symptoms (significant decrease in efficacy or occurrence of fluctuations in motor&#x0D;&lt;br&gt;             function or motor dysfunction), which affects quality of life.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Good compliance, patients and their families have the willingness to participate in&#x0D;&lt;br&gt;             the clinical trial of "bilateral implantation surgery of nervous stimulation system",&#x0D;&lt;br&gt;             voluntarily participate in this trial and sign informed consent form, patients can&#x0D;&lt;br&gt;             follow up regularly, and can accurately complete of assessment items, or the family&#x0D;&lt;br&gt;             members, guardians, or caregivers may assist the patients.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Severe cognitive impairment (MMSE score: illiterate&lt;17, elementary school&lt;20, junior&#x0D;&lt;br&gt;             high school or above&lt;24), poor compliance due to dementia, and/or inability to sign&#x0D;&lt;br&gt;             informed consent form&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patients with a history of severe mental illness and a Hamilton Depression Scale&#x0D;&lt;br&gt;             (HAMD) score&gt;24&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Seizure history in the last 1 year&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patients with severe heart, liver and kidney diseases, severe hypertension and severe&#x0D;&lt;br&gt;             orthostatic hypotension that affect their health status.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patients with severe diabetes or serious cardiovascular and cerebrovascular diseases&#x0D;&lt;br&gt;             that affect their health status&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Confirmed malignant tumor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Patients with surgical contraindications (e.g., the presence of active implants&#x0D;&lt;br&gt;             (whether turned on or not), or the presence of non-active implants that may affect the&#x0D;&lt;br&gt;             deep brain stimulation system, stereotactic nucleus lesioning, etc.), or other&#x0D;&lt;br&gt;             surgical procedures within six months that the researchers believe have an impact on&#x0D;&lt;br&gt;             this trial, or other neurosurgery contraindications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Patients who have suffered a previous cranial neurological injury&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Women who are pregnant or preparing for pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Patients with severe alcohol dependence and drug abuse&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Patients who received electric shock therapy within 30 days before surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Patients who are abnormally sensitive to temperature or who are allergic to heat&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Subjects who are currently participating in other clinical trials or have participated&#x0D;&lt;br&gt;             in other clinical studies that have not reached the primary endpoint within three&#x0D;&lt;br&gt;             months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. Patients who are not suitable to participate in this clinical study in the opinion of&#x0D;&lt;br&gt;             the investigator.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Rechargeable implantable deep brain stimulation system;Device: Rechargeable implantable deep brain stimulation system
    </Intervention>
    <Primary_outcome>Change in motor examination score evaluated using the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part ? in "med off" state relative to baseline
    </Primary_outcome>
    <Secondary_outcome>Change in motor examination score evaluated using the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part ? in "med on" state relative to baseline;Change in motor experiences of daily living score evaluated using the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part ? relative to baseline;Change in non-motor experiences of daily living score evaluated using the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part ? relative to baseline;Change in motor complications score evaluated using the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part ? relative to baseline;Change in "ON" time and "OFF" time relative to the baseline;Change in motor examination score evaluated using the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part ? with stimulation in "med on" and "med off" states relative to baseline;Change in daily levodopa equivalent dose relative to baseline;Change in the Parkinson's Disease Questionnaire (PDQ-39) score relative to baseline;Evaluation of equipment operational performance;Incidence of adverse events
    </Secondary_outcome>
    <Secondary_ID>LPDBS-2023
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13650367
    </Internal_Number>
    <TrialID>DRKS00032400
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Optimization of Deep Brain Stimulation site and algorithm patterns for Essential Tremor - a randomized two arm pilot study
    </Public_title>
    <Scientific_title>Optimization of Deep Brain Stimulation site and algorithm patterns for Essential Tremor - a randomized two arm pilot study - OPTI-ET                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum Freiburg
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230731
    </Date_registration3>
    <Date_registration>31/07/2023
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00032400
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>02/10/2023
    </Date_enrollement>
    <Target_size>24
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Randomized controlled study; Masking: Blinded (masking used); Control: active; Assignment: parallel; Study design purpose: treatment 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Volker A.
    </Contact_Firstname>
    <Contact_Lastname>Coenen
    </Contact_Lastname>
    <Contact_Address>Breisacher Straße 64 
    </Contact_Address>
    <Contact_Email>volker.coenen@uniklinik-freiburg.de
    </Contact_Email>
    <Contact_Tel>+49 761 270-50630
    </Contact_Tel>
    <Contact_Affiliation>Universitätsklinikum Freiburg - Abteilung für Stereotaktische und Funktionelle Neurochirurgie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1.	Male or female aged 21 years minimum and 85 years maximum on the day of experimental procedures&#x0D;&lt;br&gt;2.	Diagnosed with Essential Tremor (ET) affecting their hand(s)&#x0D;&lt;br&gt;3.	Patients with essential tremor who are eligible for Vim/DRT DBS Surgery according to the guidelines of the DGN (www.dgn.org) or patients with Essential Tremor and VIM/DRT-DBS implantation and undergoing replacement of their battery-depleted IPG&#x0D;&lt;br&gt;4.	Implanted with DBS lead(s) in the thalamic ViM/DRT region to treat ET and whose leads are temporarily externalized via extension cables. Lead(s) may be implanted initially (first time) or chronically (patient undergoing replacement of their battery-depleted IPG) &#x0D;&lt;br&gt;5.	For acute stimulation setting: Presence of tremor in the hand of grade 2 or more on a clinical rating scale with OFF medication/OFF stimulation state on the day of experiment. The tremor needs to be markedly reduced (++ improvement according to Coenen et al. 2020) by means of conventional tonic DBS, as determined by the Investigator&#x0D;&lt;br&gt;6.	Patients who have provided written informed consent
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1.	For acute stimulation setting: Presence of factors that may make assessment of the tremor ambiguous on the day of the experiment (e.g. lead implantation “stun effect“, alcohol consumption), as determined by the Investigator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;For acute and chronic study:&#x0D;&lt;br&gt;2.	Imaging of the leads in relation to neural structures not available &#x0D;&lt;br&gt;3.	Dementia symptoms&#x0D;&lt;br&gt;4.	Pregnant or breastfeeding women&#x0D;&lt;br&gt;5.	Implanted with another active device (cardiac pacemaker etc.)
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G25.0;Essential tremor;G25.0
    </Condition>
    <Intervention>Group 1: In the chronic part of the study, the electrode for deep brain stimulation is implanted in the so-called dentatorurothalamic bundle (DRT) in all patients. However, in study arm 1, the electrode is oriented to stimulate the "DRTx" sub-region.&lt;br&gt;Group 2: In the chronic part of the study, the electrode for deep brain stimulation is implanted in the so-called dentatorurothalamic bundle (DRT) in all patients. However, in study arm 2, the electrode is oriented to stimulate the "DRTu" sub-region.&lt;br&gt;Group 3: A proportion of patients (including those enrolled in the chronic part of the study and who are randomized into either arm 1 or arm 2) will voluntarily enroll in an acute part of the study during implantation. In this acute part patients undergo different stimulation intervals and their acute effect on the tremor is measured for a short time.
    </Intervention>
    <Primary_outcome>Chronic Part: Time to treatment failure defined as reduction in FTMTRS improvement (rate ) to less than 50% in 3 consecutive FTMTRS readings. &lt;br&gt;&lt;br&gt;Acute Part: Explore acute effects of tonic DBS and intermittent DBS programmed per study algorithm. Clinical assessment using Fahn-Tolosa-Marin-Tremor Rating Scale (FTMTRS) (for optimized stimuli). Tremor spectral power density (calculated from the wearable motion sensors). The maximum percentage stimulus pause which still results in a measurable tremor reduction as compared to no stimulation (calculated from the drawing task). Dose response relations between tremor (spectral power) and stimulus parameters (% stimulus pause time, amplitude and frequency). Parameters of the hand trajectories made during the drawing tasks (e.g. time to complete the task, deviation from the average trajectory). Energy of the tonic and intermittent stimulus as optimized per study algorithm
    </Primary_outcome>
    <Secondary_outcome>Chronic Study Part only:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;1. SARA score (with and without tremor item 6) at 3, 6, 9, 12, 15, 18 months to&#x0D;&lt;br&gt;explore effects of differential dominant DRTx or DRTu stimulation and their effects on short-term and long-term evolution of ataxia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;2. Fahn-Tolosa-Marin-Tremor Rating Scale (FTMTRS) at 3, 6, 9,12, 15, 18 months. Quantitative Tremor Analysis (accelerometry and non-invasive electromyography, nystagmography) measuring frequency and total power at 6, 12, 18 months. In order to xplore effects of differential dominant DRTx or DRTu stimulation and their effects on short-term and long-term efficacy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;3. Quality of Life in Essential Tremor (QUEST) at 6, 12, 18 months. To explore quality of life  of various temporal patterns to control tremor symptoms in the hand by DBS for ET.
    </Secondary_outcome>
    <Secondary_ID>P003881
    </Secondary_ID>
    <Source_Support>Universitätsklinikum Freiburg - Abteilung für Stereotaktische und Funktionelle Neurochirurgie;CereGate GmbH
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/06/2023
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ekfr@uniklinik-freiburg.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-761-27072500
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ekfr@uniklinik-freiburg.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00032400#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13204299
    </Internal_Number>
    <TrialID>NCT05959161
    </TrialID>
    <Last_Refreshed_on>2 August 2023
    </Last_Refreshed_on>
    <Public_title>Study on Brain Network Mechanism of Deep Brain Stimulation for Parkinson's Disease
    </Public_title>
    <Scientific_title>Study on Brain Network Mechanism of Deep Brain Stimulation for Parkinson's (A Retrospective Study)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Tianjin Huanhu Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230717
    </Date_registration3>
    <Date_registration>17/07/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05959161
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 1, 2023
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:The clinical diagnosis of PD is consistent with the United Kingdom&#x0D;&lt;br&gt;        Parkinson's Disease Society Brain Bank criteria, with disease duration over 5 years, age&#x0D;&lt;br&gt;        under 75, acute levodopa motor response =30%, and indication for STN-DBS. -&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria: patients with severe cognitive impairment, severe psychiatric&#x0D;&lt;br&gt;        disorders, acute levodopa motor response less than 30%, atypical parkinsonism, and&#x0D;&lt;br&gt;        contraindications to surgery -&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Deep Brain Stimulation;Non-motor Symptoms
    </Condition>
    <Intervention>Procedure: DBS
    </Intervention>
    <Primary_outcome>motor symptom
    </Primary_outcome>
    <Secondary_ID>TianjinHH
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13736463
    </Internal_Number>
    <TrialID>NL-OMON53748
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>The TREMBLE study: Multicentre randomized controlled trial of awake versus asleep tractography based Deep Brain Stimulation for Essential Tremor
    </Public_title>
    <Scientific_title>The TREMBLE study: Multicentre randomized controlled trial of awake versus asleep tractography based Deep Brain Stimulation for Essential Tremor - TREMBLE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>Academisch Medisch Centrum
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230714
    </Date_registration3>
    <Date_registration>2023-07-14
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/53748
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>64
    </Inclusion_agemax>
    <Inclusion_gender/>
    <Date_enrollement>2023-05-01
    </Date_enrollement>
    <Target_size>110
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized  controlled trial, Open (masking not used), Active, Other, Treatment
    </Study_design>
    <Phase/>
    <Countries>The Netherlands
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address>Academisch Medisch Centrum  Meibergdreef 9
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Academisch Medisch Centrum
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;p&gt;- Age &amp;gt; 18 years; - Idiopathic essential tremor - Disabling tremor despite &lt;br&gt;optimal pharmacological treatment - A life expectancy of at least two years&lt;/p&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;p&gt;- Legally incompetent adults;&lt;br&gt;- Previous tremor-neurosurgery (e.g., DBS, thalamotomy);&lt;br&gt;- Contraindications for DBS surgery, such as a physical disorder making surgery &lt;br&gt;hazardous;&lt;br&gt;- Psychosis;&lt;br&gt;- Current depression;&lt;br&gt;- Unable to provide written informed consent.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;essential tremor &lt;br&gt;trembling;10028037;10009720;essential tremor;trembling
    </Condition>
    <Intervention>&lt;p&gt;Patients are randomized for DBS under general anesthesia or DBS under local &lt;br&gt;anesthesia. According to the standard DBS procedure, two brain-electrodes are &lt;br&gt;connected to an implanted neurostimulator, which is placed subcutaneously in &lt;br&gt;the subclavicular area.&lt;/p&gt;&lt;br&gt;;Deep brain stimulation;Essential tremor;General anesthesia;Tractograhy
    </Intervention>
    <Primary_outcome>&lt;p&gt;The primary outcome measure is the amount of decrease in tremor indicated by&lt;br /&gt;&lt;br&gt;change in the Essential Tremor Rating Assessment Scale score after 6 months of&lt;br /&gt;&lt;br&gt;thalamic DBS.&lt;/p&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>&lt;p&gt;-The Amsterdam Linear Disability Score for functional health status&lt;br /&gt;&#x0D;&lt;br&gt;-Quality of Life in Essential Tremor Questionnaire&lt;br /&gt;&#x0D;&lt;br&gt;-Patient satisfaction with the treatment&lt;br /&gt;&#x0D;&lt;br&gt;-Patient evaluation of treatment burden&lt;br /&gt;&#x0D;&lt;br&gt;-Operating time&lt;br /&gt;&#x0D;&lt;br&gt;-Hospitalization time&lt;br /&gt;&#x0D;&lt;br&gt;-Change of tremor medication&lt;br /&gt;&#x0D;&lt;br&gt;-Side effects and complications&lt;/p&gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>NL80368.018.23
    </Secondary_ID>
    <Source_Support>Ministerie van OC&amp;W
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>29/06/2023
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13707117
    </Internal_Number>
    <TrialID>NCT05962489
    </TrialID>
    <Last_Refreshed_on>27 February 2024
    </Last_Refreshed_on>
    <Public_title>Sleep-specific DBS Therapy in Parkinson's Disease
    </Public_title>
    <Scientific_title>Sleep-specific DBS Therapy in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Minnesota
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230628
    </Date_registration3>
    <Date_registration>28/06/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05962489
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 22, 2023
    </Date_enrollement>
    <Target_size>64
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: Single (Participant). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Luke Johnson, PhD;Luke Johnson, PhD
    </Contact_Lastname>
    <Contact_Email>joh03032@umn.edu;joh03032@umn.edu
    </Contact_Email>
    <Contact_Tel>612-625-9900;612-625-9900
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Diagnosis of idiopathic PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. At least 21 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Existing or planned 7T brain imaging&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Surgery at UMN to implant DBS system in GPi or STN with directional lead(s) is planned&#x0D;&lt;br&gt;             as part of routine clinical care&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Surgery at UMN to implant bilateral DBS system in GPi or STN with directional lead(s)&#x0D;&lt;br&gt;             is planned as part of routine clinical care (or has already occurred, as long as the&#x0D;&lt;br&gt;             initial programming session is at least 2 weeks away)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Other significant neurological disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. History of dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients with post-operative complications or adverse effects (e.g. ON stimulation&#x0D;&lt;br&gt;             dystonias) that affect patient safety or confound the experiment will be excluded from&#x0D;&lt;br&gt;             further study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Pregnant women&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Known radiation exposure within the last year that is determined to be unsafe when&#x0D;&lt;br&gt;             compounded with the expected radiation dose from intraoperative fluoroscopy to place&#x0D;&lt;br&gt;             ECoG strip&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Deep Brain Stimulation;Parkinson's Disease and Parkinsonism;Dystonia
    </Condition>
    <Intervention>Other: Clinically optimized deep brain stimulation
    </Intervention>
    <Primary_outcome>pallidopeduncular and pedunculopallidal pathway activation;pallidopeduncular and pedunculopallidal pathway activation;GPe activation;GPe activation;Actigraphy;Actigraphy;Clinical Rating Scales;Clinical Rating Scales
    </Primary_outcome>
    <Secondary_ID>STUDY00018981
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13341977
    </Internal_Number>
    <TrialID>NCT06012461
    </TrialID>
    <Last_Refreshed_on>11 September 2023
    </Last_Refreshed_on>
    <Public_title>Closed-loop DBS in Parkinson's Disease
    </Public_title>
    <Scientific_title>Safety and Effectiveness of Closed-loop DBS in Parkinson's Disease: A Long-term Follow-up Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Tsinghua University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230618
    </Date_registration3>
    <Date_registration>18/06/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06012461
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 30, 2023
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Weizhi Pan, B.S.;Huiling Yu, M.D.
    </Contact_Lastname>
    <Contact_Email>neln@mail.tsinghua.edu.cn;hellokittylene@163.com
    </Contact_Email>
    <Contact_Tel>+86-010-62796172;86-010-62794952
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Diagnosis of primary Parkinson's disease: Diagnosis of primary Parkinson's disease&#x0D;&lt;br&gt;             should meet the diagnostic criteria outlined in the "Diagnosis Standards for&#x0D;&lt;br&gt;             Parkinson's Disease in China" published in 2016 or the diagnostic criteria for primary&#x0D;&lt;br&gt;             Parkinson's disease by the International Parkinson and Movement Disorder Society (MDS)&#x0D;&lt;br&gt;             published in 2015.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Good response to levodopa combination therapy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Significant reduction in drug efficacy or significant impact on the patient's quality&#x0D;&lt;br&gt;             of life due to prominent motor complications.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Intolerable adverse reactions to medication affecting its efficacy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Presence of uncontrollable tremors despite medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patients who have undergone pallidotomy or other brain surgeries.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patients with secondary Parkinson syndromes or Parkinson plus syndromes.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients with concurrent central nervous system and peripheral nervous system&#x0D;&lt;br&gt;             diseases.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patients with severe systemic diseases, unstable vital signs, or those who cannot&#x0D;&lt;br&gt;             tolerate clinical assessments.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patients with severe psychiatric disorders.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Patients who are unable to provide informed consent due to cognitive or communication&#x0D;&lt;br&gt;             impairments or those who refuse to sign the informed consent form.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Closed-loop DBS stimulation for 24 hours;Other: Open-loop DBS stimulation for 24 hours;Other: Closed-loop DBS stimulation for 72 hours;Other: Open-loop DBS stimulation for 72 hours
    </Intervention>
    <Primary_outcome>Movement disorders evaluation;Sleep Structure Evaluation;Diary Outcomes in Parkinson's Disease
    </Primary_outcome>
    <Secondary_outcome>Safety (Stimulation-related AEs) and Subjective Satisfactory;Total Electrical Energy Delivered to patients
    </Secondary_outcome>
    <Secondary_ID>CDBS_PD_2023
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Engineering Research Center of Neuromodulation, Tsinghua University;Beijing Tiantan Hospital;Peking Union Medical College Hospital;Beijing Pins Medical Co., Ltd
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13212452
    </Internal_Number>
    <TrialID>NCT05968976
    </TrialID>
    <Last_Refreshed_on>7 August 2023
    </Last_Refreshed_on>
    <Public_title>Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET
    </Public_title>
    <Scientific_title>The TREMBLE Study: Multicentre Randomized Controlled Trial of Awake Versus Asleep Tractography Based Deep Brain Stimulation for Essential Tremor
    </Scientific_title>
    <Acronym>TREMBLE
    </Acronym>
    <Primary_sponsor>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230609
    </Date_registration3>
    <Date_registration>09/06/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05968976
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 1, 2023
    </Date_enrollement>
    <Target_size>110
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Netherlands
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Maarten Bot, MD, PhD;Maarten Bot, MD, PhD
    </Contact_Lastname>
    <Contact_Email>m.bot@amsterdamumc.nl;m.bot@amsterdamumc.nl
    </Contact_Email>
    <Contact_Tel>0031621514048;0031621514048
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &gt; 18 years;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic essential tremor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Disabling tremor despite optimal pharmacological treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A life expectancy of at least two years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Legally incompetent adults;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous tremor-neurosurgery (e.g., DBS, thalamotomy);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Contraindications for DBS surgery, such as a physical disorder making surgery&#x0D;&lt;br&gt;             hazardous;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychosis;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current depression;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unable to provide written informed consent.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor;Deep Brain Stimulation;Diffusion Tensor Imaging;Magnetic Resonance;Central Nervous System Diseases
    </Condition>
    <Intervention>Procedure: Awake DBS;Procedure: Asleep DBS
    </Intervention>
    <Primary_outcome>Essential Tremor Rating Assessment Scale (TETRAS)
    </Primary_outcome>
    <Secondary_outcome>The Amsterdam Linear Disability Score for functional health status;Quality of Life in Essential Tremor Questionnaire;Global Impression of Change;EQ-5D-5L
    </Secondary_outcome>
    <Secondary_ID>NL80368.018.23
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University Medical Center Groningen;Medical Center Haaglanden;The Elisabeth-TweeSteden Hospital;Maastricht University Medical Center;Radboud University Medical Center;Medisch Spectrum Twente
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13173999
    </Internal_Number>
    <TrialID>NCT05909839
    </TrialID>
    <Last_Refreshed_on>18 July 2023
    </Last_Refreshed_on>
    <Public_title>The STEREO-DBS ET Study: 7-Tesla MRI Brain Network Analysis for Deep Brain Stimulation in Essential Tremor
    </Public_title>
    <Scientific_title>The STEREO-DBS Study: 7-Tesla MRI Brain Network Analysis for Deep Brain Stimulation in Essential Tremor
    </Scientific_title>
    <Acronym>STEREO-ET
    </Acronym>
    <Primary_sponsor>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230609
    </Date_registration3>
    <Date_registration>09/06/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05909839
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 9, 2023
    </Date_enrollement>
    <Target_size>500
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Netherlands
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Maarten Bot, MD, PhD;Maarten Bot, MD, PhD
    </Contact_Lastname>
    <Contact_Email>m.bot@amsterdamumc.nl;m.bot@amsterdamumc.nl
    </Contact_Email>
    <Contact_Tel>0031621514048;0031621514048
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &gt; 18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic essential tremor who underwent DBS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Legally incompetent adults&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No written informed consent&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Other: 7T MRI network analysis for deep brain stimulation in essential tremor
    </Intervention>
    <Primary_outcome>Essential Tremor Rating Assessment Scale (TETRAS)
    </Primary_outcome>
    <Secondary_outcome>The Amsterdam Linear Disability Score for functional health status;Quality of Life in Essential Tremor Questionnaire;Global Impression of Change;EQ-5D-5L
    </Secondary_outcome>
    <Secondary_ID>W21_056 # 21.062
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13650110
    </Internal_Number>
    <TrialID>DRKS00032006
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Pooling Event Related Potentials With Anatomy, Lead-Localization &amp; Clinical effects
    </Public_title>
    <Scientific_title>Pooling Event Related Potentials With Anatomy, Lead-Localization &amp; Clinical effects - PERP-WALC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Universität zu Köln
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230605
    </Date_registration3>
    <Date_registration>05/06/2023
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00032006
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>22/06/2023
    </Date_enrollement>
    <Target_size>115
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: basic science  
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Till A. 
    </Contact_Firstname>
    <Contact_Lastname>Dembek
    </Contact_Lastname>
    <Contact_Address>Kerpener Str. 62
    </Contact_Address>
    <Contact_Email>till.dembek@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>+49 221 478 97602
    </Contact_Tel>
    <Contact_Affiliation>Uniklinik Köln, Klinik und Poliklinik für Neurologie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: - Deep brain stimulation for Parkinson’s disease, Essential tremor or dystonia&#x0D;&lt;br&gt;- Obtained capacity to consent&#x0D;&lt;br&gt;- Verbal as well as written informed consent to study participation
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: - Failure to meet inclusion criteria
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20.9 &lt;br&gt;G25.0 &lt;br&gt;G24.9;Essential tremor;Dystonia, unspecified;G20.9;G25.0;G24.9
    </Condition>
    <Intervention>Group 1: Patients who have received deep brain stimulation due to idiopathic Parkinson's disease will receive a one-time combined EEG and EMG measurement with simultaneous change of stimulation parameters.&lt;br&gt;Group 2: Patients who have received deep brain stimulation due to essential tremor will receive a one-time combined EEG and EMG measurement with simultaneous change of stimulation parameters.&lt;br&gt;Group 3: Patients who have received deep brain stimulation due to dystonia will receive a one-time combined EEG and EMG measurement with simultaneous change of stimulation parameters.
    </Intervention>
    <Primary_outcome>Study aim: Subjects who have received deep brain stimulation for Parkinson's disease, essential tremor or dystonia will undergo EEG measurement to record event related cortical potentials (ERPs) triggered by stimulation. These will then be correlated with clinical data such as available testing protocols, but also analyzed in connection with imaging data to identify areas and fiber connections involved in the origin and transmission of ERPs. This is an exploratory, basic science study with no predefined endpoints.
    </Primary_outcome>
    <Source_Support>Uniklinik Köln
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>08/11/2022
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00032006#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13559788
    </Internal_Number>
    <TrialID>NCT05897775
    </TrialID>
    <Last_Refreshed_on>27 November 2023
    </Last_Refreshed_on>
    <Public_title>Coordinated Reset Deep Brain Stimulation for Essential Tremor
    </Public_title>
    <Scientific_title>Coordinated Reset Deep Brain Stimulation for Essential Tremor
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Minnesota
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230601
    </Date_registration3>
    <Date_registration>01/06/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05897775
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 21, 2023
    </Date_enrollement>
    <Target_size>23
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 1/Phase 2
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Jing Wang, PhD;Jing Wang, PhD;Jing Wang, PhD
    </Contact_Lastname>
    <Contact_Email>;wang3444@umn.edu;wang3444@umn.edu
    </Contact_Email>
    <Contact_Tel>;(612) 626-6071;612-626-6071
    </Contact_Tel>
    <Contact_Affiliation>University of Minnesota;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of Essential Tremor (ET)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age of 21 or over&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Will be implanted with Boston Scientific Vercise Rechargeable Genus deep brain&#x0D;&lt;br&gt;             stimulation (DBS) system&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  7 Tesla (7T) MRI pre-operative scan under Noam Harel PhD's (Center for Magnetic&#x0D;&lt;br&gt;             Research (University of Minnesota IRB #1210M22183) protocol "Imaging of DBS targets at&#x0D;&lt;br&gt;             7T MRI"&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Planned post-operative CT scan&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of musculoskeletal disorders that affect movement of the limbs or gait&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other significant neurological disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of dementia or cognitive impairment (Mini-Mental Score &amp;lt; 26)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Significant psychiatric disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  On medication that could cause tremor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Prior brain surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant women&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of non-ET central nervous system disease or injury for at least three (3)&#x0D;&lt;br&gt;             months prior to implantation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any suspicion of Parkinsonian tremor, including presence of Parkinsonian features such&#x0D;&lt;br&gt;             as bradykinesia, rigidity, or postural instability&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other significant medical disorder that could impede study participation&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor;Upper Extremity Essential Tremor
    </Condition>
    <Intervention>Device: Deep brain stimulation
    </Intervention>
    <Primary_outcome>Tremor Research Group Essential Tremor Rating Scale (TETRAS)
    </Primary_outcome>
    <Secondary_outcome>Instrumented Tremor Measurement;Bain Tremor Disability Scale (BTDS);Quality of Life in Essential Tremor (QUEST);Quantitative Archimedes Spirals;Dot Approximation Task;Brief Ataxia Rating Scale (BARS);Quantitative Gait Analysis;Quantitative Speech Analysis
    </Secondary_outcome>
    <Secondary_ID>CR-DBS
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13526721
    </Internal_Number>
    <TrialID>NCT05893186
    </TrialID>
    <Last_Refreshed_on>13 November 2023
    </Last_Refreshed_on>
    <Public_title>Multiple Objective Particle Swarm Optimization Postural Instability Gait Disorder
    </Public_title>
    <Scientific_title>Multiple Objective Particle Swarm Optimization Postural Instability Gait Disorder
    </Scientific_title>
    <Acronym>MOPSO PIGD
    </Acronym>
    <Primary_sponsor>University of Minnesota
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230512
    </Date_registration3>
    <Date_registration>12/05/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05893186
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>89 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 25, 2021
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: Triple (Participant, Care Provider, Investigator). 
    </Study_design>
    <Phase>Early Phase 1
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Scott Cooper, MD, PhD;Zuzanna Pasek;Zuzanna Pasek
    </Contact_Lastname>
    <Contact_Email>;pasek013@umn.edu;pasek013@umn.edu
    </Contact_Email>
    <Contact_Tel>;612-624-0018;612-624-0018
    </Contact_Tel>
    <Contact_Affiliation>University of Minnesota;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Bilateral DBS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Directional DBS electrode system&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MRI, at least 7 Tesla, with diffusion tensor imaging, prior to DBS surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Head CT, at least 1mm cuts, following DBS surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  At least 3 months since initial activation of the neurostimulator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neurological or musculoskeletal disorder that significantly affects gait, balance, or&#x0D;&lt;br&gt;             limb movements&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Prior stereotactic neurosurgery other than DBS for movement disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Deep Brain Stimulation, STN;Other: GP Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Gait test
    </Primary_outcome>
    <Secondary_outcome>Balance Test;Bradykinesia test;Rigidity Test
    </Secondary_outcome>
    <Secondary_ID>NEUR-2019-28436
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13650019
    </Internal_Number>
    <TrialID>DRKS00031878
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Central clinical database of the Collaborative Research Centre's INF project (CRC/TRR295) "ReTune" to integrate the clinical core dataset
    </Public_title>
    <Scientific_title>Central clinical database of the Collaborative Research Centre's INF project (CRC/TRR295) "ReTune" to integrate the clinical core dataset                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Charité Universitätsmedizin Berlin / Klinik für Neurologie mit Experimenteller Neurologie Sektion Bewegungsstörungen und Neuromodulation
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230512
    </Date_registration3>
    <Date_registration>12/05/2023
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00031878
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>01/04/2023
    </Date_enrollement>
    <Target_size>632
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: treatment 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>TRR 295
    </Contact_Firstname>
    <Contact_Lastname>Coordinator
    </Contact_Lastname>
    <Contact_Address>Charitéplatz 1
    </Contact_Address>
    <Contact_Email>trr295@charite.de
    </Contact_Email>
    <Contact_Tel>+49(0)30 450 560 373
    </Contact_Tel>
    <Contact_Affiliation>Charité – Universitätsmedizin Berlin
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All patients are eligible for inclusion who: #1 Have been included in a corresponding study of a subproject of TR 295 and have consented to data transfer to the central clinical database as part of inclusion in the respective study.&#x0D;&lt;br&gt;OR #2 Patients with movement disorders Parkinson's disease, tremor, dystonia (G20-G26: Extrapyramidal diseases and movement disorders) who are receiving DBS treatment as part of their therapy and who have consented to inclusion in the central clinical database. OR #3 Patient:s with movement disorders Parkinson's disease, tremor, dystonia (G20-G26: Extrapyramidal diseases and movement disorders) who are eligible for DBS treatment as part of their therapy but have not opted for DBS treatment and have consented to inclusion in the central clinical database (control group).
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: No signed informed consent form / inclusion criteria are not met
    </Exclusion_Criteria>
    <Condition>Patients with movement disorders Parkinson's disease,tremor, dystonia (G20-G26)
    </Condition>
    <Intervention>Group 1: As part of usual care: Implantation of deep brain stimulation device&lt;br&gt;Group 2: As part of usual care: No treatment with deep brain stimulation, because patients refuse this treatment.
    </Intervention>
    <Primary_outcome>Quality of life (EQ-5D-5L)&lt;br&gt;Baseline = t0 / Follow-up = 12 months
    </Primary_outcome>
    <Secondary_outcome>Not specified
    </Secondary_outcome>
    <Source_Support>Deutsche Forschungsgemeinschaft
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>25/02/2022
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ethikkommission@uni-wuerzburg.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Universität Würzburg, Institut für Pharmakologie und Toxikologie
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-931-3148315
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ethikkommission@uni-wuerzburg.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00031878#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13039712
    </Internal_Number>
    <TrialID>NCT05843084
    </TrialID>
    <Last_Refreshed_on>8 May 2023
    </Last_Refreshed_on>
    <Public_title>The STEREO-DBS Study: 7-Tesla MRI Brain Network Analysis for Deep Brain Stimulation
    </Public_title>
    <Scientific_title>The STEREO-DBS Study: 7-Tesla MRI Brain Network Analysis for Deep Brain Stimulation
    </Scientific_title>
    <Acronym>STEREO-DBS
    </Acronym>
    <Primary_sponsor>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230411
    </Date_registration3>
    <Date_registration>11/04/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05843084
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 11, 2023
    </Date_enrollement>
    <Target_size>500
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Netherlands
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Maarten Bot, MD, PhD
    </Contact_Lastname>
    <Contact_Email>m.bot@amsterdamumc.nl
    </Contact_Email>
    <Contact_Tel>0031621514048
    </Contact_Tel>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        1.2 Inclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        In order to be eligible to participate in this study, a subject must meet all of the&#x0D;&lt;br&gt;        following criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &gt; 18 years;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic PD who underwent STN DBS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        1.3 Exclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        A potential subject who meets any of the following criteria will be excluded from&#x0D;&lt;br&gt;        participation in this study:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Legally incompetent adults;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No written informed consent.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Diffusion Magnetic Resonance Imaging;Brain;Subthalamic Nucleus;Deep Brain Stimulation;Human;Treatment Outcome
    </Condition>
    <Intervention>Procedure: 7T MRI network analysis for deep brain stimulation in Parkinson's disease
    </Intervention>
    <Primary_outcome>Unified Parkinson's Disease Rating Scale (UPDRS-III)
    </Primary_outcome>
    <Secondary_outcome>The Amsterdam Linear Disability Score for functional health status;Parkinson's disease questionnaire-39;Starkstein apathy scale
    </Secondary_outcome>
    <Secondary_ID>W20_540 # 20.599
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13039076
    </Internal_Number>
    <TrialID>NCT05822388
    </TrialID>
    <Last_Refreshed_on>8 May 2023
    </Last_Refreshed_on>
    <Public_title>Cognitive Decline Following Deep Brain Stimulation
    </Public_title>
    <Scientific_title>A Neural Basis for Cognitive Decline Following Deep Brain Stimulation
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Medical University of South Carolina
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230410
    </Date_registration3>
    <Date_registration>10/04/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05822388
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 1, 2023
    </Date_enrollement>
    <Target_size>55
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Daniel H Lench, PhD;Daniel H Lench, PhD;Daniel H Lench, PhD
    </Contact_Lastname>
    <Contact_Email>;lenchd@musc.edu;lenchd@musc.edu
    </Contact_Email>
    <Contact_Tel>;843-792-9115;843-792-9115
    </Contact_Tel>
    <Contact_Affiliation>Medical University of South Carolina;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects above 18 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects who will undergo DBS surgery as part of their clinical care for PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uncorrected visual or hearing impairments, as indicated by self-report&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who are pregnant or expect to become pregnant during the course of the&#x0D;&lt;br&gt;             study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals with claustrophobia, or the inability to lie supine position in the MRI&#x0D;&lt;br&gt;             scanner&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  COPD with oxygen dependence&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-MRI compatible metal implants (surgical clips or staples, cardiac pacemakers etc.)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Movement Disorders
    </Condition>
    <Intervention>Procedure: Deep Brain Stimulation Surgical Procedures as Part of Routine Clinical Care
    </Intervention>
    <Primary_outcome>Change in Cognition;Brain Microstructure (DKI)
    </Primary_outcome>
    <Secondary_outcome>Brain Functional Connectivity;Brain Microstructure (DTI)
    </Secondary_outcome>
    <Secondary_ID>Pro00125181
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13649253
    </Internal_Number>
    <TrialID>DRKS00030841
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Transcranial Temporal Interference Stimulation of Deep Brain Regions in Parkinson's disease and health Controls
    </Public_title>
    <Scientific_title>Transcranial Temporal Interference Stimulation of Deep Brain Regions in Parkinson's disease and health Controls - TETRIS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Universität Oldenburg/Evang. Krankenhaus Oldenburg
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230301
    </Date_registration3>
    <Date_registration>01/03/2023
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00030841
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>45 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>01/03/2023
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Randomized controlled study; Masking: Blinded (masking used); Control: active//No treatment / Standard of care; Assignment: crossover; Study design purpose: basic science  
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Karsten 
    </Contact_Firstname>
    <Contact_Lastname>Witt
    </Contact_Lastname>
    <Contact_Address>Marienstraße 11
    </Contact_Address>
    <Contact_Email>karsten.witt@uni-oldenburg.de
    </Contact_Email>
    <Contact_Tel>+49 (0)441 236 649
    </Contact_Tel>
    <Contact_Affiliation>Universität Oldenburg/Evang. Krankenhaus Oldenburg
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: - German as mother tongue&#x0D;&lt;br&gt;- Normale or corrected vision&#x0D;&lt;br&gt;- Dexterity&#x0D;&lt;br&gt;(- Diagnosis of idiopathic Parkinson's disease)
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Neurological or psychiatric diagnosis other than PD&#x0D;&lt;br&gt;Medication with effects on the central nervous system (besides PD medication)&#x0D;&lt;br&gt;Non-removable metallic parts in/at the body&#x0D;&lt;br&gt;Implanted neurostimulation&#x0D;&lt;br&gt;Contraindications for mri &#x0D;&lt;br&gt;Diagnosis of epilepsy (in the family)
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: Parkinson's disease patients, deep brain regions will be targeted using trans cranial temporal interference stimulation while the patients execute different tasks to measure motor learning, motor performance and effort behaviour&lt;br&gt;&lt;br&gt;Group 2: Healthy controls , deep brain regions will be targeted using trans cranial temporal interference stimulation hile the participants execute different tasks to measure motor learning, motor performance and effort behaviour
    </Intervention>
    <Primary_outcome>Motor performance by a finger tapping task&lt;br&gt;Motor learning by a sequential finger tapping task&lt;br&gt;Motivational behaviour by an effort/reward task&lt;br&gt;Probabilistic learning by an effort/reward task
    </Primary_outcome>
    <Secondary_outcome>Explorative evaluation of side effects
    </Secondary_outcome>
    <Source_Support>Universität Oldenburg, Abt. Neurologie
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>28/02/2023
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>med.ethikkommission@uni-oldenburg.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Geschäftsstelle der medizinischen Ethikkommission, Fakultät VI Medizin und Gesundheitswissenschaften, Carl von Ossietzky Universität Oldenburg, Gebäude V04 (Raum 1-137)
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-441-7983109
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>med.ethikkommission@uni-oldenburg.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00030841#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12890656
    </Internal_Number>
    <TrialID>NCT05753449
    </TrialID>
    <Last_Refreshed_on>13 March 2023
    </Last_Refreshed_on>
    <Public_title>Burst-Type Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease
    </Public_title>
    <Scientific_title>Burst-Type Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease: A Pilot Study of Tolerability and Efficacy
    </Scientific_title>
    <Acronym>BURST
    </Acronym>
    <Primary_sponsor>Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230207
    </Date_registration3>
    <Date_registration>07/02/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05753449
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 24, 2022
    </Date_enrollement>
    <Target_size>5
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Nestor Tomycz, MD;Clinical Trials Contact
    </Contact_Lastname>
    <Contact_Email>Nestor.Tomycz@ahn.org;clinicaltrials@ahn.org
    </Contact_Email>
    <Contact_Tel>412-359-6200;412-330-6151
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Bilateral DBS-STN (subthalamic nucleus) target for idiopathic Parkinson's disease&#x0D;&lt;br&gt;             implanted minimum 6 months prior to the day of study enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Stable DBS programming settings and Parkinson's disease medications defined as no&#x0D;&lt;br&gt;             changes to either within past 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Comfortable using DBS controller to turn off device prior to study visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to provide informed consent and complete follow-up visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  DBS technology other than Boston scientific Genus/Gevia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unable to complete follow-up visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  DBS brain targets other than STN (subthalamic nucleus)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signs of progressive cognitive decline&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Deep Brain Stimulation
    </Condition>
    <Intervention>Device: Burst-type DBS electrical stimulation programming;Device: Standard of care DBS programming
    </Intervention>
    <Primary_outcome>Change in Unified Parkinson's Disease Rating Scale (UPDRS) v-III Motor Examination Score
    </Primary_outcome>
    <Secondary_ID>2022-234
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Boston Scientific Corporation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13156886
    </Internal_Number>
    <TrialID>NCT05713721
    </TrialID>
    <Last_Refreshed_on>3 July 2023
    </Last_Refreshed_on>
    <Public_title>Sensorimotor Integration in Monogenic Parkinson-dystonia Syndromes
    </Public_title>
    <Scientific_title>SensoMo-PD: Sensorimotor Integration in Monogenic Parkinson-dystonia Syndromes
    </Scientific_title>
    <Acronym>SensoMo-PD
    </Acronym>
    <Primary_sponsor>University Hospital Schleswig-Holstein
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230127
    </Date_registration3>
    <Date_registration>27/01/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05713721
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>100 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2023
    </Date_enrollement>
    <Target_size>120
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Anne Weissbach, MD;Anne Weissbach, MD;Anne Weissbach, MD
    </Contact_Lastname>
    <Contact_Email>;anne.weissbach@neuro.uni-luebeck.de;anne.weissbach@neuro.uni-luebeck.de
    </Contact_Email>
    <Contact_Tel>;+49 451 3101 8219;+49 451 3101 8219
    </Contact_Tel>
    <Contact_Affiliation>Institute of Systems Motor Science;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion criteria for mutation carriers:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pathogenic Parkin, PINK1, GCH1, or TAF1 gene variant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &gt;18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion criteria for healthy control participants:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No movement disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &gt;18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No medication with influences on the central nervous system&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &lt;18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medication that reduces the seizure threshold&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson;Dystonia;DYT3;DYT5;PINK1 Gene Deletion;Dystonia, Familial
    </Condition>
    <Intervention>Device: Transcranial magnetic stimulation (TMS);Other: Video-based clinical examination;Other: 24 hours drug withdrawal of dopaminergic medication;Other: Evaluation of deep brain stimulation
    </Intervention>
    <Primary_outcome>Contrast sensorimotor integration in patients with three different monogenic Parkinson-dystonia syndromes.;Define whether asymptomatic mutation carriers show abnormalities in sensorimotor integration and clinical signs of Parkinson and dystonia upon video examination.;Correlate clinical symptom severity with changes in sensorimotor integration.;Evaluate treatment effects on sensorimotor integration, e.g., for PARK-Parkin/PARK-PINK1 and DYT/PARK-GCH1 chronic dopaminergic medication and for DYT/PARK-TAF1 deep brain stimulation effects.
    </Primary_outcome>
    <Secondary_ID>MJFF-022062
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Michael J. Fox Foundation for Parkinson's Research
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12891268
    </Internal_Number>
    <TrialID>NCT05765110
    </TrialID>
    <Last_Refreshed_on>13 March 2023
    </Last_Refreshed_on>
    <Public_title>SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease
    </Public_title>
    <Scientific_title>SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease
    </Scientific_title>
    <Acronym>EMO-SPEECH-PD
    </Acronym>
    <Primary_sponsor>University Hospital Inselspital, Berne
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230111
    </Date_registration3>
    <Date_registration>11/01/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05765110
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>30 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 3, 2023
    </Date_enrollement>
    <Target_size>80
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Czechia;Switzerland;Czechia;Switzerland
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Paul Krack, Prof.;Paul Krack, Prof.;Paul Krack, Prof.
    </Contact_Lastname>
    <Contact_Email>;paul.krack@insel.ch;paul.krack@insel.ch
    </Contact_Email>
    <Contact_Tel>;31 66 4 03 71;31 66 4 03 71
    </Contact_Tel>
    <Contact_Affiliation>University Hospital Inselspital, Berne;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Patients with Parkinson's Disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic PD according to the Movement Disorders Society Criteria;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age of participants &gt; 30 and = 75 years;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Treatment with or without bilateral deep brain stimulation in the subthalamic nucleus;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fluent in German or French&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dysarthria caused in addition by a condition other than PD (e.g. stroke, myasthenia);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical diagnosis of aphasia;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Brain disease other than Parkinson's disease (e.g. atypical Parkinsonism, Alzheimer's&#x0D;&lt;br&gt;             disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury,&#x0D;&lt;br&gt;             epilepsy, etc.).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment (Montreal Cognitive Assessment (MoCa) &lt; 24/30 points);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Depression with acute suicidal ideation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Healthy Controls&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adults from 50-70 years old;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fluent in German or French&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of Parkinson's disease;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment (Montreal Cognitive Assessment (MoCa) &lt; 24/30 points);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Suffering from brain disease (e.g. atypical Parkinsonism, Alzheimer's disease,&#x0D;&lt;br&gt;             vascular dementia, multiple sclerosis, stroke, traumatic brain injury, epilepsy,&#x0D;&lt;br&gt;             etc.);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical diagnosis of aphasia, dysarthria, and stuttering;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Suffering from or diagnosed with psychiatric illnesses according to DSM-V criteria&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Dopaminergic OFF drug state;Other: DBS OFF state;Other: Dopaminergic ON drug state;Other: DBS ON state
    </Intervention>
    <Primary_outcome>Part I: Changes from baseline in best acoustic speech variables to detect changes of dopaminergic and stimulation motor effect in Parkinson's disease patients;Part II: Changes from baseline in best acoustic and linguistic speech variables to detect changes of dopaminergic and stimulation neuropsychological effect in Parkinson's disease patients;Part III: Changes from baseline in best acoustic and linguistic speech variables to detect changes of dopaminergic and stimulation cognitive effect in Parkinson's disease patients;Part III: Changes from baseline in best acoustic and linguistic speech variables to detect changes of dopaminergic and stimulation cognitive effect in Parkinson's disease patients
    </Primary_outcome>
    <Secondary_outcome>Dyskinesia severity;Momentary mood state;Momentary anxiety state;Bradyphrenia assessment
    </Secondary_outcome>
    <Secondary_ID>2022-01304
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Czech Technical University in Prague
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13203099
    </Internal_Number>
    <TrialID>NCT05715138
    </TrialID>
    <Last_Refreshed_on>2 August 2023
    </Last_Refreshed_on>
    <Public_title>Comparison of Pallidal With Subthalamic Deep Brain Stimulation for Cervical Dystonia
    </Public_title>
    <Scientific_title>A Randomized Controlled Trial Comparing PAllidal and SubThalamic Deep Brain Stimulation for Cervical Dystonia(the PASTS-CD Study)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Chinese PLA General Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230110
    </Date_registration3>
    <Date_registration>10/01/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05715138
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 1, 2023
    </Date_enrollement>
    <Target_size>98
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Zhiqi Mao, PhD;Bin Liu, MD;Zhiqi Mao, PhD;Zhiqi Mao, Ph.D
    </Contact_Lastname>
    <Contact_Email>;;markmaoqi@126.com;markmaoqi@126.com
    </Contact_Email>
    <Contact_Tel>;;8618910155994;8618910155994
    </Contact_Tel>
    <Contact_Affiliation>Chinese PLA General Hospital;Chinese PLA General Hospital;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Diagnosed as idiopathic or hereditary isolated CD;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Severe functional impairment;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Oral medication and injection of botulinum toxin become ineffective (&gt; 3 months since&#x0D;&lt;br&gt;             last injection), or refuse to adopt botulinum toxin injection;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. No secondary causes of CD;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Age 18-80 years old;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Normal neurological examination except for dystonia;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Normal brain MRI;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. The subject or their family members can fully understand the trial and sign the&#x0D;&lt;br&gt;             informed consent;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Good compliance and willingness to receive regular follow-ups.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Diagnosed as secondary CD;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. CD with obvious trunk/limb involvement, or Meige syndrome;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. History of severe mental disorders, dementia, or epilepsy;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Previous dystonia surgery (pallidotomy, thalamotomy, DBS, etc);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Accompanied by other neurological diseases (Parkinson's disease, essential tremor,&#x0D;&lt;br&gt;             multiple sclerosis, stroke, etc);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. The patient has or needs other implantable devices (cardiac pacemakers,&#x0D;&lt;br&gt;             defibrillators, cochlear implants, spinal cord stimulators, etc);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Pregnant women or women who are waiting to become pregnant during the trial;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Poor health condition.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cervical Dystonia
    </Condition>
    <Intervention>Procedure: GPi-DBS;Procedure: STN-DBS;Device: GPi-DBS devices;Device: STN-DBS devices
    </Intervention>
    <Primary_outcome>Change from baseline Toronto Western Spasmodic Torticollis Rating Scale - Severity subscale (TWSTRS-Severity) at 3 months;Change from baseline Tsui scale at 3 months;Change from baseline Toronto Western Spasmodic Torticollis Rating Scale - Severity subscale (TWSTRS-Severity) at 6 months;Change from baseline Tsui scale at 6 months;Change from baseline Toronto Western Spasmodic Torticollis Rating Scale - Severity subscale (TWSTRS-Severity) at 1 year;Change from baseline Tsui scale at 1 year
    </Primary_outcome>
    <Secondary_outcome>Change of Toronto Western Spasmodic Torticollis Rating Scale - Disability subscale (TWSTRS-Disability);Change of Toronto Western Spasmodic Torticollis Rating Scale - Pain subscale (TWSTRS-Pain);Change of 36-item Short Form General Health Survey (SF-36);Change of Hamilton Anxiety Scale (HAMA);Change of 24-item Hamilton Depression Scale (HAMD);Change of Mini-mental State Examination (MMSE);Change of Montreal Cognitive Assessment (MoCA);Total electrical energy delivered (TEED);Adverse effects
    </Secondary_outcome>
    <Secondary_ID>ChinaPLAGH_LB
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13630548
    </Internal_Number>
    <TrialID>NCT06008717
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Double-Blind Clinical Trial of Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease
    </Public_title>
    <Scientific_title>A Prospective, Randomized Feasibility Clinical Trial Evaluating Bilateral Stimulation of the Dorsolateral Region of the Subthalamic Nucleus Receiving Hyperdirect (M1/SMA) Input in Subjects With Early-Stage Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Mallory Hacker
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20221223
    </Date_registration3>
    <Date_registration>23/12/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06008717
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>50 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 1, 2025
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. A clinical diagnosis of idiopathic Parkinson's disease (PD). The diagnosis will be&#x0D;&lt;br&gt;             based upon the presence of at least two of the three cardinal motor signs of this&#x0D;&lt;br&gt;             disorder (akinesia/bradykinesia, rest tremor, and rigidity) with at least one of the&#x0D;&lt;br&gt;             signs being rest tremor or bradykinesia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Clear and dramatic beneficial response to dopaminergic therapy, defined as =30% in&#x0D;&lt;br&gt;             UPDRS III with administration of the patient's medication during the screening&#x0D;&lt;br&gt;             neurological examination.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Hoehn and Yahr (H&amp;Y) stage II when OFF medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. No contraindications to surgery (i.e., subject does not have uncontrollable medical or&#x0D;&lt;br&gt;             psychiatric illness; Exclusion Criteria).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Age between 50 and 75 years old.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Dopaminergic therapy for greater than one year and less than four years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Available for follow-up for the entire duration of the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Informed Consent (Appendix C): The subject is willing and able to provide written&#x0D;&lt;br&gt;             informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. MRI within normal range (Exclusion Criteria).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Subjects receiving antidepressant medication used specifically for the treatment of&#x0D;&lt;br&gt;             depression must be on stable doses for at least eight weeks prior to enrolling in the&#x0D;&lt;br&gt;             study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Subjects must agree to maintain a stable regimen, if deemed medically appropriate by&#x0D;&lt;br&gt;             the treating physician, of any psychotropic medications throughout the blinded&#x0D;&lt;br&gt;             treatment phase.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Evidence of an alternative diagnosis or secondary parkinsonism, as suggested by:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Features unusual early in the clinical course (e.g., prominent postural&#x0D;&lt;br&gt;                  instability, freezing phenomena, or hallucinations unrelated to medications in&#x0D;&lt;br&gt;                  the first 3 years after symptom onset)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Dementia preceding motor symptoms&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Neurologic signs of upper motor neuron or cerebellar involvement&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Significant orthostatic hypotension unrelated to medications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Unequivocal cortical sensory loss (i.e., graphesthesia, sterognosis with intact&#x0D;&lt;br&gt;                  primary sensory modalities), clear limb ideomotor apraxia, or progressive aphasia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Vertical supranuclear gaze palsy, or selective slowing of vertical saccades&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Unequivocal cerebellar abnormalities on examination, such as cerebellar gait,&#x0D;&lt;br&gt;                  limb ataxia, or cerebellar oculomotor abnormalities (e.g., sustained gaze-evoked&#x0D;&lt;br&gt;                  nystagmus, macro square wave jerks, hypermetric saccades)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Documentation of a condition known to produce parkinsonism and plausibly&#x0D;&lt;br&gt;                  connected to the subject's symptoms (e.g., MRI scan with evidence of significant&#x0D;&lt;br&gt;                  brain atrophy, lacunar infarcts, or iron deposits in the putamen; history of&#x0D;&lt;br&gt;                  stroke, exposure to toxins, or encephalitis; or neuroleptic use within the past 6&#x0D;&lt;br&gt;                  months)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  The expert evaluating physician, based on the full diagnostic assessment,&#x0D;&lt;br&gt;                  believes that an alternative syndrome is more likely than PD.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Uncontrolled medical condition or clinically significant medical disease that would&#x0D;&lt;br&gt;             increase the risk of developing pre- or postoperative complications (e.g., significant&#x0D;&lt;br&gt;             cardiac or pulmonary disease, uncontrolled hypertension).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Dementia as evidenced by a Dementia Rating Score of less than 123.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Diagnosis of probable behavioral variant frontotemporal dementia or primary&#x0D;&lt;br&gt;             progressive aphasia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Currently active diagnosis of a major psychiatric disorder.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Previous brain operation or injury.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Active participation in another clinical trial for the treatment of PD.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Subjects with cardiac pacemakers or medical conditions that require repeat MRI scans.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Evidence of existing dyskinesia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Any current substance use disorder.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Any history of recurrent or unprovoked seizures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Any prior movement disorder treatments that involved intracranial surgery or device&#x0D;&lt;br&gt;             implantation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Any other active implanted intracranial device (e.g., cochlear implant) or implanted&#x0D;&lt;br&gt;             device to treat movement disorders (e.g., duodopa pump) whether turned on or off.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. A condition requiring or likely to require the use of magnetic resonance imaging (MRI)&#x0D;&lt;br&gt;             or diathermy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         15. History of suicide attempt.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         16. A female who is breastfeeding or of child-bearing potential with a positive urine&#x0D;&lt;br&gt;             pregnancy test or not using adequate contraception.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         17. Inability or unwillingness of subject to give written informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         18. Parkinsonian features restricted to the lower limbs for more than three years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         19. Treatment with a dopamine receptor blocker or a dopamine-depleting agent in a dose and&#x0D;&lt;br&gt;             time course consistent with drug-induced parkinsonism.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         20. Normal functional neuroimaging of the presynaptic dopaminergic system, as measured by&#x0D;&lt;br&gt;             DaTSCAN.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         21. Rapid progression of gait impairment requiring regular use of a wheelchair.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         22. Early bulbar dysfunction, defined as one of severe dysphonia, dysarthria (speech&#x0D;&lt;br&gt;             unintelligible most of the time), or dysphagia (requiring soft food, nasogastric (NG)&#x0D;&lt;br&gt;             tube, or gastrostomy feeding).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         23. Inspiratory respiratory dysfunction defined as either diurnal or nocturnal inspiratory&#x0D;&lt;br&gt;             stridor or frequent inspiratory sighs.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         24. Recurrent (&gt;1/year) falls because of impaired balance within 3 years of onset.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         25. Otherwise unexplained pyramidal tract signs, defined as pyramidal weakness or clear&#x0D;&lt;br&gt;             pathologic hyperreflexia (excluding mild reflex asymmetry in the more affected limb&#x0D;&lt;br&gt;             and isolated extensor plantar response).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         26. Bilateral symmetric parkinsonism throughout the disease course. The patient or&#x0D;&lt;br&gt;             caregiver reports bilateral symptom onset with no side predominance, and no side&#x0D;&lt;br&gt;             predominance is observed on objective examination.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: active subthalamic nucleus deep brain stimulation plus optimal drug therapy;Device: inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy
    </Intervention>
    <Primary_outcome>frequency and severity of adverse events;frequency and severity of adverse cognitive outcome
    </Primary_outcome>
    <Secondary_outcome>Stopped or Reversed Motor Progression
    </Secondary_outcome>
    <Secondary_ID>G220314
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13735780
    </Internal_Number>
    <TrialID>NL-OMON53065
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>Randomized trial comparing steered Deep Brain Stimulation with ring-shaped Deep Brain Stimulation for advanced Parkinson*s disease
    </Public_title>
    <Scientific_title>Randomized trial comparing steered Deep Brain Stimulation with ring-shaped Deep Brain Stimulation for advanced Parkinson*s disease - STEEred vs RING-mode DBS for Parkinson*s disease (STEERING) trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>Academisch Medisch Centrum
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20221216
    </Date_registration3>
    <Date_registration>2022-12-16
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/53065
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>64
    </Inclusion_agemax>
    <Inclusion_gender/>
    <Date_enrollement>2017-12-13
    </Date_enrollement>
    <Target_size>96
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized  controlled trial, Double blinded (masking used), Active, Crossover, Treatment
    </Study_design>
    <Phase>4
    </Phase>
    <Countries>Germany;Netherlands
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address>Meibergdreef 9
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Academisch Medisch Centrum
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;p&gt;Age &gt;= 18 years&lt;br&gt;bilaterally implanted with the Boston Scientific or Medtronic system in the STN &lt;br&gt;for idiopathic Parkinson*s Disease at least 6 months previous to study &lt;br&gt;enrollment&lt;br&gt;the optimal ring-mode stimulation setting has been found for the patient: &lt;br&gt;changing settings will either (a) not improve the motor scores or (b) cause &lt;br&gt;stimulation-induced side-effects&lt;br&gt;Patients who have received this system by participating in the GALAXY-trial can &lt;br&gt;only be randomized after completion of the GALAXY trial.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;p&gt;no adequate stimulation response in ring-mode on one of the steerable levels &lt;br&gt;(second and third contact point on each lead)&lt;br&gt;Legally incompetent adults&lt;br&gt;Active psychosis&lt;br&gt;No written informed consent&lt;/p&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Parkinson &lt;br&gt;Parkinson's disease;10028037;Parkinson;Parkinson's disease
    </Condition>
    <Intervention>&lt;p&gt;After a period of searching for the optimal steered mode settings, patients &lt;br&gt;will be randomized and blindly receive two different programming forms of DBS &lt;br&gt;stimulation: ring mode and steered mode during two consecutive periods of two &lt;br&gt;months each. The patient, the assessor and the investigator performing the &lt;br&gt;statistical analyses will be blind to the order in which the two settings are &lt;br&gt;administered. The patient*s physician may be unblinded if stimulation-related &lt;br&gt;problems occur.&lt;/p&gt;&lt;br&gt;;Deep Brain Stimulation;Parkinson Disease;steering
    </Intervention>
    <Primary_outcome>&lt;p&gt;The primary outcome measure is a score of motor symptoms in daily living as&lt;br /&gt;&lt;br&gt;expressed in the Movement Disorders Society Unified Parkinson Disease Rating&lt;br /&gt;&lt;br&gt;(MDS-UPDRS) motor evaluation in standardized OFF-drug phase. This score is&lt;br /&gt;&lt;br&gt;measured in the total of all patients included, the subgroup of patients whose&lt;br /&gt;&lt;br&gt;ring-mode stimulation has yielded a suboptimal effect (as evaluated by the&lt;br /&gt;&lt;br&gt;patients* physician) and the subgroup of patients whose ring-mode stimulation&lt;br /&gt;&lt;br&gt;has yielded a good effect (as evaluated by the patients* physician).The&lt;br /&gt;&lt;br&gt;combined subgroups form the total of all included patients. &lt;/p&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>&lt;p&gt;Secondary outcome consists of symptom scales, percentage of patients with great&lt;br /&gt;&#x0D;&lt;br&gt;symptom improvement (an MDS-UPDRS score in OFF-phase of 30% or greater), used&lt;br /&gt;&#x0D;&lt;br&gt;stimulation settings, medication use, stimulation-induced side-effects,&lt;br /&gt;&#x0D;&lt;br&gt;activities of daily living scales and a quality of life questionnaire. At the&lt;br /&gt;&#x0D;&lt;br&gt;end of the trial, patients will be asked to choose between the two used&lt;br /&gt;&#x0D;&lt;br&gt;programs to evaluate, which one was perceived as the best. A sub-analysis will&lt;br /&gt;&#x0D;&lt;br&gt;be performed to evaluate whether good DBS responders and suboptimal DBS&lt;br /&gt;&#x0D;&lt;br&gt;responders score differently on primary and secondary endpoints.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>NL61838.018.17
    </Secondary_ID>
    <Source_Support>Ministerie van OC&amp;W
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Not available
    </Ethics_review_status>
    <Ethics_review_approval_date>25/08/2017;14/12/2022;21/12/2022
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>;&lt;p&gt;Kamer G4-214&lt;br /&gt;&#x0D;
Postbus 22660&lt;br /&gt;&#x0D;
1100 DD Amsterdam&lt;br /&gt;&#x0D;
020 566 7389&lt;br /&gt;&#x0D;
mecamc@amsterdamumc.nl&lt;/p&gt;&#x0D;
;&lt;p&gt;Kamer G4-214&lt;br /&gt;&#x0D;
Postbus 22660&lt;br /&gt;&#x0D;
1100 DD Amsterdam&lt;br /&gt;&#x0D;
020 566 7389&lt;br /&gt;&#x0D;
mecamc@amsterdamumc.nl&lt;/p&gt;&#x0D;

    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13734506
    </Internal_Number>
    <TrialID>NL-OMON51791
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>AI-DBS: Applying Personalized Deep Brain Stimulation using *Neuronal Fingerprints*
    </Public_title>
    <Scientific_title>AI-DBS: Applying Personalized Deep Brain Stimulation using *Neuronal Fingerprints* - AI-DBS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>Amsterdam UMC
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220818
    </Date_registration3>
    <Date_registration>2022-08-18
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/51791
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>64
    </Inclusion_agemax>
    <Inclusion_gender/>
    <Date_enrollement>2022-09-26
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Observational non invasive
    </Study_type>
    <Study_design>Open (masking not used), Uncontrolled, Basic science
    </Study_design>
    <Phase/>
    <Countries>The Netherlands
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address>Meibergdreef   9
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Amsterdam UMC
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;p&gt;- Age 18 years or older&lt;br&gt;- Diagnosed with Parkinson's Disease and eligible for DSB&lt;br&gt;- Parkinson's Disease patients receiving Medtronic PerceptTM PC STN DBS in the &lt;br&gt;care as usual setting between &lt;/p&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;p&gt;- Inability to provide informed consent&lt;/p&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Parkinson Disease &lt;br&gt;shaking;10028037;Parkinson Disease;shaking
    </Condition>
    <Intervention>&lt;p&gt;&lt;/p&gt;&lt;br&gt;;Artificial Intelligence;Deep Brain Stimulation;Neuronal Fingerprints;Parkinson's Disease
    </Intervention>
    <Primary_outcome>&lt;p&gt;The development of a patient specific profile of neuronal activity that is&lt;br /&gt;&lt;br&gt;associated with the presence and severity of the symptoms, forming a *neuronal&lt;br /&gt;&lt;br&gt;fingerprint*. &lt;/p&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>&lt;p&gt;N\A&lt;/p&gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>NL80384.018.22
    </Secondary_ID>
    <Source_Support>Medtronic;Ministerie van Economische Zaken en Klimaat;Medtronic en Rune Labs;Rune Labs
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>15/08/2022
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13051786
    </Internal_Number>
    <TrialID>NCT05506085
    </TrialID>
    <Last_Refreshed_on>15 May 2023
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation for Laryngeal Dystonia: From Mechanism to Optimal Application
    </Public_title>
    <Scientific_title>Deep Brain Stimulation for Laryngeal Dystonia: From Mechanism to Optimal Application
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Indiana University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220719
    </Date_registration3>
    <Date_registration>19/07/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05506085
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 1, 2022
    </Date_enrollement>
    <Target_size>12
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Rita Patel, PhD;S. Elizabeth Zauber, MD;Kunal Gupta, MD, PhD;Rita Patel, PhD;Rita Patel, PhD
    </Contact_Lastname>
    <Contact_Email>;;;patelrir@iu.edu;patelrir@iu.edu
    </Contact_Email>
    <Contact_Tel>;;;8128553886;812-855-3886
    </Contact_Tel>
    <Contact_Affiliation>Indiana University;Indiana University;Indiana University;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with ADLD and ADLD plus tremor, as diagnosed by routine clinical examination&#x0D;&lt;br&gt;             by laryngologist, speech language pathologist, and neurologist.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients undergoing globus pallidus interna (GPi) deep brain stimulation (DBS) for&#x0D;&lt;br&gt;             ADLD with tremor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age range of 18-80 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Native speakers of American English will be recruited since there are known&#x0D;&lt;br&gt;             differences in voice and neural signals of native and non-native speakers&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No evidence for dementia as assessed by neurologist.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No evidence for severe untreated mood disorder as assessed by neurologist, or as&#x0D;&lt;br&gt;             evident on self-report (Beck Depression Inventory-II score &gt; 29, Beck Anxiety&#x0D;&lt;br&gt;             Inventory Score &gt; 26.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  At least 3 months since last botulinum toxin injection and the patients would need to&#x0D;&lt;br&gt;             be fully symptomatic with no residual effects of botulinum toxin on voice quality.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals younger than 18 years and older than 80 years of age.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women who plan to become pregnant during the study period or are currently&#x0D;&lt;br&gt;             breastfeeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Prior history of stroke, brain surgery, or other neurological disorder besides the one&#x0D;&lt;br&gt;             under study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Prior laryngeal framework surgeries or other disorders affecting the vocal folds&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who are asymptomatic due to treatment with botulinum toxin into the vocal&#x0D;&lt;br&gt;             folds.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of ferromagnetic implants and cardiac implants that would be contraindicated&#x0D;&lt;br&gt;             to MRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Gagging or discomfort that would preclude the placement of the endoscope to visualize&#x0D;&lt;br&gt;             the larynx&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia, severe depression or severe anxiety.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any clinical condition or medication judged by the investigators to potentially&#x0D;&lt;br&gt;             preclude the patient from safely completing awake brain surgery and research&#x0D;&lt;br&gt;             protocols.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Laryngeal Dystonia;Adductor Spastic Dysphonia of Dystonia
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Change in total number of Vocal fold movements;Change in Acoustic voice recordings;Microelectrode recording
    </Primary_outcome>
    <Secondary_outcome>Change in Neuropsychological testing: Trails A;Change in Neuropsychological testin: Trails B;Change in Neuropsychological testing: Controlled Oral Word Association Animal fluency;Change in Resting state Functional Magnetic Resonance Imaging (fMRI);Change in Voice Handicap Index;Change in Speech Intelligibility
    </Secondary_outcome>
    <Secondary_ID>14578
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institutes of Health (NIH)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13203379
    </Internal_Number>
    <TrialID>NCT05795218
    </TrialID>
    <Last_Refreshed_on>2 August 2023
    </Last_Refreshed_on>
    <Public_title>directSTIM™ Deep Brain Stimulation System Post-Market Clinical Follow-up Study on Essential Tremor
    </Public_title>
    <Scientific_title>A Prospective, Multi-center, Single Arm, Observational, Post-market Clinical Follow-up Study on the Use of the directSTIM™ Deep Brain Stimulation System to Treat Essential Tremor
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Aleva Neurotherapeutics SA
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220705
    </Date_registration3>
    <Date_registration>05/07/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05795218
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2023
    </Date_enrollement>
    <Target_size>21
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Alain Dransart;Alain Dransart
    </Contact_Lastname>
    <Contact_Email>;clinical@aleva-neuro.com
    </Contact_Email>
    <Contact_Tel>;+4121 353 8764
    </Contact_Tel>
    <Contact_Affiliation>Aleva Neurotherapeutics SA;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is 18 years of age or older.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient with main tremor symptoms in upper limbs.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient was referred for DBS surgery to treat Essential Tremor and chose the&#x0D;&lt;br&gt;             directSTIM DBS System&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has a postural or kinetic tremor severity score of at least 3 out of 4 in the&#x0D;&lt;br&gt;             extremity intended for treatment on the Fahn-Tolosa-Marin Clinical Rating Scale for&#x0D;&lt;br&gt;             Tremor with medication, for the worst limb (i.e. most affected by disease)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient accepts to abstain from caffeine for 8 hours and from alcohol for 12 hours&#x0D;&lt;br&gt;             before visit.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient accepts to turn stimulation off for 1 hour prior to the 3-month follow-up&#x0D;&lt;br&gt;             visit.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is willing to provide a written informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is available for the study visit, and other study requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment, or any characteristic that would limit study candidate's ability&#x0D;&lt;br&gt;             to complete study assessments, such as:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Active major psychiatric disorder (including clinically significant depression as&#x0D;&lt;br&gt;                  rated by the clinician)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Patient had dementia interfering with their ability to co-operate or comply with&#x0D;&lt;br&gt;                  study requirements or comprehend the informed consent (mini-mental exam score &lt;24&#x0D;&lt;br&gt;                  or otherwise not capable of discernment)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Presence of an electrical or electromagnetic implant (e.g. cochlear implant,&#x0D;&lt;br&gt;                  pacemaker)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Previous brain ablation/surgical procedure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Neurological injury, evidence of supraspinal central nervous system disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  History of seizures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Diathermy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Abuse of drugs or alcohol.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient had botulinum toxin injection less than 6 months prior to enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is participating in another clinical study that would confound data analysis.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Change in the motor performance subscale of the Fahn Tolosa Marin Essential Tremor Rating Scale (FTM ETRS) score of target limb
    </Primary_outcome>
    <Secondary_outcome>Proportions of Adverse Events and Device Deficiencies observed;Change in total motor score on the Fahn Tolosa Marin Essential Tremor Rating Scale
    </Secondary_outcome>
    <Secondary_ID>CLI-12082
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13735157
    </Internal_Number>
    <TrialID>NL-OMON52442
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>Registry of Deep Brain Stimulation with the VERCISE(TM) System for treatment of Dystonia
    </Public_title>
    <Scientific_title>Registry of Deep Brain Stimulation with the VERCISE(TM) System for treatment of Dystonia - Vercise DBS Dystonia Registry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Boston Scientific International BV
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220701
    </Date_registration3>
    <Date_registration>2022-07-01
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/52442
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>64
    </Inclusion_agemax>
    <Inclusion_gender/>
    <Date_enrollement>2021-05-03
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Observational non invasive
    </Study_type>
    <Study_design>Open (masking not used), Uncontrolled, Treatment
    </Study_design>
    <Phase/>
    <Countries>Belgium;Germany;Hungary;Italy;Korea (the Republic of);Netherlands;Poland;Russian Federation ;Spain;United Kingdom
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address>Vestastraat 6
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Boston Scientific International BV
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;p&gt;-Subject meets criteria established in the locally applicable VERCISE System &lt;br&gt;Directions for Use (DFU) for dystonia&lt;br&gt;-Subject is at least 7 years old. Parent or guardian consent is required in &lt;br&gt;patients who are younger than 18 years at the time of consent&lt;/p&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;p&gt;Subject meets any contraindication in the VERCISE System locally applicable &lt;br&gt;Directions for Use&lt;/p&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Dystonia &lt;br&gt;movement disorder;10028037;10009720;Dystonia;movement disorder
    </Condition>
    <Intervention>&lt;p&gt;&lt;/p&gt;&lt;br&gt;;Deep Brain Stimulation;Dystonia;Registry
    </Intervention>
    <Primary_outcome>&lt;p&gt;Clinical endpoints:&lt;br /&gt;&lt;br&gt;The following clinical endpoints will be analyzed for each sub-group of&lt;br /&gt;&lt;br&gt;dystonia separately (Primary vs. Secondary):&lt;br /&gt;&lt;br&gt;• Proportion of subjects with 30% or greater reduction in Baseline BFMDRS or&lt;br /&gt;&lt;br&gt;TWSTRS score at 26 weeks, 52 weeks, 2 years, and 3 years post first lead&lt;br /&gt;&lt;br&gt;placement&lt;br /&gt;&lt;br&gt;• Change in BFMDRS scores from Baseline to 26 weeks, 52 weeks, 2 years, and 3&lt;br /&gt;&lt;br&gt;years post first lead placement&lt;br /&gt;&lt;br&gt;• Change in TWSTRS scores from Baseline to 26 weeks, 52 weeks, 2 years, and 3&lt;br /&gt;&lt;br&gt;years post first lead placement&lt;br /&gt;&lt;br&gt;• Change in SF-36v2 score (SF-10v2 in patients under the age of 18 years at the&lt;br /&gt;&lt;br&gt;time of consent) from Baseline to 26 weeks, 52 weeks, 2 years, and 3 years post&lt;br /&gt;&lt;br&gt;first lead placement&lt;br /&gt;&lt;br&gt;• Change in GDS scores from Baseline to 26 weeks, 52 weeks, 2 years, and 3&lt;br /&gt;&lt;br&gt;years post first lead placement&lt;br /&gt;&lt;br&gt;• Clinical Global Impression of Change (CGI-C) rating score, as assessed by&lt;br /&gt;&lt;br&gt;neurologist, at 26 weeks, 52 weeks, 2 years, and 3 years post first lead&lt;br /&gt;&lt;br&gt;placement&lt;br /&gt;&lt;br&gt;• Clinical Global Impression of Change - Subject (CGI-C: Sub), as assessed by&lt;br /&gt;&lt;br&gt;subject, at 26 weeks, 52 weeks, 2 years, and 3 years post first lead placement&lt;br /&gt;&lt;br&gt;• Clinical Global Impression of Change - Caregiver (CGI-C: Crg), as assessed by&lt;br /&gt;&lt;br&gt;caregiver, at 26 weeks, 52 weeks, 2 years, and 3 years post first lead&lt;br /&gt;&lt;br&gt;placement&lt;/p&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>&lt;p&gt;Safety parameters:&lt;br /&gt;&#x0D;&lt;br&gt;Rates of occurrence of all serious adverse events (SAEs) and all adverse device&lt;br /&gt;&#x0D;&lt;br&gt;effects (ADEs), including serious adverse device effects (SADEs) and&lt;br /&gt;&#x0D;&lt;br&gt;unanticipated serious adverse device effects (USADEs) at 3 years post first&lt;br /&gt;&#x0D;&lt;br&gt;lead placement&lt;br /&gt;&#x0D;&lt;br&gt;&lt;br /&gt;&#x0D;&lt;br&gt;Heatlh economics endpoints:&lt;br /&gt;&#x0D;&lt;br&gt;• Total cost of treatment and resource utilization from Baseline through end of&lt;br /&gt;&#x0D;&lt;br&gt;study (RUI)&lt;br /&gt;&#x0D;&lt;br&gt;• Change in economic value from Baseline to 26 weeks, 52 weeks, 2 years and 3&lt;br /&gt;&#x0D;&lt;br&gt;years post first lead placement&lt;/p&gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>NCT02686125;NL70665.058.19
    </Secondary_ID>
    <Source_Support>Bedrijven
    </Source_Support>
    <Ethics_review_status>Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>03/07/2020;01/07/2022
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>&lt;p&gt;metc-ldd@lumc.nl&lt;/p&gt;&#x0D;
;&lt;p&gt;metc-ldd@lumc.nl&lt;/p&gt;&#x0D;

    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13648400
    </Internal_Number>
    <TrialID>DRKS00029222
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Potsdam Dream Research Parkinson
    </Public_title>
    <Scientific_title>Potsdam Dream Research Parkinson - PotsDReam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    </Scientific_title>
    <Primary_sponsor>Ernst von Bergmann Klinikum
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220620
    </Date_registration3>
    <Date_registration>20/06/2022
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00029222
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>01/06/2022
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: other 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Holger
    </Contact_Firstname>
    <Contact_Lastname>Joswig
    </Contact_Lastname>
    <Contact_Address>Charlottenstr. 72
    </Contact_Address>
    <Contact_Email>holger.joswig@klinikumevb.de
    </Contact_Email>
    <Contact_Tel>+4933124137902
    </Contact_Tel>
    <Contact_Affiliation>Ernst von Bergmann Klinikum
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All consentable patients &gt; 18 years old with diagnosed Parkinson's disease, who either receive DBS or a Levodopa- / Apomorphin-pump and who are physically and psychologically able to document their dreams.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Excluded are all minors and non-consentable patients and those unable to document their dreams.
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: Deep brain stimulation (DBS) or Levodopa-/Apomorphin-pump-implantation
    </Intervention>
    <Primary_outcome>Dream content according to the Calvin S. Hall and Robert Van de Castle system
    </Primary_outcome>
    <Secondary_outcome>L-Dopa equivalent dose, disease burden using Hoehn and Yahr (H &amp; Y) scale, Unified Parkinson's Disease Rating Scale-I, II, III, IV (UPDRS) during on and off, Life quality using Short-Form 36 (SF-36), Parkinson’s Disease Questionnaire (PDQ-39), Self-efficacy, psychological well being using the Ardouin Scale of Behavior in Parkinson's Disease (ASBPD), Impulse control disorders using the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP-RS), Cognition using the Mattis Dementia Rating Scale (MDRS), Questions regarding Religiosity / Spirituality in addition to the Daily Spiritual Experience Scale (DSES).
    </Secondary_outcome>
    <Source_Support>Ernst von Bergmann Klinikum
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>17/05/2022
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ethik@laekb.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Landesärztekammer Brandenburg Ethikkommission
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-355-7801053
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ethik@laekb.de
    </Ethics_review_contact_email>
    <results_date_completed>27/10/2023
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00029222#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13585554
    </Internal_Number>
    <TrialID>NCT05416905
    </TrialID>
    <Last_Refreshed_on>19 December 2023
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation for Idiopathic Craniofacial Dystonia: GPi or STN
    </Public_title>
    <Scientific_title>Multicenter Evaluation of Deep Brain Stimulation for Idiopathic Craniofacial Dystonia: Globus Pallidus intErnus or Subthalamic Nucleus
    </Scientific_title>
    <Acronym>MEIGES
    </Acronym>
    <Primary_sponsor>Beijing Tiantan Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220609
    </Date_registration3>
    <Date_registration>09/06/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05416905
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 22, 2022
    </Date_enrollement>
    <Target_size>110
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Jianguo Zhang, MD, PhD;Yutong Bai, MD, PhD;Jianguo Zhang, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;baiyutong88@qq.com;zjguo73@126.com
    </Contact_Email>
    <Contact_Tel>;13611420134;+86-13601294613
    </Contact_Tel>
    <Contact_Affiliation>Beijing Tiantan Hospital;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Adult subject (male or female, 18-75 years);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Diagnosed with idiopathic craniofacial dystonia for more than 1 year, including at&#x0D;&lt;br&gt;             least one of the eye and oromandibular region. Cervical dystonia may be present;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Treated with oral drugs or botulinum toxin injections, but with no satisfactory&#x0D;&lt;br&gt;             curative effect;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Normal cognitive function with MMSE score = 24;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Informed consent signed.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Only cervical dystonia, or combined with dystonia in other parts of the body other&#x0D;&lt;br&gt;             than the cervical region;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Diagnosed with other neuropsychiatric diseases(Alzheimer's disease, amyotrophic&#x0D;&lt;br&gt;             lateral sclerosis, Parkinson's disease, etc.);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. History of brain surgery;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Severe depression with HRSD score = 35;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Contraindications to neurosurgery(cerebral infarction, hydrocephalus, cerebral&#x0D;&lt;br&gt;             atrophy, sequelae of cerebrovascular disease, etc);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Contraindications to CT or MRI scanning(claustrophobia, etc);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. pregnant or breastfeeding female, or has positive pregnancy test prior to&#x0D;&lt;br&gt;             randomization;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Contraindications to general anesthesia (severe arrhythmia, severe anemia, abnormal&#x0D;&lt;br&gt;             liver and kidney function, etc.);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Expected lifetime &lt; 12 months;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Currently receiving an investigational drug or device;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Other circumstances that the investigator considers unsuitable to participate in this&#x0D;&lt;br&gt;             study or that may pose a significant risk to the patient (inability to understand or&#x0D;&lt;br&gt;             comply with research procedures and follow-up, etc.).&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Craniofacial Dystonia;Deep Brain Stimulation
    </Condition>
    <Intervention>Device: STN-DBS;Device: GPi-DBS
    </Intervention>
    <Primary_outcome>Burke-Fahn-Marsden dystonia rating scale-motor score (BFMDRS-M) difference Day 365
    </Primary_outcome>
    <Secondary_outcome>Blepharospasm disability index (BDSI) difference;Jankovic rating scale (JRS) difference;Mini-mental state examination (MMSE) difference;Montreal cognitive assessment (MoCA) difference;Hamilton depression scale (HRSD) difference;Hamilton anxiety scale (HAMA) difference;Medical outcomes study shortform-36 (SF-36) difference;Programming parameters difference;Burke-Fahn-Marsden dystonia rating scale-motor score (BFMDRS-M) difference Day 90;Burke-Fahn-Marsden dystonia rating scale-motor score (BFMDRS-M) difference Day 180;Burke-Fahn-Marsden dystonia rating scale-disability score (BFMDRS-D) difference
    </Secondary_outcome>
    <Secondary_ID>HX-A-2022022
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Peking Union Medical College Hospital;Peking University People's Hospital;Civil Aviation General Hospital;Chinese PLA General Hospital;Beijing Pins Medical Co., Ltd
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13648302
    </Internal_Number>
    <TrialID>DRKS00029073
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Electrophysiological characterization of neuronal networks in tic patients with deep brain stimulation
    </Public_title>
    <Scientific_title>Electrophysiological characterization of neuronal networks in tic patients with deep brain stimulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>Klinik für Stereotaxie und Funktionelle Neurochirurgie, Klinikum der Universität zu Köln
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220527
    </Date_registration3>
    <Date_registration>27/05/2022
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00029073
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>25/05/2022
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Randomized controlled study; Masking: Open (masking not used); Control: No treatment / Standard of care; Assignment: crossover; Study design purpose: basic science  
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Thomas
    </Contact_Firstname>
    <Contact_Lastname>Schüller
    </Contact_Lastname>
    <Contact_Address>Kerpener Straße 62
    </Contact_Address>
    <Contact_Email>thomas.schueller@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>0221 478 98844
    </Contact_Tel>
    <Contact_Affiliation>Klinik für Psychiatrie und Psychotherapie, Klinikum der Universität zu Köln
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: - Fluent in the German language&lt;br&gt;- Age 18 to 65 years&lt;br&gt;- Chronic motor tic disorder (F95.1) or chronic motor and vocal tic disorder (F95.2) as main diagnosis according to the International Classification of Diseases 10 (ICD 10)&lt;br&gt;- Deep brain stimulation (Percept PC Neurostimulator)
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: - Active suicidal ideation &lt;br&gt;- Current psychotic symptomatology&lt;br&gt;- Active or recent substance abuse (except intake of cannabis-based substances, if consumed for treatment of tics)&lt;br&gt;- Serious systemic medical disease &lt;br&gt;- Severe neurological disorder of the central nervous system such as stroke, epilepsy, neoplasia&lt;br&gt;- Mental retardation&lt;br&gt;- Withdrawal of consent
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;F95.1 &lt;br&gt;F95.2;Chronic motor or vocal tic disorder;Combined vocal and multiple motor tic disorder [de la Tourette];F95.1;F95.2
    </Condition>
    <Intervention>Group 1: Arm 1: Patients with tic disorder will be interviewed once and asked to perform computerized tasks with Deep Brain Stimulation turned on.&lt;br&gt;&lt;br&gt;The following assessments will be performed:&lt;br&gt;1) Carious questionnaires to assess the severity of Tourette's disorder and other psychological symptoms.&lt;br&gt;2) Application of the electroencephalographic (EEG) cap. During the computerized tasks EEG is used to measure brain activity.&lt;br&gt;3) Infrared 3-D scanner is used to localize the exact position of the EEG electrodes.&lt;br&gt;4) Patients are asked to indicate the urge before the tic. This will take place in six blocks of five minutes each, during which the tics will be freely performed or the tics will be suppressed as best as possible. Video will be recorded during this task. In addition, adhesive electrodes will be attached to the muscles of the most common tics.&lt;br&gt;5) Finger-tapping task: This is a computerized task with two different conditions. In one condition, patients are asked to press in the direction of a presented arrow with the corresponding left or right finger. In a second condition, patients are asked to decide for themselves whether to press with the left or right finger within a period of four to eight seconds.&lt;br&gt;Group 2: Arm 2: Patients with tic disorder will be interviewed once and asked to perform computerized tasks with Deep Brain Stimulation turned off.&lt;br&gt;&lt;br&gt;The following assessments will be performed:&lt;br&gt;1) Carious questionnaires to assess the severity of Tourette's disorder and other psychological symptoms.&lt;br&gt;2) Application of the electroencephalographic (EEG) cap. During the computerized tasks EEG is used to measure brain activity.&lt;br&gt;3) Infrared 3-D scanner is used to localize the exact position of the EEG electrodes.&lt;br&gt;4) Patients are asked to indicate the urge before the tic. Th
    </Intervention>
    <Primary_outcome>1) Urge correlated connectivity between cortical areas (SMA, PFC, ACC) and the DBS target in the theta (4-8 Hz) and beta (15-30 Hz) frequency bands.
    </Primary_outcome>
    <Secondary_outcome>2) Movement planning and movement execution-correlated connectivity between cortical areas (SMA, PFC) and DBS target in the delta (1-4 Hz) and theta (4-8 Hz) frequency band.&lt;br&gt;3) Connectivity between cortical areas (SMA, PFC, ACC) and DBS target in the delta (1-4 Hz), theta (4-8 Hz), alpha (8-12 Hz), and beta (15-30 Hz) frequency bands at rest.&lt;br&gt;4) Modulation of connectivity profiles in 1., 2., &amp; 3. by THS.
    </Secondary_outcome>
    <Source_Support>Deutsche Forschungsgemeinschaft
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>13/12/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00029073#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12784015
    </Internal_Number>
    <TrialID>NCT05397340
    </TrialID>
    <Last_Refreshed_on>30 January 2023
    </Last_Refreshed_on>
    <Public_title>Asymmetric Targeted DBS for PD With PIGD
    </Public_title>
    <Scientific_title>Deep Brain Stimulation of Asymmetric Targets Versus Bilateral Subthalamic Nucleus (STN) for Parkinson's Disease With Postural Instability/Gait Difficulty: a Prospective, Randomized, Double-blinded Trial
    </Scientific_title>
    <Acronym>ATS-PIGD
    </Acronym>
    <Primary_sponsor>Ruijin Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220518
    </Date_registration3>
    <Date_registration>18/05/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05397340
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 1, 2022
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Dianyou Li, MD, PhD;Dianyou Li, MD, PhD;Dianyou Li, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;ldy11483@rjh.com.cn;ldy11483@rjh.com.cn
    </Contact_Email>
    <Contact_Tel>;+0086-021-64370045;
    </Contact_Tel>
    <Contact_Affiliation>Ruijin Hospital;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosis of idiopathic Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  postural instability/gait difficulty (PIGD) phenotypes in the on-medication condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Atypical parkinsonism&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of stroke, encephalitis, neuroleptic uses, MRI scan with evidence of&#x0D;&lt;br&gt;             significant brain atrophy, lacunar infracts, or other conditions that might interfere&#x0D;&lt;br&gt;             with intracranial surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of cognitive, or psychiatric or other co-morbidities (e.g., dementia,&#x0D;&lt;br&gt;             epilepsy, cranial traumatism, brain tumor, schizophrenia, severe depression or bipolar&#x0D;&lt;br&gt;             disorder, personality disorder, etc.) that might interfere with the patient's ability&#x0D;&lt;br&gt;             to complete the evaluations or to provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of anatomical abnormalities in the target region&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical history that would increase pre-/post-operative&#x0D;&lt;br&gt;             complications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other conditions considered by the investigators that might interfere with the surgery&#x0D;&lt;br&gt;             procedure, the follow-ups, and the interpretation of the data&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Deep brain stimulation
    </Intervention>
    <Primary_outcome>Change from Baseline in the Movement Disorder Society-sponsord Unified Parkinson's Disease Rating Scale Part III at 12 months;Change from Baseline in balance ability on the Burg Balance Scale (BBS) at 12 months;Change from Baseline in the number of freezing episodes on the Timed Up and Go test at 12 months
    </Primary_outcome>
    <Secondary_outcome>Change from Baseline in completion time on the Timed Up and Go test at 12 months;Change from Baseline in completion time on the Timed Up and Go test at 6 months;Change from Baseline in the number of steps on the Timed Up and Go test at 12 months;Change from Baseline in the number of steps on the Timed Up and Go test at 6 months;Change from Baseline in the Movement Disorder Society-sponsord Unified Parkinson's Disease Rating Scale Part III at 6 months;Change from Baseline in balance confidence on the Activities-Specific Balance Confidence Scale (ABC) at 12 months;Change from Baseline in balance confidence on the Activities-Specific Balance Confidence Scale (ABC) at 6 months;Change from Baseline in freezing of gait on the New Freezing of Gait Questionnaire (NFOG-Q) at 12 months;Change from Baseline in freezing of gait on the New Freezing of Gait Questionnaire (NFOG-Q) at 6 months;Change from Baseline in dysphagia severity on the Swallowing Disturbance Questionnaire (SDQ) at 12 months;Change from Baseline in dysphagia severity on the Swallowing Disturbance Questionnaire (SDQ) at 6 months;Change from Baseline in gait impairment on the Gait and Fall Questionnaire (GFQ) at 12 months;Change from Baseline in gait impairment on the Gait and Fall Questionnaire (GFQ) at 6 months;Change from Baseline in medication usage on the Levodopa Equivalent Daily Dose at 12 months;Change from Baseline in medication usage on the Levodopa Equivalent Daily Dose at 6 months;Change from Baseline in maximal phonatory time at 12 months;Change from Baseline in maximal phonatory time at 6 months;Change from Baseline in dysphonia severity index (DSI) at 12 months;Change from Baseline in dysphonia severity index (DSI) at 6 months;Change from Baseline in cognition on the Montreal Cognitive Assessment at 12 months;Change from Baseline in cognition on the Montreal Cognitive Assessment at 6 months;Adverse events;Change from Baseline in balance ability on the Burg Balance Scale (BBS) at 6 months;Change from Baseline in the number of freezing episodes on the Timed Up and Go test at 6 months
    </Secondary_outcome>
    <Secondary_ID>Asym Stim-PIGD
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12835117
    </Internal_Number>
    <TrialID>NCT05382858
    </TrialID>
    <Last_Refreshed_on>20 February 2023
    </Last_Refreshed_on>
    <Public_title>PSA Versus STN DBS for TD-PD
    </Public_title>
    <Scientific_title>Deep Brain Stimulation of the Posterior Subthalamic Area (PSA) Versus Subthalamic Nucleus (STN) for Tremor-dominant Parkinson's Disease: a Prospective, Randomized, Double-blinded, Cross-over Trial
    </Scientific_title>
    <Acronym>PSA-STN
    </Acronym>
    <Primary_sponsor>Ruijin Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220501
    </Date_registration3>
    <Date_registration>01/05/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05382858
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 1, 2022
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Dianyou Li, MD, PhD;Dianyou Li, MD, PhD;Dianyou Li, MD,PhD
    </Contact_Lastname>
    <Contact_Email>;ldy11483@rjh.com.cn;ldy11483@rjh.com.cn
    </Contact_Email>
    <Contact_Tel>;+0086-021-64370045;
    </Contact_Tel>
    <Contact_Affiliation>Ruijin Hospital;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosis of idiopathic Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  tremor-dominant subtype in the on-medication condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  modified Hoehn-Yahr scale of 2 to 4 in the on-medication condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  receiving regular anti-parkinsonian drugs for more than 6 weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  good compliance and written informed consent provided&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Atypical parkinsonism&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of stroke, encephalitis, neuroleptic uses, MRI scan with evidence of&#x0D;&lt;br&gt;             significant brain atrophy, lacunar infracts, or other conditions that might interfere&#x0D;&lt;br&gt;             with the intracranial surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of cognitive, or psychiatric or other co-morbidities (e.g., dementia,&#x0D;&lt;br&gt;             epilepsy, cranial traumatism, brain tumor, schizophrenia, severe depression or bipolar&#x0D;&lt;br&gt;             disorder, personality disorder, etc.) that might interfere with the patient's ability&#x0D;&lt;br&gt;             to complete the evaluations or to provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of anatomical abnormalities in the target region&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical history that would increase pre-/post-operative&#x0D;&lt;br&gt;             complications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other conditions considered by the investigators that might interfere with the surgery&#x0D;&lt;br&gt;             procedure, the follow-ups, and the interpretation of the data&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Deep brain stimulation
    </Intervention>
    <Primary_outcome>Change from baseline Movement Disorder Society-sponsord Unified Parkinson's Disease Rating Scale Part III at 4 months;Change from baseline Movement Disorder Society-sponsord Unified Parkinson's Disease Rating Scale Part III at 6 months
    </Primary_outcome>
    <Secondary_outcome>Change from baseline Berg balance scale to 4 months;Change from baseline Berg balance scale to 6 months;Change from baseline 39-item Parkinsons disease questionnaire to 4 months;Change from baseline 39-item Parkinsons disease questionnaire to 6 months;Change from baseline Levodopa equivalent daily dose to 4 months;Change from baseline Levodopa equivalent daily dose to 6 months;Change from baseline maximal phonatory time to 4 months;Change from baseline maximal phonatory time to 6 months;Change from baseline dysphonia severity index to 4 months;Change from baseline dysphonia severity index to 6 months;Change from baseline Mini-Mental Status Exam to 4 months;Change from baseline Mini-Mental Status Exam to 6 months;Change from baseline Beck depression inventory to 4 months;Change from baseline Beck depression inventory to 6 months;Adverse events;Change from baseline Timed up and go test to 6 months;Change from baseline Fahn-Tolosa-Marin Clinical Rating Scale for Tremor to 4 months;Change from baseline Fahn-Tolosa-Marin Clinical Rating Scale for Tremor to 6 months;Change from baseline Timed up and go test to 4 months
    </Secondary_outcome>
    <Secondary_ID>TDPSA
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Suzhou Sceneray Medical Co. , Ltd
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13648056
    </Internal_Number>
    <TrialID>DRKS00028703
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Extending the Data-Driven Characterization of Neural Markers During Deep Brain Stimulation for Patients with Parkinson’s Disease
    </Public_title>
    <Scientific_title>Extending the Data-Driven Characterization of Neural Markers During Deep Brain Stimulation for Patients with Parkinson’s Disease - PD-Interaktiv I                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum Freiburg
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220425
    </Date_registration3>
    <Date_registration>25/04/2022
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00028703
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>35 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>12/01/2023
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: N/A: single arm study; Masking: Open (masking not used); Control: uncontrolled; Assignment: single; Study design purpose: treatment 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Volker
    </Contact_Firstname>
    <Contact_Lastname>Coenen
    </Contact_Lastname>
    <Contact_Address>Breisacher Straße 64
    </Contact_Address>
    <Contact_Email>volker.coenen@uniklinik-freiburg.de
    </Contact_Email>
    <Contact_Tel>0761 270-50630
    </Contact_Tel>
    <Contact_Affiliation>Klinik für NeurochirurgieAbteilung für Stereotaktische und Funktionelle Neurochirurgie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1.Patients diagnosed with PD according to UK PDS Brain Bank Criteria.&#x0D;&lt;br&gt;2. Written informed consent.&#x0D;&lt;br&gt;3. Patients who are eligible for STN DBS surgery according to the guidelines of the DGN
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Contraindication for stereotactic neurosurgery or other surgery.&#x0D;&lt;br&gt;2. Dementia (Mattis Dementia Rating Score = 130).&#x0D;&lt;br&gt;3. Acute psychosis assessed by a psychiatric physician.&#x0D;&lt;br&gt;4. Inability to give written informed consent.&#x0D;&lt;br&gt;5. Medications that are likely to cause interactions in the opinion of the investigator.&#x0D;&lt;br&gt;6. Fertile women not using adequate contraceptive methods.&#x0D;&lt;br&gt;7. Current or planned pregnancy, nursing period.&#x0D;&lt;br&gt;8. Contraindication for undergoing MRI.&#x0D;&lt;br&gt;9. Contraindication for undergoing Diathermy (either shortwave, microwave, and/or&#x0D;&lt;br&gt;ultrasound diathermy).&#x0D;&lt;br&gt;10. Patient incapable to follow and perform the task instructions
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: Step 1: Implantation of DBS and ECoG electodes. 2nd step: Experimental measurements over 5 days. 3rd step: implantation of cables and generator for conventional continuous stimulation. Follow-up up to one year.
    </Intervention>
    <Primary_outcome>O1: Understanding the influence of previously applied stimulation patterns onto the&lt;br&gt;current motor performance.&lt;br&gt;O2: Detection and characterization of novel, potentially multivariate, neural markers.&lt;br&gt;O3: Investigation of neural markers derived from electrocorticogram signals.&lt;br&gt;O4: Characterization of alternative stimulation strategies.
    </Primary_outcome>
    <Secondary_outcome>O2: Detection and characterization of novel, potentially multivariate, neural markers for decoding of motor peformance. End-point: average performance difference (in r-values) between the subject-specific decoding models that incorporate EEG features and the STN LFPs model
    </Secondary_outcome>
    <Source_Support>Klinik für NeurochirurgieAbteilung für Stereotaktische und Funktionelle Neurochirurgie
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>10/03/2022
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-761-27072600
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00028703#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13398449
    </Internal_Number>
    <TrialID>NCT05348837
    </TrialID>
    <Last_Refreshed_on>16 October 2023
    </Last_Refreshed_on>
    <Public_title>Naturalistic Sleep Assessed by Wearable Devices in Parkinson Disease
    </Public_title>
    <Scientific_title>Naturalistic Sleep Assessed by Wearable Devices in Parkinson Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Colorado, Denver
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220421
    </Date_registration3>
    <Date_registration>21/04/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05348837
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 1, 2022
    </Date_enrollement>
    <Target_size>15
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Alexander Baumgartner, MD;Lisa Hirt;Pamela Gerecht, PhD
    </Contact_Lastname>
    <Contact_Email>;lisa.hirt@cuanschutz.edu;pamela.davidgerecht@cuanschutz.edu
    </Contact_Email>
    <Contact_Tel>;720-848-2080;303-724-4134
    </Contact_Tel>
    <Contact_Affiliation>University of Colorado - Anschutz Medical Campus;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Research subjects must be willing and able to do the following:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be able to learn to use and maintain a wristband-style sleep monitor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Wear a wristband-style sleep monitor for two weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be able to learn to use and maintain a headband sleep monitor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Wear a headband sleep monitor for two weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Log daily routine events, such sleeping, eating, and medication regimens for the&#x0D;&lt;br&gt;             two-week study period&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Withhold dopaminergic medications after 5:00pm for three consecutive nights&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Subjects will be excluded if they:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Carry a diagnosis of dementia (e.g., Parkinson's Disease Dementia or Dementia with&#x0D;&lt;br&gt;             Lewy Bodies)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently use or recently (within past 30 days) used a sedative-hypnotic agent for&#x0D;&lt;br&gt;             sleep (e.g., Zolpidem, Suvorexant, Eszopiclone)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fulfill criteria or carry a diagnosis of a circadian sleep-wake rhythm disorder, as&#x0D;&lt;br&gt;             defined by the International Classification of Sleep Disorders, Third Edition&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Procedure: Deep brain stimulation
    </Intervention>
    <Primary_outcome>Change in total sleep time (TST) as measured by polysomnogram-capable headband
    </Primary_outcome>
    <Secondary_outcome>Change in sleep efficiency (SE) as measured by polysomnogram-capable headband;Change in sleep onset latency (SOL) as measured by polysomnogram-capable headband;Change in wake after sleep onset (WASO) as measured by polysomnogram-capable headband;Change in total sleep time (TST) as measured by actigraphy;Change in sleep efficiency (SE) as measured by actigraphy;Change in sleep onset latency (SOL) as measured by actigraphy;Change in wake after sleep onset (WASO) as measured by actigraphy
    </Secondary_outcome>
    <Secondary_ID>22-0393
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12652905
    </Internal_Number>
    <TrialID>NCT05402163
    </TrialID>
    <Last_Refreshed_on>14 November 2022
    </Last_Refreshed_on>
    <Public_title>CANadian Adaptive DBS TriAl
    </Public_title>
    <Scientific_title>Adaptive/Closed Loop vs. Continuous/Open Loop Deep Brain Stimulation of Subthalamic Nucleus: a Two-Phase, Cross-Over, Double-Blind Trial in Patients With Parkinson's Disease
    </Scientific_title>
    <Acronym>CANADA
    </Acronym>
    <Primary_sponsor>University of Toronto
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220404
    </Date_registration3>
    <Date_registration>04/04/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05402163
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2023
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Canada
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  PD treated with bilateral STN DBS using Medtronic lead&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to provide informed consent and comply with study protocol&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Need to replace the implantable pulse generator (IPG) due to battery end of life&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of disabling gait and/or balance and/or speech issues, as clinically judged&#x0D;&lt;br&gt;             by the PI and the patient&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence that these disabling gait and/or balance and/or speech issues are worsened by&#x0D;&lt;br&gt;             DBS, i.e. they improve after turning DBS off.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use of contact 1 and/or 2 on one hemisphere and/or 9 and/or 10 on the other one&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Good LFP signal (assessable only after IPG replacement with Percept) in at least one&#x0D;&lt;br&gt;             hemisphere&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous DBS surgery without Medtronic products&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Potential use of any therapeutic stimulation configuration (such as bipolar) during&#x0D;&lt;br&gt;             the study which will prevent the use of aDBS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of any other disorders potentially impacting the outcome measures (e.g.&#x0D;&lt;br&gt;             orthopaedic issues)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medically unstable&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe non-motor problems, such as depression, dementia, etc.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Adaptive DBS;Device: Continuous DBS
    </Intervention>
    <Primary_outcome>Change in Activities of Daily Living using the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part II;Change in Quality of Life (QoL) using Parkinson's Disease Questionnaire (PDQ39);Change in Gait using the Zeno Walkway by Protokinetics;Change in Speech Quality using the Praat software (Phonetic Sciences)
    </Primary_outcome>
    <Secondary_outcome>Change in Motor Outcomes (adaptive DBS vs continuous DBS arms) using Unified Parkinson's Disease Rating Scale part III (motor examination)
    </Secondary_outcome>
    <Secondary_ID>17-5527
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12110509
    </Internal_Number>
    <TrialID>IRCT20220227054136N1
    </TrialID>
    <Last_Refreshed_on>4 April 2022
    </Last_Refreshed_on>
    <Public_title>The effect of deep brain stimulation on cognitive disorders in Parkinson's disease patients
    </Public_title>
    <Scientific_title>Visual-spatial attention and risk decision making of  Parkinson's disease Patients in Comparison with healthy individuals and the effect of deep brain stimulation on it                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Kordestan university
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220321
    </Date_registration3>
    <Date_registration>2022-03-21
    </Date_registration>
    <Source_Register>IRCT
    </Source_Register>
    <web_address>http://en.irct.ir/trial/62205
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 years
    </Inclusion_agemin>
    <Inclusion_agemax>no limit
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2022-03-11
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive.
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Iran (Islamic Republic of)
    </Countries>
    <Contact_Firstname>Mahshad Sohrabi Jahromi
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Tavakoli4 , N Edalat Blvd , Shiraz
    </Contact_Address>
    <Contact_Email>m.sohrabi1374@gmail.com
    </Contact_Email>
    <Contact_Tel>+98 71 5444 9616
    </Contact_Tel>
    <Contact_Affiliation>The University of Kordestan
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: all Parkinson's disease patients&lt;br&gt;Persons with a minimum age of 15 years&lt;br&gt;Minimum literacy
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: People with neurodegenerative diseases except for Parkinson's patients&lt;br&gt;Inability to perform tests for any reason&lt;br&gt;Dissatisfaction with participation in research
    </Exclusion_Criteria>
    <Condition>parkinson,s disease. &lt;br&gt;Parkinson's disease
    </Condition>
    <Intervention>Intervention 1: Control group 1 : This group includes Parkinson's patients without the need for deep brain stimulation surgery and no therapeutic interventions are performed on them. Intervention 2: Control group 2 : This group includes healthy people without Parkinson's disease and no therapeutic intervention is performed on them. Intervention 3: Intervention group: Parkinson's patients are candidates for deep brain stimulation surgery performed by a surgical intervention surgeon.
    </Intervention>
    <Primary_outcome>Spatial visual attention scores in the Simon task. Timepoint: First pre-test about 20 to 10 days before surgery, second pre-test about 3 to 1 day before surgery, first post-test 1 to 7 days after surgery, second post-test about 40 days after surgery, third post-test about 3 Month after surgery. Method of measurement: simon task.;Risk ratings in the Cambridge Risk Task have been modified. Timepoint: First pre-test about 20 to 10 days before surgery, second pre-test about 3 to 1 day before surgery, first post-test 1 to 7 days after surgery, second post-test about 40 days after surgery, third post-test about 3 Month after surgery. Method of measurement: Modified Cambridge Risk Task.
    </Primary_outcome>
    <Source_Support>cognitive sciences and technologies council
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/02/2022
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Ethics committee of Shiraz University of Medical Sciences
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12188228
    </Internal_Number>
    <TrialID>NCT05314322
    </TrialID>
    <Last_Refreshed_on>19 April 2022
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation on Dual-task Gait Performance in PD
    </Public_title>
    <Scientific_title>The Impacts of Deep Brain Stimulation on Dual-task Gait Performance in Parkinson's Disease: Focusing on Long-term Outcome and the Effects of Stimulation Modes
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>National Yang Ming University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220316
    </Date_registration3>
    <Date_registration>16/03/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05314322
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>50 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 1, 2022
    </Date_enrollement>
    <Target_size>24
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Taiwan
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Yea-Ru Yang, PhD
    </Contact_Lastname>
    <Contact_Email>yryang@nycu.edu.tw
    </Contact_Email>
    <Contact_Tel>+886-2-2876-7279
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age: 50~80 yrs old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hoehn and Yahr stage = IV after DBS operation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Implanted DBS system for at least 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MMSE =24&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other neurological disorders&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any major systemic, psychiatric, visual, and musculoskeletal disturbances or other&#x0D;&lt;br&gt;             causes of walking inability&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Procedure: Deep brain stimulation with high frequency;Procedure: Deep brain stimulation with low frequency
    </Intervention>
    <Primary_outcome>Dual-task gait performance: Stride length;Dual-task gait performance: Double limb support time;Executive function - Inhibition control;Executive function - Shifting attention;Executive function - Working memory;Cognitive function;Non-motor symptoms
    </Primary_outcome>
    <Secondary_outcome>Usual gait performance: Stride length;Usual gait performance: Double limb support time;Brain activity: Prefrontal Cortex;Brain activity: Supplementary Motor Cortex;Brain activity: Premotor Cortex;Functional activity: Gait and balance performance;Functional activity: Lower limb function;Balance performance;Motor symptoms;Parkinson's Disease patients' Quality of life
    </Secondary_outcome>
    <Secondary_ID>2022-02-016A
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12188702
    </Internal_Number>
    <TrialID>NCT05320523
    </TrialID>
    <Last_Refreshed_on>19 April 2022
    </Last_Refreshed_on>
    <Public_title>Simultaneous DBS of the GPi and the NBM in Patients With Parkinson's Disease and Mild Cognitive Impairment
    </Public_title>
    <Scientific_title>Simultaneous Deep Brain Stimulation of the Globus Pallidus Internus and the Nucleus Basalis of Meynert in Patients With Parkinson's Disease and Mild Cognitive Impairment
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Sao Paulo General Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220314
    </Date_registration3>
    <Date_registration>14/03/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05320523
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>50 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 20, 2021
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Rubens G Cury, MD, PhD
    </Contact_Lastname>
    <Contact_Email>rubens_cury@usp.br
    </Contact_Email>
    <Contact_Tel>+551126617877
    </Contact_Tel>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age at the time of enrollment: 50 - 75 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of idiopathic PD according to Movement Disorders Society (MDS) criteria&#x0D;&lt;br&gt;             (Albanese et al., 2017).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mild cognitive impairment (MCI) related to Parkinson's disease according to MDS&#x0D;&lt;br&gt;             criteria. (Livtan et al. 2012).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Duration of bilateral idiopathic PD: = 5 years of motor symptoms.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Modified Hoehn and Yahr stage = 2 on off medication state.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  UPDRS subset III (motor) = 30 points on off medication state.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Levodopa must improve PD symptoms by = 30% in a levodopa challenge test, as measured&#x0D;&lt;br&gt;             by UPDRS subset III score.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of motor complications related to Parkinson's disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be willing and able to comply with all visits and study related procedures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to understand the study requirements and the treatment procedures and to provide&#x0D;&lt;br&gt;             written informed consent before any study-specific tests or procedures are performed.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Alcohol or drug abuse.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any significant psychiatric problems, including acute confusional state (delirium),&#x0D;&lt;br&gt;             ongoing psychosis, or clinically significant depression.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Contraindications for deep brain stimulation (DBS) surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Heart failure, heart disease or any condition that contraindicates surgical&#x0D;&lt;br&gt;             procedures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pacemaker or other active implanted stimulators.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clearly established Parkinson's disease dementia according to Movement Disorders&#x0D;&lt;br&gt;             Criteria.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participation in another drug, device, or biologics trial concurrently.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Mild Cognitive Impairment
    </Condition>
    <Intervention>Device: Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM.;Device: GPi stimulation;Device: NBM stimulation;Device: Sham stimulation
    </Intervention>
    <Primary_outcome>Safety of combined bilateral Globus Pallidus internus (GPi) and Nucleus Basalis of Meynert (NBM) stimulation in patients with moderate to advanced Parkinson's disease with mild cognitive impairment as determined by reported adverse events.
    </Primary_outcome>
    <Secondary_outcome>Change in Parkinson's Disease - Cognitive Rating Scale (PD-CRS).;Change in Mattis Dementia Rating Scale.;Change in Verbal Fluency Battery.;Change in Trail Making Task.;Change in Stroop Test.;Change in Symbol Digit Modalities Test.;Change in Parkinson's Disease Questionnaire for quality of life (PDQ-39).;Change in Questionnaire of the EuroQol-group (EQ-5D-5L).;Change in Unified Parkinson's Disease Rating Scale section I (UPDRS I).;Change in Unified Parkinson's Disease Rating Scale section II (UPDRS II).;Change in Unified Parkinson's Disease Rating Scale section III (UPDRS III).;Change in Unified Parkinson's Disease Rating Scale section IV (UPDRS IV).;Change in objective assessment of gait measured by a sensor (MobilityLab) that assess step speed.;Change in objective assessment of gait measured by a sensor (MobilityLab) that assess number of steps per minute.;Change in objective assessment of gait measured by a sensor (MobilityLab) that assess distance between heels.;Change in objective assessment of gait measured by a sensor (MobilityLab) that assess balance.;Change in objective assessment of gait measured by Time Up and Go - Test 3 meters (TUG test 3M).;Change in objective assessment of gait measured by Time Up and Go dual task - Test 3 meters (TUG dual task - test 3M).;Change in objective assessment of gait measured by freezing of gait score (FOG score).;Change in New Freezing of Gait Questionnaire (N-FOG).;Change in Falls Efficacy Scale International (FES-I).;Change in Activities-Specific Balance Confidence Scale (ABC scale).;Change in Beck Depression Inventory (BDI).;Change in Beck Anxiety Inventory (BAI).;Change in Starkstein Apathy Scale.;Change in Neuropsychiatric Inventory (NPI).;Change in Ardouin Scale of Behavior in Parkinson's Disease.
    </Secondary_outcome>
    <Secondary_ID>38865720.1.0000.0068
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13116006
    </Internal_Number>
    <TrialID>NCT05307055
    </TrialID>
    <Last_Refreshed_on>13 June 2023
    </Last_Refreshed_on>
    <Public_title>Evaluation of Neurocognitive Changes in Parkinson's Disease After Low Frequency Burst Stimulation
    </Public_title>
    <Scientific_title>Evaluation of Neurocognitive Changes in Parkinson's Disease After Low Frequency Burst Stimulation of Bilateral Subthalamic Nucleus
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Southern California
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220314
    </Date_registration3>
    <Date_registration>14/03/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05307055
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 11, 2022
    </Date_enrollement>
    <Target_size>32
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Darrin Lee, MD PhD;Darrin Lee, MD PhD;Darrin Lee
    </Contact_Lastname>
    <Contact_Email>;darrin.lee@med.usc.edu;Darrin.Lee@med.usc.edu
    </Contact_Email>
    <Contact_Tel>;9495220866;949-522-0866
    </Contact_Tel>
    <Contact_Affiliation>University of Southern California, Keck School of Medicine;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Male or female patients who had previously undergone bilateral STN deep brain&#x0D;&lt;br&gt;             stimulation implantation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Age &gt;18 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Stable medication regimen for at least 3 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient informed and able to give written consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Able to comply with all testing, follow-ups and study appointments and protocols&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. History of epilepsy or seizure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. History of dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. History of major substance abuse&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: STN DBS - Theta Burst;Device: STN DBS - Gamma
    </Intervention>
    <Primary_outcome>Evaluation of motor symptoms;Evaluation of executive functioning;Neuroimaging
    </Primary_outcome>
    <Secondary_ID>HS-20-00676
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>11986636
    </Internal_Number>
    <TrialID>NCT05262348
    </TrialID>
    <Last_Refreshed_on>7 March 2022
    </Last_Refreshed_on>
    <Public_title>An Open-label Clinical Trial to Compare the Safety and Effectiveness of Adaptive Versus Conventional Deep Brain Stimulation
    </Public_title>
    <Scientific_title>A Prospective, Multi-center, Open-label, Pivotal Clinical Trial to Compare the Safety and Effectiveness of Adaptive Versus Conventional Stimulation in Advanced Levodopa-Responsive Parkinson's Disease Treated With Bilateral Deep Brain Stimulation
    </Scientific_title>
    <Acronym>ADVENT
    </Acronym>
    <Primary_sponsor>Newronika
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220221
    </Date_registration3>
    <Date_registration>21/02/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05262348
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>55 Years
    </Inclusion_agemin>
    <Inclusion_agemax>95 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 2022
    </Date_enrollement>
    <Target_size>51
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Jason Jones
    </Contact_Lastname>
    <Contact_Email>jason.jones@newronika.com
    </Contact_Email>
    <Contact_Tel>901-451-4792
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patient is =55 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patient has been diagnosed with levodopa-responsive idiopathic Parkinson's disease for&#x0D;&lt;br&gt;             =5 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. The disease stage is II, III or IV according to the Hoehn and Yahr scale&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient has history of improvement of Parkinson's symptoms as a direct result of&#x0D;&lt;br&gt;             administering levodopa&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. PD-related symptoms are not adequately controlled with medication, including motor&#x0D;&lt;br&gt;             complications of recent onset (&gt;4 months duration)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Patient experiences persistent disabling PD-related symptoms or drug side effects&#x0D;&lt;br&gt;             (e.g., dyskinesia, motor fluctuations, or disabling "off periods") despite optimal&#x0D;&lt;br&gt;             medical therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Patient has been selected for bilateral STN or Gpi DBS, independently from this study,&#x0D;&lt;br&gt;             in accordance with local standard of care DBS screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Patient has been selected to receive Medtronic leads model 3389 or 37086,&#x0D;&lt;br&gt;             independently from this study, in accordance with local standard of care DBS screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Patient has DBS circuit integrity assessed and confirmed by impedance testing, before&#x0D;&lt;br&gt;             IPG implantation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. =6 hours per day (waking hours) with poor motor symptoms control (time "OFF" plus time&#x0D;&lt;br&gt;             "ON" with dyskinesia) despite optimal medical therapy, as assessed by the 3-day diary&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Montreal Cognitive Assessment (MoCA) &gt;26 in MedON condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Beck Depression Inventory II (BDI-II) score &lt;17 in MedON condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. UPDRS-III improvement by =33% following intake of anti-parkinsonian medications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. Patient is able to understand the study requirements and the treatment procedures and&#x0D;&lt;br&gt;             has provided written informed consent to participate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         15. Patient is willing and capable of completing a 3-day diary and reaches a sufficient&#x0D;&lt;br&gt;             level of agreement (&gt; 75%) with study personnel responses&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         16. Patient has a responsible caregiver who will help completing the 3-day diary, provide&#x0D;&lt;br&gt;             feedback on activities of daily living (ADL), and ensure the patient complies with&#x0D;&lt;br&gt;             visit schedule&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         17. Patient is willing to maintain a constant anti-PD medication treatment (best medical&#x0D;&lt;br&gt;             management) for at least one month prior to study enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         18. Patient is willing and able to attend all study-required visits, complete the study&#x0D;&lt;br&gt;             procedures and attend appropriate follow up visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patient has contraindications for DBS surgery, including any intracranial abnormality&#x0D;&lt;br&gt;             (e.g., generalized atrophy, vascular malformation, hydrocephalus, hematoma, cavernous&#x0D;&lt;br&gt;             or venous angioma, tumor or metastases, midline shift, etc.) or metallic implant&#x0D;&lt;br&gt;             (e.g., aneurysm clip, cochlear implant, etc.)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patient has a history of suicide attempt or current active suicidal ideation as&#x0D;&lt;br&gt;             determined by a positive response to Item 2-5 of suicide ideation sub-scale of the&#x0D;&lt;br&gt;             Columbia Suicide Severity Rating Scale (CSSR-S)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patient has dementia, major depression, seizures, congestive heart failure,&#x0D;&lt;br&gt;             uncontrolled diabetes, dialysis, substance use disorders as described in DSM-V, or any&#x0D;&lt;br&gt;             other severe medical condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient has any medical condition that could interfere with study procedures, confound&#x0D;&lt;br&gt;             the assessment of study endpoints, or prevent a proper data collection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patient had confirmation of diagnosis of a terminal illness associated with survival&#x0D;&lt;br&gt;             &lt;12 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Patient needs repeated MRI scans&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Patient requires diathermy, transcranial magnetic stimulation (TMS), or&#x0D;&lt;br&gt;             electroconvulsive therapy (ECT)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Patient carries an electrical or electromagnetic implant (e.g., cochlear prosthesis,&#x0D;&lt;br&gt;             pacemaker, neurostimulator, etc.)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Patient has, or plans to obtain, an implanted electrical stimulation medical device&#x0D;&lt;br&gt;             and/or an implanted medication pump (e.g., DUOPATM infusion pump) and/or is treated&#x0D;&lt;br&gt;             with a portable infusion pump&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Patient is on anticoagulant therapy which cannot be paused for &gt;5 days before IPG&#x0D;&lt;br&gt;             implant surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Patient with a history of cranial surgery including ablation procedure or any other&#x0D;&lt;br&gt;             previous neurosurgical procedure for the treatment of PD symptoms on either side of&#x0D;&lt;br&gt;             the brain&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Patient is currently participating in another clinical study (excluding any sub-study&#x0D;&lt;br&gt;             of the present study)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Patient is a female who is breastfeeding or of child-bearing potential with a positive&#x0D;&lt;br&gt;             urine pregnancy test or not using adequate contraception.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: adaptive DBS delivered through AlphaDBS IPG System;Device: conventional DBS delivered through AlphaDBS IPG System
    </Intervention>
    <Primary_outcome>To assess safety;To compare change in Good on time (GOT) when the patient receives aDBS versus change in GOT when the patient receives cDBS.
    </Primary_outcome>
    <Secondary_outcome>Success rate, number of patients with at least 2 hours improvement in each treatment mode;Patient fluctuations;UPDRS III;UdysRS;Percentage of time in which the system is used in aDBS mode
    </Secondary_outcome>
    <Secondary_ID>NWK_AlphaDBS_PIV_2022
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13201771
    </Internal_Number>
    <TrialID>NCT05269862
    </TrialID>
    <Last_Refreshed_on>2 August 2023
    </Last_Refreshed_on>
    <Public_title>Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation
    </Public_title>
    <Scientific_title>Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation
    </Scientific_title>
    <Acronym>ROAM-DBS
    </Acronym>
    <Primary_sponsor>Abbott Medical Devices
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220117
    </Date_registration3>
    <Date_registration>17/01/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05269862
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 24, 2022
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States;Germany;Spain;United Kingdom;Germany;Spain;United Kingdom;United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Bradley White;Devyani Nanduri
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Abbott;Abbott Medical Devices Neuromodulation
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject is a participant in the ADROIT study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subject is over 21 years old.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Subject is able to read and write.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Subject is indicated for implant with an Infinity IPG for Parkinson's disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Subject has not previously been implanted with a DBS system.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. The treating physician believes Virtual Clinic is appropriate as a component in the&#x0D;&lt;br&gt;             treatment regime for this subject.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Subject will have access to the Abbott Virtual Clinic system through a participating&#x0D;&lt;br&gt;             site.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Subject will have internet access on their Patient Controller in a location suitable&#x0D;&lt;br&gt;             for a Virtual Clinic session.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Subject, or a legally acceptable representative, must provide written informed consent&#x0D;&lt;br&gt;             prior to any study-related procedure.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject is currently enrolled or plans to enroll in an investigational study that may&#x0D;&lt;br&gt;             confound the results of this study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subject has anatomic or comorbid conditions, or other medical, social, or&#x0D;&lt;br&gt;             psychological conditions that, in the investigator's opinion, could limit the&#x0D;&lt;br&gt;             subject's ability to participate in the study or to comply with follow-up&#x0D;&lt;br&gt;             requirements, or impact the scientific soundness of the study results.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. As assessed by the treating physician, lead misplacement would prevent the DBS therapy&#x0D;&lt;br&gt;             from providing clinically meaningful benefit.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Subject is unable to use the Virtual Clinic feature.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Subject will not be able, in the investigator's opinion, to demonstrate or articulate&#x0D;&lt;br&gt;             symptoms during a Virtual Clinic visit.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature;Device: Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)
    </Intervention>
    <Primary_outcome>Primary Efficacy Endpoint: The time to achieve a 1 point improvement Patient's Global Impression of change (PGIC) relative to the subject's status at the end of the initial programming visit;Primary Safety Endpoint: Rate of programming related adverse events for the Virtual Clinic cohort
    </Primary_outcome>
    <Secondary_outcome>Patient Global Impression (PGI);Patient Global Impression (PGI);Clinical Global Impression (CGI);Clinical Global Impression (CGI);Parkinson's Disease Questionnaire (PDQ-39);Parkinson's Disease Questionnaire (PDQ-39);Levodopa Equivalent Dose (LED);Levodopa Equivalent Dose (LED);Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS);Home Monitoring (Tremor);Home Monitoring (Dyskinesia);"On Time" (time each day without troublesome symptoms or side effects) (derived from Home Monitoring);Health care resource utilization: Number of hospitalizations and ER visits;Time to resolve programming related adverse events
    </Secondary_outcome>
    <Secondary_ID>ABT-CIP-10413
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13516707
    </Internal_Number>
    <TrialID>NCT05150093
    </TrialID>
    <Last_Refreshed_on>6 November 2023
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor
    </Public_title>
    <Scientific_title>Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Massachusetts Eye and Ear Infirmary
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20211127
    </Date_registration3>
    <Date_registration>27/11/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05150093
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 21, 2022
    </Date_enrollement>
    <Target_size>120
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Kristina Simonyan, MD, PhD;Kristina Simonyan, MD, PhD;Kristina Simonyan, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;simonyan_lab@meei.harvard.edu;simonyan_lab@meei.harvard.edu
    </Contact_Email>
    <Contact_Tel>;617-573-6016;617-573-6016
    </Contact_Tel>
    <Contact_Affiliation>Massachusetts Eye and Ear;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Clinical indications to proceed with DBS implantation, as determined by the clinical&#x0D;&lt;br&gt;             multidisciplinary movement disorders board, including: a) definitive diagnosis of&#x0D;&lt;br&gt;             essential tremor or dystonia, b) medically refractory disease, c) adequate performance&#x0D;&lt;br&gt;             on neuropsychological evaluation as determined by a licensed clinical&#x0D;&lt;br&gt;             neuropsychologist.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. The ability to comply with test directions, complete pre-operative task training, and&#x0D;&lt;br&gt;             provide informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Age 18-80 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        1. Inability to understand or perform the task outlined in the protocol during a&#x0D;&lt;br&gt;        pre-surgery training session. 2. Significant hearing loss.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        3. Cortical venous anatomy that could potentially obstruct ECoG electrode placement, as&#x0D;&lt;br&gt;        determined by the surgeon, visualized on pre-op MRI or during surgery.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Laryngeal Dystonia;Spasmodic Dysphonia;Tremor;Dystonia
    </Condition>
    <Intervention>Procedure: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Correlations between brain signals and intraoperative voice and speech production performance.;Changes in standard clinical outcome for dystonia patients;Changes in standard clinical outcome for tremor patients
    </Primary_outcome>
    <Secondary_ID>2021P003236
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Massachusetts General Hospital;University of Utah;University of California, San Francisco
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13646901
    </Internal_Number>
    <TrialID>DRKS00026263
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Optimising deep brain stimulation therapy using micro and macroelectrode recordings of the nucleus subthalamicus
    </Public_title>
    <Scientific_title>Optimising deep brain stimulation therapy using micro and macroelectrode recordings of the nucleus subthalamicus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum Köln
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210921
    </Date_registration3>
    <Date_registration>21/09/2021
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00026263
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>01/10/2021
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: basic science  
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Joshua
    </Contact_Firstname>
    <Contact_Lastname>Strelow
    </Contact_Lastname>
    <Contact_Address>Kerpener Str. 62
    </Contact_Address>
    <Contact_Email>joshua.strelow@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>0221 478 98578
    </Contact_Tel>
    <Contact_Affiliation>Universitätsklinikum Köln
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: • Patients with IPS and ET&lt;br&gt;• Patients of all genders&lt;br&gt;• Implantation of stimulation electrodes as per clinical routine&lt;br&gt;• Declaration of consent&lt;br&gt;• Patient age must be between 18 and 80 years
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients that are non-cooperative or non-competent
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20.1 &lt;br&gt;G25.0;Essential tremor;G20.1;G25.0
    </Condition>
    <Intervention>Group 1: Patients with essential tremor undergoing DBS therapy. During surgery, we will record electrophysiological data. Clinical routine is not altered. At 3-months follow-up, as per clinical routine, we will determine the best clinical contact (randomised), with the patient being unaware (blinded) of which stimulation parameters are set. Intraoperative and 3-months follow-up settings are then compared.&lt;br&gt;Group 2: Patients with Parkinson's disease undergoing DBS therapy. We will record electrophysiological data intrraopertatively. Clinical routine is not altered.  At 3-months follow-up, as per clinical routine, we will determine the best clinical contact (randomised), with the patient being unaware (blinded) of which stimulation parameters are set. Intraoperative and 3-months follow-up settings are then compared.
    </Intervention>
    <Primary_outcome>Optimal stimulation volume according to ß-peak activity compared to clinically assessed optimal stimulation volumes based on a monopolar contact review
    </Primary_outcome>
    <Secondary_ID>Uni-Koeln-4595
    </Secondary_ID>
    <Source_Support>Universitätsklinikum Köln;Medtronic GmbH
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>27/07/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00026263#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13646769
    </Internal_Number>
    <TrialID>DRKS00026085
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Evaluation of conscious Signal interpretation TheRapy Improvement for DEep brain stimulation (DBS) in chronically implanted patients
    </Public_title>
    <Scientific_title>Evaluation of conscious Signal interpretation TheRapy Improvement for DEep brain stimulation (DBS) in chronically implanted patients - STRIDE CHRONIC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum Freiburg
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210920
    </Date_registration3>
    <Date_registration>20/09/2021
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00026085
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>20/09/2021
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: N/A: single arm study; Masking: Open (masking not used); Control: uncontrolled; Assignment: single; Study design purpose: treatment 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Bastian
    </Contact_Firstname>
    <Contact_Lastname>Sajonz
    </Contact_Lastname>
    <Contact_Address>Breisacher Str. 64
    </Contact_Address>
    <Contact_Email>bastian.sajonz@uniklinik-freiburg.de
    </Contact_Email>
    <Contact_Tel>+4976127050630
    </Contact_Tel>
    <Contact_Affiliation>Universitätsklinikum Freiburg Klinik für Neurochirurgie Abteilung Stereotaktische und Funktionelle Neurochirurgie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. male or female patients aged at least 20 and no older than 85 years; &#x0D;&lt;br&gt;2. patients with any of the following diagnoses: &#x0D;&lt;br&gt;a. Essential tremor, DBS implanted in the subthalamic region, &#x0D;&lt;br&gt;b. Tremor-dominant PD, DBS implanted in the thalamic target, &#x0D;&lt;br&gt;c. Drug-refractory PD with fluctuations, DBS target in the subthalamic nucleus (STN), &#x0D;&lt;br&gt;d. Neuropathic pain, DBS implanted in the thalamic target; &#x0D;&lt;br&gt;3. Patients implanted with a DBS system at least 3 months ago - either as part of STRIDE (preceding study to this protocol), or as part of routine clinical routine; &#x0D;&lt;br&gt;4. Written informed consent.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. patients with dementia symptoms, 2. pregnant or breastfeeding women
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20 &lt;br&gt;G25.0 &lt;br&gt;M79.20 &lt;br&gt;G11.2 &lt;br&gt;G11.1;Parkinson disease;Essential tremor;Late-onset cerebellar ataxia;Early-onset cerebellar ataxia;G25.0;M79.20;G11.2;G11.1
    </Condition>
    <Intervention>Group 1: Patients with DBS systems present to the clinic at regular intervals as part of routine clinical practice for fine-tuning of their settings. On one such visit, two additional examinations are to be performed: first, the conventional DBS will be switched off for a short time, and single-blinded testing of sensoric stimulations will be performed (patient will be asked, "When I adjust this, do you feel anything?"), followed by testing (a random sequence of on/off is run with the sensoric stimulations; it is recorded whether the patient correctly identifies sensations).&lt;br&gt;&lt;br&gt;Second, after this brief calibration session, the patient will perform study-specific gait tests. Three gait tests are performed, one in each of the conditions "No stimulation," "Conventional DBS," and "Sensory DBS".&lt;br&gt;&lt;br&gt;All stimulation settings are safe and are performed within the intended purpose of the implanted DBS system and under the supervision of a study physician. Gait testing is performed in order to check whether perceiving the applied stimulation signals can improve the gait pattern.
    </Intervention>
    <Primary_outcome>Correct interpretation and assignment of signals by the patient. Unchanged or improved arrhythmicity of the gait pattern.
    </Primary_outcome>
    <Secondary_outcome>- Qualitatively characterize patients' perceptions when exposed to sensory stimulation signals that are useful for the patient &#x0D;&lt;br&gt;- Quantify improvements in the patient's gait pattern achieved through the additional sensory stimulation signals.
    </Secondary_outcome>
    <Source_Support>Universitätsklinikum Freiburg Klinik für Neurochirurgie Abteilung Stereotaktische und Funktionelle Neurochirurgie;CereGate GmbH
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>07/09/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-761-27072600
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00026085#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13524759
    </Internal_Number>
    <TrialID>NCT05089682
    </TrialID>
    <Last_Refreshed_on>13 November 2023
    </Last_Refreshed_on>
    <Public_title>Manipulating and Optimizing Brain Rhythms for Enhancement of Sleep
    </Public_title>
    <Scientific_title>Morpheus - Manipulating and Optimizing Brain Rhythms for Enhancement of Sleep
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Mayo Clinic
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210816
    </Date_registration3>
    <Date_registration>16/08/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05089682
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 22, 2021
    </Date_enrollement>
    <Target_size>4
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Gregory Worrell, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Mayo Clinic
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  DBS in one of the defined nuclei of interest during the period of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be willing and able to give written and oral informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to complete all required study procedures including travelling to Mayo Clinic&#x0D;&lt;br&gt;             and staying overnight&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All women of childbearing potential and women who have been amenorrheic for less than&#x0D;&lt;br&gt;             1 year must practice effective contraception during the study. This includes a barrier&#x0D;&lt;br&gt;             method such as condom or diaphragm with spermicide; barrier intrauterine device (IUD)&#x0D;&lt;br&gt;             or abstinence.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment (judged by the clinician taking consent as not having sufficient&#x0D;&lt;br&gt;             mental capacity to understand the study and its requirements). This is including&#x0D;&lt;br&gt;             anyone who, in the opinion of the clinician taking consent is unlikely to retain&#x0D;&lt;br&gt;             sufficient mental capacity for the duration of their involvement in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with any other medical condition that would interfere with study conduct or&#x0D;&lt;br&gt;             make it unsafe for them to participate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy test positive.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Neurological Disease;Parkinson Disease;Epilepsy
    </Condition>
    <Intervention>Device: DBS Stimulation during sleep
    </Intervention>
    <Primary_outcome>Participants to Complete Study
    </Primary_outcome>
    <Secondary_outcome>Total Sleep Time;Psychomotor Vigilance Test;Karolinska Sleepiness Scale;Latency to Sleep Onset;Latency to Rapid Eye Movement (REM) Sleep;Number of Sleep Cycles;Number of Awakenings Per Night
    </Secondary_outcome>
    <Secondary_ID>19-001216
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>01/11/2023
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT05089682
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12651412
    </Internal_Number>
    <TrialID>NCT05011773
    </TrialID>
    <Last_Refreshed_on>14 November 2022
    </Last_Refreshed_on>
    <Public_title>Manipulating and Optimising Brain Rhythms for Enhancement of Sleep
    </Public_title>
    <Scientific_title>Manipulating and Optimising Brain Rhythms for Enhancement of Sleep
    </Scientific_title>
    <Acronym>MORPHEUS
    </Acronym>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210804
    </Date_registration3>
    <Date_registration>04/08/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05011773
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 3, 2021
    </Date_enrollement>
    <Target_size>4
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United Kingdom
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Alexander L Green, FRCS(SN)
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Oxford University Hospitals NHS Trust
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Either already implanted with DBS electrodes or undergoing DBS implantation in one of&#x0D;&lt;br&gt;             the defined nuclei of interest (for Surrey or Rochester: STN, PPN, Hypothalamus,&#x0D;&lt;br&gt;             PAG/PVG - for the Mayo clinic, may use hippocampus or ANT) for standard clinical care&#x0D;&lt;br&gt;             during the period of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male or female, aged 18 to 85&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be willing and able to give written and oral informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to complete all required study procedures including travelling to the Sleep&#x0D;&lt;br&gt;             Centre and staying overnight&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  By the time of the first visit to Surrey, participants should have already had their&#x0D;&lt;br&gt;             stimulation settings programmed by the Functional Neurosurgery team and have been&#x0D;&lt;br&gt;             stable on the settings for at least two weeks, as per their routine clinical care.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For patients with chronic pain, they should be stable on their current medication and&#x0D;&lt;br&gt;             settings&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment (judged by the clinician taking consent as not having sufficient&#x0D;&lt;br&gt;             mental capacity to understand the study and its requirements). This is including&#x0D;&lt;br&gt;             anyone who, in the opinion of the clinician taking consent is unlikely to retain&#x0D;&lt;br&gt;             sufficient mental capacity for the duration of their involvement in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with any other medical condition that would interfere with study conduct or&#x0D;&lt;br&gt;             make it unsafe for them to participate. Such conditions may be poorly controlled&#x0D;&lt;br&gt;             diabetes, poorly controlled/end stage heart disease, renal failure as well as&#x0D;&lt;br&gt;             recurrent, uncontrolled seizures or epilepsy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants who have started new medication or changed doses 3 weeks prior to a study&#x0D;&lt;br&gt;             visit may not be eligible as deemed by the PI of the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients on medication that can affect the study results (such as hypnotics -&#x0D;&lt;br&gt;             benzodiazepines and analogues), at the discretion of the PI.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients currently taking ketamine&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Alcohol intake exceeding 28 units per week.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;MSA - Multiple System Atrophy;Chronic Pain;Epilepsy
    </Condition>
    <Intervention>Device: Deep brain stimulation
    </Intervention>
    <Primary_outcome>Sleep stages;Sleep inertia
    </Primary_outcome>
    <Secondary_outcome>Control of sleep
    </Secondary_outcome>
    <Secondary_ID>20/PR/0409
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Surrey Sleep Research Centre, Surrey, UK;Mayo Clinic;University of California, San Francisco
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13644068
    </Internal_Number>
    <TrialID>DRKS00021799
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Organization of cortical and subcortical neural networks in psychiatric patients treated with deep brain stimulation
    </Public_title>
    <Scientific_title>Organization of cortical and subcortical neural networks in psychiatric patients treated with deep brain stimulation - None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>Klinik für Stereotaxie und Funktionelle NeurochirurgieUniversitätsklinikum Köln
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210621
    </Date_registration3>
    <Date_registration>21/06/2021
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00021799
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>01/08/2021
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: Prognosis 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Thibaut
    </Contact_Firstname>
    <Contact_Lastname>Sesia
    </Contact_Lastname>
    <Contact_Address>Kerpener Str. 62
    </Contact_Address>
    <Contact_Email>thibaut.sesia@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>0049(0)22147882772
    </Contact_Tel>
    <Contact_Affiliation>Klinik für Stereotaxie und Funktionelle Neurochirurgie Universitätsklinikum Köln (AöR)
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: - Selected for deep brain stimulation therapy independently of this study&lt;br&gt;- Good general condition&lt;br&gt;- be able to consent&lt;br&gt;- be able to sign the declaration of consent
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Unable to give consent
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;F42.9 &lt;br&gt;F95.2;Obsessive-compulsive disorder, unspecified;Combined vocal and multiple motor tic disorder [de la Tourette];F42.9;F95.2
    </Condition>
    <Intervention>Group 1: Change in cortical network communication following DBS treatment (deep brain stimulation)
    </Intervention>
    <Primary_outcome>Change in cerebral band frequency post treatment (e.g. theta, gamma bands).
    </Primary_outcome>
    <Secondary_outcome>Change in cross frequency coherence post treatment (e.g. theta-gamma bands).
    </Secondary_outcome>
    <Source_Support>Klinik Fuer Stereotaxie und Funktionelle NeurochirurgieUniklinikum Koeln
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>09/11/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00021799#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13104773
    </Internal_Number>
    <TrialID>NCT04976569
    </TrialID>
    <Last_Refreshed_on>5 June 2023
    </Last_Refreshed_on>
    <Public_title>Neuromodulation of Sleep Architecture by STN-DBS in Parkinsonian Patients
    </Public_title>
    <Scientific_title>Neuromodulation of Sleep Architecture by STN-DBS in Parkinsonian Patients
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Tsinghua University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210616
    </Date_registration3>
    <Date_registration>16/06/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04976569
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>50 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 10, 2021
    </Date_enrollement>
    <Target_size>5
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Huiling Yu, MD
    </Contact_Lastname>
    <Contact_Email>yuhuiling@mail.tsinghua.edu.cn
    </Contact_Email>
    <Contact_Tel/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Diagnosis of Parkinson's disease: The diagnostic criteria for Parkinson's disease are&#x0D;&lt;br&gt;             the Clinical Diagnostic Criteria of UK PD Society Brain Bank Clinical Diagnostic&#x0D;&lt;br&gt;             Criteria or 2015 MDS Clinical Diagnostic Criteria for PD.All diagnoses of Parkinson's&#x0D;&lt;br&gt;             disease were made by three neurologists who were experienced in the field of movement&#x0D;&lt;br&gt;             disorders.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Bilateral STN-DBS has been implanted for more than 1 year, and stable drug therapy&#x0D;&lt;br&gt;             regimen and parameter program control regimen have been maintained for 6 weeks or&#x0D;&lt;br&gt;             more;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients with onset age of 50 years and above;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Do not use phenobarbital, chloral hydrate, benzodiazepines and non-benzodiazepines as&#x0D;&lt;br&gt;             sedatives and hypnotics at night.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patients who underwent pallidotomy and other brain surgery;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Other patients with secondary Parkinson's syndrome and Parkinsonism-plus syndrome;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients with other central nervous system and peripheral nervous system diseases;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patients complicated with severe medical system diseases, patients with unstable vital&#x0D;&lt;br&gt;             signs and unable to tolerate clinical evaluation;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patients with severe mental illness;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Use phenobarbital, chloral hydrate, benzodiazepines and non-benzodiazepines as&#x0D;&lt;br&gt;             sedatives and hypnotics at night;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Patients who cannot complete informed consent due to cognitive and communication&#x0D;&lt;br&gt;             barriers, or refuse to sign informed consent.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Sleep Disorder
    </Condition>
    <Intervention>Device: STN-DBS stimulation pattern change
    </Intervention>
    <Primary_outcome>ratio of slow wave sleep;ratio of rem sleep;Sleep Efficiency
    </Primary_outcome>
    <Secondary_outcome>Motor Function Evaluation
    </Secondary_outcome>
    <Secondary_ID>STN_DBS_Sleep_TsinghuaU
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Beijing Tsinghua Changgeng Hospital
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13646375
    </Internal_Number>
    <TrialID>DRKS00025490
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Imaging-based registry for quality of life and symptom control after deep brain stimulation in movement disorders
    </Public_title>
    <Scientific_title>Imaging-based registry for quality of life and symptom control after deep brain stimulation in movement disorders - DBS-Registry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum FreiburgKlinik für NeurochirurgieAbteilung Stereotaktische und Funktionelle Neurochirurgie
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210615
    </Date_registration3>
    <Date_registration>15/06/2021
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00025490
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>19/10/2021
    </Date_enrollement>
    <Target_size>400
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: treatment 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Bastian
    </Contact_Firstname>
    <Contact_Lastname>Sajonz
    </Contact_Lastname>
    <Contact_Address>Breisacher Str. 64
    </Contact_Address>
    <Contact_Email>bastian.sajonz at uniklinik-freiburg.de
    </Contact_Email>
    <Contact_Tel>+4976127050630
    </Contact_Tel>
    <Contact_Affiliation>Universitätsklinikum Freiburg Klinik für Neurochirurgie Abteilung Stereotaktische und Funktionelle Neurochirurgie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1.) All patients who are admitted to the Medical Center - University of Freiburg, Dept. of Stereotactic and Functional Neurosurgery, and receive or have received a new DBS implantation since 01 Jan 2013.&#x0D;&lt;br&gt;(2.) Written informed consent.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: None
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20 &lt;br&gt;G24 &lt;br&gt;G25.0;Parkinson disease;Dystonia;Essential tremor;G25.0
    </Condition>
    <Intervention>Group 1:  Clinical outcomes (especially bleeding complications) and long-term effects of DBS will be assessed. For this purpose, parts of the routinely collected data of the control visits will be data of the control visits will be documented in the registry.
    </Intervention>
    <Primary_outcome>Baseline/descriptive data (all patients): &lt;br&gt;&lt;br&gt;(1) Baseline data (demographics, duration of movement disorder, handedness)&lt;br&gt;(2) Pre-existing conditions and preoperative medication&lt;br&gt;(3) Surgery-related haemorrhage in routine postoperative imaging&lt;br&gt;(4) Acquisition of data from intraoperative procedure: Type of anesthesia, number and type of temporary test electrodes used, results of intraoperative test measurements, implanted stimulation system (type, manufacturer) and date of implantation (electrodes and stimulator), and any follow-up operations on the stimulation system and their indication &lt;br&gt;(5) High-resolution magnetic resonance imaging of the skull (3T) including structural anatomical data as well as diffusion-tensor magnetic resonance imaging (DTI) and subsequent fiber tracking to visualize the respective target structure (depending on implantation site and indication)&lt;br&gt;(6) Stimulation settings during routine controls &lt;br&gt;(7) Calculation/simulation of the electric fields around the stimulation electrode and their position with respect to the target structure (EFS = electric field simulation), distance between field and target structure as a measure of field simulations&lt;br&gt;(8) Acquisition of functional disease-specific diagnostic data collected as part of routine clinical practice (e.g., neuropsychological testing, PET examinations, and gait laboratory testing)&lt;br&gt;(9) Quality of life (EQ-5D-5L)&lt;br&gt;&lt;br&gt;Outcome measures (PD): &lt;br&gt;- Mattis Dementia Rating Scale (DRS-2)&lt;br&gt;- Quality of life disease-specific (PDQ-39)&lt;br&gt;- Unified Parkinson's Disease Rating Scale (UPDRS) IIII&lt;br&gt;- Non-motor Symptoms Scale (NMSS)&lt;br&gt;- Barratt Impulsiveness Scale (BIS-11)&lt;br&gt;- Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS)&lt;br&gt;- Beck's Depression Inventory Revision (BDI II)&lt;br&gt;- Self-Report Manic Inventory&lt;br&gt;- L-DOPA Equivalent of Parkinson's Disease Medication (LED)&lt;br&gt;&lt;br&gt;Target variables (tremor): &lt;br&gt;- Essential Tremor Rating Assessment Scale (TETRAS)&lt;br&gt;- Examination of tremor intensity and tremor frequency preoperatively and at postoperative appointments with on and off stimulation&lt;br&gt;- Mattis Dementia Rating Scale (DRS-2)&lt;br&gt;- Scale for the assessment and rating of ataxia (SARA)&lt;br&gt;- Beck's Depression Inventory Revision (BDI II)&lt;br&gt;- Quality of life disease-specific (QUEST)&lt;br&gt;&lt;br&gt;Target variables (dystonia): &lt;br&gt;- For cervical dystonia, Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)&lt;br&gt;- For cervical dystonia Quality of life disease-specific: Craniocervical dystonia questionnaire (CDQ-24)&lt;br&gt;- For all other dystonias: Unified Dystonia Rating Scale (UDRS) 
    </Primary_outcome>
    <Secondary_outcome>A distinction between primary and secondary endpoints will not be made in this registry. Rather, a list of equivalent outcome parameters is defined.
    </Secondary_outcome>
    <Source_Support>Universitätsklinikum FreiburgKlinik für NeurochirurgieAbteilung Stereotaktische und Funktionelle Neurochirurgie
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>18/05/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-761-27072600
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00025490#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>11052125
    </Internal_Number>
    <TrialID>NCT04928079
    </TrialID>
    <Last_Refreshed_on>21 June 2021
    </Last_Refreshed_on>
    <Public_title>6-year Follow-up of Dysphagia in Patients With Parkinson's Disease
    </Public_title>
    <Scientific_title>6-year Follow-up of Dysphagia in Patients With Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Second Affiliated Hospital, School of Medicine, Zhejiang University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210609
    </Date_registration3>
    <Date_registration>09/06/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04928079
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2014
    </Date_enrollement>
    <Target_size>116
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Wei Luo, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  idiopathic PD according to the United Kingdom PD Society Brain Bank Clinical&#x0D;&lt;br&gt;             Diagnostic Criteria.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  (1) Parkinsonian syndromes;(2) with severe lung disease, severe liver insufficiency&#x0D;&lt;br&gt;             and cardiac insufficiency; (3) Kubota water drinking test grade =3; (4) have had or&#x0D;&lt;br&gt;             combined other diseases that affect swallowing function; (5) Nasal feeding, gastric&#x0D;&lt;br&gt;             reflux or gastrostomy; (6) Mental disorders Or patients with low intelligence and&#x0D;&lt;br&gt;             cognitive function, unable to understand and cooperate with the examination.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Dysphagia
    </Condition>
    <Intervention>Procedure: deep brain stimulation;Drug: Anti-Parkinsonian Drugs
    </Intervention>
    <Primary_outcome>penetration - aspiration score;residue score
    </Primary_outcome>
    <Secondary_outcome>water swallow test;SDQ-C
    </Secondary_outcome>
    <Secondary_ID>(2020)LunShenYan( 191 )
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12908156
    </Internal_Number>
    <TrialID>NCT04922411
    </TrialID>
    <Last_Refreshed_on>27 March 2023
    </Last_Refreshed_on>
    <Public_title>Cortical Network Modulation by Subthalamic Nucleus DBS
    </Public_title>
    <Scientific_title>Cortical Network Modulation by Subthalamic Nucleus Deep Brain Stimulation
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Washington University School of Medicine
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210604
    </Date_registration3>
    <Date_registration>04/06/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04922411
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>25 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 23, 2021
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Tamara G Hershey;Samantha Ranck, MSW, MA, LPC;Samantha Ranck, MSW, MA, LPC
    </Contact_Lastname>
    <Contact_Email>;blankens@wustl.edu;blankens@wustl.edu
    </Contact_Email>
    <Contact_Tel>;314-362-6514;314-362-6514
    </Contact_Tel>
    <Contact_Affiliation>Washington University Medical School;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pilot Group: Participants who enroll as part of the Pilot Group of up to10, will&#x0D;&lt;br&gt;             follow the same inclusion criteria as the Control group with the exception of matching&#x0D;&lt;br&gt;             the age and sex distribution of the DBS group. Pilot participants will be males or&#x0D;&lt;br&gt;             females between 20 and 75 years of age who do not meet criteria for clinically&#x0D;&lt;br&gt;             definite PD.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Control Group: Participants who enroll as part of the Control Group will match the age&#x0D;&lt;br&gt;             and sex distributions of the DBS groups. Control participants will be males or females&#x0D;&lt;br&gt;             between 50 and 75 years of age who do not meet criteria for clinically definite PD.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pre-Surgical DBS Group: Participants with PD who have been clinically consented for&#x0D;&lt;br&gt;             bilateral STN DBS surgery will be recruited from the DBS program within the Movement&#x0D;&lt;br&gt;             Disorders Clinic at WUSM. Pre-surgical STN DBS patients will be males or females&#x0D;&lt;br&gt;             between 50 and 75 years of age who meet criteria for clinically definite PD.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Post-Surgical DBS Group: Participants with PD who have had bilateral STN DBS surgery&#x0D;&lt;br&gt;             will be males or females between 50 and 75 years of age who meet criteria for&#x0D;&lt;br&gt;             clinically definite PD.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pilot Group: Exclusions include any significant past or current neurologic or&#x0D;&lt;br&gt;             psychiatric diagnosis or any other condition which could interfere with testing (e.g.&#x0D;&lt;br&gt;             severe visual loss, non-English speaking, and illiteracy) and contraindications for&#x0D;&lt;br&gt;             MRI.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Control Group: Exclusions include any significant past or current neurologic or&#x0D;&lt;br&gt;             psychiatric diagnosis or any other condition which could interfere with testing (e.g.&#x0D;&lt;br&gt;             severe visual loss, non-English speaking, and illiteracy) and contraindications for&#x0D;&lt;br&gt;             MRI.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pre-Surgical DBS Group: Patients will have already passed clinical screening for&#x0D;&lt;br&gt;             neurological and psychiatric comorbidities, including dementia. From this group of&#x0D;&lt;br&gt;             potential subjects, we will also exclude those with contraindications for MRI&#x0D;&lt;br&gt;             pre-surgically, inability to tolerate off medication or off DBS states, or any other&#x0D;&lt;br&gt;             condition which could interfere with testing (e.g. severe visual loss, non-English&#x0D;&lt;br&gt;             speaking, illiteracy).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Post-Surgical DBS Group: Patients will have already passed clinical screening for&#x0D;&lt;br&gt;             neurological and psychiatric comorbidities, including dementia. From this group of&#x0D;&lt;br&gt;             potential subjects, we will also exclude those with contraindications for MRI&#x0D;&lt;br&gt;             pre-surgically, clinically determined dementia manifesting after surgery, significant&#x0D;&lt;br&gt;             complications of surgery (e.g. stroke), inability to tolerate off medication or off&#x0D;&lt;br&gt;             DBS states, or any other condition which could interfere with testing (e.g. severe&#x0D;&lt;br&gt;             visual loss, non-English speaking, illiteracy).&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Deep Brain Stimulation
    </Condition>
    <Intervention>Device: STN DBS
    </Intervention>
    <Primary_outcome>Functional Connectivity measures
    </Primary_outcome>
    <Secondary_ID>1R01NS109487-01A1;201908154
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institute of Neurological Disorders and Stroke (NINDS)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13646227
    </Internal_Number>
    <TrialID>DRKS00025287
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Connectivity based study for risk behaviour for Patients with idiopathic Parkinson´s Syndrome after Deep Brain Stimulation
    </Public_title>
    <Scientific_title>Connectivity based study for risk behaviour for Patients with idiopathic Parkinson´s Syndrome after Deep Brain Stimulation - KORINTH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
    </Scientific_title>
    <Primary_sponsor>Universität zu Köln
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210531
    </Date_registration3>
    <Date_registration>31/05/2021
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00025287
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>25/05/2021
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Randomized controlled study; Masking: Blinded (masking used); Control: placebo; Assignment: crossover; Study design purpose: basic science  
    </Study_design>
    <Phase>4
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Juan Carlos
    </Contact_Firstname>
    <Contact_Lastname>Baldermann
    </Contact_Lastname>
    <Contact_Address>Kerpener Straße 62
    </Contact_Address>
    <Contact_Email>juan.baldermann@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>022147897602
    </Contact_Tel>
    <Contact_Affiliation>Uniklinik Köln
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Diagnosis: Idiopathic Parkinsons Syndrome&lt;br&gt;Therapy with Deep Brain Stimulation in the Nucleus subtalamicus on both sides&lt;br&gt;Minimum age: 18 Years&lt;br&gt;Fluent in German
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Dementia&lt;br&gt;Instable psychiatric disorder in need of treatment
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: Deep brain stimulation of the STN in ventral, dorsal, and regular clinical stimulation setting&lt;br&gt;Group 2: Switched-off deep brain stimulation
    </Intervention>
    <Primary_outcome>Impulsivity measured with the CGT (30 minutes after stimulation setting)
    </Primary_outcome>
    <Secondary_outcome>Motor status&lt;br&gt;Dyskinesia&lt;br&gt;Futher Impulsivity scores
    </Secondary_outcome>
    <Source_Support>Universität zu Köln
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>04/05/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00025287#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13737974
    </Internal_Number>
    <TrialID>NL-OMON55259
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>A double-blind crossover study to evaluate the safety and efficacy of adaptive Deep Brain Stimulation delivered through AlphaDBS System in patients with Parkinson*s Disease
    </Public_title>
    <Scientific_title>A double-blind crossover study to evaluate the safety and efficacy of adaptive Deep Brain Stimulation delivered through AlphaDBS System in patients with Parkinson*s Disease - A study with adaptive DBS in patients with Parkinson*s Disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Newronika SpA
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210519
    </Date_registration3>
    <Date_registration>2021-05-19
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/55259
    </web_address>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>64
    </Inclusion_agemax>
    <Inclusion_gender/>
    <Date_enrollement/>
    <Target_size>3
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized  controlled trial, Double blinded (masking used), Active, Crossover, Treatment
    </Study_design>
    <Phase/>
    <Countries>Italy;Netherlands;Poland
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address>Via G.B. Pioda  9
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>D.O.Research Sagl
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;p&gt;1. Diagnosis of idiopathic PD; &lt;br&gt;2. Subject is bilaterally treated with DBS in the STN using a Medtronic Activa &lt;br&gt;PC or Activa RC IPG (mono-channnel or dual channel);&lt;br&gt;3. DBS implant for at least 3 years and in need of battery replacement within &lt;br&gt;12 months after consent; &lt;br&gt;4. Patients must be able to understand and sign the informed consent document.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;p&gt;1. Patients with severe cognitive decline, as resulting from MoCA assessment &lt;br&gt;(MoCA score &lt; 10);&lt;br&gt;2. Patients with major psychiatric issues or any other condition that, based on &lt;br&gt;the physician opinion, could interfere with the study conduct (e.g. severe &lt;br&gt;depression, psychosis, etc.);&lt;br&gt;3. Patients with any medical conditions potentially interfering with DBS &lt;br&gt;battery replacement surgery (e.g. severe hypertension, active cancer, intake of &lt;br&gt;drugs interfering with the coagulation etc.);&lt;br&gt;4. Need to replace or reposition the leads during the IPG replacement procedure;&lt;br&gt;5. Patients with &gt; 10 recurrent falls experienced in the 3 months prior to &lt;br&gt;consent;&lt;br&gt;6. Patients that cannot tolerate an interruption of DBS stimulation for at &lt;br&gt;least 30 min;&lt;br&gt;7. Patients taking less than one levodopa dose per day;&lt;br&gt;8. Patients without suitable LFPs recordings or with significant artifacts&lt;br&gt;9. Pregnant or breastfeeding women.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Morbus Parkinson &lt;br&gt;Parkinson's Disease;10028037;Morbus Parkinson;Parkinson's Disease
    </Condition>
    <Intervention>&lt;p&gt;The study treatment, adaptive DBS (aDBS), will be tested in comparison with &lt;br&gt;conventional DBS (cDBS). Following personalized algorithm set up and «AlphaDBS» &lt;br&gt;System calibration, patients will be randomly assigned to either one of the &lt;br&gt;stimulation mode sessions (i.e. aDBS or cDBS). &lt;br&gt;&lt;br&gt;The study will consist of a hospitalization phase in which patients will &lt;br&gt;undergo surgery for removal of the old IPG, implant of the «AlphaDBS» System &lt;br&gt;and set up of the personalized algorithm. Then, patients will be randomized to &lt;br&gt;either aDBS or cDBS stimulation (one day in each mode), and on fourth day &lt;br&gt;discharged to the second phase of the protocol (home) where they will be &lt;br&gt;exposed to additional 28 days of DBS (14 days in each mode). &lt;/p&gt;&lt;br&gt;;adaptive DBS;AlphaDBS;Deep Brain Stimulation;Parkinson's Disease
    </Intervention>
    <Primary_outcome>&lt;p&gt;Safety Analysis (primary objective): safety will be evaluated on all patients&lt;br /&gt;&lt;br&gt;randomized and receiving at least one of the treatments. It will include the&lt;br /&gt;&lt;br&gt;comparison of: 1) TEED delivered to the patient during aDBS and cDBS&lt;br /&gt;&lt;br&gt;experimental sessions; 2) AEs during the 2 stimulation modes.&lt;/p&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>&lt;p&gt;Preliminary Efficacy Analysis (secondary objective): clinical efficacy will be&lt;br /&gt;&#x0D;&lt;br&gt;evaluated through intention-to-treat analysis. Exploratory analysis will be&lt;br /&gt;&#x0D;&lt;br&gt;performed to obtain summary data to inform decisions on future clinical&lt;br /&gt;&#x0D;&lt;br&gt;development phases. Differences in clinical endpoints when patients receive&lt;br /&gt;&#x0D;&lt;br&gt;aDBS or cDBS will be compared by appropriate statistical tests. The time&lt;br /&gt;&#x0D;&lt;br&gt;courses of UPDRS III scores, motor symptoms fluctuations, *time off* and *time&lt;br /&gt;&#x0D;&lt;br&gt;on* as collected by Patient Diaries and UDysRS during aDBS and cDBS treatments&lt;br /&gt;&#x0D;&lt;br&gt;will be compared. &lt;/p&gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>NCT04681534;NL73291.068.20
    </Secondary_ID>
    <Source_Support>industry
    </Source_Support>
    <Ethics_review_status>Not available;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900;19/05/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>;
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13646258
    </Internal_Number>
    <TrialID>DRKS00025329
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>New forms of thalamic deep brain stimulation for Parkinson’s disease and Essential tremor
    </Public_title>
    <Scientific_title>New forms of thalamic deep brain stimulation for Parkinson’s disease and Essential tremor - Thalamic DBS in tremor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
    </Scientific_title>
    <Primary_sponsor>Klinik für Neurologie, UKE Hamburg
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210518
    </Date_registration3>
    <Date_registration>18/05/2021
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00025329
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>30 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>19/07/2017
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Non-randomized controlled study; Masking: Blinded (masking used); Control: Other; Assignment: parallel; Study design purpose: treatment 
    </Study_design>
    <Phase>4
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Monika
    </Contact_Firstname>
    <Contact_Lastname>Pötter-Nerger
    </Contact_Lastname>
    <Contact_Address>Martinistrasse 52
    </Contact_Address>
    <Contact_Email>m.poetter-nerger@uke.de
    </Contact_Email>
    <Contact_Tel>040-74100
    </Contact_Tel>
    <Contact_Affiliation>UKE, Neurologie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) diagnosed ET or idiopathic PD (2) implantation with  DBS devices allowing short pulse widths and directional stimulation (3) at least three months postoperatively after DBS implantation. 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Unability to understand the study procedure
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G25.0 &lt;br&gt;G20.1;Essential tremor;G25.0;G20.1
    </Condition>
    <Intervention>Group 1: In PD patients with predominant tremor:&lt;br&gt;Assessment of 4 different DBS stimulation conditions in randomised order with at least 30 min in between. Patients and assessor are blinded, the second therapeutic investigator changes stimulation conditions.&lt;br&gt;1. DBS Off 2. conventional, omnidirectional STIM ON (60µs) 3. Short-pulse, omnidirectional STIM ON (30µs) 4. Unidirectional STIM On with 60µs&lt;br&gt;The assessment has a duration of about half a day.&lt;br&gt;&lt;br&gt;&lt;br&gt;Group 2: In patients with Essential tremor:&lt;br&gt;Assessment of 4 different DBS stimulation conditions in randomised order with at least 30 min in between. Patients and assessor are blinded, the second therapeutic investigator changes stimulation conditions.&lt;br&gt;1. DBS Off 2. conventional, omnidirectional STIM ON (60µs) 3. Short-pulse, omnidirectional STIM ON (30µs) 4. Unidirectional STIM On with 60µs&lt;br&gt;The assessment has a duration of about half a day.&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>We aime to evaluate the effect of short pulse and directional DBS in the VIM / PSA in PD patients 
    </Primary_outcome>
    <Secondary_outcome>We aime to compare DBS efficiency with conventional and new stimulation forms in PD and ET patients
    </Secondary_outcome>
    <Source_Support>Deutsche Forschungsgemeinschaft
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>18/07/2017
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ethik@aekhh.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Ärztekammer Hamburg
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-40-2022990
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ethik@aekhh.de
    </Ethics_review_contact_email>
    <results_date_completed>31/01/2021
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00025329#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13643609
    </Internal_Number>
    <TrialID>DRKS00021068
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Is VIM-DBS in ET-plus patients as effective as in ET patients?
    </Public_title>
    <Scientific_title>Is VIM-DBS in ET-plus patients as effective as in ET patients?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Klinik und Poliklinik für Neurologie, Uniklinik Köln
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210503
    </Date_registration3>
    <Date_registration>03/05/2021
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00021068
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>27/07/2019
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: treatment 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Julia K.
    </Contact_Firstname>
    <Contact_Lastname>Steffen
    </Contact_Lastname>
    <Contact_Address>Kerpener Straße 62
    </Contact_Address>
    <Contact_Email>julia.steffen@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>+492214784013
    </Contact_Tel>
    <Contact_Affiliation>Klinik und Poliklinik für Neurologie, Uniklinik Köln
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: ET patients with VIM/PSA-DBS, implantation at our center (Universitiy Hospital of Cologne), preoperative written and video documentation that allows classification in either ET or ET-plus
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Insufficient preoperative documentation that would allow classification in ET and ET-plus, DBS-implantation less than 3 months ago
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G25.0;Essential tremor;G25.0
    </Condition>
    <Intervention>Group 1: Patients with thalamic DBS are retrospective classified in ET and ET-plus. Tremor is analyzed before and after DBS in stimulation-OFF and -ON and amount of tremor reduction is calculated and compared between groups. Tremor assessement is conducted using the Tremor Rating Scale (TRS) and is based on TRS-videos. For TRS evaluation patients have to perform certain movement and tasks, that typically evoke tremor. Most TRS-vides are analyzed retrospectively as they were taken prior to the study. For some patients videos are taken separately for the study. Videos will be taken in stimulation-OFF and -ON. All preoperative videos were taken prior to and independently of the study.&lt;br&gt;&lt;br&gt;Group 2: ET patients are used as control and comparison to ET-p. Same analysis are performed in this group
    </Intervention>
    <Primary_outcome>DBS-response (%) measured via TRS in ON vs OFF Point of time is variable as it is mainly a retrospective study.
    </Primary_outcome>
    <Secondary_outcome>TRS-ON-Score of ET-plus vs ET. Point of time is not defined due to the retrospective character of the study
    </Secondary_outcome>
    <Source_Support>Klinik und Poliklinik für Neurologie, Uniklinik Köln
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>27/06/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_date_completed>09/03/2020
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00021068#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12293977
    </Internal_Number>
    <TrialID>NCT05381688
    </TrialID>
    <Last_Refreshed_on>30 May 2022
    </Last_Refreshed_on>
    <Public_title>VIM DBS Respiratory Modulation: N-of-1 Trial
    </Public_title>
    <Scientific_title>Respiratory Modulation by VIM Deep Brain Stimulation: N-of-1 Trial of Breath-holding and Peak Expiratory Flow
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210427
    </Date_registration3>
    <Date_registration>27/04/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05381688
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 9, 2021
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Alex L Green, FRCS
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Oxford
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Scheduled for VIM DBS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of ET or DT&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  None&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor;Dystonic Tremor
    </Condition>
    <Intervention>Procedure: VIM DBS
    </Intervention>
    <Primary_outcome>Breath-hold (urge to breath)
    </Primary_outcome>
    <Secondary_outcome>Breath-hold (break point);Peak Expiratory Flow Rate;Dyspnoea-12 Questionnaire;Oscillometry;Maximum inspiratory pressure
    </Secondary_outcome>
    <Secondary_ID>256285/1
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>11356867
    </Internal_Number>
    <TrialID>NCT04811807
    </TrialID>
    <Last_Refreshed_on>13 September 2021
    </Last_Refreshed_on>
    <Public_title>Clinical Response of Impulsivity After Brain Stimulation in Parkinson's Disease
    </Public_title>
    <Scientific_title>Multicentre Observational Study of Impulsive Behaviours Following Deep Brain Stimulation in Parkinson's Disease
    </Scientific_title>
    <Acronym>CRIPS
    </Acronym>
    <Primary_sponsor>King's College London
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210319
    </Date_registration3>
    <Date_registration>19/03/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04811807
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2021
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>Observational [Patient Registry]
    </Study_type>
    <Study_design/>
    <Phase/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Selected for DBS to treat motor symptoms of Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  English language fluency&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  nil&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Impulsive Behavior;Impulse Disorders;Gambling, Pathological;Eating, Binge;Hoarding Disorder;Hypersexuality;Compulsive Shopping;Dopamine Dysregulation Syndrome;Caregiver Burnout;Parkinson Disease
    </Condition>
    <Intervention>Device: Subthalamic Nucleaus Deep brain stimulation
    </Intervention>
    <Primary_outcome>change in severity of ICBs and development of new ICBs;Descriptive analysis of recurrence of ICBs in those with history of ICBs using scores on QUIP-RS/PICs;Descriptive analysis of de novo cases of Impulsive control disorders ICD/ICBs
    </Primary_outcome>
    <Secondary_outcome>predictive factors for de novo, recurrence and change in severity of ICD/ICBs;change in ICB relate to quality of life in patients and carers;change in ICD relates to changes in mood;change in ICD relates to change in personality traits
    </Secondary_outcome>
    <Secondary_ID>285162
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>South London and Maudsley NHS Foundation Trust;NHS Greater Glasgow and Clyde;King's College Hospital NHS Trust;Walton Centre NHS Foundation Trust;Newcastle-upon-Tyne Hospitals NHS Trust;Oxford University Hospitals NHS Trust;Barking, Havering and Redbridge University Hospitals NHS Trust;Salford Royal NHS Foundation Trust
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12534913
    </Internal_Number>
    <TrialID>NCT04758624
    </TrialID>
    <Last_Refreshed_on>19 September 2022
    </Last_Refreshed_on>
    <Public_title>Elucidating the Temporality of Structural and Functional Connectivity Changes in Essential Tremor After Successful Deep Brain Stimulation to the Dentato-rubro-thalamic Tract
    </Public_title>
    <Scientific_title>Elucidating the Temporality of Structural and Functional Connectivity Changes in Essential Tremor After Successful Deep Brain Stimulation to the Dentato-rubro-thalamic Tract
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>The University of Texas Health Science Center, Houston
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210212
    </Date_registration3>
    <Date_registration>12/02/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04758624
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 4, 2021
    </Date_enrollement>
    <Target_size>72
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Albert J Fenoy, MD;Robert Ritter III;Robert Ritter III
    </Contact_Lastname>
    <Contact_Email>;Robert.Ritter@uth.tmc.edu;Robert.Ritter@uth.tmc.edu
    </Contact_Email>
    <Contact_Tel>;713-500-8914;713-500-8914
    </Contact_Tel>
    <Contact_Affiliation>The University of Texas Health Science Center, Houston;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  the diagnosis of Essential Tremor, made by a movement disorder neurologist, where&#x0D;&lt;br&gt;             tremor is not secondary to any disease process or traumatic insult&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  distal appendicular tremor, with minimal proximal component&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  tremor refractory to multiple medication regimens and/or where the medications cause&#x0D;&lt;br&gt;             intolerable side effects&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  tremor judged to be severely impacting their quality of life.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  significant neurological disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  significant dementia or neurocognitive limitations as assessed by neuropsychiatry&#x0D;&lt;br&gt;             (when necessary)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe psychiatric illness with suicidal ideations&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  previous surgery to destroy the target region of the brain&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  surgical contraindications to DBS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  current major medical problems that affect brain anatomy,neurochemistry, or function,&#x0D;&lt;br&gt;             e.g., liver insufficiency, kidney insufficiency, cardiovascular problems, systemic&#x0D;&lt;br&gt;             infections, cancer, hypothyroidism, auto-immune diseases, and any current of history&#x0D;&lt;br&gt;             of brain disorder (seizure disorder, stroke, dementia, meningitis, encephalitis,&#x0D;&lt;br&gt;             degenerative neurologic diseases and head injury with loss of consciousness for any&#x0D;&lt;br&gt;             period of time)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  family history of hereditary neurologic disorder, besides essential tremors ET&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  floating metallic objects in the body&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  alcohol or substance abuse/dependence in the past 6 months.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Structural connectivity as indicated by fractional anisotropy (FA) as measured by diffusion tensor imaging (DTI) MRI;Structural connectivity as indicated by fractional anisotropy (FA) as measured by diffusion tensor imaging (DTI) MRI;Structural connectivity as indicated by mean diffusivity as measured by diffusion tensor imaging (DTI) MRI;Structural connectivity as indicated by mean diffusivity as measured by diffusion tensor imaging (DTI) MRI;Structural connectivity as indicated by radial diffusivity as measured by diffusion tensor imaging (DTI) MRI;Structural connectivity as indicated by radial diffusivity as measured by diffusion tensor imaging (DTI) MRI;Structural connectivity as indicated by axial diffusivity as measured by diffusion tensor imaging (DTI) MRI;Structural connectivity as indicated by axial diffusivity as measured by diffusion tensor imaging (DTI) MRI;Functional connectivity as indicated by blood oxygen level dependent (BOLD) signal as measured by resting state functional MRI (rsfMRI);Functional connectivity as indicated by blood oxygen level dependent (BOLD) signal as measured by resting state functional MRI (rsfMRI);Functional connectivity as indicated by blood oxygen level dependent (BOLD) signal as measured by resting state functional MRI (rsfMRI);Functional connectivity as indicated by blood oxygen level dependent (BOLD) signal as measured by resting state functional MRI (rsfMRI);Tremor as assessed by score on The Essential Tremor Rating Scale (TETRAS);Tremor as assessed by score on The Essential Tremor Rating Scale (TETRAS);Tremor as assessed by score on The Essential Tremor Rating Scale (TETRAS);Tremor as assessed by score on The Essential Tremor Rating Scale (TETRAS);Tremor as assessed by score on The Essential Tremor Rating Scale (TETRAS);Tremor as assessed by score on The Essential Tremor Rating Scale (TETRAS);Spectral power recorded during intraoperative electrocorticography (ECoG);Spectral power recorded during intraoperative electrocorticography (ECoG)
    </Primary_outcome>
    <Secondary_outcome>Ataxia as assessed by score on the Scale for the Assessment and Rating of Ataxia (SARA);Ataxia as assessed by score on the Scale for the Assessment and Rating of Ataxia (SARA);Ataxia as assessed by score on the Scale for the Assessment and Rating of Ataxia (SARA);Ataxia as assessed by score on the Scale for the Assessment and Rating of Ataxia (SARA);Tremor amplitude as assessed by accelerometric power;Tremor amplitude as assessed by accelerometric power
    </Secondary_outcome>
    <Secondary_ID>HSC-MS-20-0739
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institutes of Health (NIH)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10820164
    </Internal_Number>
    <TrialID>NCT04828798
    </TrialID>
    <Last_Refreshed_on>12 April 2021
    </Last_Refreshed_on>
    <Public_title>Directional Versus Nondirectional DBS for ET
    </Public_title>
    <Scientific_title>Directional Versus Nondirectional Deep Brain Stimulation of the VIM Thalamic Nucleus for Essential Tremor: Assessment of Therapeutic Window, Speech, Gait and Balance
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Oregon Health and Science University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210208
    </Date_registration3>
    <Date_registration>08/02/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04828798
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 1, 2021
    </Date_enrollement>
    <Target_size>24
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Zoe Fanning;Zoe Fanning
    </Contact_Lastname>
    <Contact_Email>fanningz@ohsu.edu;fanningz@ohsu.edu
    </Contact_Email>
    <Contact_Tel>503-494-7772;503-494-7772
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A tremor syndrome of bilateral upper limb action tremor with at least 3 years'&#x0D;&lt;br&gt;             duration&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who have decided not to receive DBS for control of their&#x0D;&lt;br&gt;             medication-refractory essential tremor.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with secondary tremor (ie not Essential Tremor), such as side effects from&#x0D;&lt;br&gt;             medications, secondary to another identified neurologic disease (eg multiple&#x0D;&lt;br&gt;             sclerosis, -----Parkinson's disease, dystonia).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Prior history of deep brain stimulation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Prior history of thalamotomy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A history or signs of dystonia, ataxia or parkinsonism.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Task specific tremor.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Orthostatic tremor.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with cardiac pacemakers, defibrillators, or neurostimulators.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who require MRI, ECT, rTMS, or diathermy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with other type of neurological disease or injury.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Device: Deep brain stimulation of the VIM Thalamic nuclei
    </Intervention>
    <Primary_outcome>Therapeutic window
    </Primary_outcome>
    <Secondary_outcome>Improvement of tremor;Compare the effects of directional versus nondirectional DBS on self perception of speech;Compare the effects of directional versus nondirectional DBS on balance and gait;Compare the effects of directional versus nondirectional DBS on perceptual assessment of voice and speech
    </Secondary_outcome>
    <Secondary_ID>99920724
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13645426
    </Internal_Number>
    <TrialID>DRKS00024072
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>The role of low frequency stimulation of the mesiotemporal region in memory enhancement
    </Public_title>
    <Scientific_title>The role of low frequency stimulation of the mesiotemporal region in memory enhancement                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>Universitätsklinik für Neurologie, Evangelisches Krankenhaus Oldenburg Abteilung für Neurologie, Fakultät für Medizin und Gesundheitswissenschaften, Carl von Ossietzky Universität Oldenburg
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210205
    </Date_registration3>
    <Date_registration>05/02/2021
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00024072
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>35 Years
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>14/06/2021
    </Date_enrollement>
    <Target_size>7
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Non-randomized controlled study; Masking: Blinded (masking used); Control: historical//Other; Assignment: crossover; Study design purpose: other 
    </Study_design>
    <Phase>1
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Charlotte
    </Contact_Firstname>
    <Contact_Lastname>Büttner
    </Contact_Lastname>
    <Contact_Address>Heiligengeisthöfe 4
    </Contact_Address>
    <Contact_Email>charlotte.buettner@uni-oldenburg.de
    </Contact_Email>
    <Contact_Tel>0049 441 789 4657
    </Contact_Tel>
    <Contact_Affiliation>Abteilung für Neurologie, Fakultät für Medizin und Gesundheitswissenschaften, Carl-von-Ossietzky Universität Oldenburg
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Dystonia patients will be included, if they have received DBS in the GPi, if they match the age range of 35-65 years and if they are female. Further, a pre-operative MRI or CT is required to locate the placement of electrodes using lead DBS.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients will be excluded from the study, if thy show any kind of cognitive impairment and/or if the electrode was not correctly placed in the GPi, according to LeadDBS. 
    </Exclusion_Criteria>
    <Condition>Dystonia
    </Condition>
    <Intervention>Group 1: Patients with Dystonia, who received misplaced DBS electrodes in the mesitemporal region (these data already exist), who received neuropsychological testing under three different stimulation conditions  (no stimulation, 20Hz und 120Hz).&lt;br&gt;Group 2: Patients with Dystonia with correctly placed electrodes in the Globus pallidus Interna, who receive neuropsychological testing under three stimulation conditions (no stimulation, 20 Hz and 120 Hz).
    </Intervention>
    <Primary_outcome>The goal of this study is to provide a control group for already existing and also ethically approved data. To see whether the results can be replicated by stimulating correctly placed electrodes of the GPi, comparable cases need to be provided. The proposed study is considered purely experimental and is not aimed to give any therapeutic insight. &lt;br&gt;&lt;br&gt;Cognitive Performance is measured using four neuropsychological tests: Word-Pair learning, Digit ordering, stroop task and verbal fluency. All tests are done on three days under different stimulation conditions (no stimulation, 20Hz and 120 Hz Stimulation).
    </Primary_outcome>
    <Secondary_outcome>Secondary outcome are neurological examination and a wellbeing questionnaire. 
    </Secondary_outcome>
    <Source_Support>Abteilung für Neurologie, Fakultät für Medizin und Gesundheitswissenschaften, Carl-von-Ossietzky Universität Oldenburg
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>16/12/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>med.ethikkommission@uni-oldenburg.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Geschäftsstelle der medizinischen Ethikkommission, Fakultät VI Medizin und Gesundheitswissenschaften, Carl von Ossietzky Universität Oldenburg, Gebäude V04 (Raum 1-137)
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-441-7983109
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>med.ethikkommission@uni-oldenburg.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00024072#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13524150
    </Internal_Number>
    <TrialID>NCT04735458
    </TrialID>
    <Last_Refreshed_on>13 November 2023
    </Last_Refreshed_on>
    <Public_title>Investigating Inhibitory Control Networks in Parkinson's Disease
    </Public_title>
    <Scientific_title>Investigating Inhibitory Control Networks in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Alabama at Birmingham
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210128
    </Date_registration3>
    <Date_registration>28/01/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04735458
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 1, 2021
    </Date_enrollement>
    <Target_size>90
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Nicole Bentley, MD;Nicole Bentley, MD;Nicole Bentley, MD
    </Contact_Lastname>
    <Contact_Email>;jbentley@uabmc.edu;jbentley@uabmc.edu
    </Contact_Email>
    <Contact_Tel>;205-975-0011;205-975-0011
    </Contact_Tel>
    <Contact_Affiliation>University of Alabama at Birmingham;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Eligible for DBS surgery based on multi-disciplinary consensus review&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a diagnosis of Parkinson's disease or Essential Tremor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A minimum of 18 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willingness to participate in the paradigms described in the protocol&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to provide full and informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Are not surgical candidates due to co-morbid conditions or pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have not undergone an adequate trial of conservative medical management&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a clinical presentation for which DBS surgery is not indicated&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Are not able to participate in study-related activities&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Procedure/Surgery: Response Inhibition and Deep Brain Stimulation in Parkinson's disease
    </Intervention>
    <Primary_outcome>Accuracy via Simon Task (% correct);Response times via Simon Task (sec);Simon Effect on Response times (sec);Simon Effect on Accuracy (% correct);United Parkinson's disease Rating Scale part 3: Motor Examination Score 0-108 (Higher score represents worse symptoms);Dementia Rating Scale Score 0-144 points (Higher score represents better symptoms)
    </Primary_outcome>
    <Secondary_ID>1K23NS117735-01A1;IRB300003605
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institute of Neurological Disorders and Stroke (NINDS)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13124567
    </Internal_Number>
    <TrialID>NCT04712552
    </TrialID>
    <Last_Refreshed_on>20 June 2023
    </Last_Refreshed_on>
    <Public_title>In Vivo Measurement of the Accuracy of the "Neurolocate" Module of the Neurosurgical Robot "Neuromate" in Its Application to Deep Brain Stimulation
    </Public_title>
    <Scientific_title>In Vivo Measurement of the Accuracy of the "Neurolocate" Module of the Neurosurgical Robot "Neuromate" in Its Application to Deep Brain Stimulation
    </Scientific_title>
    <Acronym>NEUROLOCATE
    </Acronym>
    <Primary_sponsor>Centre Hospitalier Universitaire de Nice
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210114
    </Date_registration3>
    <Date_registration>14/01/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04712552
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 26, 2021
    </Date_enrollement>
    <Target_size>18
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>France
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Denys FONTAINE
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Centre Hospitalier Universitaire de Nice
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients aged 18 to 70 years old requiring a stereotactic robot-guided deep brain&#x0D;&lt;br&gt;             stimulation procedure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signature of the Informed Consent Form&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Affiliation to the French social security system&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Contraindication to MRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hypersensitivity to gadoteric acid, meglumine or any product containing gadolinium.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Anterior and posterior commissure anatomy modifying brain anatomy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient unable to complete the Comfort Questionnaire due to cognitive or speech&#x0D;&lt;br&gt;             impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant or breastfeeding women&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Dystonia;Tremor
    </Condition>
    <Intervention>Procedure: deep brain stimulation
    </Intervention>
    <Primary_outcome>Euclidean distance between the point theoretically aimed at by the robot and the point actually reached
    </Primary_outcome>
    <Secondary_outcome>Occupancy time of the operating room;comfort of the patient
    </Secondary_outcome>
    <Secondary_ID>19-PP-22
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13217582
    </Internal_Number>
    <TrialID>NCT04725773
    </TrialID>
    <Last_Refreshed_on>21 August 2023
    </Last_Refreshed_on>
    <Public_title>Apraxia in Parkinson's Disease Patients With Deep Brain Stimulation
    </Public_title>
    <Scientific_title>Apraxia in Parkinson's Disease Patients With Deep Brain Stimulation
    </Scientific_title>
    <Acronym>Apraxia DBS
    </Acronym>
    <Primary_sponsor>University of Florida
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210113
    </Date_registration3>
    <Date_registration>13/01/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04725773
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 1, 2021
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Bhavana Patel, DO;Bhavana Patel, DO;Bhavana Patel, DO
    </Contact_Lastname>
    <Contact_Email>;Bhavana.Patel@neurology.ufl.edu;Bhavana.Patel@neurology.ufl.edu
    </Contact_Email>
    <Contact_Tel>;(352) 294-5400;352-294-5400
    </Contact_Tel>
    <Contact_Affiliation>University of Florida;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patients with PD as defined by the UK Brain Bank Criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Male or female, ages 18 to 80 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Chronically implanted DBS of either the STN or GPi for a minimum of 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Other neurological diagnoses (e.g. Alzheimer's disease, atypical parkinsonism, stroke)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. History of previous neurosurgical intervention that was not DBS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients with DBS of targets other than the STN or GPi, or leads in both targets&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patients in whom there is poor manual dexterity for a reason other than PD (e.g.&#x0D;&lt;br&gt;             orthopedic injury, amputation)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patients with a diagnosis of PD dementia&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Deep Brain Stimulation;Parkinson Disease;Apraxia, Motor
    </Condition>
    <Intervention>Device: Deep brain stimulation effect on apraxia
    </Intervention>
    <Primary_outcome>Evaluate for the presence or absence of ideomotor apraxia in PD patients;Evaluate for the presence or absence of ideational apraxia in PD patients;Evaluate for the presence or absence of limb-kinetic apraxia in PD patients;Evaluate for the presence or absence of limb-kinetic apraxia in PD patients
    </Primary_outcome>
    <Secondary_ID>IRB202001999
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13124506
    </Internal_Number>
    <TrialID>NCT04677621
    </TrialID>
    <Last_Refreshed_on>20 June 2023
    </Last_Refreshed_on>
    <Public_title>TEND Study:Telemedicine Nurse DBS for Parkinson's Disease
    </Public_title>
    <Scientific_title>Telemedicine Nurse DBS for Parkinson's Disease: The TEND Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Florida
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201217
    </Date_registration3>
    <Date_registration>17/12/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04677621
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>100 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 2023
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Supportive Care. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Michael Okun, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Florida
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pre-operative Inclusion Criteria: A good response to levodopa is required in order to&#x0D;&lt;br&gt;             exclude patients with Parkinson's plus syndromes, and will be defined as a 30%&#x0D;&lt;br&gt;             improvement in parkinsonian motor signs based upon the Unified PD Rating Scale (UPDRS)&#x0D;&lt;br&gt;             motor examination subscore, following the administration of 1.5 times the typical&#x0D;&lt;br&gt;             dopaminergic dose during the screening neurological examination. Patients must also&#x0D;&lt;br&gt;             have PD for a minimum of 5 years duration.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Additional inclusion criteria consist of: 1) Hoehn &amp; Yahr stage II or worse when off;&#x0D;&lt;br&gt;             2) Intractable, disabling motor fluctuations and/or tremor; 3) Age between 30-75&#x0D;&lt;br&gt;             years; 4) Unsatisfactory clinical response to maximal medical management (with trials&#x0D;&lt;br&gt;             of both higher and lower doses of antiparkinsonian drugs). 5) A stable/optimal medical&#x0D;&lt;br&gt;             regimen of antiparkinsonian drug therapy for at least one month prior to surgery; 6)&#x0D;&lt;br&gt;             access to high-speed internet in the home.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical disease that would increase the risk of developing pre-&#x0D;&lt;br&gt;             or postoperative complications (e.g. significant cardiac or pulmonary disease,&#x0D;&lt;br&gt;             uncontrolled hypertension).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of secondary or atypical parkinsonism.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MRI scan with significant evidence of brain atrophy or other abnormalities.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia as evidenced by impairment in two neuropsychological domains and impaired or&#x0D;&lt;br&gt;             borderline neuropsychological function in one additional domain.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A major untreated psychiatric disorder.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Nurse Telehealth;Other: STANDARD DBS
    </Intervention>
    <Primary_outcome>The number of participant clinic visits
    </Primary_outcome>
    <Secondary_outcome>PDQ-39 Scores
    </Secondary_outcome>
    <Secondary_ID>OCR39945;PRO00042966;IRB202002994-N
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13347259
    </Internal_Number>
    <TrialID>NCT04703556
    </TrialID>
    <Last_Refreshed_on>18 September 2023
    </Last_Refreshed_on>
    <Public_title>Recording and Modulation of Brain Activity Through Chronically Implanted Stimulation Electrodes
    </Public_title>
    <Scientific_title>Recording and Modulation of Brain Activity Through Chronically Implanted Stimulation Electrodes in Patients With Parkinson's Disease
    </Scientific_title>
    <Acronym>PDNeuroGAIT
    </Acronym>
    <Primary_sponsor>Jocelyne Bloch
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201201
    </Date_registration3>
    <Date_registration>01/12/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04703556
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 4, 2021
    </Date_enrollement>
    <Target_size>8
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Switzerland
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age: 18 years old or more&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Informed Consent as documented by signature&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosed with Parkinson's disease, and being treated with deep brain stimulation&#x0D;&lt;br&gt;             therapies.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Exhibiting severe locomotor deficits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agree to comply in good faith with all conditions of the recordings.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to follow the procedures of the study, e.g. due to language problems,&#x0D;&lt;br&gt;             psychological disorders, dementia, etc. of the participant,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participation in another investigational study in the preceding 30 days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous enrolment into the current study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Devices for deep brain stimulation
    </Intervention>
    <Primary_outcome>Changes in gait performance induced by DBS parameters;Changes in gait performance induced by DBS parameters;Changes in gait performance induced by DBS parameters;Changes in gait quality induced by DBS parameters;Changes in global motor scores induced by DBS parameters;Changes in brain dynamics induced by DBS parameters;Changes in brain dynamics induced by DBS parameters
    </Primary_outcome>
    <Secondary_ID>DBSgait2020
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Hôpital du Valais
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10817698
    </Internal_Number>
    <TrialID>NCT04650958
    </TrialID>
    <Last_Refreshed_on>12 April 2021
    </Last_Refreshed_on>
    <Public_title>SUNDYS: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel-group Trial
    </Public_title>
    <Scientific_title>Subthalamic Nucleus Deep Brain Stimulation in Isolated Generalized or Segmental Dystonia: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel-group Trial
    </Scientific_title>
    <Acronym>SUNDYS
    </Acronym>
    <Primary_sponsor>Ruijin Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201119
    </Date_registration3>
    <Date_registration>19/11/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04650958
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>14 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2021
    </Date_enrollement>
    <Target_size>38
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Bomin Sun;Kejia Hu, MD, PhD;Kejia Hu, MD,PhD
    </Contact_Lastname>
    <Contact_Email>;dockejiahu@gmail.com;dockejiahu@gmail.com
    </Contact_Email>
    <Contact_Tel>;18930113801;+86 18930113801
    </Contact_Tel>
    <Contact_Affiliation>Ruijin Hospital;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patients must meet criteria for the diagnosis of isolated generalized or segmental&#x0D;&lt;br&gt;             dystonia, including idiopathic and inherited dystonia, as defined by the Phenomenology&#x0D;&lt;br&gt;             and Classification of Dystonia: A Consensus Update 2013;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patients will be = 14 years old;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. The course of disease will be = 3 years;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patients will have:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Significant dystonia symptoms;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Compromised life quality;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. Unsatisfactory response to oral treatment with anticholinergic agents&#x0D;&lt;br&gt;                  antiepileptic agents, anti-dopamine agents, dopaminergic agents, or muscle&#x0D;&lt;br&gt;                  relaxants;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               4. Unsatisfactory response to or contraindication for previous botulinum toxin&#x0D;&lt;br&gt;                  treatment; and&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               5. Ability to provide written informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patients with a diagnosis or probable diagnosis of acquired, compound, and complex&#x0D;&lt;br&gt;             dystonia, as defined by the Phenomenology and Classification of Dystonia: A Consensus&#x0D;&lt;br&gt;             Update 2013;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Previous brain surgery for dystonia;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients with cognitive impairment (MMSE score &lt;24) or moderate-severe depressive&#x0D;&lt;br&gt;             disorder (BDI&gt;25);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patients with marked brain atrophy identified by magnetic resonance imaging (MRI) or&#x0D;&lt;br&gt;             computed tomography (CT);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patients with other medical or psychiatric comorbidities that could increase the&#x0D;&lt;br&gt;             surgical risk or interfere with completion of the trial;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Patients with increased bleeding risk, or other factors contraindicating neurosurgery&#x0D;&lt;br&gt;             or general anesthesia;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Patients unable to cooperate with the assessments during the follow-up.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Dystonia
    </Condition>
    <Intervention>Procedure: Deep brain stimulation
    </Intervention>
    <Primary_outcome>The change from baseline to 3 months after stimulation of Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) score
    </Primary_outcome>
    <Secondary_outcome>Abnormal Involuntary Movement Scale (AIMS);36-item Short-Form General Health survey (SF-36);Beck Depression Inventory-II (BDI);Beck Anxiety Inventory (BAI);Montreal Cognitive Assessment (MoCA);Cambridge Neuropsychological Test Automated Battery (CANTAB);The rate of response;The rate of adverse event (AE);Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS)
    </Secondary_outcome>
    <Secondary_ID>Ruijin_SUNDYS
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Renmin Hospital of Wuhan University;Shanghai Tongji Hospital, Tongji University School of Medicine;Second Affiliated Hospital of Soochow University;West China Hospital
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12728319
    </Internal_Number>
    <TrialID>NCT04650932
    </TrialID>
    <Last_Refreshed_on>9 January 2023
    </Last_Refreshed_on>
    <Public_title>Dual Frequency Stimulation in Parkinson's Disease
    </Public_title>
    <Scientific_title>Dual Frequency, Dual Region Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of California, Davis
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201116
    </Date_registration3>
    <Date_registration>16/11/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04650932
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 22, 2022
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Kiarash Shahlaie, MD, PhD;Kiarash Shahlaie, MD, PhD;Jessica Beatty, MS
    </Contact_Lastname>
    <Contact_Email>;krshahlaie@ucdavis.edu;jabeatty@ucdavis.edu
    </Contact_Email>
    <Contact_Tel>;916-703-5505;916-734-0901
    </Contact_Tel>
    <Contact_Affiliation>University of California, Davis;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who are 18 years and older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals with idiopathic Parkinson's Disease who previously underwent implantation&#x0D;&lt;br&gt;             with the Boston Scientific VerciseTM DBS system&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who have been implanted with the Boston Scientific VerciseTM DBS system&#x0D;&lt;br&gt;             for at least 3 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals diagnosed with advanced PD who had bilateral dorsal subthalamic nucleus&#x0D;&lt;br&gt;             DBS surgery, as standard of care for motor improvement, with distal contacts of the&#x0D;&lt;br&gt;             electrodes implanted into the ventral STN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals unable to provide consent and/or lack capacity to consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals diagnosed with any cognitive or physical impairments that would limit&#x0D;&lt;br&gt;             their ability to participate in the cognitive testing&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who score below 15 on the Montreal Cognitive Assessment Test-Blind&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who score above 20 on the Center for Epidemiologic Studies Depression&#x0D;&lt;br&gt;             Scale&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant women (note: pregnant women are not candidates for DBS surgery), and&#x0D;&lt;br&gt;             prisoners&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-English speaking individuals. Cognitive tasks will only be conducted in English.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Deep brain stimulation
    </Intervention>
    <Primary_outcome>Mean Change from Baseline in Depression Scores on the Center for Epidemiologic Studies Depression Scale (CES-D);Mean Change from Baseline in Impulsiveness Scores on the Barratt Impulsiveness Scale (BIS-11);Mean Change from Baseline in Neuropsychiatric Inventory (NPI);Mean Change from Baseline in Movement Scores on Part III of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS);Mean Change from Baseline in Cognitive Performance Scores on the Montreal Cognitive Assessment - Blind (MoCA);Mean Change from Baseline in Depression Scores on the CES-D Short Version (CES-D-R10);Mean Change from Baseline in Motor and Non-Motor Aspects of Daily Living Scores on Parts I and II of the MDS-UPDRS
    </Primary_outcome>
    <Secondary_outcome>Mean Change from Baseline in Decision-Making Scores on Probabilistic Gambling Task;Mean Change from Baseline in Inter-Temporal Choice Scores on a Temporal Discounting Task;Mean Change from Baseline in Verbal Fluency Scores on Word Generation Task
    </Secondary_outcome>
    <Secondary_ID>1633883
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13642428
    </Internal_Number>
    <TrialID>DRKS00017327
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Neuronal Oscillations in Parkinson Disease and Essential Tremor
    </Public_title>
    <Scientific_title>Neuronal Oscillations in Parkinson Disease and Essential Tremor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Klinik für Stereotaxie und Funktionelle Neurochirurgie  Universitätsklinikum Köln
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201103
    </Date_registration3>
    <Date_registration>03/11/2020
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00017327
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>01/04/2021
    </Date_enrollement>
    <Target_size>24
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: N/A: single arm study; Masking: Open (masking not used); Control: uncontrolled; Assignment: single; Study design purpose: treatment 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Veerle
    </Contact_Firstname>
    <Contact_Lastname>Visser-Vandewalle
    </Contact_Lastname>
    <Contact_Address>Kerpener Str. 62
    </Contact_Address>
    <Contact_Email>veerle.visser-vandewalle@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>+49 221 478-82793
    </Contact_Tel>
    <Contact_Affiliation>Direktorin der Klinik für Stereotaxie und Funktionelle Neurochirurgie Universitätsklinikum Köln
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients undergoing deep brain stimulation (DBS) of the ventral intermediate nucleus (VIM) or posterior subthalamic area (PSA) for treatment of essential tremor (ET)&#x0D;&lt;br&gt;Patients undergoing DBS of the subthalamic nucleus (STN), internal globus pallidus (GPi) or VIM with medically refractory tremor-dominant Parkinson's disease (PD)&#x0D;&lt;br&gt;Selection by multidisciplinary teams consisting of neurologists, psychiatrists and functional neurosurgeons&#x0D;&lt;br&gt;Patients must be able to give consent&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Cognitive impairment (judge by interdisciplinary team)&#x0D;&lt;br&gt;Intracranial bleeding, confusion, severe CSF leak, infection or any other complication after first stage of surgery&#x0D;&lt;br&gt;Patients with accompanying severe medical or psychiatric disorders will also be excluded
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G25.0 &lt;br&gt;G20.0;Essential tremor;G25.0;G20.0
    </Condition>
    <Intervention>Group 1: Deep brain stimulation of the ventral intermediate nucleus (VIM) or posterior subthalamic area (PSA) in essential tremor (ET) or the subthalamic nucleus (STN), internal globus pallidus (GPi) or VIM in Parkinson's disease (PD).
    </Intervention>
    <Primary_outcome>Identify spectral changes in the LFP during and before the onset of tremor.&lt;br&gt;&lt;br&gt;Local field potentials will be recorded from externalized DBS leads between stage 1 and stage 2 surgery (either 1 or 2 days after lead implantation). We will use a TMSi Porti amplifier and custom-written software to record the time series signal. At a later stage, the time series signal will be pre-processed (filtered, detrended) and analysed (time-frequency decomposition) to examine changes in the time-frequency spectrogram related to tremor.
    </Primary_outcome>
    <Secondary_outcome>Study the temporal dynamics of spectral changes related to tremor.
    </Secondary_outcome>
    <Secondary_ID>U1111-1236-0949
    </Secondary_ID>
    <Source_Support>Direktorin der Klinik für Stereotaxie und Funktionelle Neurochirurgie Universitätsklinikum Köln
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>29/10/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00017327#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10382482
    </Internal_Number>
    <TrialID>NCT04618887
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>A Comparative Study of GPI's DBS and Pallidotomy in the Treatment of Meige Syndrome
    </Public_title>
    <Scientific_title>A Comparative Study of GPI's DBS and Pallidotomy in the Treatment of Meige Syndrome
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Peking University People's Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20201101
    </Date_registration3>
    <Date_registration>01/11/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04618887
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2020
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>China
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients confirmed Meige sydrome&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who cannot finish the neurosurgery or the postoperative evaluation&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Meige Syndrome;Meigs Syndrome;Meige Disease;Meig Syndrome;Blepharospasm;Blepharospasm of Left Eyelid;Blepharospasm of Right Eyelid;Blepharospasm of Both Eyelids;Blepharospasm Oromandibular Dystonia
    </Condition>
    <Intervention>Procedure: pallidotomy;Procedure: deep brain stimulation
    </Intervention>
    <Primary_outcome>Symptom;complications
    </Primary_outcome>
    <Secondary_outcome>quality of life;depression scale
    </Secondary_outcome>
    <Secondary_ID>MeigeSyndrome
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10518829
    </Internal_Number>
    <TrialID>NCT04617873
    </TrialID>
    <Last_Refreshed_on>25 January 2021
    </Last_Refreshed_on>
    <Public_title>DBS and SCS Therapy Improve Motor Function in Multiple System Atrophy With Predominant Parkinsonism
    </Public_title>
    <Scientific_title>Deep Brain Stimulation and Spinal Cord Stimulation Therapy Improve Motor Function in Multiple System Atrophy With Predominant Parkinsonism: a Multi-center, Prospective, Open Label Clinical Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>zhangyuqing
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201030
    </Date_registration3>
    <Date_registration>30/10/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04617873
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>30 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 5, 2021
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Yuqing Zhang, MD;Jiping Li, MD;Jiping Li, MD
    </Contact_Lastname>
    <Contact_Email>;yhljp89@163.com;yhljp89@163.com
    </Contact_Email>
    <Contact_Tel>;8610-83198899-8630;8610-83198899-8630
    </Contact_Tel>
    <Contact_Affiliation>Capital Medical University- Xuanwu Hospital;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        inclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. meet the clinical diagnostic criteria of possible MSA-P;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. with moderate to severe parkinsonism motor symptoms;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. accept levodopa treatment for at least 6 months, and stable medication dose for at&#x0D;&lt;br&gt;             least 4 weeks;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. severe orthostatic hypotension;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. score of Hamilton Depression Scale is more than 24.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. score of Mini-mental State Examination is less than 24;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. elevated risks for bleeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. with evident lesions on MRI structural images at T8-12 spinal cord segment&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Multiple System Atrophy, Parkinson Variant (Disorder)
    </Condition>
    <Intervention>Procedure: Bilateral STN-DBS and T10-T12 SCS
    </Intervention>
    <Primary_outcome>change in motor examination( Movement Disorders Society's revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III) at 3 months postoperatively;change in motor examination( Movement Disorders Society's revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III) at 12 months postoperatively;change in PD-related quality of life(PDQ-39)
    </Primary_outcome>
    <Secondary_outcome>change in the score of Gait and Fall Questionnaire (GFQ) at 3 months postoperatively;change in the score of Gait and Fall Questionnaire (GFQ) at 12 months postoperatively;change in severity of freezing of gait (New Freezing of Gait Questionnaire,NFOGQ) at 3 months postoperatively;change in severity of freezing of gait (New Freezing of Gait Questionnaire,NFOGQ) at 12 months postoperatively;Clinical Global Impression-Global Improvement (CGI-GI) at 3 months postoperatively;Clinical Global Impression-Global Improvement (CGI-GI) at 12 months postoperatively;change in the score of Berg Balance Scale(BBS) at 3 months postoperatively;change in the score of Berg Balance Scale(BBS) at 12 months postoperatively
    </Secondary_outcome>
    <Secondary_ID>2020005
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10382300
    </Internal_Number>
    <TrialID>NCT04616521
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>ADP Study: A Multicenter, Prospective, Single Arm, Open Label Study
    </Public_title>
    <Scientific_title>Asymmetric Deep Brain Stimulation for Parkinson's Disease: A Multicenter, Prospective, Single Arm, Open Label Study
    </Scientific_title>
    <Acronym>ADP
    </Acronym>
    <Primary_sponsor>Ruijin Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201030
    </Date_registration3>
    <Date_registration>30/10/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04616521
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 1, 2020
    </Date_enrollement>
    <Target_size>1000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Dianyou Li, MD, PhD
    </Contact_Lastname>
    <Contact_Email>ldy11483@rjh.com.cn
    </Contact_Email>
    <Contact_Tel>13817864569
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosed with idiopathic Parkinson's disease based on the MDS clinical diagnostic&#x0D;&lt;br&gt;             criteria for Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Aged more than 18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Levodopa challenge test indicating a preoperative levodopa responsiveness over 24%&#x0D;&lt;br&gt;             based on MDS UPDRS-III&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  the modified Hoehn-Yahr Scale between 2 and 4 under on-medication condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Compliance with written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Atypical parkinsonian syndrome&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of stroke, encephalitis, neuroleptic uses, MRI scan with evidence of&#x0D;&lt;br&gt;             significant brain atrophy, lacunar infracts, or other conditions that might interfere&#x0D;&lt;br&gt;             with the intracranial surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of cognitive, or psychiatric or other co-morbidities (e.g., dementia,&#x0D;&lt;br&gt;             epilepsy, cranial traumatism, brain tumor, schizophrenia, severe depression or bipolar&#x0D;&lt;br&gt;             disorder, personality disorder, etc.) that might interfere with the patient's ability&#x0D;&lt;br&gt;             to complete the evaluations or to provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of anatomical abnormalities in the target region&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical history or that increases pre-/post-operative&#x0D;&lt;br&gt;             complications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other conditions considered by the investigators that might interfere with the surgery&#x0D;&lt;br&gt;             procedure, the follow-ups, and the interpretation of the data&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Procedure: Deep brain stimulation
    </Intervention>
    <Primary_outcome>Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale - Part III (MDS UPDRS-III)
    </Primary_outcome>
    <Secondary_outcome>Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale - Part I, II, IV;Time-Up-Go (TUG) task;Berg Balance Scale, BBS;Gait and Falls Questionnaire, GFQ;Montreal Cognitive Assessment (MoCA);Beck Depression Inventory, BDI;Beck Anxiety Inventory, BAI;Apathy Estimation Scale, AES;Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Current Full, QUIP-CF;Epworth Sleepiness Scale, ESS;Non-Motor Symptoms Scale, NMSS;Scales for Outcomes in PArkinson's disease - Autonomic, SCOPA-AUT;8-item Parkinson's Disease Questionnaire (PDQ-8);5-Level EuroQol Five Dimensions Questionnaire, EQ-5D-5L;Levodopa Equivalent Daily Dose, LEDD;Adverse Events, Severe Adverse Events
    </Secondary_outcome>
    <Secondary_ID>Ruijin_ADP
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Huashan Hospital;Shanghai Tongji Hospital, Tongji University School of Medicine;The First Affiliated Hospital with Nanjing Medical University;First Affiliated Hospital, Sun Yat-Sen University;The First Affiliated Hospital of Guangzhou Medical University;West China Hospital;Second Affiliated Hospital of Soochow University;Tianjin Huanhu Hospital;Guangzhou General Hospital of Guangzhou Military Command;The Affiliated Hospital of Xuzhou Medical University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13665820
    </Internal_Number>
    <TrialID>NCT04577651
    </TrialID>
    <Last_Refreshed_on>29 January 2024
    </Last_Refreshed_on>
    <Public_title>Cartesia eXTend 3D Study
    </Public_title>
    <Scientific_title>Study to Evaluate Boston Scientific Vercise Cartesia 16-contact Directional Lead (X/HX) With Deep Brain Stimulation (DBS) Systems for the Treatment of Parkinson's Disease (PD)
    </Scientific_title>
    <Acronym>eXTend 3D
    </Acronym>
    <Primary_sponsor>Boston Scientific Corporation
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200926
    </Date_registration3>
    <Date_registration>26/09/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04577651
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 2, 2020
    </Date_enrollement>
    <Target_size>58
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany;Netherlands;United Kingdom;Germany;Netherlands;United Kingdom
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Natalie Bloom Lyons
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Boston Scientific Neuromodulation Corporation
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Key Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Candidate for DBS implant in the treatment of Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Must be on stable anti-parkinsonian medications for 28 days prior to Informed Consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Persistent disabling Parkinson's disease symptoms such as dyskinesias, motor&#x0D;&lt;br&gt;             fluctuations, or disabling "off" periods despite optimal medical therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be willing and able to comply with all visits and study related procedures (e.g.,&#x0D;&lt;br&gt;             using the remote control, charging system, etc.).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Key Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any intracranial abnormality or medical condition that would contraindicate DBS&#x0D;&lt;br&gt;             surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have any significant psychiatric or cognitive condition likely to compromise the&#x0D;&lt;br&gt;             subject's ability to comply with requirements of the study protocol (e.g. bipolar,&#x0D;&lt;br&gt;             schizophrenia, mood disorder with psychotic features, cluster B personality disorders)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any current drug or alcohol abuse, as determined by the investigator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any history of recurrent or unprovoked seizures&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: 16-contact Directional Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Change in motor function
    </Primary_outcome>
    <Secondary_outcome>Change in motor function;Change in Quality of Life
    </Secondary_outcome>
    <Secondary_ID>A4092
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13565462
    </Internal_Number>
    <TrialID>NCT04605263
    </TrialID>
    <Last_Refreshed_on>4 December 2023
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation (DBS) of the Pedunculopontine Nucleus (PPN)
    </Public_title>
    <Scientific_title>Effects of Deep Brain Stimulation (DBS) of the Pedunculopontine Nucleus (PPN) on Gait, Postural Stability, Freezing of Gait (FOG), and Falls
    </Scientific_title>
    <Acronym>PPNGB01
    </Acronym>
    <Primary_sponsor>St. Joseph's Hospital and Medical Center, Phoenix
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200831
    </Date_registration3>
    <Date_registration>31/08/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04605263
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 1, 2021
    </Date_enrollement>
    <Target_size>8
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Guillermo Moguel-Cobos, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Muhammad Ali Movement Disorders Clinic Physician
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inclusion Criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Informed consent signed by the subject.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Diagnosed with Parkinson's disease per UK Parkinson's Disease Society Brain Bank&#x0D;&lt;br&gt;                  (Queens Square) criteria for at least 4 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. Demonstrates levodopa responsiveness of at least 30%&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               4. Experiences tremor or motor complications including wearing off and/or dyskinesia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               5. DBS candidate per FDA guidelines as outlined in criteria 2-4&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               6. Candidate for STN targeting per the consensus committee&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               7. Subject exhibits gait instability, or a history of at least one fall within the&#x0D;&lt;br&gt;                  last year, or a history of falls on tests of Static or Dynamic Stability.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               8. PD Stage 2-3 with predominant axial symptoms or FOG refractory to Levodopa &gt; 600&#x0D;&lt;br&gt;                  mg and UPDRS Part III Subscore of &gt;6.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               9. Subject is ambulatory and able to walk for limited periods of time without using&#x0D;&lt;br&gt;                  an assistive device.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;              10. 18-75 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;              11. Primary English speaking&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;              12. Physically and cognitively capable of completing evaluations and consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;              13. Medically cleared for surgery and anesthesia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;              14. Female subjects with child-bearing potential have a negative serum pregnancy test&#x0D;&lt;br&gt;                  prior to DBS surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Dementia per DSM-V criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Condition precluding MRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. History of supraspinal CNS disease other than PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. History of schizophrenia, delusions, or currently uncontrolled visual hallucinations&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Subjects who require rTMS, ECT, diathermy, or repeat MRI procedures to treat a medical&#x0D;&lt;br&gt;             condition.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Subjects with a history of seizure disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Subjects who have made a suicide attempt within the prior year,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Subjects with any medical contraindications to undergoing DBS surgery (eg, infection,&#x0D;&lt;br&gt;             coagulopathy, or significant cardiac or other medical risk factors for surgery)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Subjects with an implanted stimulator such as a cardiac pacemaker, defibrillator,&#x0D;&lt;br&gt;             neurostimulator and cochlear implant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Subjects who are pregnant or nursing.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Patient that is unwilling or unable to comply with the requirements of this protocol,&#x0D;&lt;br&gt;             including the presence of any condition (physical, mental, or social) that is likely&#x0D;&lt;br&gt;             to affect the subject's ability to comply with the protocol.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Any other reasons that, in the opinion of the investigator, the candidate is&#x0D;&lt;br&gt;             determined to be unsuitable for entry into the study.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: STN-PPN DBS Surgery;Procedure: Deep Brain Stimulation Surgery (DBS)
    </Intervention>
    <Primary_outcome>STN-PPN Stimulation Effect on Fall Risk
    </Primary_outcome>
    <Secondary_outcome>STN-PPN on Linear and Nonlinear Measures of Gait;STN-PPN on Linear and Nonlinear Measures of Balance;STN-PPN on Attention;STN-PPN on Subjective Measures of Alertness;STN-PPN on Subjective Measures of Sleep;STN-PPN on Subjective Measures of Non-Motor Symptoms;STN-PPN on Subjective Measures of Balance in Daily Life
    </Secondary_outcome>
    <Secondary_ID>PHX-19-500-412-30-04
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Arizona State University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13619758
    </Internal_Number>
    <TrialID>NCT04547712
    </TrialID>
    <Last_Refreshed_on>15 January 2024
    </Last_Refreshed_on>
    <Public_title>Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease
    </Public_title>
    <Scientific_title>Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease
    </Scientific_title>
    <Acronym>ADAPT-PD
    </Acronym>
    <Primary_sponsor>MedtronicNeuro
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200820
    </Date_registration3>
    <Date_registration>20/08/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04547712
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 14, 2020
    </Date_enrollement>
    <Target_size>85
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Single (Participant). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States;Canada;France;Netherlands;Canada;France;Netherlands;United States;United Kingdom
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Helen Bronte-Stewart, MD, MSE
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Stanford University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        General&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject has idiopathic Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subject is implanted with Percept PC (Model B35200) and Medtronic DBS leads (Model&#x0D;&lt;br&gt;             3387, 3389, B33005 or B33015) and extensions (Model 37085, 37086, or B34000)&#x0D;&lt;br&gt;             bilaterally in the same target (physician confirmed), STN or GPi&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. In the opinion of the investigator, the subject responds to DBS Therapy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Based on the opinion of the investigator, the subject's cDBS parameters and PD&#x0D;&lt;br&gt;             medications are stable and expected to remain stable from enrollment through the end&#x0D;&lt;br&gt;             of the aDBS Evaluation phase&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. (Primary Cohort) Subject is configured to ring mode monopolar or dual monopolar&#x0D;&lt;br&gt;             stimulation using contacts 1 and/or 2 (9 and/or 10) on at least one side.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        5. (Directional Stimulation Cohort) Subject is configured to directional monopolar or dual&#x0D;&lt;br&gt;        monopolar stimulation using contacts 1 and/or 2 (9 and/or 10) 6. Subject is willing and&#x0D;&lt;br&gt;        able to attend all study-required visits and complete the study procedures (e.g. 1-month&#x0D;&lt;br&gt;        recall questionnaires, MDS-UPDRS III) 7. Subject has the ability to understand and provide&#x0D;&lt;br&gt;        written informed consent for participation in the study prior to the study-related&#x0D;&lt;br&gt;        procedures being conducted 8. Subject is a male or non-pregnant female. If female of&#x0D;&lt;br&gt;        child-bearing potential, and if sexually active, must be using, or agree to use, a&#x0D;&lt;br&gt;        medically-acceptable method of birth control as confirmed by the investigator 9. For&#x0D;&lt;br&gt;        subjects with the SenSight system: Subject is configured to the following stimulation&#x0D;&lt;br&gt;        rates: 55, 85, 110, 125, 145, 164 or 180 Hz (as required for sensing/aDBS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        LFP Screening Inclusion Criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        1. Subject has required Beta band (8-30 Hz) amplitude detected on either left and/or right&#x0D;&lt;br&gt;        DBS leads&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject and/or caregiver is unable to utilize the patient programmer&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subject has more than one lead in each hemisphere of the brain&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Subject has cortical leads or additional unapproved hardware implanted in the brain&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Subject has more than one INS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. At enrollment, the subject's INS has a predicted battery life of &lt;1 year&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Subject has Beck Depression Inventory II (BDI-II) &gt; 25&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Subject requires diathermy, transcranial magnetic stimulation (TMS), or&#x0D;&lt;br&gt;             electroconvulsive therapy (ECT)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Subject has a metallic implant in the head, (eg, aneurysm clip, cochlear implant)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Subject has, or plans to obtain, an implanted electrical stimulation medical device&#x0D;&lt;br&gt;             anywhere in the body (eg, cardiac pacemaker, defibrillator, spinal cord stimulator)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Subject has, or plans to obtain, an implanted medication pump for the treatment of&#x0D;&lt;br&gt;             Parkinson's disease (eg, DUOPATM infusion pump) and/or portable infusion pump&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Based on the opinion of the investigator, the subject has an abnormal neurological&#x0D;&lt;br&gt;             examination that would preclude them from study participation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Subject is breast feeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Subject is under the age of 18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. Subject is currently enrolled in or plans to enroll in any concurrent drug and/or&#x0D;&lt;br&gt;             device study that may confound the results of this study as determined by the&#x0D;&lt;br&gt;             Medtronic study team&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         15. Subject is unable to use or tolerate wearable&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         16. Subjects with signal artifact on all 6 aDBS sense pathways (3 each on both DBS leads)&#x0D;&lt;br&gt;             which preclude the clinician from setting thresholds&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Adaptive DBS
    </Intervention>
    <Primary_outcome>On time without troublesome dyskinesia
    </Primary_outcome>
    <Secondary_outcome>Stimulation energy use
    </Secondary_outcome>
    <Secondary_ID>MDT19001
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10375222
    </Internal_Number>
    <TrialID>NCT04524377
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Evaluation of the Influence of Deep Brain Stimulation on the Spinal Deformities Associated With Parkinson's Disease
    </Public_title>
    <Scientific_title>Evaluation of the Influence of Deep Brain Stimulation on the Spinal Deformities Associated With Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Charite University, Berlin, Germany
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200814
    </Date_registration3>
    <Date_registration>14/08/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04524377
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 25, 2019
    </Date_enrollement>
    <Target_size>47
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Philipp Spindler;Philipp Spindler;Philipp Spindler
    </Contact_Lastname>
    <Contact_Email>;philipp.spindler@charite.de;philipp.spindler@charite.de
    </Contact_Email>
    <Contact_Tel>;+49(0)30450660778;+49(0)30450660778
    </Contact_Tel>
    <Contact_Affiliation>Charite University, Berlin, Germany;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  women and men, over 18 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  medical indication for deep brain Stimulation for Parkinson's Disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  signed declaration of consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  withdrawal of consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  non-Parkinson's-associated diseases of the spine&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  pregnancy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Spine Degeneration;Spine Deformity;Spinal Disease
    </Condition>
    <Intervention>Procedure: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Sagittal Imbalance
    </Primary_outcome>
    <Secondary_outcome>Spine Mobility;Oswestry Disability Index (ODI);Visual Analoge Scale (VAS);Unified Parkinsons Disease Rating Scala (Part III Motor Examination) (UPDRS-Part III);Parkinsons Disease Questionaire 39 (PDQ-39);Pelvic incidence (PI);Pelvit tilt (PT);Sacral slope (SS);Lumbar Lordisis (LL);Mismatch of Pelvic incidence and LL (PI - LL);Scoliosis
    </Secondary_outcome>
    <Secondary_ID>40000256
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>9599746
    </Internal_Number>
    <TrialID>ChiCTR2000034982
    </TrialID>
    <Last_Refreshed_on>27 July 2020
    </Last_Refreshed_on>
    <Public_title>A clinical trial for deep brain stimulation of the superior cerebellar peduncle in the treatment of acquired dystonia
    </Public_title>
    <Scientific_title>A clinical trial for deep brain stimulation of the superior cerebellar peduncle in the treatment of acquired dystonia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>Department of Functional Neurosurgery, RuiJin Hospital, affiliated with Shanghai Jiaotong University School of Medicine
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200726
    </Date_registration3>
    <Date_registration>2020-07-26
    </Date_registration>
    <Source_Register>ChiCTR
    </Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=57034
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2020-08-01
    </Date_enrollement>
    <Target_size>surgery group:30;
    </Target_size>
    <Study_type>Interventional study
    </Study_type>
    <Study_design>Single arm
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>Dianyou Li
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>197 Second Ruijin Road, Huangpu District, Shanghai, China
    </Contact_Address>
    <Contact_Email>ldy11483@rjh.com.cn
    </Contact_Email>
    <Contact_Tel>+86 17717412052
    </Contact_Tel>
    <Contact_Affiliation>Ruijin Hospital, Affiliated to Shanghai Jiaotong University, School of Medicine
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 7 to 75 years old;&#x0D;&lt;br&gt;2. patients with acquired dystonia whose vore clinical manifestations are rigidity and have clear etiology;&#x0D;&lt;br&gt;3. the course of dystonia is more than 2 years.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Can not tolerate general anesthesia for various reasons;&#x0D;&lt;br&gt;2. Any intracranial abnormalities that hinder DBS surgery;&#x0D;&lt;br&gt;3. whether there are any obvious mental disorders that may affect subjects' compliance with the requirements of the study program (e.g., bipolar disorder, schizophrenia, mood disorder with psychotic characteristics, group B personality disorder) severe cognitive impairment, MMSE &lt; 24;&#x0D;&lt;br&gt;4. any drug or alcohol abuse according to DSM-V standards;&#x0D;&lt;br&gt;5. any history of recurrent or unprovoked seizures. Any major disease that may interfere with the research process or may confuse the end point assessment of the study;&#x0D;&lt;br&gt;6. any lifelong disease with a life expectancy of less than 1 year.
    </Exclusion_Criteria>
    <Condition>Acquired dystonia
    </Condition>
    <Intervention>surgery group:SCP DBS;
    </Intervention>
    <Primary_outcome>muscle tone;
    </Primary_outcome>
    <Secondary_outcome>pronunciation;swallowing;pain;cognition;emotion;quality of life;
    </Secondary_outcome>
    <Source_Support>National Natural Science Foundation of China (81200981)
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>12/05/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Yifeng Wang
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13642678
    </Internal_Number>
    <TrialID>DRKS00017721
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Prospective study to define clinical markers which predict 36 months outcome in the early disease phase (part I) and treatment response to deep brain stimulation (part II) in late stages of Parkinson’s disease.
    </Public_title>
    <Scientific_title>Prospective study to define clinical markers which predict 36 months outcome in the early disease phase (part I) and treatment response to deep brain stimulation (part II) in late stages of Parkinson’s disease. - LOC-PD: Part I, LOC-EARLY; Part II, LOC-DBS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum Tübingen, Abteilung Neurologie mit Schwerpunkt Neurodegenerative Erkrankungen
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200709
    </Date_registration3>
    <Date_registration>09/07/2020
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00017721
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>05/05/2020
    </Date_enrollement>
    <Target_size>400
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: Prognosis 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Ina
    </Contact_Firstname>
    <Contact_Lastname>Wolfstädter
    </Contact_Lastname>
    <Contact_Address>Hoppe-Seyler-Str. 3
    </Contact_Address>
    <Contact_Email>Ina.Wolfstaedter@med.uni-tuebingen.de
    </Contact_Email>
    <Contact_Tel>07071 2980472
    </Contact_Tel>
    <Contact_Affiliation>Universitätsklinikum Tübingen,Abteilung Neurologie mit Schwerpunkt Neurodegenerative Erkrankungen
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Part I, LOC-EARLY: age = 18 years; PD diagnosis according to the MDS Task Force Criteria; disease duration = 3 years; ability to give consent and communicate well with the investigator, to understand and comply with the requirements of the study; written informed consent prior to undertaking any study-related procedures.&lt;br&gt;&lt;br&gt;Part II LOC-DBS: Age between 18 and 80 years; eligible for DBS surgery according to best-practice strategies (DGN S3-Leitlinie Parkinson), response to levodopa &gt; 30% verified by scores of the MDS-UPDRS-III assessed twice or medication-resistant disabling PD tremor; no signs of PDD; no neurosurgical contraindications; no relevant psychiatric (active depression, psychosis, suicidal ideation), or somatic competing disease; eligibility for DBS confirmed during an inpatient DBS screening procedure by an interdisciplinary board of neurologists, neurosurgeons, and psychiatrists; patients written informed consent for DBS surgery; ability to give consent and communicate well with the investigator, to understand and comply with the requirements of the study and good German language skills (primary or secondary language); having given written informed consent prior to undertaking any study-related procedures.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Part I, LOC-EARLY:&lt;br&gt;Under any administrative or legal supervision or unable to give informed consent; participation in any clinical investigation of a new investigational compound or therapy within 4 weeks prior to baseline visit, and for any other limitation of participation based on local regulations; patients with conditions/concomitant diseases making them non-evaluable for the defined outcomes (e.g. pre-existing neurological disease, brain disease other than PD, e.g. head trauma, stroke, encephalitis);&lt;br&gt;alcohol, medication, or drug dependency or abuse (except for nicotine); inability to meet specific protocol requirements (e.g., need for hospitalization, not able to read and understand the protocol); patient is directly involved in the conduct of the protocol: the investigator or a sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof; patient is uncooperative or has any condition that could make the patient potentially non-compliant to the study procedures; patients with presence of postural instability (MDS-UPDRS-III Item 3.12 = 1) at time of study inclusion;&lt;br&gt;- For the prediction of the dichotomous outcome referring to cognitive worsening:&lt;br&gt;Patients with diagnosis of dementia or cognitive impairment (MoCA=26) at time of study inclusion will not be included into the analysis&lt;br&gt;&lt;br&gt;Part II, LOC-DBS:&lt;br&gt;Under any administrative or legal supervision or unable to give informed consent; participation in any clinical investigation of a new investigational compound or therapy within 4 weeks prior to baseline visit, and for any other limitation of participation based on local regulations;&lt;br&gt;diagnosis of dementia at time of study inclusion; surgical contraindication for implantation surgery; patients with conditions/concomitant diseases making them non-evaluable for the defined outcomes; alcohol, medication, or drug dependency or abuse (except for nicotine); inability to meet specific protocol requirements (e.g., need for hospitalization, not able to read and understand the protocol); patient is directly involved in the conduct of the protocol: the investigator or a sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof; patient is uncooperative or has any condition that could make the patient potentially non-compliant to the study procedures.
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: LOC-EARLY:&lt;br&gt;Mandatory assessments:&lt;br&gt;Visit 0, 1, 2, 3: Demographics, medical history, medication, neurological exam, MDS-UPDRS-III/IV, Hoehn &amp;Yahr score, MoCA, PD-NMSQ, Schellong-Test (UMSARS-III), BDI-II, GDS, blood sampling.&lt;br&gt;&lt;br&gt;Optional assessments:&lt;br&gt;Visit 0, 1, 2, 3: MRI, PDQ-39, Sniffing Sticks, RBDSQ, ADS, Parkinson Psychosis Questionnaire, Restless Leg Questionnaire, ESS, Starkstein Apathy Scale, PSP Rating Scale, Verbal fluency, Luria Sequence, Munich Dysphagia Test, UMSARS, lumbar puncture, tear fluid, stool and urin sampling.&lt;br&gt;Group 2: LOC-DBS: &lt;br&gt;Mandatory assessments:&lt;br&gt;Visit 0, 2, 3, 4: Demographics, body weight and size, medical history, medication, neurological exam, MDS-UPDRS-I/II/III/IV, Hoehn &amp;Yahr Score, MoCA, Schellong-Test (UMSARS-III), PDQ-39, BDI-II, blood sampling (only at Visit 0), MRT (only at Visit 0).&lt;br&gt;&lt;br&gt;Visit 1: CT, Dokumentation der Sicherheitsmaße. &lt;br&gt;&lt;br&gt;Optional assessments:&lt;br&gt;Visit 0, 1, 2, 3, 4: PD-NMSQ, lumbar puncture, tear fluid, stool and urin sampling.
    </Intervention>
    <Primary_outcome>The main objective in part I (LOC-EARLY) is to evaluate the predictive value of a single or a combination of markers (demographics, scale scores, environmental, imaging, biomarker data) commonly assessed within the clinical daily routine to predict each of three independent disease specific outcomes after 36 months in early PD. Presence of the following outcomes at months 36 is recorded:&lt;br&gt;Postural instability (Item 3.12 = 1, MDS-UPDRS-III) (primary outcome). &lt;br&gt;&lt;br&gt;The primary objective in part II (LOC-DBS) is to evaluate the predictive value of a single or a combination of markers predicting a beneficial outcome of DBS surgeryaccording to the following criteria: Preserved or less reduced cognitive function at 36 months (MoCA score continuously scaled) (primary outcome).
    </Primary_outcome>
    <Secondary_outcome>Part I, LOC-EARLY: Cognitive worsening: diagnosis of cognitive impairment (PD-MCI) or PDD according to Level I cognitive testing, (MoCA = 26) (secondary outcome); differential atypical PD diagnosis: appearance of “red flags” indicating an atypical Parkinsonian syndrome (secondary outcome); diagnosis of atypical PD according to consensus guidelines (secondary outcome). &lt;br&gt;&lt;br&gt;Part II, LOC-DBS: Improvement of MDS-UPDRS-III scores of at least 30% when comparing preoperative MDS-UPDRS-III scores without intake of dopaminergic medication (MedOff) and postoperative MDS-UPDRS-III scores in MedOff condition and with brain stimulator active (StimOn) at 36-month visit (secondary outcome).
    </Secondary_outcome>
    <Source_Support>Bundesministerium für Bildung und Forschung
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>07/04/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link>http://drks.de/search/en/trial/DRKS00017721#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12182885
    </Internal_Number>
    <TrialID>NCT04461730
    </TrialID>
    <Last_Refreshed_on>19 April 2022
    </Last_Refreshed_on>
    <Public_title>Role of Basal Ganglia and Thalamus in Perceptual Consciousness and Metacognition
    </Public_title>
    <Scientific_title>Role of Basal Ganglia and Thalamus in Perceptual Consciousness and Metacognition
    </Scientific_title>
    <Acronym>METACTION
    </Acronym>
    <Primary_sponsor>University Hospital, Grenoble
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200626
    </Date_registration3>
    <Date_registration>26/06/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04461730
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 2021
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>ELENA MORO
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University Hospital, Grenoble
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Major patient in need of brain stimulation therapy for motor disorders (Parkinson's&#x0D;&lt;br&gt;             disease, tremor, dystonia) or psychiatric disorders (OCD).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Outpatient or inpatient follow-up&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fluent in French and able to understand the study procedures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient affiliated to social security&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written agreement to participate in the patient's study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intellectual abilities compatible with the performance of cognitive or motor tasks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Persons referred to in Articles L1121-5 to L1121-8 of the CSP (pregnant women,&#x0D;&lt;br&gt;             parturient women, mothers, etc.) who is breastfeeding, person deprived of liberty by&#x0D;&lt;br&gt;             judicial or administrative decision, person subject to a legal protection measure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients in whom transient cessation of stimulation is not tolerated&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject in period of exclusion from another study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject cannot be contacted in case of emergency&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject under administrative or judicial supervision&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;OCD;Dystonia
    </Condition>
    <Intervention>Device: deep brain stimulation
    </Intervention>
    <Primary_outcome>Behavioral effect of DBS on confidence
    </Primary_outcome>
    <Secondary_outcome>Effect of DBS on EEG markers of confidence
    </Secondary_outcome>
    <Secondary_ID>2019-A02328-49;38RC19.271
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13665649
    </Internal_Number>
    <TrialID>NCT04449068
    </TrialID>
    <Last_Refreshed_on>29 January 2024
    </Last_Refreshed_on>
    <Public_title>Observational Database on Deep Brain Stimulation in Tourette Syndrome
    </Public_title>
    <Scientific_title>Pre et Post-operative Evaluation of Patients With Tourette Syndrome Treated With High Frequency Bilateral Stimulation of the Anterior Part of the Internal Pallid Globus
    </Scientific_title>
    <Acronym>POSTSTIC
    </Acronym>
    <Primary_sponsor>Assistance Publique - Hôpitaux de Paris
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200623
    </Date_registration3>
    <Date_registration>23/06/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04449068
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 12, 2021
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>France
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Andreas HARTMANN, MD;Andres Hartmann, MD
    </Contact_Lastname>
    <Contact_Email>andreas.hartmann@aphp.fr;andreas.hartmann@aphp.fr
    </Contact_Email>
    <Contact_Tel>1 42 16 13 16;01 42 16 13 16
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Tourette syndrome severe and drug-resistant eligible for bilateral deep brain&#x0D;&lt;br&gt;             stimulation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person who voluntarily and knowledgeably agreed to participate in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non affiliation to a French social security system (recipient or assign) excluding AME&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome
    </Condition>
    <Intervention>Other: Neurological and neuropsychological Follow-up after deep brain stimulation
    </Intervention>
    <Primary_outcome>Measure the severity of tics
    </Primary_outcome>
    <Secondary_ID>APHP190808
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13583620
    </Internal_Number>
    <TrialID>NCT04432285
    </TrialID>
    <Last_Refreshed_on>19 December 2023
    </Last_Refreshed_on>
    <Public_title>Long-term Outcome of DBS Versus Botulinum Toxin Treatment in Cervical Dystonia
    </Public_title>
    <Scientific_title>Long-term Outcome in Cervical Dystonia Patients Treated With Chronic Pallidal Deep Brain Stimulation Compared to Repeated Botulinum Toxin Injections - a Cross-sectional Observational Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Oslo University Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200611
    </Date_registration3>
    <Date_registration>11/06/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04432285
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 6, 2020
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Norway
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Inger Marie Skogseid, MDPhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Oslo University Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  DBS-group: Patients with isolated cervical dystonia (focal or part of segmental&#x0D;&lt;br&gt;             dystonia) who have been operated at Oslo University between June 2004 and June 2017&#x0D;&lt;br&gt;             and treated with bilateral GPi-DBS for a minimum of 3 years, and who give their&#x0D;&lt;br&gt;             informed consent to participate in this follow-up study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  BoNT-group: Patients who are receiving regular BoNT-injections at Oslo University&#x0D;&lt;br&gt;             Hospital for isolated cervical dystonia (focal or part of segmental dystonia), who are&#x0D;&lt;br&gt;             gender-and age-matched to the operated patients, and who give their informed consent&#x0D;&lt;br&gt;             to participate in this follow-up study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia/inability to respond to the CDIP-58.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cervical Dystonia
    </Condition>
    <Intervention>Device: DBS-device, implanted in GPi bilaterally;Drug: Botulinum toxin
    </Intervention>
    <Primary_outcome>Total score of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS).
    </Primary_outcome>
    <Secondary_outcome>Severity, Disability and Pain subscores of the TWSTRS;Total score of the Cervical Dystonia Impact Profile 58 (CDIP-58)
    </Secondary_outcome>
    <Secondary_ID>96307
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10366324
    </Internal_Number>
    <TrialID>NCT04408573
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Cycling Deep Brain Stimulation on Parkinson's Disease Gait
    </Public_title>
    <Scientific_title>Effects of Cycling Deep Brain Stimulation on Parkinson's Disease Gait
    </Scientific_title>
    <Acronym>DBS
    </Acronym>
    <Primary_sponsor>University of Sao Paulo General Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200525
    </Date_registration3>
    <Date_registration>25/05/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04408573
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 19, 2020
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Rubens G Cury, MD, PhD;Rubens G Cury, MD, PhD;Rubens G Cury, MD PhD
    </Contact_Lastname>
    <Contact_Email>;rubens_cury@usp.br;rubens_cury@usp.br
    </Contact_Email>
    <Contact_Tel>;55 11 26617877;55 11 26617877
    </Contact_Tel>
    <Contact_Affiliation>University of Sao Paulo General Hospital;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of idiopathic Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently receiving Deep Brain Stimulation as a Parkinson's disease treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hoehn &amp; Yahr stage between 2-4 during off-medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Underlying gait disorders despite optimal medical and stimulation treatment: score&#x0D;&lt;br&gt;             over or equal to 1 in the subitem 2.12 of the MDS-UPDRS scale&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willingness to comply with all study procedures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active moderate/severe psychiatric condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active infection or other uncontrolled moderate/grave comorbidities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Treatment with experimental drug&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy or breast-feeding&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Cycling deep brain stimulation
    </Intervention>
    <Primary_outcome>Change in the part II of the Unified Parkinson's disease rating scale;Change in the New Freezing of Gait Questionnaire
    </Primary_outcome>
    <Secondary_outcome>Change in Falls Efficacy Scale;Change in The Parkinson's Disease Questionnaire (PDQ-39);Change in Activities-Specific Balance Confidence Scale (ABC scale);Number of falls
    </Secondary_outcome>
    <Secondary_ID>67914017.6.0000.0068
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>9245716
    </Internal_Number>
    <TrialID>ChiCTR2000032852
    </TrialID>
    <Last_Refreshed_on>18 May 2020
    </Last_Refreshed_on>
    <Public_title>Clinical study of deep brain stimulation in the treatment of Meige syndrome
    </Public_title>
    <Scientific_title>Clinical study of deep brain stimulation in the treatment of Meige syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>West China Hospital, Sichuan University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200513
    </Date_registration3>
    <Date_registration>2020-05-13
    </Date_registration>
    <Source_Register>ChiCTR
    </Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=53568
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2020-05-25
    </Date_enrollement>
    <Target_size>STN DBS group:18;GPi DBS group:18;
    </Target_size>
    <Study_type>Interventional study
    </Study_type>
    <Study_design>Parallel
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>Wei Wang
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China
    </Contact_Address>
    <Contact_Email>wcnsww@163.com
    </Contact_Email>
    <Contact_Tel>+86 18980601521
    </Contact_Tel>
    <Contact_Affiliation>West China Hospital, Sichuan University
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients diagnosed as primary Meige syndrome;&#x0D;&lt;br&gt;2. Patients who fail to control the symptoms and seriously affect the quality of life after the treatment of oral drugs and botulinum toxin;&#x0D;&lt;br&gt;3. Patients in good health except for dystonia;&#x0D;&lt;br&gt;4. Patients with normal screening results by MMSE;&#x0D;&lt;br&gt;5. The subjects or their families can fully understand the treatment and sign the informed consent;&#x0D;&lt;br&gt;6. The patients with good compliance can cooperate with the patients who complete the postoperative follow-up requirements.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with abnormal changes of basal ganglia on imaging;&#x0D;&lt;br&gt;2. Patients with serious progressive nervous system, cardiovascular system, respiratory system or digestive system diseases; patients with unstable mental state;&#x0D;&lt;br&gt;3. Patients with contraindications to surgery or anesthesia, such as taking anticoagulant and antiplatelet drugs for a long time;&#x0D;&lt;br&gt;4. Women who plan to be pregnant, or are in pregnancy and lactation;&#x0D;&lt;br&gt;5. Patients who have or need other implantable devices, such as pacemakers, defibrillators, cochlear implants and chiropractic root stimulators;&#x0D;&lt;br&gt;6. Patients who need 3.0T MRI for many times in the future clinical trials due to their own reasons;&#x0D;&lt;br&gt;7. Patients who have participated in other clinical trials.
    </Exclusion_Criteria>
    <Condition>Meige syndrome
    </Condition>
    <Intervention>STN DBS group:Accept bilateral STN DBS;GPi DBS group:Accept bilateral GPi DBS;
    </Intervention>
    <Primary_outcome>Burke- fahn-marsden Dystonia Rating scale (BFMDRS);
    </Primary_outcome>
    <Secondary_outcome>Mini-Mental State Examination, MMSE;Montreal Cognitive Assessment, MoCA;Hamilton Dpression Scale, HAMD;Hamilton Anxiety Scale, HAMA;Health-related quality of life (QOL), SF-36;
    </Secondary_outcome>
    <Source_Support>Beijing pinchi medical equipment co., LTD
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>21/04/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Shaolin Deng
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10364411
    </Internal_Number>
    <TrialID>NCT04383665
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Low Frequency Subthalamic Nucleus Deep Brain Stimulation to Improve Verbal Fluency
    </Public_title>
    <Scientific_title>Evaluation of Neurocognitive Changes in Parkinson's Disease Patients Following Acute Low Frequency Deep Brain Stimulation
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Southern California
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200507
    </Date_registration3>
    <Date_registration>07/05/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04383665
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 31, 2020
    </Date_enrollement>
    <Target_size>12
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Darrin J Lee, MD PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Southern California
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Male or female patients who had previously undergone bilateral STN deep brain&#x0D;&lt;br&gt;             stimulation implantation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Age &gt;18 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Stable medication regimen for at least 3 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient informed and able to give written consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Able to comply with all testing, follow-ups and study appointments and protocols&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. History of epilepsy or seizure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. History of major substance abuse&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients with baseline settings at less than 1.5 V will be excluded from the study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: STN DBS 10Hz;Device: STN DBS 130Hz;Device: STN DBS off
    </Intervention>
    <Primary_outcome>Delis-Kaplan Executive Function System Verbal fluency;Delis-Kaplan Executive Function System Color Word Interference Task;Random number generation
    </Primary_outcome>
    <Secondary_ID>HS-19-00518
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13396658
    </Internal_Number>
    <TrialID>NCT04563143
    </TrialID>
    <Last_Refreshed_on>16 October 2023
    </Last_Refreshed_on>
    <Public_title>Novel Paradigms of Deep Brain Stimulation for Movement Disorders
    </Public_title>
    <Scientific_title>Novel Paradigms of Deep Brain Stimulation for Movement Disorders
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>The Cleveland Clinic
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200422
    </Date_registration3>
    <Date_registration>22/04/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04563143
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 17, 2020
    </Date_enrollement>
    <Target_size>16
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Kenneth Baker, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>The Cleveland Clinic
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosis of idiopathic Parkinson's disease for greater than 3 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  determined appropriate for deep brain stimulation surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  able to give consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  secondary Parkinson's disease, stroke, progressive central nervous system disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  dementia that disallows the subject ability to consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  current alcohol or substance abuse&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  hearing or visual impairment precluding cognitive or sensory testing&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Novel DBS Stimulation
    </Intervention>
    <Primary_outcome>Upper extremity motor speed;Verbal Fluency
    </Primary_outcome>
    <Secondary_outcome>Cognitive Reaction Time;EEG - sensorimotor evoked potentials;EEG - Oscillatory activity;EMG;fMRI - Bold response;MEG;Movement Disorders Society Unified Parkinson Disease Rating Scale - III
    </Secondary_outcome>
    <Secondary_ID>19-1637
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Farmer Foundation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13733366
    </Internal_Number>
    <TrialID>NL-OMON50651
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>Infusion VErsus STimulation, a cost-effectiveness analysis of the treatment in advanced Parkinson's disease comparing Continuous Intrajejunal Levodopa Infusion to the traditional standard treetment Deep Brain Stimulation;
    </Public_title>
    <Scientific_title>Infusion VErsus STimulation, a cost-effectiveness analysis of the treatment in advanced Parkinson's disease comparing Continuous Intrajejunal Levodopa Infusion to the traditional standard treetment Deep Brain Stimulation; - INVEST (Infusion VErsus STimulation) study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>Academisch Medisch Centrum
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200414
    </Date_registration3>
    <Date_registration>2020-04-14
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/50651
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>64
    </Inclusion_agemax>
    <Inclusion_gender/>
    <Date_enrollement>2014-12-19
    </Date_enrollement>
    <Target_size>66
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Open (masking not used), Uncontrolled, Treatment
    </Study_design>
    <Phase/>
    <Countries>The Netherlands
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address>Meibergdreef 9
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Academisch Medisch Centrum
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;p&gt;- idiopathic Parkinson's Disease with bradykinesia and at least two of the &lt;br&gt;following signs; resting tremor, rigidity, and asymmetry;&lt;br&gt;- despite optimal pharmacological treatment, at least one of the following &lt;br&gt;symptoms: severe response fluctuations, dyskinesias, painful dystonia or &lt;br&gt;bradykinesia;&lt;br&gt;-a life expectancy of at least two years.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;p&gt;-age below 18 years&lt;br&gt;- previous PD-neurosurgery (e.g., DBS, pallidotomy, thalamotomy);&lt;br&gt;- previous CLI (through a PEG-tube or Nasal Jejuna| tube);&lt;br&gt;- Hoehn and Yahr stage 5 at the best moment during the day;&lt;br&gt;- dementia or indication for severe cognitive impairment, such as PD-CRS &lt;65;&lt;br&gt;- psychosis;&lt;br&gt;- current depression;&lt;br&gt;- other, severely disabling condition;&lt;br&gt;- contraindications for DBS surgery, such as a physical disorder making surgery &lt;br&gt;hazardous;&lt;br&gt;- contraindications for PEG surgery such as interposed organs, ascites and &lt;br&gt;oesophagogastric varices, or for Duodopa;&lt;br&gt;- pregnancy, breastfeeding, and women of child bearing age not using a reliable &lt;br&gt;method of contraception;&lt;br&gt;- No informed consent;&lt;br&gt;- legally incompetent adults.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Parkinson &lt;br&gt;Parkinson's Disease;10028037;Parkinson;Parkinson's Disease
    </Condition>
    <Intervention>&lt;p&gt;Patients will be randomized to CLI or DBS. For CLI treatment, a tube will be &lt;br&gt;placed in the jejunum via a percutaneous endoscopic gastrostomy (PEG). This &lt;br&gt;tube is connected to an external pump that delivers the levodopa-gel. For DBS &lt;br&gt;treatment, 2 electrodes will be implanted in the brain. The electrodes are &lt;br&gt;connected to an implanted pulse generator, which will be placed subcutaneously &lt;br&gt;in the subclavian area. &lt;/p&gt;&lt;br&gt;;Continuous Levodopa Infusion;cost-effectiveness;Deep Brain Stimulation;Parkinson Disease
    </Intervention>
    <Primary_outcome>&lt;p&gt;The primary health economic outcomes of the randomized trial are the costs per&lt;br /&gt;&lt;br&gt;unit on the PDQ-39 and the costs per QALY for the cost-effectiveness and&lt;br /&gt;&lt;br&gt;cost-utility analyses respectively. &lt;/p&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>&lt;p&gt;Secondary clinical outcomes are quality of life (PDQ-39), PD motor symptoms&lt;br /&gt;&#x0D;&lt;br&gt;(UPDRS), dyskinesias (CDRS), 3-day motor symptom diary), adverse effects and&lt;br /&gt;&#x0D;&lt;br&gt;complications, treatment failure, non-motor symptoms such as autonomic&lt;br /&gt;&#x0D;&lt;br&gt;functions and sleep (Non Motor Symptom Checklist, Rotterdam Symptom Checklist),&lt;br /&gt;&#x0D;&lt;br&gt;PD-medication, disability, functional health status (ALDS), patient and&lt;br /&gt;&#x0D;&lt;br&gt;physician preferences, patient satisfaction, caregiver burden,&lt;br /&gt;&#x0D;&lt;br&gt;neuropsychological and psychiatric assessment, stopping treatment, starting&lt;br /&gt;&#x0D;&lt;br&gt;with the alternative than initially started treatment, and medical and&lt;br /&gt;&#x0D;&lt;br&gt;non-medical care costs (iMCQ, iPCQ).&lt;/p&gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>2014.001501.32;NCT02480803;NL51240.018.14
    </Secondary_ID>
    <Source_Support>Ministerie van OC&amp;W;Medtronic B.V.;Medtronic;verstrekker van DBS materiaal
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>28/11/2014;19/05/2016;15/06/2016;17/08/2016;10/11/2016;04/12/2017;11/04/2019;14/04/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;;;;;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>;;;;;;;
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;;;;;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;;;;;;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12360310
    </Internal_Number>
    <TrialID>NCT04342754
    </TrialID>
    <Last_Refreshed_on>20 June 2022
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation in Forel's H Field in Tourette's Syndrome
    </Public_title>
    <Scientific_title>Bilateral Deep Brain Stimulation of Forel's H Field in Tourette's Syndrome: Prospective, Randomized, Crossover, Double-blind Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Sao Paulo General Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200401
    </Date_registration3>
    <Date_registration>01/04/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04342754
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>14 Years
    </Inclusion_agemin>
    <Inclusion_agemax>100 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 27, 2019
    </Date_enrollement>
    <Target_size>8
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Rubens G Cury, MD PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Sao Paulo General Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with Tourette's Syndrome diagnosis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age equal to or above 14 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe impairment of motor tics (Yale Global Tic Severity Scale = 35/50).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who are refractory to drug treatment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients intellectually able to understand and sign the consent form.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Possibility to adhere to research and periodic medical visits after surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to consent to your participation in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with non-stabilized psychiatric comorbidities, such as anxiety and&#x0D;&lt;br&gt;             depression.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Concomitant treatment with other experimental drugs.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women who are pregnant or breastfeeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients undergoing previous neurosurgical procedures for the treatment of Tourette's&#x0D;&lt;br&gt;             Syndrome.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome
    </Condition>
    <Intervention>Device: Deep Brain Stimulation (DBS);Device: Sham Stimulation
    </Intervention>
    <Primary_outcome>Percent of change in the score of Yale Global Tic Severity Scale (YGTSS) pré and pós stimulation, comparing device On(active) and device OFF (sham) conditions.
    </Primary_outcome>
    <Secondary_outcome>Change in psychiatric symptoms - Anxiety;Change in Quality of Life;Change in psychiatric symptom - Depression;Change in psychiatric symptom - obsessive-compulsive disorder;Change in psychiatric symptom - attention deficit hyperactivity disorder;assessment of structural connectivity patterns
    </Secondary_outcome>
    <Secondary_ID>3.158.435
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13544631
    </Internal_Number>
    <TrialID>NCT04329676
    </TrialID>
    <Last_Refreshed_on>20 November 2023
    </Last_Refreshed_on>
    <Public_title>directSTIM Deep Brain Stimulation System Study
    </Public_title>
    <Scientific_title>A Prospective, Multi-center, Post-market Clinical Follow-up Study of the directSTIM Deep Brain Stimulation (DBS) System
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Aleva Neurotherapeutics SA
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200313
    </Date_registration3>
    <Date_registration>13/03/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04329676
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 9, 2021
    </Date_enrollement>
    <Target_size>62
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Alain Dransart;Alain Dransart
    </Contact_Lastname>
    <Contact_Email>;clinical@aleva-neuro.com
    </Contact_Email>
    <Contact_Tel>;+4121 353 8764
    </Contact_Tel>
    <Contact_Affiliation>Aleva Neurotherapeutics SA;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Established diagnosis of idiopathic Parkinson's Disease for 4 years or more according&#x0D;&lt;br&gt;             to the United Kingdom Parkinson's disease Brain Bank criteria, with disabling motor&#x0D;&lt;br&gt;             complications despite optimal medical treatment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is eligible for bilateral DBS for STN therapy according to center's routine&#x0D;&lt;br&gt;             criteria and according to the directSTIM DBS system Indications for Use statement.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient who is willing to provide a written informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient complies with the study follow-up, in particular the follow-up visits, and&#x0D;&lt;br&gt;             other study requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is not eligible for DBS per center criteria.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has a cognitive impairment, or exhibits any characteristic, that would limit&#x0D;&lt;br&gt;             study candidate's ability to complete study assessments, such as:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Active major psychiatric disorder.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Dementia (MoCa Dementia Rating Scale score &lt;26 or otherwise not capable of&#x0D;&lt;br&gt;                  discernment).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Presence of an electrical or electromagnetic implant (e.g. cochlear implant,&#x0D;&lt;br&gt;                  pacemaker).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Previous surgery for the treatment of Parkinson's disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Previous brain ablation procedure.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Epilepsy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Coagulopathies.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Abuse of drugs or alcohol.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is participating in another clinical study that would confound data analysis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is pregnant or nursing. As for other DBS systems, the effects of the device on&#x0D;&lt;br&gt;             an unborn child are not established.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Procedure: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Change in UPDRS III score without medication;Materiovigilance
    </Primary_outcome>
    <Secondary_outcome>Therapeutic Window (TW);UPDRS
    </Secondary_outcome>
    <Secondary_ID>CLI-12011
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13643539
    </Internal_Number>
    <TrialID>DRKS00020967
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Stimulation Induced ceREbellar syndrome after VIM/DRT-DBS – the SIREN-Study
    </Public_title>
    <Scientific_title>Stimulation Induced ceREbellar syndrome after VIM/DRT-DBS – the SIREN-Study - SIREN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum Freiburg Klinik für Neurochirurgie Abteilung Stereotaktische und Funktionelle Neurochirurgie
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200228
    </Date_registration3>
    <Date_registration>28/02/2020
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00020967
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>10/03/2020
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: diagnostic 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Bastian
    </Contact_Firstname>
    <Contact_Lastname>Sajonz
    </Contact_Lastname>
    <Contact_Address>Breisacher Str. 64
    </Contact_Address>
    <Contact_Email>bastian.sajonz@uniklinik-freiburg.de
    </Contact_Email>
    <Contact_Tel>+4976127050630
    </Contact_Tel>
    <Contact_Affiliation>Universitätsklinikum Freiburg Klinik für Neurochirurgie Abteilung Stereotaktische und Funktionelle Neurochirurgie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. adult patients who have been treated with DBS as part of their essential tremor and who are connected to the Outpatient Clinic for Stereotactic and Functional Neurosurgery at the University Hospital Freiburg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;2. written consent&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. inability to provide informed consent;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;2. patients who are no longer able to walk or only able to walk assisted by a walker
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G25.0 &lt;br&gt;G46.4;Essential tremor;Cerebellar stroke syndrome;G25.0;G46.4
    </Condition>
    <Intervention>Group 1: The following examinations with stimulation switched on and off are performed as part of a regular outpatient visit in patients with essential tremor treated with DBS:&lt;br&gt;- objective tremor test (frequency, power)&lt;br&gt;- scale-based tremor testing (Flag-Tolosa-Marin-Tremor-Rating-Scale) (video-assisted)&lt;br&gt;- scale-based testing of coordination/balance:&lt;br&gt;Scale for the Assessment and Rating of Ataxia (SARA) (video-based)&lt;br&gt;Tinetti Balance Assessment Tool&lt;br&gt;- Studies of movement and postural control (video-assisted):&lt;br&gt;Timed-Up-And-Go Test&lt;br&gt;Hand Coordination Test&lt;br&gt;Postural control&lt;br&gt;- Investigation of further clinical parameters&lt;br&gt;Pallesthesia&lt;br&gt;Nystagmus
    </Intervention>
    <Primary_outcome>The primary factor to be investigated is the difference in tremor frequency (DBS OFF - THS ON)
    </Primary_outcome>
    <Secondary_outcome>Difference in Tremor Power (DBS OFF-ON)&#x0D;&lt;br&gt;Occurrence of nystagmus when the stimulation is switched off&#x0D;&lt;br&gt;Relevant diseases: other cerebellar ataxia, impairment of the affinity to the cerebellum (spinal ataxia, polyneuropathy) &#x0D;&lt;br&gt;Age&#x0D;&lt;br&gt;Pallesthesia of the right and left lower extremity&#x0D;&lt;br&gt;Stimulation parameters (localization, amplitude, frequency, pulse width)&#x0D;&lt;br&gt;Handling of the stimulation by the patient Demand-adapted reduction of the stimulation during the day (yes vs. no)? night-time reduction of stimulation (yes, night switch-off vs. yes, night-time reduction vs. no)?
    </Secondary_outcome>
    <Source_Support>Universitätsklinikum Freiburg Klinik für Neurochirurgie Abteilung Stereotaktische und Funktionelle Neurochirurgie
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>25/02/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-761-27072600
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_email>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>30/03/2023
    </results_date_posted>
    <results_date_completed>20/12/2021
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00020967#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>9186593
    </Internal_Number>
    <TrialID>ISRCTN56186994
    </TrialID>
    <Last_Refreshed_on>4 May 2020
    </Last_Refreshed_on>
    <Public_title>Investigating the possibility and benefit of closed-loop deep brain stimulation by detecting the voluntary movement and postural tremor on patients with tremor
    </Public_title>
    <Scientific_title>Closed-loop Deep Brain Stimulation for Tremor: CDBSoT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200214
    </Date_registration3>
    <Date_registration>14/02/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN56186994
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/12/2018
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Multicentre interventional study (Diagnostic)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>United Kingdom
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Aged 25 to 80 years&lt;br&gt;                2. Diagnosis of essential tremor or dystonia tremor&lt;br&gt;                3. Undergoing DBS for tremor symptoms&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Intracranial bleeding, confusion, CSF leak or any other complication after the first stage of surgery&lt;br&gt;                2. Lack of capacity to consent (judged by the clinician taking consent as not having sufficient mental capacity to understand the study and its requirements). Anyone who, in the opinion of the clinician taking consent, is unlikely to retain sufficient mental capacity for the duration of their involvement in the study.&lt;br&gt;                3. Cognitive impairment/lack of capacity to perform the experimental tasks. In cases where capacity was borderline and difficult to judge subjectively, we will additionally conduct a short (10 min) quantitative assessment of cognitive function using the Mini Mental State Exam (MMSE). Patients with a score of &lt;20 will be excluded from the study.&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Essential Tremor (ET) or Dystonia tremor in which tremor mainly affect voluntary movement or while maintaining postures &lt;br&gt;Nervous System Diseases &lt;br&gt;Essential tremor (ET), dystonia tremor
    </Condition>
    <Intervention>&lt;br&gt;                The researchers will assess which stimulation parameters have the best effect to suppress tremor. This procedure is part of the normal clinical procedure and will take approximately 1 hour.&lt;br&gt;&lt;br&gt;                The participants will be asked to do some simple movement tasks, such as gripping a device that measures the force generated, during standard clinical deep brain stimulation (DBS) and with stimulation turned off. Meanwhile, the thalamic local field potentials (LFP), EEG, EMG, and accelerometer signals will be recorded. This procedure is for the researchers to prepare the models for movement or postural tremor decoding and will take approximately 1 hour.&lt;br&gt;&lt;br&gt;                Participants will be asked to perform some voluntary movements and/or maintaining some specific postures to evoke tremor. These will be self-paced movements typically seen in everyday life, such as drawing, reaching and picking up a cup, or holding a book. They will then receive continuous DBS, adaptive DBS or no DBS during these movements or postures. Adaptive DBS (also known as ‘closed loop DBS’) responds to the detection of movements and tremor. This procedure is for testing the performance of the adaptive DBS and will take approximately 1 hour.&lt;br&gt;&lt;br&gt;                In this study, the control conditions include continuous DBS and when the stimulation turned off, therefore provides within-subject control. The effect of adaptive DBS is evaluated in terms of decoding performance (accuracy, sensitivity, and false-positive rate), saved energy compared to continuous DBS, and tremor suppression.&lt;br&gt;
    </Intervention>
    <Primary_outcome>&lt;br&gt;                1. Voluntary movement and postural tremor decoding performance assessed through recorded LFPs and accelerometer signals at baseline, 1h, and 2h.&lt;br&gt;                2. Effectiveness and efficiency of the proposed adaptive DBS assessed by the energy saved compared to continuous DBS and the suppression of tremor compared with when the DBS is turned off measured using accelerometer and patient’s self-report at baseline, 1h, and 2h.&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Different feature contributions for voluntary movement and posture tremor decoding assessed through recorded LFPs and accelerometer signals at baseline, 1h, and 2h.&lt;br&gt;                2. The possibility for predicting the onsets of voluntary movement and postural tremor using LFPs, thus the DBS can be switched on in advance assessed by recorded LFPs and accelerometer signals at baseline, 1h, and 2h.&lt;br&gt;                3. Possibilities of movement/tremor decoding on different contacts using the anatomy information of the DBS electrodes for the patients at baseline, 1h, and 2h.&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;MR/P012272/1, MC_UU_12024/1, IRAS 249989
    </Secondary_ID>
    <Source_Support>Medical Research Council, Rosetrees Trust
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 23/10/2018, Ethics Committee of the South Central - Oxford B Research Ethics Committee (Level 3, Block B, Whitefriars Building, Lewins Mead, Bristol BS1 2NT; +44 02071048058; nrescommittee.southcentral-oxfordb@nhs.net), ref: 18/SC/0436
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>31/01/2022
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10728107
    </Internal_Number>
    <TrialID>NCT04255719
    </TrialID>
    <Last_Refreshed_on>16 March 2021
    </Last_Refreshed_on>
    <Public_title>Unilateral GPi vs Unilateral STN DBS in the Same Patient With PD
    </Public_title>
    <Scientific_title>Unilateral Pallidal vs Unilateral Subthalamic Nucleus Deep Brain Stimulation in the Same Patient With Parkinson Disease: A Randomized Controlled Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Ruijin Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200202
    </Date_registration3>
    <Date_registration>02/02/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04255719
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>55 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 1, 2020
    </Date_enrollement>
    <Target_size>9
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with idiopathic Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Aged between 55 and 75 years, both male and female&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who have undergone combined unilateral STN and contralateral GPi DBS for more&#x0D;&lt;br&gt;             than 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A Hoehn-Yahr (H-Y) stage of less than 4 in the off-medication state&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A left-extremity to right-extremity ratio of less than 0.15 on the Unified Parkinson's&#x0D;&lt;br&gt;             Disease Rating Scale part ? (UPDRS-?) in the both off-medication and on-medication&#x0D;&lt;br&gt;             states&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of serious psychosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of intractable epilepsy (i.e., seizures)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosed by the investigators that patients with severe cardiac, liver and kidney&#x0D;&lt;br&gt;             diseases, or other serious health conditions&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia (A Mini-Mental State Examination (MMSE) score of &lt; 24), inability to&#x0D;&lt;br&gt;             comprehend the experimental protocol or voluntarily provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Lack of cooperation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Additional reasons for exclusion at the discretion of the clinical investigator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Poorly controlled depression or anxiety&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Past history of suicidal attempt&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Deep Brain Stimulation;Globus Pallidus Interna;Subthalamic Nucleus
    </Condition>
    <Intervention>Procedure: DBS
    </Intervention>
    <Primary_outcome>Difference in Timed Up-and-Go (TUG) task scores between treatment conditions in the on- and off- medication states
    </Primary_outcome>
    <Secondary_outcome>Differences in total Uni?ed Parkinson's Disease Rating Scale Part ? (UPDRS ?) scores between two treatment conditions in the on- and off- medication states;Differences in Burg Balance Scale (BBS) scores between two treatment conditions in the on- and off- medication states.;Differences in postural angles between two treatment conditions in the on- and off- medication states.;Differences in Water Swallow Test (WST) scores between treatment conditions in the on- and off- medication states.;Differences in Swallowing Disturbance Questionnaire (SDQ) scores between treatment conditions in the on- and off- medication states.;Differences in voice parameters between treatment conditions in the on- and off- medication states.;Differences in Voice Handicap Index (VHI) between treatment conditions in the on- and off- medication states.
    </Secondary_outcome>
    <Secondary_ID>2020 UPS study
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>9178999
    </Internal_Number>
    <TrialID>ISRCTN51601294
    </TrialID>
    <Last_Refreshed_on>27 April 2020
    </Last_Refreshed_on>
    <Public_title>Finding brain signals that might guide the delivery of deep brain stimulation
    </Public_title>
    <Scientific_title>An investigation into the chronic neurophysiological biomarkers of Parkinson's disease (PD) and their application to closed loop deep brain stimulation (DBS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
    </Scientific_title>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200131
    </Date_registration3>
    <Date_registration>31/01/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN51601294
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>10/01/2020
    </Date_enrollement>
    <Target_size>38
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Non-randomised; Interventional; Design type: Treatment, Device, Physical, Surgery (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>United Kingdom
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Participant is willing and able to give informed consent for participation in the study&lt;br&gt;                2. Male or female, aged 18 to 80 years old&lt;br&gt;                3. Diagnosed with Parkinson’s disease, essential tremor or dystonia&lt;br&gt;                4. Has completed stage 1 of a two-stage surgery for deep brain stimulation as therapy for their movement disorder&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Cognitive impairment (judged by the clinician taking consent as not having sufficient mental capacity to understand the study and its requirements). This is including anyone who, in the opinion of the clinician taking consent, is unlikely to retain sufficient mental capacity for the duration of their involvement in the study&lt;br&gt;                2. Intracranial bleeding, cerebrospinal fluid leak or any other complication after the first stage of surgery&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Parkinson's disease &lt;br&gt;Nervous System Diseases &lt;br&gt;Parkinson disease
    </Condition>
    <Intervention>&lt;br&gt;                The study will take place either in the Neurosciences Ward or the Charles Wolfson clinical research facility (one floor below the ward) in the John Radcliffe University Hospital according to the patient's preference. The above represents only one study site.&lt;br&gt;&lt;br&gt;                Patients will be enrolled who are undergoing surgery for deep brain stimulation as therapy for a movement disorder. Surgery will be performed purely on clinical grounds. Some of such patients have a staged surgery with stage 1 consisting of electrode implantation and stage 2 consisting of the connection of the electrodes to a subcutaneous stimulator and battery unit. This staging is performed for clinical reasons (such as testing of stimulation effects prior to committing to implantation of an expensive stimulator and battery unit) or service reasons (such as maximising the efficiency of surgical operating time). It is these patients who the researchers hope to study. Patients will be studied over up to two days between stage 1 and stage 2, which are usually separated by 4-7 days. On each study day, the patient will undergo recording and testing that may last up to 4 hours. Thus the patient is only asked to volunteer for one or two days study and no other visits are required. Whether the study takes one or two days depends on the patients’ preference.&lt;br&gt;&lt;br&gt;                Study day 1 will consist of:&lt;br&gt;                1. Further explanation and consent&lt;br&gt;                Suitable patients to approach will be identified by the surgical team. The study will be described to them and a PIL left with them so that they can read it over at least 24 hours. On the day of the proposed study, the researchers will go over the PIL and answer any questions the participant may have. If they would like to 
    </Intervention>
    <Primary_outcome>&lt;br&gt;                Measured before and after feedback-controlled stimulation:&lt;br&gt;                1. Kinematic recordings (accelerometer and BRAIN test in all patients) related to movement speed, spasms and the presence of tremor&lt;br&gt;                2. Scores on standard, disease-specific clinical rating scales (UPDRS and UDysRS in Parkinson’s disease, TETRAS in essential tremor and BFMRS and UDysRS in dystonia) and on Speech Intelligibility Test (all patients)&lt;br&gt;                3. Scalp EEG (brain waves), depth EEG and EMG (muscle) recordings (all patients)&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>There are no secondary outcome measures
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;CPMS 42210, IRAS 271953
    </Secondary_ID>
    <Source_Support>Medical Research Council, National Institute for Health Research (NIHR) (UK)
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 03/05/2011, South Central - Oxford C Research Ethics Committee (Level 3, Block B, Whitefriars Building, Lewins Mead,  Bristol, BS1 2NT, UK; Tel: +44 (0)207 104 8241, 0207 104 8041; Email: nrescommittee.southcentral-oxfordc@nhs.net), ref: 11/SC/0100
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>09/07/2024
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10352110
    </Internal_Number>
    <TrialID>NCT04223427
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Effects of Directional Subthalamic Deep Brain Stimulation on Gait and Balance in Parkinson's Disease Patients
    </Public_title>
    <Scientific_title>Effects of Directional Subthalamic Deep Brain Stimulation on Gait and Balance in Parkinson's Disease Patients - MApping Gait and Balance Issues With Current Shaping
    </Scientific_title>
    <Acronym>MAGIC
    </Acronym>
    <Primary_sponsor>University Hospital, Rouen
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191210
    </Date_registration3>
    <Date_registration>10/12/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04223427
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 14, 2020
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Marie-Laure Welter
    </Contact_Lastname>
    <Contact_Email>Marie-Laure.Welter@chu-rouen.fr
    </Contact_Email>
    <Contact_Tel>02 32 88 86 98
    </Contact_Tel>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Age between 18 and 70 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Diagnosis of Parkinson's Disease; as defined by the United Kingdom Parkinson's Disease&#x0D;&lt;br&gt;             Society Brain Bank (UKPDSBB) criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients eligible for subthalamic bilateral deep brain stimulation (STN-DBS) according&#x0D;&lt;br&gt;             to local inclusion criteria;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Freezing of gait in the OFF-dopa condition with item 2.13 of the MDS-UPDRS &gt; 0 in&#x0D;&lt;br&gt;             usual life;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patient having read and understood the information letter and signed the Informed&#x0D;&lt;br&gt;             Consent Form&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Patient affiliated with, or beneficiary of a social security category&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Stability of others medical disorders or that do not interfere with the research&#x0D;&lt;br&gt;             protocol.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Woman of childbearing potential with effective contraception according to WHO&#x0D;&lt;br&gt;             definition (estrogen-progestin or intra-uterine device or tubal ligation) since at&#x0D;&lt;br&gt;             least 3 months (negative urinary pregnancy test at inclusion)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Actual and severe psychiatric pathology or other neurological disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Dementia (MMS &lt;24/30)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Contraindication to research MRI (without contrast product) such as claustrophobia,&#x0D;&lt;br&gt;             metallic splinters in the eyes, ferromagnetic foreign bodies close to nerve&#x0D;&lt;br&gt;             structures, cardiac, ORL and neurological devices not MRI compatible, wearing of&#x0D;&lt;br&gt;             osteosynthseis equipment prior to 1980, metal prostheses, bypass valves&#x0D;&lt;br&gt;             ventriculoperitoneal neurosurgery, tattoos containing iron particles…&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Contraindication to surgery: hemostasis trouble, anticoagulants or antiagregants&#x0D;&lt;br&gt;             treatment, ongoing infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Hypersensitivity to contrasts agents&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Persons under guardianship, tutorship or any other administrative or judicial measure&#x0D;&lt;br&gt;             of deprivation of rights and liberty&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Subject at the time of exclusion from other biomedical research or participating in&#x0D;&lt;br&gt;             any other biomedical research or therapeutic trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Pregnant or parturient or lactating woman or lack of proven and effective&#x0D;&lt;br&gt;             contraception according to WHO definition (estrogen-progestin or intra-uterine device&#x0D;&lt;br&gt;             or tubal ligation) (for women of childbearing age)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Procedure: Directional and single ring STN-DBS on gait
    </Intervention>
    <Primary_outcome>Changes in the principal components analysis (PCA) of the gait initiation kinetics during gait initiation with cognitive interference
    </Primary_outcome>
    <Secondary_ID>2018/0427/HP
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13730272
    </Internal_Number>
    <TrialID>NL-OMON47557
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>The GALAXY study: General Anesthesia versus Local Anesthesia in StereotaXY for Deep Brain Stimulation in Parkinson*s disease, a randomized controlled trial.
    </Public_title>
    <Scientific_title>The GALAXY study: General Anesthesia versus Local Anesthesia in StereotaXY for Deep Brain Stimulation in Parkinson*s disease, a randomized controlled trial. - GALAXY (General Anesthesia versus Local Anesthesia in stereotaXY)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Academisch Medisch Centrum
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20191209
    </Date_registration3>
    <Date_registration>2019-12-09
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/47557
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>64
    </Inclusion_agemax>
    <Inclusion_gender/>
    <Date_enrollement>2016-05-23
    </Date_enrollement>
    <Target_size>110
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized  controlled trial, Open (masking not used), Active, Other, Treatment
    </Study_design>
    <Phase/>
    <Countries>The Netherlands
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address>Meibergdreef 9
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Academisch Medisch Centrum
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;p&gt;- Age &gt; 18 years; &lt;br&gt;- Idiopathic PD with bradykinesia and at least two of the following signs; &lt;br&gt;resting tremor, rigidity, and asymmetry;&lt;br&gt;- Despite optimal pharmacological treatment, at least one of the following &lt;br&gt;symptoms: severe response fluctuations, dyskinesias, painful dystonia or &lt;br&gt;bradykinesia; &lt;br&gt;- A life expectancy of at least two years. &lt;/p&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;p&gt;- Legally incompetent adults&lt;br&gt;- Previous PD-neurosurgery (e.g., DBS, pallidotomy, thalamotomy); &lt;br&gt;- Contraindications for DBS surgery, such as a physical disorder making surgery &lt;br&gt;hazardous;&lt;br&gt;- Hoehn and Yahr stage 5 at the best moment during the day;&lt;br&gt;- Psychosis;&lt;br&gt;- Current depression;&lt;br&gt;- No written informed consent;&lt;/p&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Parkinson's disease &lt;br&gt;primary parkinsonism &lt;br&gt;shaking palsy;10028037;10009720;Parkinson's disease;primary parkinsonism;shaking palsy
    </Condition>
    <Intervention>&lt;p&gt;Patients will be randomized to DBS under general anesthesia or DBS under local &lt;br&gt;anesthesia. As is standard procedure, 2 electrodes will be implanted in the &lt;br&gt;brain connected to an implanted pulse generator, which will be placed &lt;br&gt;subcutaneously in the subclavian area.&lt;/p&gt;&lt;br&gt;;Deep brain stimulation;General anesthesia;Parkinson's disease
    </Intervention>
    <Primary_outcome>&lt;p&gt;The primary outcome measures is the number of patients with significant&lt;br /&gt;&lt;br&gt;postoperative cognitive, mood and behavioral adverse effects indicated by a&lt;br /&gt;&lt;br&gt;stringent composite score of &gt;1 within 6 months after STN DBS.&lt;/p&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>&lt;p&gt;Secondary outcome measures are:&lt;br /&gt;&#x0D;&lt;br&gt;- Motor score: MDS-UPDRS&lt;br /&gt;&#x0D;&lt;br&gt;- Clinical Dyskinesia Rating Scale (CDRS)&lt;br /&gt;&#x0D;&lt;br&gt;- Daily functioning: MDS-UPDRS (activities of daily living section), Functional&lt;br /&gt;&#x0D;&lt;br&gt;health status (ALDS)&lt;br /&gt;&#x0D;&lt;br&gt;- Quality of life: PDQ-39&lt;br /&gt;&#x0D;&lt;br&gt;- Treatment satisfaction (See F-vragenlijsten, Treatment satisfaction)&lt;br /&gt;&#x0D;&lt;br&gt;- Burden of therapy (See F-vragenlijsten, Burden of therapy)&lt;br /&gt;&#x0D;&lt;br&gt;- Surgery time, duration of hospital admittance&lt;br /&gt;&#x0D;&lt;br&gt;- PD- medication changes&lt;br /&gt;&#x0D;&lt;br&gt;- Other adverse effects and complications than those registered in the&lt;br /&gt;&#x0D;&lt;br&gt;composite score&lt;br /&gt;&#x0D;&lt;br&gt;- Other psychiatric effects and complications than those registered in the&lt;br /&gt;&#x0D;&lt;br&gt;composite score, measured with: Young Mania Rating Scale, Columbia Suicide&lt;br /&gt;&#x0D;&lt;br&gt;Severity Rating Scale, Hamilton Depression Rating Scale, Hamilton Anxiety&lt;br /&gt;&#x0D;&lt;br&gt;Rating Scale, Starkstein Apathy Rating Scale.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>NL53375.018.15
    </Secondary_ID>
    <Source_Support>Ministerie van OC&amp;W;is aangevraagd
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>17/02/2016;14/04/2016;02/03/2017;28/02/2019;09/12/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>;;;;
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;;;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13605407
    </Internal_Number>
    <TrialID>NCT04218526
    </TrialID>
    <Last_Refreshed_on>8 January 2024
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation of the Cuneiform Nucleus for Levodopa-resistant Freezing of Gait in Parkinson's Disease
    </Public_title>
    <Scientific_title>Deep Brain Stimulation of the Cuneiform Nucleus for Levodopa-resistant Freezing of Gait in Parkinson's Disease
    </Scientific_title>
    <Acronym>DBS + FOG
    </Acronym>
    <Primary_sponsor>Jonathan Jagid
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191202
    </Date_registration3>
    <Date_registration>02/12/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04218526
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 27, 2020
    </Date_enrollement>
    <Target_size>4
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Jonathan R Jagid, MD;Letitia Fisher, BLA;Letitia Fisher, BLA
    </Contact_Lastname>
    <Contact_Email>;lfisher@miami.edu;lfisher@miami.edu
    </Contact_Email>
    <Contact_Tel>;305-243-3056;305-243-7108
    </Contact_Tel>
    <Contact_Affiliation>University of Miami;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Confirmed Parkinson's Disease according to movement disorder neurologist with&#x0D;&lt;br&gt;             documented exclusion of other disorders such as fronto-temporal dementia (FTD)/&#x0D;&lt;br&gt;             frontal gait disorder/normal pressure hydrocephalus (NPH)/progressive supranuclear&#x0D;&lt;br&gt;             palsy (PSP)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. PD stage3 ON medication, with severe gait dysfunction and predominant axial symptoms:&#x0D;&lt;br&gt;             Movement Disorder Society-Unified Parkinson's Disease Rating Scale Tremor Dominant&#x0D;&lt;br&gt;             (MDS-UPDRS TD), Postural Instability Gait Difficulty (PIGD) ratio = 0.90 and Freezing&#x0D;&lt;br&gt;             Of Gait Questionnaire (FOGQ) score &gt; 12.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Age 40-75 with good response to Levodopa (defined as greater than 20% improvement in&#x0D;&lt;br&gt;             UPDRS score)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. FOG refractory to LEVODOPA&gt;600 mg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. 6. Minimal tremor, bradykinesia, and rigidity symptoms, or well controlled with&#x0D;&lt;br&gt;             Levodopa and/or with already implanted STN/GPi DBS.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. a) Poor candidate for STN or GPi DBS due to good control of tremor, bradykinesia, and&#x0D;&lt;br&gt;             rigidity symptoms with Levodopa b) or Post-operative STN/GPi DBS PD patients with&#x0D;&lt;br&gt;             significant residual non-levodopa responsive postural and gait instability&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Must agree to full 6-month participation in study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Individuals with major executive dysfunction&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Individuals with dementia, as defined by the Mattis Dementia Rating Scale-2 (DRS-2)&#x0D;&lt;br&gt;             score = 130&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Individuals with other neurocognitive impairments&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Individuals who have depression, as defined for example by the Beck Depression&#x0D;&lt;br&gt;             Inventory II (BDI-II) &gt; 25&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Presence of major medical co-morbidities and other surgical contra-indications such as&#x0D;&lt;br&gt;             coagulopathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Individuals who require diathermy, transcranial magnetic stimulation (TMS), or&#x0D;&lt;br&gt;             electroconvulsive therapy (ECT)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Individuals with a history of prior intracranial surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Individuals with a metallic implant in their head that is not MRI compatible (e.g.,&#x0D;&lt;br&gt;             aneurysm clip, cochlear implant)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Individuals with active implantable devices anywhere in the body (e.g. cardiac&#x0D;&lt;br&gt;             pacemaker, defibrillator, spinal cord stimulator, implanted medication pump)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Individuals who are pregnancy or desire to become pregnant during the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Individuals who are breastfeeding12.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Individuals who are on investigational drugs and any other intervention (not part of&#x0D;&lt;br&gt;             the guidelines for management of Parkinson's Disease) known to have a potential impact&#x0D;&lt;br&gt;             on outcome&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Subjects utilizing recreational drugs at the time of screening will be excluded from&#x0D;&lt;br&gt;             the study with the exception of medicinal marijuana&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Vercise DBS System
    </Intervention>
    <Primary_outcome>Percent Change in Gait Velocity;Percent change in UPDRS Part III on/off stimulation
    </Primary_outcome>
    <Secondary_outcome>Percent Change in FOG Questionnaire;Percent Change in PDQ 39;Percent Change in PDQ-L;Percent Change in Muscle Amplitude;Percent Change in number of Falls
    </Secondary_outcome>
    <Secondary_ID>20190702
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Boston Scientific Corporation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13302048
    </Internal_Number>
    <TrialID>NCT04184791
    </TrialID>
    <Last_Refreshed_on>28 August 2023
    </Last_Refreshed_on>
    <Public_title>Computational Modeling of 60 Hz Subthalamic Nucleus Deep Brain Stimulation for Gait Disorder in Parkinson's Disease
    </Public_title>
    <Scientific_title>Computational Modeling of 60 Hz Subthalamic Nucleus Deep Brain Stimulation for Gait Disorder in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Northwell Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191122
    </Date_registration3>
    <Date_registration>22/11/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04184791
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 15, 2020
    </Date_enrollement>
    <Target_size>22
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Ritesh Ramdhani, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Northwell Health
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Male or female, aged 21-80&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patients diagnosed with Parkinson's disease (PD)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. PD subjects who have bilateral STN-DBS (greater than 3 months) or in the preoperative&#x0D;&lt;br&gt;             stage of being implanted with bilateral STN-DBS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Have underlying gait disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Currently treated with oral levodopa therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Willingness to comply with all study procedures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Cognitive deficits based on historical record that limit participant compliance with&#x0D;&lt;br&gt;             study protocol&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Vestibular disorder or musculoskeletal problems affecting gait or balance&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Change in Gait and Balance using Wearable Sensors;Accuracy of Predicting Gait Response to 60hz with Machine Learning;Accuracy of Predicting Best Stimulation Frequency (60hz vs. High Frequency) with Machine Learning
    </Primary_outcome>
    <Secondary_outcome>Change in Hand Tremor Severity;Change in Speed of Limb Movements
    </Secondary_outcome>
    <Secondary_ID>R21NS111301;19-0217
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institute of Neurological Disorders and Stroke (NINDS);The University of Tennessee, Knoxville
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13642554
    </Internal_Number>
    <TrialID>DRKS00017528
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Short pulses in neurostimulation for Parkinson's Disease
    </Public_title>
    <Scientific_title>Short pulses in neurostimulation for Parkinson's Disease - SPIN-PD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
    </Scientific_title>
    <Primary_sponsor>Klinik und Poliklinik für Neurologie der Universitätskliniken zu Köln
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20191106
    </Date_registration3>
    <Date_registration>06/11/2019
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00017528
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>15/08/2019
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Randomized controlled study; Masking: Blinded (masking used); Control: Other; Assignment: crossover; Study design purpose: treatment 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Jan Niklas
    </Contact_Firstname>
    <Contact_Lastname>Petry-Schmelzer
    </Contact_Lastname>
    <Contact_Address>Kerpener Straße 62
    </Contact_Address>
    <Contact_Email>jan.petry-schmelzer@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>0221-478-84791
    </Contact_Tel>
    <Contact_Affiliation>Universitätskliniken Köln Klinik und Poliklinik für Neurologie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Bilateral Implantation of electrodes for deep brain stimulation of the subthalamic nucleus for the treatment of idiopathic Parkinson's disease:&#x0D;&lt;br&gt;a. at least 3 months prior to study participation&#x0D;&lt;br&gt;b. the implanted pulse generator enables a pulse width of 30µs per clinical routine (Boston Scientific Vercise, Vercise PC and Gevia; Abbott Medical Infinity DBS System&#x0D;&lt;br&gt;2. The patient is not allowed to participate at another studies during which an adjustment of medication or stimulation parameters is needed at the same time&#x0D;&lt;br&gt;3. Patients need to agree with video and voice recordings and sign a patient consent form
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Inclusion criteria not completed.
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: Deep brain stimulation with a pulse width of 30µs for 4 weeks, followed by a deep brain stimulation with 60µs for 4 weeks.&lt;br&gt;Group 2: Deep brain stimulation with a pulse width of 60µs for 4 weeks, followed by a deep brain stimulation with 30µs for 4 weeks.
    </Intervention>
    <Primary_outcome>- Motor Diary during the last three days before the next follow-up visit after 4 weeks of deep brain stimulation with one of the two pulse widths (30µs or 60µs)&lt;br&gt;- co-primary endpoint: Unified Parkinson's disease rating scale in MedOFF/StimON at follow-up visit
    </Primary_outcome>
    <Secondary_outcome>After four weeks of deep brain stimulation with one of the two pulse widths respectively (30µs or 60µs):&#x0D;&lt;br&gt;- energy consumption&#x0D;&lt;br&gt;- Parkinson's disease Questionnaire 39&#x0D;&lt;br&gt;- Non-motor symptom scale, Non-motor symptoms questionnaire&#x0D;&lt;br&gt;- reading of a German standard text&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;additionally:&#x0D;&lt;br&gt;- preferred setting after finishing the study
    </Secondary_outcome>
    <Source_Support>Klinik und Poliklinik für Neurologie
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>14/08/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>26/01/2023
    </results_date_posted>
    <results_date_completed>03/12/2020
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00017528#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12844754
    </Internal_Number>
    <TrialID>NCT04116996
    </TrialID>
    <Last_Refreshed_on>27 February 2023
    </Last_Refreshed_on>
    <Public_title>Globus Pallidus Stimulation to Treat Insomnia
    </Public_title>
    <Scientific_title>Stimulation of the External Pallidal Segment for Insomnia in Patients With Parkinson's Disease
    </Scientific_title>
    <Acronym>GPS-I
    </Acronym>
    <Primary_sponsor>Mayo Clinic
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20191002
    </Date_registration3>
    <Date_registration>02/10/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04116996
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2019
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Pablo Castillo, MD;Pablo R Castillo, MD
    </Contact_Lastname>
    <Contact_Email>;castillo.pablo@mayo.edu
    </Contact_Email>
    <Contact_Tel>;904-953-2000
    </Contact_Tel>
    <Contact_Affiliation>Mayo Clinic
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  40-80 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Symptomatic with Parkinsonism for 7-20 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe insomnia based on ISI score&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant dementia (MMSE &lt;23)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hoehn &amp; Yahr [Hoehn, 1967 #1839] stage I or V disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other significant neurological or psychiatric disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous pallidotomy or thalamotomy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous placement of other implantable devices&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Secondary parkinsonism (non-idiopathic parkinsonism)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to travel to Jacksonville for post-operative study visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe sleep apnea&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Insomnia due to pain or untreated mood disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Contraindications to 3T MRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Circadian rhythm sleep disorders.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current use of hypnotics&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: DEEP BRAIN STIMULATION
    </Intervention>
    <Primary_outcome>Change in Insomnia Severity Index
    </Primary_outcome>
    <Secondary_outcome>Change in Parkinson's Sleep Scale (PDSS)
    </Secondary_outcome>
    <Secondary_ID>17-010112
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13642866
    </Internal_Number>
    <TrialID>DRKS00018838
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation induced Cortical Modulation in Tourette syndrome
    </Public_title>
    <Scientific_title>Deep Brain Stimulation induced Cortical Modulation in Tourette syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>Klinik für Psychiatrie und Psychotherapie, Uniklinik Köln
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191002
    </Date_registration3>
    <Date_registration>02/10/2019
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00018838
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>27/05/2020
    </Date_enrollement>
    <Target_size>15
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: N/A: single arm study; Masking: Open (masking not used); Control: uncontrolled; Assignment: single; Study design purpose: basic science  
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Thomas
    </Contact_Firstname>
    <Contact_Lastname>Schüller
    </Contact_Lastname>
    <Contact_Address>Kerpener Str. 62
    </Contact_Address>
    <Contact_Email>thomas.schueller@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>022147898844
    </Contact_Tel>
    <Contact_Affiliation>Klinik für Psychiatrie und Psychotherapie, Uniklinik Köln
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: - Suficient German language skills&lt;br&gt;- Age between 18 and 65 Jahren&lt;br&gt;- Ability to give informed consent&lt;br&gt;- Diagnosis Tourette syndrome (ICD 10)&lt;br&gt;- Thalamic deep brain stimulation&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: - Suicidal tendencies&lt;br&gt;- Psychotic symptoms&lt;br&gt;- Drug addiction &lt;br&gt;- Pregnancy or nursing period&lt;br&gt;- Severe internistic illness&lt;br&gt;- Severe neurological disorder&lt;br&gt;- Mental retardation&lt;br&gt;- Accomodation via PsychKG §14&lt;br&gt;- Use of benzodiazepine&lt;br&gt;- Withdrawal of informed consent&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;F95.2;Combined vocal and multiple motor tic disorder [de la Tourette];F95.2
    </Condition>
    <Intervention>Group 1: We aim to include patients with Tourette syndrome and bilateral thalamic deep brain stimulation (DBS) electrodes. The study comprises informed consent, completion of psychmetric scales, preparation of EEG recordings and EEG recordings themselves. The on and off DBS phases will be performed pseudorandomized and counterbalanced. Each phase will last 5 minutes. The complete study will last approximatley 90 minutes.
    </Intervention>
    <Primary_outcome>Changes in EEG frequency bands evoked by thalamic deep brain stimulation. Recordings will follow an ABABAB design. The primary outcome is the EEG signal difference between on and off stimulation.
    </Primary_outcome>
    <Secondary_outcome>Predicition of EEG changes by overlap of volumes of tissue activitated with specific thalamic nuclei.
    </Secondary_outcome>
    <Source_Support>Köln Fortune
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>03/09/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_date_completed>01/12/2021
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00018838#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10343873
    </Internal_Number>
    <TrialID>NCT04116177
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Flexible vs. Standard Deep Brain Stimulation Programming in Parkinson Disease Patients
    </Public_title>
    <Scientific_title>Flexible vs. Standard Programming in Parkinson's Disease Patients Receiving Subthalamic Implant: a Double-blind Cross-over Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Toronto
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190925
    </Date_registration3>
    <Date_registration>25/09/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04116177
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 2016
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Canada
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        1) Patients with a diagnosis of PD according to the British Parkinson's Disease Society&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Brain Bank criteria (Hughes, Daniel, Kilford, &amp; Lees, 1992), who fulfilled the&#x0D;&lt;br&gt;             inclusion and exclusion criteria proposed by the core assessment programme for&#x0D;&lt;br&gt;             surgical interventional therapies in PD panel (Defer, Widner, Marié, Rémy, &amp; Levivier,&#x0D;&lt;br&gt;             1999)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Male and female patients with idiopathic PD, who have symptoms responsive to L-dopa&#x0D;&lt;br&gt;             medications, but who have significant impairment related to PD that is no longer well&#x0D;&lt;br&gt;             controlled with pharmacotherapy (i.e., refractory to optimized medical therapy)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients considered as STN-DBS candidates as per current standard of care. These&#x0D;&lt;br&gt;             patients will subsequently undergo STN-DBS surgery and maintain stimulation therapy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Quality of life and social functioning influenced by levodopa-responsive signs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. No major comorbidities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        1) Exclusion criteria will include patients with other significant neurologic or&#x0D;&lt;br&gt;        psychiatric illnesses or cognitive deficit.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Deep brain stimulation
    </Intervention>
    <Primary_outcome>Change of Overall Global functioning (PGIC)
    </Primary_outcome>
    <Secondary_outcome>Measure of Quality of life (PDQ-39);Clinical change in motor symptoms using Unified Parkinson Disease Rating Scale I-IV;Clinical change in motor symptoms;Number of falls;Change in the presence and severity of depressive symptoms using the Beck Depression Inventory (BDI);Walking speed measure using Prokinetics gait analysis/Zeno Walkway;Step length measured using Prokinetics gait analysis/Zeno Walkway;Cadence measured using Prokinetics gait analysis/Zeno Walkway;Double support time measured using Prokinetics gait analysis/Zeno Walkway
    </Secondary_outcome>
    <Secondary_ID>15-9700
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10342161
    </Internal_Number>
    <TrialID>NCT04093908
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Prediction of STN DBS Motor Response in PD
    </Public_title>
    <Scientific_title>Machine Learning Prediction of Motor Response After STN DBS in Parkinson Patients, a Retrospective Multicenter Validation Study
    </Scientific_title>
    <Acronym>DBS-PREDICT
    </Acronym>
    <Primary_sponsor>Maastricht University Medical Center
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190917
    </Date_registration3>
    <Date_registration>17/09/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04093908
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 1, 2019
    </Date_enrollement>
    <Target_size>322
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Netherlands
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  underwent STN DBS for Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  completed one year follow up after surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        - missing data in postoperative UPDRS II, III, IV&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Prediction of motor outcome after STN DBS based on preoperative variables
    </Intervention>
    <Primary_outcome>area under the curve of the receiver operator curve;predictive accuracy;true positive prediction rate;false positive prediction rate
    </Primary_outcome>
    <Secondary_ID>2019-0739-A9
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10342133
    </Internal_Number>
    <TrialID>NCT04093544
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Expanding the Therapeutic Window of Deep Brain Stimulation in Parkinson's Disease by Means of Directional Leads
    </Public_title>
    <Scientific_title>Expanding the Therapeutic Window of Deep Brain Stimulation in Parkinson's Disease by Means of Directional Leads: a Double-blind Cross-over Pilot Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Toronto
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190907
    </Date_registration3>
    <Date_registration>07/09/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04093544
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 15, 2018
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Canada
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Alfonso Fasano, MD;Alfonso Fasano, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;alfonso.fasano@uhn.ca
    </Contact_Email>
    <Contact_Tel>;+1 416 603 5800
    </Contact_Tel>
    <Contact_Affiliation>University of Toronto
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        1. Patients with a diagnosis of Parkinson's disease (PD) according to the British&#x0D;&lt;br&gt;             Parkinson's Disease Society Brain Bank criteria, who fulfilled the inclusion and&#x0D;&lt;br&gt;             exclusion criteria proposed by the core assessment programme for surgical&#x0D;&lt;br&gt;             interventional therapies in PD panel&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Male and female patients with idiopathic PD, who have symptoms responsive to L- dopa&#x0D;&lt;br&gt;             medications, but who have significant impairment related to PD that is no longer well&#x0D;&lt;br&gt;             controlled with pharmacotherapy (i.e., refractory to optimized medical therapy)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients considered as subthalamic nucleus deep brain stimulation (STN-DBS) candidates&#x0D;&lt;br&gt;             as per current standard of care. These patients will subsequently undergo STN-DBS&#x0D;&lt;br&gt;             surgery and maintain stimulation therapy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patients aged 18 to 80 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Quality of life and social functioning influenced by levodopa-responsive symptoms 6)&#x0D;&lt;br&gt;             No major comorbidities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria will include patients with other significant neurologic or psychiatric&#x0D;&lt;br&gt;        illnesses or cognitive deficit.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Deep brain stimulation
    </Intervention>
    <Primary_outcome>Number/incidence of adverse events
    </Primary_outcome>
    <Secondary_outcome>Change from baseline in a measure of health related quality of life and non-motor symptoms of Parkinson's disease using the Parkinson's disease Questionnaire (PDQ-39);Patients Global Impression of Change (PGIC);Change in articulation rate of speech using a Phonetics Software;Change in dysfluency of speech using a Phonetics Software;Change in intelligibility of speech using a Phonetics Software;Change in the Movement Disorders sponsored Unified Parkinson's disease Rating Scale (MDS-UPDRS), a measure of various motor and non-motor symptoms used to assess the clinical course of Parkinson's longitudinally.;Change in the presence and severity of depressive symptoms using the Beck Depression Inventory (BDI);Walking speed measured with the Zeno Walkway;Step length measured with the Zeno Walkway;Double support time measured with the Zeno Walkway;Cadence measured with the Zeno Walkway;Percentage of ON time without troublesome dyskinesias during waking hours;Number of falls or near-falls;Change in levodopa equivalent daily dose (LEDD);Measure of resting-state local field potentials and functional connectivity of the brain using magnetoencephalography (MEG)
    </Secondary_outcome>
    <Secondary_ID>17-5705
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10341145
    </Internal_Number>
    <TrialID>NCT04080674
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Using DBS to Probe Basal Ganglia Dysfunction
    </Public_title>
    <Scientific_title>Studying the Role of the Basal Ganglia in Motor Symptoms Using Deep Brain Stimulation
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190902
    </Date_registration3>
    <Date_registration>02/09/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04080674
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 1, 2019
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United Kingdom
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Peter Brown, MD;Peter Brown, MD
    </Contact_Lastname>
    <Contact_Email>;peter.brown@ndcn.ox.ac.uk
    </Contact_Email>
    <Contact_Tel>;01865 572 482
    </Contact_Tel>
    <Contact_Affiliation>University of Oxford;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant is willing and able to give informed consent for participation in the&#x0D;&lt;br&gt;             study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male or Female, aged 18 to 80 years old.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosed with Parkinson's disease, Essential Tremor or Dystonia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Undergoing two-stage surgery for deep brain stimulation as therapy for their movement&#x0D;&lt;br&gt;             disorder.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment (judged by the clinician on the care team or in the research team&#x0D;&lt;br&gt;             as a participant not having sufficient mental capacity to understand the study and its&#x0D;&lt;br&gt;             requirements). This includes anyone who, in the opinion of clinicians on the care team&#x0D;&lt;br&gt;             or clinicians in the research team, is unlikely to retain sufficient mental capacity&#x0D;&lt;br&gt;             for the duration of their involvement in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intracranial bleeding, confusion, cerebrospinal fluid leak or any other complication&#x0D;&lt;br&gt;             after the first stage of surgery.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson's Disease;Tremor;Dystonia
    </Condition>
    <Intervention>Other: Feed-back controlled deep brain stimulation
    </Intervention>
    <Primary_outcome>Kinematic recordings;Electromyographic signals;Disease relevant rating scale
    </Primary_outcome>
    <Secondary_ID>271953
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13103349
    </Internal_Number>
    <TrialID>NCT04071847
    </TrialID>
    <Last_Refreshed_on>5 June 2023
    </Last_Refreshed_on>
    <Public_title>Abbott DBS Post-Market Study of Outcomes for Indications Over Time
    </Public_title>
    <Scientific_title>Abbott DBS Post-Market Study of Outcomes for Indications Over Time
    </Scientific_title>
    <Acronym>ADROIT
    </Acronym>
    <Primary_sponsor>Abbott Medical Devices
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190826
    </Date_registration3>
    <Date_registration>26/08/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04071847
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 26, 2019
    </Date_enrollement>
    <Target_size>1000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States;Australia;Finland;France;Germany;Italy;Spain;Taiwan;United Kingdom;Australia;Finland;France;Germany;Italy;Spain;Taiwan;United Kingdom;United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Devyani Nanduri;Tucker Tomlinson, PHD
    </Contact_Lastname>
    <Contact_Email>;tucker.tomlinson@abbott.com
    </Contact_Email>
    <Contact_Tel>;+19725269646
    </Contact_Tel>
    <Contact_Affiliation>Abbott Medical Devices Neuromodulation;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject is scheduled for a new implant or IPG device replacement surgery with a&#x0D;&lt;br&gt;             market-released Abbott DBS system within 180 days.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subject, or a legally acceptable representative, must provide written informed consent&#x0D;&lt;br&gt;             prior to any study-related procedure.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject is currently enrolled or plans to enroll in an investigational study that may&#x0D;&lt;br&gt;             confound the results of this study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subject has anatomic or comorbid conditions, or other medical, social, or&#x0D;&lt;br&gt;             psychological conditions that, in the investigator's opinion, could limit the&#x0D;&lt;br&gt;             subject's ability to participate in the study or to comply with follow-up&#x0D;&lt;br&gt;             requirements, or impact the scientific soundness of the study results.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Study center is located in the United States, and indication for DBS implant is not&#x0D;&lt;br&gt;             Parkinson's disease or disabling tremor.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Study center is located in the United States, and the intended lead implant location&#x0D;&lt;br&gt;             is not at, or in close proximity to, the STN, GPi, or VIM thalamus.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Movement Disorders;Parkinson Disease;Essential Tremor;Tremor;Dystonia;Primary Dystonia;Secondary Dystonia
    </Condition>
    <Intervention>Device: Deep Brain Stimulation (DBS)
    </Intervention>
    <Primary_outcome>Change from baseline to 6 months in disease-specific motor rating scale. For subjects with Parkinson's disease, MDS-UPDRS Part III.;Change from baseline to1 year in disease-specific motor rating scale. For subjects with Parkinson's disease, MDS-UPDRS Part III.;Change from baseline to 2 years in disease-specific motor rating scale. For subjects with Parkinson's disease, MDS-UPDRS Part III.;Change from baseline to 3 years in disease-specific motor rating scale. For subjects with Parkinson's disease, MDS-UPDRS Part III.;Change from baseline to 4 years in disease-specific motor rating scale. For subjects with Parkinson's disease, MDS-UPDRS Part III.;Change from baseline to 5 years in disease-specific motor rating scale. For subjects with Parkinson's disease, MDS-UPDRS Part III.;Change from baseline to 6 months in disease-specific motor rating scale. For subjects with disabling tremor, FTM-TRS.;Change from baseline to 1 year in disease-specific motor rating scale. For subjects with disabling tremor, FTM-TRS.;Change from baseline to 2 years in disease-specific motor rating scale. For subjects with disabling tremor, FTM-TRS.;Change from baseline to 3 years in disease-specific motor rating scale. For subjects with disabling tremor, FTM-TRS.;Change from baseline to 4 years in disease-specific motor rating scale. For subjects with disabling tremor, FTM-TRS.;Change from baseline to 5 years in disease-specific motor rating scale. For subjects with disabling tremor, FTM-TRS.;Change from baseline to 6 months in disease-specific motor rating scale. For subjects with dystonia (except for cervical dystonia), BFMDRS movement scale.;Change from baseline to 1 year in disease-specific motor rating scale. For subjects with dystonia (except for cervical dystonia), BFMDRS movement scale.;Change from baseline to 2 years in disease-specific motor rating scale. For subjects with dystonia (except for cervical dystonia), BFMDRS movement scale.;Change from baseline to 3 years in disease-specific motor rating scale. For subjects with dystonia (except for cervical dystonia), BFMDRS movement scale.;Change from baseline to 4 years in disease-specific motor rating scale. For subjects with dystonia (except for cervical dystonia), BFMDRS movement scale.;Change from baseline to 5 years in disease-specific motor rating scale. For subjects with dystonia (except for cervical dystonia), BFMDRS movement scale.;Change from baseline to 6 months in disease-specific motor rating scale. For subjects with cervical dystonia, TWSTRS severity scale.;Change from baseline to 1 year in disease-specific motor rating scale. For subjects with cervical dystonia, TWSTRS severity scale.;Change from baseline to 2 years in disease-specific motor rating scale. For subjects with cervical dystonia, TWSTRS severity scale.;Change from baseline to 3 years in disease-specific motor rating scale. For subjects with cervical dystonia, TWSTRS severity scale.;Change from baseline to 4 years in disease-specific motor rating scale. For subjects with cervical dystonia, TWSTRS severity scale.;Change from baseline to 5 years in disease-specific motor rating scale. For subjects with cervical dystonia, TWSTRS severity scale.;Incidence of device- and procedure-related serious adverse events at 6 months;Incidence of device- and procedure-related serious adverse events at 1 year;Incidence of device- and procedure-related serious adverse events at 2 years;Incidence of device- and procedure-related serious adverse events at 3 years;Incidence of device- and procedure-related serious adverse events at 4 years;Incidence of device- and procedure-related serious adverse events at 5 years
    </Primary_outcome>
    <Secondary_ID>ABT-CIP-10300
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10338595
    </Internal_Number>
    <TrialID>NCT04047498
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Alternating DBS for Stepping Control in Parkinson's Disease
    </Public_title>
    <Scientific_title>Studying Stepping Control in Parkinson's Disease Using Alternating DBS
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190801
    </Date_registration3>
    <Date_registration>01/08/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04047498
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 1, 2019
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United Kingdom
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Peter Brown, MD;Peter Brown, MD;Thomas Foltynie, MD PhD
    </Contact_Lastname>
    <Contact_Email>;peter.brown@ndcn.ox.ac.uk;t.foltynie@ucl.ac.uk
    </Contact_Email>
    <Contact_Tel>;01865 572 482;0845 155 5000
    </Contact_Tel>
    <Contact_Affiliation>University of Oxford;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  PD patients with bilateral subthalamic nucleus DBS electrodes and stimulators&#x0D;&lt;br&gt;             implanted for at least 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to give consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Lack of capacity to consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment/lack of capacity to perform experimental task. The investigators&#x0D;&lt;br&gt;             will additionally conduct a short (10 min) quantitative assessment of cognitive&#x0D;&lt;br&gt;             function using a validated test (MMSE). Patients with a score &lt; 20 will be excluded&#x0D;&lt;br&gt;             from the study.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Alternating DBS
    </Intervention>
    <Primary_outcome>Stepping control will be assessed as the ability to adjust the stepping speed (m/s) in each stimulation condition.;Stepping control will be assessed as the ability to limit the variance in stepping speed (m/s) in each stimulation condition.
    </Primary_outcome>
    <Secondary_outcome>The investigators will test if patients automatically adjust to the stimulation rhythm;The investigators will how well other motor symptoms including tremor, rigidity and bradykinesia are controlled with alternating DBS.
    </Secondary_outcome>
    <Secondary_ID>230144
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University College, London
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13207732
    </Internal_Number>
    <TrialID>NCT04043403
    </TrialID>
    <Last_Refreshed_on>7 August 2023
    </Last_Refreshed_on>
    <Public_title>Bilateral Closed Loop Deep Brain Stimulation for Freezing of Gait Using Neural and Kinematic Feedback
    </Public_title>
    <Scientific_title>Bilateral Closed Loop Deep Brain Stimulation for Freezing of Gait Using Neural and Kinematic Feedback
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Stanford University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190730
    </Date_registration3>
    <Date_registration>30/07/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04043403
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 28, 2019
    </Date_enrollement>
    <Target_size>14
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Helen M. Bronte-Stewart, MD,MSE;Helen Bronte-Stewart, MD MSE;Sudeep Aditham
    </Contact_Lastname>
    <Contact_Email>;bronte-stewart-lab@stanford.edu;bronte-stewart-lab@stanford.edu
    </Contact_Email>
    <Contact_Tel>;6507232116;650-723-6709
    </Contact_Tel>
    <Contact_Affiliation>Stanford University;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically-established PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Meets criteria for STN DBS eligibility as part of patient's standard medical care or&#x0D;&lt;br&gt;             already implanted in the STN with Percept(TM) PC&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The presence of complications of medication such as wearing off signs, fluctuating&#x0D;&lt;br&gt;             responses and/or dyskinesias, and/or medication refractory tremor, and/or impairment&#x0D;&lt;br&gt;             in the quality of life on or off medication due to these factors.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability and willingness to return for study visits, at the initial programming and&#x0D;&lt;br&gt;             after three, six and twelve months of DBS.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &gt; 18&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Freezing of gait questionnaire (FOG-Q) score = 1 and/or gait sub-score (Item 3.10) of&#x0D;&lt;br&gt;             MDS- UPDRS III = 1&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Greater than or equal to 1.2 microVp between 8-35 Hz on either the LSTN or RSTN&#x0D;&lt;br&gt;             (Percept (TM) PC cohort only)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Untreated psychiatric disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hoehn and Yahr stage 5 on or off medication (non-ambulatory)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &gt; 80&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Major surgical morbidities such as severe hypertension, coagulopathy and certain&#x0D;&lt;br&gt;             metabolic conditions that might increase the risk of hemorrhage or other surgical&#x0D;&lt;br&gt;             complications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of a cardiac pacemaker/defibrillator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to understand/sign consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Requires rTMS, ECT, MRI (Summit(R) RC+S cohort only), or diathermy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Are pregnant or lactating&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has a cranial metallic implant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of seizures or epilepsy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Open Loop DBS;Device: Adaptive (Closed Loop) DBS;Device: Intermittent Open Loop DBS
    </Intervention>
    <Primary_outcome>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to Stimulation Condition;Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to quality of life;Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to speech;Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to gait
    </Primary_outcome>
    <Secondary_outcome>The Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III;Gait Parameters: Arrhythmicity;Gait Parameters: Mean Shank Angular Velocity;Gait Parameters: Mean Gait Cycle Time;Percent Time Freezing
    </Secondary_outcome>
    <Secondary_ID>52548
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13573507
    </Internal_Number>
    <TrialID>NCT04058457
    </TrialID>
    <Last_Refreshed_on>11 December 2023
    </Last_Refreshed_on>
    <Public_title>DBS and Respiration
    </Public_title>
    <Scientific_title>Deep Brain Stimulation in Parkinson's Disease: Respiratory Testing
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190718
    </Date_registration3>
    <Date_registration>18/07/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04058457
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 1, 2021
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United Kingdom
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Alex Green, FRCS;Alex Green, FRCS;Alex Green, FRCS
    </Contact_Lastname>
    <Contact_Email>;alex.green@nds.ox.ac.uk;alex.green@nds.ox.ac.uk
    </Contact_Email>
    <Contact_Tel>;01865227645;01865234762
    </Contact_Tel>
    <Contact_Affiliation>University of Oxford;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant is willing and able to give informed consent for participation in the&#x0D;&lt;br&gt;             study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male or female, aged 18 years or above.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Planned for required DBS surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fluent in the English language&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For experimental group: diagnosed with Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Female who is pregnant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject is currently participating in a clinical investigation that includes an active&#x0D;&lt;br&gt;             treatment arm which may affect the respiratory system.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acute respiratory problem at time of experimental session: e.g. rhinosinusitis,&#x0D;&lt;br&gt;             pharyngitis, asthma exacerbation&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: DBS
    </Intervention>
    <Primary_outcome>Change in breathlessness;Change in breathlessness
    </Primary_outcome>
    <Secondary_outcome>Change in pulmonary function;Change in airways resistance;Change in respiratory muscle strength;Change in surface electromyography of respiratory muscles;Change in hypercapnic ventilatory response;Change in breath-hold;Change in daily activity;Change in daily activity;MRI structural connectivity
    </Secondary_outcome>
    <Secondary_ID>256825
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Oxford Brookes University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>8443057
    </Internal_Number>
    <TrialID>ChiCTR1900024555
    </TrialID>
    <Last_Refreshed_on>21 October 2019
    </Last_Refreshed_on>
    <Public_title>Prospective randomized double-blind controlled trial for deep brain stimulation of the thalamus and the posterior subthalamic nucleus in the treatment of essential tremor
    </Public_title>
    <Scientific_title>Differential study of PSA target and VIM target DBS surgery for idiopathic tremor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Department of Functional Neurosurgery, RuiJin Hospital, affiliated with Shanghai Jiaotong University School of Medicine
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190716
    </Date_registration3>
    <Date_registration>2019-07-16
    </Date_registration>
    <Source_Register>ChiCTR
    </Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=40864
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2019-07-09
    </Date_enrollement>
    <Target_size>Group 1 versus Group 2:12;
    </Target_size>
    <Study_type>Interventional study
    </Study_type>
    <Study_design>Cross-over
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>Dianyou Li
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>197 Second Ruijin Road, Huangpu District, Shanghai, China
    </Contact_Address>
    <Contact_Email>ldy11483@rjh.com.cn
    </Contact_Email>
    <Contact_Tel>+86 21 64370045-632001
    </Contact_Tel>
    <Contact_Affiliation>Department of Functional Neurosurgery, RuiJin Hospital, affiliated with Shanghai Jiaotong University School of Medicine
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18-75 years old at the time of enrollment;&#x0D;&lt;br&gt;2. Based on MDS 2017 consensus diagnosis for primary tremor;&#x0D;&lt;br&gt;3. Duration of ET symptoms: &gt;=3 years of motor symptoms;&#x0D;&lt;br&gt;4. If the patient takes a tremor medication, the tremor drug is stable 28 days prior to informed consent;&#x0D;&lt;br&gt;5. Written informed consent was signed prior to entering the study.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Mental illnesses that may affect the subject's ability to comply with the research protocol requirements (eg, biphasic, schizophrenia, mood disorders with psychotic characteristics, group B personality disorder);&#x0D;&lt;br&gt;2. Severe cognitive impairment, MOCA &lt;24;&#x0D;&lt;br&gt;3. Any drug or alcohol abuse currently under the DSM-V standard;&#x0D;&lt;br&gt;4. Any intracranial abnormalities that impede DBS surgery; any history of recurrent or unprovoked seizures; any previous treatment for dyskinesia involves intracranial surgery or instrument implantation; any history of hemorrhagic stroke; there may be any interference with the study procedure or may confuse the study endpoint Major disease assessed;&#x0D;&lt;br&gt;5. Life expectancy for any lifetime, &lt;1 year.
    </Exclusion_Criteria>
    <Condition>Essential tremor
    </Condition>
    <Intervention>Group 1 versus Group 2:PSA/VIM Deep brain stimulation;
    </Intervention>
    <Primary_outcome>TRS;frequency of EMG;
    </Primary_outcome>
    <Secondary_outcome>VDI;Base frequency perturbation;Amplitude perturbation;Irregularity;Overall severity;DSI;MSDA test;International Cooperative Ataxia Rating Scale;Walking speed;Step size;Time per step;Step width;Dual support time;Percentage of missed steps;
    </Secondary_outcome>
    <Source_Support>National Natural Science Foundation of China (No.81200981); Beijing Pinchi Medical Equipment Co., Ltd.
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>26/08/2013
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Yifeng Wang
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13703067
    </Internal_Number>
    <TrialID>NCT04032470
    </TrialID>
    <Last_Refreshed_on>27 February 2024
    </Last_Refreshed_on>
    <Public_title>Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)
    </Public_title>
    <Scientific_title>Boston Scientific Registry of Deep Brain Stimulations for Treatment of Essential Tremor (ET):ET Registry
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Boston Scientific Corporation
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190708
    </Date_registration3>
    <Date_registration>08/07/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04032470
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 23, 2019
    </Date_enrollement>
    <Target_size>500
    </Target_size>
    <Study_type>Observational [Patient Registry]
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Belgium;Germany;Hungary;Italy;Korea, Republic of;Portugal;Spain;Belgium;Germany;Hungary;Italy;Korea, Republic of;Portugal;Spain;United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Natalie Bloom Lyons;Stephanie Delvaux
    </Contact_Lastname>
    <Contact_Email>;BSNClinicalTrials@bsci.com
    </Contact_Email>
    <Contact_Tel>;855-213-9890
    </Contact_Tel>
    <Contact_Affiliation>Boston Scientific Corporation;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Meets criteria established in the locally applicable Directions for Use (DFU) for&#x0D;&lt;br&gt;             Essential Tremor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Is at least 18 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Meets any contraindication in locally applicable Directions for Use&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Device: Deep Brain Stimulation Systems (DBS)
    </Intervention>
    <Primary_outcome>Change in Quality of Life during the study as compared with baseline using the Quality of Life in Essential Tremor Questionnaire (QUEST)
    </Primary_outcome>
    <Secondary_ID>A4080
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>8125067
    </Internal_Number>
    <TrialID>ChiCTR1900023831
    </TrialID>
    <Last_Refreshed_on>17 June 2019
    </Last_Refreshed_on>
    <Public_title>Clinical Efficacy and Safety of Deep Brain Stimulation in the Treatment of Huntington disease: a randomized controlled trial
    </Public_title>
    <Scientific_title>Clinical Efficacy and Safety of Deep Brain Stimulation in the Treatment of Huntington disease: a randomized controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    </Scientific_title>
    <Primary_sponsor>Beijing Tiantan Hospital, Capital Medical University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190613
    </Date_registration3>
    <Date_registration>2019-06-13
    </Date_registration>
    <Source_Register>ChiCTR
    </Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=39713
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>30
    </Inclusion_agemin>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2019-07-01
    </Date_enrollement>
    <Target_size>HD-sham-DBS group:20;HD-DBS group:20;
    </Target_size>
    <Study_type>Interventional study
    </Study_type>
    <Study_design>Parallel
    </Study_design>
    <Phase>0
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>Zhang Jianguo
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>119 South Fourth Ring Road West, Fengtai District, Beijing, China 
    </Contact_Address>
    <Contact_Email>zjguo73@126.com
    </Contact_Email>
    <Contact_Tel>+86 13601294613
    </Contact_Tel>
    <Contact_Affiliation>Beijing Tiantan Hospital, Capital Medical University  
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged = 30 years;&#x0D;&lt;br&gt;2. 39 or more CAG repeats of HTT gene;&#x0D;&lt;br&gt;3. Meet HD diagnostic criteria based on genetic testing;&#x0D;&lt;br&gt;4. The major complaint is chorea; &#x0D;&lt;br&gt;5. Mini–Mental State Examination (MMSE) score &gt; 25;&#x0D;&lt;br&gt;6. Unified Huntington's Disease Rating Scale (UHDRS) =20;&#x0D;&lt;br&gt;7. Before recruitment, stable medication having been used for at least 3 months, and no plan to change medication within 12 months after randomization;&#x0D;&lt;br&gt;8. Agree to be enrolled in this trial.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Chorea caused by other diseases;&#x0D;&lt;br&gt;2. Concurrent or previously had other neurological disorders (such as stroke, optic neuromyelitis, Parkinson's disease, epilepsy, intracranial tumors, etc.);&#x0D;&lt;br&gt;3. Severe psychiatric disease, such as schizophrenia, bipolar disorder, major depression and paralysis, etc.;&#x0D;&lt;br&gt;4. Unstable condition or severe heart, lung, liver, kidney, and hematopoietic diseases;&#x0D;&lt;br&gt;5. Have a history of cancer unless it has been cured or does not require treatment for the next 5 years;&#x0D;&lt;br&gt;6. Contraindications of MRI scan.
    </Exclusion_Criteria>
    <Condition>Huntington disease
    </Condition>
    <Intervention>HD-sham-DBS group:sham-DBS;HD-DBS group:DBS;
    </Intervention>
    <Primary_outcome>UHDRS;
    </Primary_outcome>
    <Secondary_outcome>Mental Behavior Rating Scale;EQ-5D;MRI data;LFP;
    </Secondary_outcome>
    <Source_Support>Medtronic provides device while patients pay for hospitalization
    </Source_Support>
    <Ethics_review_status>Not approved
    </Ethics_review_status>
    <Ethics_review_approval_date>26/08/2013
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10334380
    </Internal_Number>
    <TrialID>NCT03992625
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Clinical Outcomes for Deep Brain Stimulation
    </Public_title>
    <Scientific_title>Clinical Outcomes for Deep Brain Stimulation for Parkinson Disease, Tremor, and Dystonia
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Washington University School of Medicine
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190613
    </Date_registration3>
    <Date_registration>13/06/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03992625
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 3, 2011
    </Date_enrollement>
    <Target_size>1000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Mwiza Ushe, M.D.;Mwiza Ushe, M.D.;Mwiza Ushe, M.D.
    </Contact_Lastname>
    <Contact_Email>;ushem@wustl.edu;ushem@wustl.edu
    </Contact_Email>
    <Contact_Tel>;3143625262;314-362-5262
    </Contact_Tel>
    <Contact_Affiliation>Washington University School of Medicine;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Levodopa responsive Parkinson disease OR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medically refractory Essential Tremor OR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medically refractory Dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia (Mattis Dementia Rating Scale &lt;130)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Structural abnormalities precluding intracranial surgery&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Essential Tremor;Dystonia
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>UPDRS
    </Primary_outcome>
    <Secondary_ID>R01NS075321;R01NS097437;R21NS098020;T32EB021955;201101744
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institute for Biomedical Imaging and Bioengineering (NIBIB);National Institute of Neurological Disorders and Stroke (NINDS)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13088833
    </Internal_Number>
    <TrialID>RBR-9msccy
    </TrialID>
    <Last_Refreshed_on>29 May 2023
    </Last_Refreshed_on>
    <Public_title>Impact of H1 Forel's field deep brain stimulation on Parkinson's disease gait disorders
    </Public_title>
    <Scientific_title>Clinical and electrophysiological analysis of forel's field h1 deep brain stimulation on motor symptoms, cognitive variables and quality of life                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Hospital Santa Marcelina
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190610
    </Date_registration3>
    <Date_registration>10/06/2019
    </Date_registration>
    <Source_Register>REBEC
    </Source_Register>
    <web_address>http://ensaiosclinicos.gov.br/rg/RBR-9msccy
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>35Y
    </Inclusion_agemin>
    <Inclusion_agemax>80Y
    </Inclusion_agemax>
    <Inclusion_gender>-
    </Inclusion_gender>
    <Date_enrollement>03/02/2015
    </Date_enrollement>
    <Target_size/>
    <Study_type>Intervention
    </Study_type>
    <Study_design>Randomized, open-label, longitudinal, crossed, prospective clinical trial. There will be not a washout period, considering that it will offered an additional procedure (surgical intervention)&lt;br&gt;
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname>Maria Sheila
    </Contact_Firstname>
    <Contact_Lastname>Rocha
    </Contact_Lastname>
    <Contact_Address>Rua Santa marcelina 177
    </Contact_Address>
    <Contact_Email>msrocha@uol.com.br
    </Contact_Email>
    <Contact_Tel>+551120706000
    </Contact_Tel>
    <Contact_Affiliation>Hospital Santa Marcelina
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients diagnosed with Idiopathic Parkinson's disease according to the criteria of Queen Square Brain Bank; be over 35 years of age and less than 80 y-old; staging of Parkinson's Disease (Hoehn and Yahr scale), greater than 2 when evaluated in the absence of antiparkinsonian drugs effect; preserved clinical response to levodopa, the patient should present at least 30 percent reduction in the score of motor score the UPDRS scale; significant motor dysfunctions for 3 hours per day or more, despite the best drug treatment; persistent motor dysfunction for at least 1 month despite drug adjustment; patient's desire to receive deep brain stimulation as a therapeutic option in PD; adequate cognitive performance for the demand associated with the necessary care in the postoperative, with the DBS equipments, and in the recognition of adverse events; availability of the caregiver or family member, and of the patient himself, to come in frequent returns to ensure the best parameters of brain stimulation
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Parkinsonism associated with other neurodegenerative diseases (multisystemic atrophy; dementia with Lewy bodies; corticobasal degeneration; frontotemporal dementia; spinocerebellar ataxia); vascular parkinsonism; parkinsonism associated with antidopaminergic drugs; normal pressure hydrocephalus; traumatic brain injury; previous surgical treatment for Parkinson's Disease (pallidotomy, thalamotomy, campotomy or deep brain stimulation); patients with uncompensated systemic pathology; Parkinson's disease associated psychosis; major depression according to DSM-IV criteria - American Psychiatric Association 2000; dementia associated with Parkinson's disease, according to the criteria of the Movement Disorders Society
    </Exclusion_Criteria>
    <Condition>Parkinson's disease; tremor; rigidity; gait disorders&#x0D;
;C10.228.140.079.862.500;C10.597.350.850;C05.651.504;C10.597.404
    </Condition>
    <Intervention>This clinical trial will randomize 30 Parkinson's disease patients to either best medical oral treatment ((levodopa; pramipexol; entacapone; amantadine) or bilateral deep brain stimulation on Forel's field. Best medical treatment will be sustained for six months (habitual dosages and regimes - there will no be changes in usual dosages), when a new evaluation will be performed. Each group will comprise 15 patients. Afterwards, the choice for surgical treatment will be offered to the patient (the patient will be control for six months); all patients and controls will be paired to age, disease severity, disease duration and clinical subtype. Clinical and neuropsychological evaluations will be performed before surgery (within 30 days) and each six months after the deep brain stimulation during two years. After this two years period, all individuals will have habitual clinical follow-up; the definition for best stimulations parameters will be achieved by the experienced neurologist step by step (each two weeks), according to the standard stimulation algorithm. This aims to figure out the best electrode contact that produced the best clinical result and less adverse events. Cardinal parkinsonian signs and symptoms will be checked at each trial using unified Parkinson's disease rating scale parameters. The best electrode point will be chosen in order to keep chronic brain stimulation. All adverse events will be carefully evaluated and noted.;Procedure/surgery;Other;H02.403.810.425;E02.331.300
    </Intervention>
    <Primary_outcome>Total score on freezing of gait questionnaire for Parkinson's disease after six months and one year of effective brain stimulation on Forel's field.;Total score on Berg Balance scale after six months and one year of effective brain stimulation on Forel's field.;Parameters of instrumented gait analysis through Mobility Lab equipment performed before and after six months and one year of effective brain stimulation on Forel's field.
    </Primary_outcome>
    <Secondary_outcome>Total scores in the Quality of Life Scale (PDQ39) obtained after six months and one year of effective brain stimulation on Forel's field.;Total motor score on UPDRS (Unified Parkinson's disease rating scale) after six months and one year of effective brain stimulation on Forel's field.;Verbal fluency score on phonemic and categorical verbal fluency tests after six months and one year of effective brain stimulation on Forel's field.;Score on depression scale (Beck depression inventory) after six months and one year of effective brain stimulation on Forel's field.
    </Secondary_outcome>
    <Source_Support>Hospital Santa Marcelina
    </Source_Support>
    <Secondary_Sponsor>Hospital Santa Marcelina
    </Secondary_Sponsor>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13216162
    </Internal_Number>
    <TrialID>NCT03984643
    </TrialID>
    <Last_Refreshed_on>21 August 2023
    </Last_Refreshed_on>
    <Public_title>Algorithms for Programming DBS Systems for ET
    </Public_title>
    <Scientific_title>Algorithms for Programming DBS Systems for ET
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Minnesota
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190610
    </Date_registration3>
    <Date_registration>10/06/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT03984643
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 1, 2019
    </Date_enrollement>
    <Target_size>25
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Matthew Johnson, PhD;Matthew Johnson, PhD
    </Contact_Lastname>
    <Contact_Email>john5101@umn.edu;john5101@umn.edu
    </Contact_Email>
    <Contact_Tel>6126266492;612-626-6492
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosis of ET&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  medication-refractory tremor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  VIM-DBS implant (unilateral or bilateral)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  7T MRI pre-operative scan under Dr. Harel's IRB (institutional review board) protocol&#x0D;&lt;br&gt;             (#1210M22183)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Post-operative CT scan&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  history of musculoskeletal disorders that affect movement of the limbs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  other significant neurological disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  prior history of stereotactic neurosurgery (other than VIM-DBS surgery)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  pregnancy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Device: Vim-Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Therapeutic Windows;Objective Measures of Tremor;Quality of Life Questionnaire: QUEST;Quality of Life Questionnaire: TETRAS
    </Primary_outcome>
    <Secondary_ID>CSENG-2018-27182
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10834372
    </Internal_Number>
    <TrialID>NCT04011449
    </TrialID>
    <Last_Refreshed_on>19 April 2021
    </Last_Refreshed_on>
    <Public_title>State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With DBS Using the Medtronic RC+S
    </Public_title>
    <Scientific_title>State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With DBS Using the Medtronic RC+S
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Minnesota
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190610
    </Date_registration3>
    <Date_registration>10/06/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04011449
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>45 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 1, 2019
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of idiopathic PD.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 45-75 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Demonstrated good response (= 30%) to Sinemet or dopamine agonist medications as&#x0D;&lt;br&gt;             assessed by total UPDRS III score (off and on meds)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical plan for unilateral STN- or GPi-DBS surgery to treat their clinical motor&#x0D;&lt;br&gt;             signs within the next four months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written documentation of willingness to participate in the study per protocol as&#x0D;&lt;br&gt;             evidenced by the informed consent process&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical disease that would increase the risk of developing pre-&#x0D;&lt;br&gt;             or post-operative complications (e.g., major cardiac or pulmonary disease)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of secondary or atypical parkinsonism&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia as evidenced by impairment in two neuropsychological domains and impaired or&#x0D;&lt;br&gt;             borderline neuropsychological function in one additional domain.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unable to undergo MR imaging (e.g., due to incompatible implanted pacemaker)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous pallidotomy or DBS surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women who are currently pregnant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MRI brain abnormalities that could indicate a neurological disorder other than&#x0D;&lt;br&gt;             idiopathic Lewy body Parkinson's disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with severe or poorly controlled depression defined according to DSM-V&#x0D;&lt;br&gt;             criteria and a scored on a validated depression assessment scale.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Immunocompromised&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Requires diathermy, electroconvulsive therapy (ECT) or transcranial magnetic&#x0D;&lt;br&gt;             stimulation (TMS) to treat a chronic condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has an implanted electronic device such as a neurostimulator, cardiac pacemaker or&#x0D;&lt;br&gt;             medication pump.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Parkinson
    </Condition>
    <Intervention>Device: Medtronic RC+S DBS system
    </Intervention>
    <Primary_outcome>Passive and Active Rigidity Quantification;Ballistic Elbow Flexion to a Target: Peak Velocity;Ballistic Elbow Flexion to a Target: Stop Reaction Time;Rapid Alternating Pronation-Supination Movements: RMS;Rapid Alternating Pronation-Supination Movements: Freezing Episodes Duration;Rapid Alternating Pronation-Supination Movements: Freezing Episodes Number;Gait: Step length;Gait: Step Time;Gait: Double Support Time;Gait: Obstacles;Gait: Freezing Episodes Duration;Gait: Freezing Episodes Number
    </Primary_outcome>
    <Secondary_ID>NEUR-2019-27724
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12359542
    </Internal_Number>
    <TrialID>NCT03884231
    </TrialID>
    <Last_Refreshed_on>20 June 2022
    </Last_Refreshed_on>
    <Public_title>A Post-Market Study Evaluating the Safety of Infinity DBS System With MR Conditional Labeling
    </Public_title>
    <Scientific_title>A Post-Market Study Evaluating the Safety of Infinity DBS System With MR Conditional Labeling
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Abbott Medical Devices
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190319
    </Date_registration3>
    <Date_registration>19/03/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03884231
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 10, 2019
    </Date_enrollement>
    <Target_size>71
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States;France;Germany;Spain;Sweden;France;Germany;Spain;Sweden;United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Binith Cheeran
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Abbott Medical Devices Neuromodulation
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject or subject's legally acceptable representative must provide written informed&#x0D;&lt;br&gt;             consent prior to any clinical investigation related procedure.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subject has been implanted, or is scheduled to be implanted, with a commercially&#x0D;&lt;br&gt;             available Infinity DBS system with MR Conditional labeling per locally approved&#x0D;&lt;br&gt;             indications for use.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Subject is scheduled to undergo a MRI procedure in compliance with the MRI Procedure&#x0D;&lt;br&gt;             Information Clinician's Manual. Anxiolytics and patient's regular medications may be&#x0D;&lt;br&gt;             administered, provided Instructions For Use (IFU) criteria are met.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Subject is willing and able to comply with study requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject has another implanted device (active or passive implanted device) that&#x0D;&lt;br&gt;             prohibits safe scanning.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subject has previously experienced an MRI-related adverse event or cannot undergo MRI&#x0D;&lt;br&gt;             for any other reason.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Subject is pregnant or nursing, or plans to become pregnant during the clinical&#x0D;&lt;br&gt;             investigation follow-up period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Subject has other anatomic or comorbid conditions, or other medical, social, or&#x0D;&lt;br&gt;             psychological conditions that, in the investigator's opinion, could limit the&#x0D;&lt;br&gt;             subject's ability to participate in the clinical investigation or to comply with&#x0D;&lt;br&gt;             follow-up requirements, or impact the scientific soundness of the clinical&#x0D;&lt;br&gt;             investigation results.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Subject is currently participating in another clinical investigation that may confound&#x0D;&lt;br&gt;             the results of this study.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Movement Disorders;Parkinson Disease;Essential Tremor;Tremor;Dystonia
    </Condition>
    <Intervention>Device: Infinity DBS System with MR Conditional labelling (Leads-only configuration);Device: Infinity DBS System with MR Conditional labelling (Full system configuration)
    </Intervention>
    <Primary_outcome>MRI-related adverse events
    </Primary_outcome>
    <Secondary_ID>ABT-CIP-10262
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>8687587
    </Internal_Number>
    <TrialID>ISRCTN13759640
    </TrialID>
    <Last_Refreshed_on>13 January 2020
    </Last_Refreshed_on>
    <Public_title>High-frequency deep brain stimulation in the treatment of movement disorders
    </Public_title>
    <Scientific_title>Prospective, feasibility trial for high-frequency deep brain stimulation in the treatment of movement disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Nevro Corp
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190111
    </Date_registration3>
    <Date_registration>11/01/2019
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN13759640
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/02/2019
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Open-label prospective single-arm feasibility study (Treatment)
    </Study_design>
    <Phase>Not Specified
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Sat
    </Contact_Firstname>
    <Contact_Lastname>Pannu
    </Contact_Lastname>
    <Contact_Address>1800 Bridge Parkway
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                To participate in the study, subjects must meet all of the following inclusion criteria:&lt;br&gt;                1. Have been clinically diagnosed with either bilateral idiopathic Parkinson’s disease or unilateral or bilateral essential tremor, which has been refractory to conservative therapy for a minimum of 3 months and completed diagnostic work-up&lt;br&gt;                2. Be 18 years of age or older at the time of enrollment&lt;br&gt;                3. Be an appropriate candidate for the surgical procedures required in this study based on the clinical judgment of the implanting physician&lt;br&gt;                4. Be capable of subjective evaluation; patient must be able to describe and rate his/her disease state progression through the UPDRS&lt;br&gt;                5. Be willing and capable of giving informed consent&lt;br&gt;                6. Be willing and able to comply with study-related requirements and procedures and attend all scheduled visits&lt;br&gt;                7. Have adequate cognitive ability to use a patient programmer and recharger as determined by the Investigator&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                To participate in this study, a subject must not meet any of the following exclusion criteria.&lt;br&gt;                1. Have a medical condition, not intended to be treated with DBS that could interfere with study procedures, accurate UPDRS or FTD reporting, and/or confound evaluation of study endpoints, as determined by the Investigator&lt;br&gt;                2. Have a current diagnosis of a focal brain tumor in a relevant DBS target region or prominent generalized cortical atrophy, as determined by the investigator&lt;br&gt;                3. Have a past medical history significant for seizures, as determined by the investigator&lt;br&gt;                4. Have a current diagnosis or condition such as a coagulation disorder, bleeding diathesis, platelet dysfunction, progressive peripheral vascular disease or uncontrolled diabetes mellitus that presents excess risk for performing the procedure as determined clinically by the investigator&lt;br&gt;                5. Have a condition that would significantly increase perioperative risk including severely diminished functional capacity due to underlying cardiac/pulmonary disease, symptomatic uncontrolled hypertension, symptomatic uncontrolled diabetes mellitus that presents excess risk for performing the procedure as determined clinically by the investigator&lt;br&gt;                6. Any previous history of surgery of ipsilateral basal ganglia surgery (radio frequency or ultrasound lesion or prior DBS implant)&lt;br&gt;                7. Any past medical history suggesting secondary or atypical parkinsonian symptoms including previous cerebrovascular accident, neurotoxin exposure, neuroleptic toxicity, tumor, encephalitis, abnormal iron deposits, or neurologic signs of cerebellar or upper motor neuron involvement or supranuclear gaze palsy&lt;br&gt;                8. Be benefiting from an interventional procedure and/or surgery to treat their movement disorder (Subjects should be enrolled at least 30 days from last benefit)&lt;br&gt;                9. Have an existing drug pump and/or another active implantable device such as a pacemaker&lt;br&gt;                10. Have a condition currently requiring or likely to require the use of diathermy, Transcranial Magnetic Stimulation (TMS) or MRI imaging that is inconsistent with Senza II system guideline in the US manual&lt;br&gt;                11. Have either a metastatic malignant neoplasm or untreated local malignant neoplasm&lt;br&gt;                12. Have a life expectancy of less than one year&lt;br&gt;                13. Have a local infection at the anticipated surgical entry site or an active systemic infection&lt;br&gt;                14. Be pregnant or plan to become pregnant during the study. Women of childbearing potential who are sexually active must use a reliable form of birth control, or be surgically sterile, or be at least 2 years post-menopausal&lt;br&gt;                15. Have a significant untreated addiction to dependency producing medications or have been a substance abuser (including opioids, benzodiazepines, alcohol and illicit drugs) within 6 months of enrollment&lt;br&gt;                16. Have a metallic aneurysm clip that could interfere with device functioning&lt;br&gt;                17. Have significant cognitive impairment or dementia that would interfere with study compliance or comprehension&lt;br&gt;                18. Have untreated clinically significant depression as evidenced by a self-report score on the Beck Depression Inventory (BDI) II &gt; 20. Patients presenting with depression may also be ruled out by clinical judgement of the in
    </Exclusion_Criteria>
    <Condition>Parkinson’s disease (PD) and essential tremor (ET) &lt;br&gt;Nervous System Diseases &lt;br&gt;Parkinson disease
    </Condition>
    <Intervention>This is an open label, prospective, feasibility study to collect data on high-frequency Deep Brain Stimulation (DBS) for the treatment of motor symptoms of Parkinson’s disease (PD) and essential tremor (ET). Stimulation will be delivered using the Senza System. The use of the Senza System for treatment of Parkinson’s disease (PD) and essential tremor (ET) is investigational. Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, the subject will proceed with a Senza system implantation. After successful system implant outcomes will be assessed via standardized assessments at 1 week, 1, 3, 6, 9 and 12 months.
    </Intervention>
    <Primary_outcome>&lt;br&gt;                The feasibility of a future definitive trial is determined using:&lt;br&gt;                1. The number of participants identified, approached, consented and completed, to inform the recruitment and timeline of a future fully-powered study&lt;br&gt;                2. The acceptability and experience of the study process to participants and completion of outcome measures, to refine future study procedures&lt;br&gt;                3. The performance of selected candidate primary outcome measures with respect to level of acceptability to participants (completion rates, perceived burden) and participant-perceived relevance and value, to determine the optimal primary outcome measure in a future study&lt;br&gt;                4. Data completeness at follow up (participant attrition), standard deviation of the likely primary outcome measure, and the variability of the comparator condition, treatment as usual, across individuals and sites, to estimate sample size for a future study&lt;br&gt;                Measured from enrolment until end of study (12 months follow up).&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                Effectiveness and safety are assessed by the following:&lt;br&gt;                1. Motor symptoms are measured using the Unified Parkinson’s Disease Rate Scale (UPDRS) at baseline, initial DBS lead implant, device activation, and 1, 2, 3, 6, and 12 month follow-up visits&lt;br&gt;                2. Tremor is measured using the FTM (Fahn-Tolosa-Marin Tremor Rating Scale) at baseline, initial DBS lead implant, device activation, and 1, 2, 3, 6, and 12 month follow-up visits&lt;br&gt;                3. Functioning is measured using the PDQ-39 (Parkinson’s Disease Questionnaire-39) at baseline, device activation, and 1, 2, 3, 6, and 12 month follow-up visits&lt;br&gt;                4. Quality of Life in Essential Tremor is measured using the QUEST (Quality of Life in Essential Tremor) questionnaires at baseline, device activation, and 1, 2, 3, 6, and 12 month follow-up visits&lt;br&gt;                5. Neurological status (motor, sensory and reflex functions) is measured using a neurological examination at every visit&lt;br&gt;                6. Incidence of adverse events (AEs) is observed at every visit&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>CA2018EU DBS
    </Secondary_ID>
    <Source_Support>Nevro Corp
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1990
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Ethik-Kommission Ärztekammer Nordrhein, 22/10/2018, ref: 2018177, Eudamed-Nr: CIV-18-05-024124
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>31/12/2022
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12341771
    </Internal_Number>
    <TrialID>NCT03832712
    </TrialID>
    <Last_Refreshed_on>6 June 2022
    </Last_Refreshed_on>
    <Public_title>The Swedish Essential Tremor (SWEET) Trial
    </Public_title>
    <Scientific_title>The Swedish Essential Tremor (SWEET) Trial - A Multicentre Randomized Controlled Trial of Deep Brain Stimulation for Essential Tremor
    </Scientific_title>
    <Acronym>SWEET
    </Acronym>
    <Primary_sponsor>Karolinska Institutet
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190111
    </Date_registration3>
    <Date_registration>11/01/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03832712
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 30, 2018
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Sweden
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Patric Blomstedt, PhD;Anders Fytagoridis, PhD;Anne-Louice Eriksson
    </Contact_Lastname>
    <Contact_Email>;;annelouice.eriksson@vll.se
    </Contact_Email>
    <Contact_Tel>;;+468907850000
    </Contact_Tel>
    <Contact_Affiliation>Umeå Universitet;Karolinska Institutet;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of ET, as decided by the movement disorder specialist; Substantial&#x0D;&lt;br&gt;             incapacity; Duration of symptoms &gt; 5 years; Age 18 - 75; unsatisfying effect from&#x0D;&lt;br&gt;             ß-blockers, or be unable to tolerate the medical therapy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment; Co-morbidity or non-compliance likely to jeopardize the result&#x0D;&lt;br&gt;             or to confuse the evaluation; Normal surgical exclusion criteria.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Procedure: Deep Brain Stimulation;Drug: Best Medical Treatment
    </Intervention>
    <Primary_outcome>Essential Tremor Rating Scale (ETRS)
    </Primary_outcome>
    <Secondary_outcome>Quality of life in ET (QUEST);electric energy consumption
    </Secondary_outcome>
    <Secondary_ID>2017-238-31
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Umeå University;Uppsala University;Lund University;University Hospital, Linkoeping;Göteborg University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13674270
    </Internal_Number>
    <TrialID>NCT03760406
    </TrialID>
    <Last_Refreshed_on>5 February 2024
    </Last_Refreshed_on>
    <Public_title>Optimization of VIM Targeting in Essential Tremor Surgery
    </Public_title>
    <Scientific_title>Optimization of VIM Targeting in Essential Tremor Surgery
    </Scientific_title>
    <Acronym>Opti-VIM
    </Acronym>
    <Primary_sponsor>University Hospital, Bordeaux
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20181126
    </Date_registration3>
    <Date_registration>26/11/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT03760406
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 18, 2018
    </Date_enrollement>
    <Target_size>22
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Antoine BENARD, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>USMR CHU de Bordeaux
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe essential tremor despite the optimal medical management&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age between 18 and 75 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Normal MRI scan&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mattis Dementia Rating Scale (MDRS) score = 130&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Affiliation to the social security&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signed informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Depression (Beck Depression Inventory scale &gt; 20)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Contra-indication to surgery or general anesthesia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cerebral atrophy on MRI scan&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant or breastfeeding women&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Procedure: Opti-VIM targeting in DBS surgery
    </Intervention>
    <Primary_outcome>Change of Fahn-Tolosa-Marin (FTM) scale score
    </Primary_outcome>
    <Secondary_outcome>Accelerometry recordings : spectral analysis;Accelerometry recordings : calculation of the total accelerometry power;Surgical complications;Device complications and dysfunction;Neurostimulation-related side effects;Quality of life: change of modified Parkinson's Disease Questionnaire-39 (mPDQ-39) scale score;Coordinates of active contacts
    </Secondary_outcome>
    <Secondary_ID>CHUBX 2018/32
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10313809
    </Internal_Number>
    <TrialID>NCT03724734
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Trial of Adaptive Deep Brain Stimulation
    </Public_title>
    <Scientific_title>A Double-blind, Cross-over Comparison of Closed Loop Versus Conventional Deep Brain Stimulation of the Subthalamic Nucleus in the Treatment of Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>St. George's Hospital, London
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20181026
    </Date_registration3>
    <Date_registration>26/10/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03724734
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2019
    </Date_enrollement>
    <Target_size>15
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Erlick Pereira, DM FRCS;Erlick AC Pereira, DM FRCS
    </Contact_Lastname>
    <Contact_Email>;epereira@sgul.ac.uk
    </Contact_Email>
    <Contact_Tel>;02087252375
    </Contact_Tel>
    <Contact_Affiliation>St George's University Hospital;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Study participants will be patients undergoing DBS of the subthalamic nucleus for the&#x0D;&lt;br&gt;             treatment of severe Parkinson's disease. Severe Parkinson's disease is defined as&#x0D;&lt;br&gt;             marked motor fluctuations (off periods and dyskinesias) despite optimal medical&#x0D;&lt;br&gt;             management. This is determined by the patient's clinical team.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to give consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment (judged by the clinician taking consent as not having sufficient&#x0D;&lt;br&gt;             mental capacity to understand the study and its requirements). This includes anyone&#x0D;&lt;br&gt;             who, in the opinion of the clinician taking consent, is unlikely to retain sufficient&#x0D;&lt;br&gt;             mental capacity for the duration of their involvement in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intracranial bleeding, confusion, cerebrospinal fluid leak or any other complication&#x0D;&lt;br&gt;             after the first stage of surgery.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Adaptive DBS;Device: Conventional DBS
    </Intervention>
    <Primary_outcome>Daytime Assessment;Night time assessment
    </Primary_outcome>
    <Secondary_outcome>Energy delivered;Tremor severity;Objective motor impairment;Speech impairment;Dyskinesia severity;Sleep quality: score;Power efficiency
    </Secondary_outcome>
    <Secondary_ID>256068
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Oxford
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13693060
    </Internal_Number>
    <TrialID>NCT03664609
    </TrialID>
    <Last_Refreshed_on>19 February 2024
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation (DBS) Retrospective Outcomes Study
    </Public_title>
    <Scientific_title>Deep Brain Stimulation (DBS) Retrospective Outcomes Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Boston Scientific Corporation
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180831
    </Date_registration3>
    <Date_registration>31/08/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT03664609
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 12, 2019
    </Date_enrollement>
    <Target_size>5000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States;Belgium;Germany;Belgium;Germany;United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Natalie Bloom Lyons;Cleo Mertz
    </Contact_Lastname>
    <Contact_Email>;BSNClinicalTrials@bsci.com
    </Contact_Email>
    <Contact_Tel>;855-213-9890
    </Contact_Tel>
    <Contact_Affiliation>Boston Scientific Neuromodulation Corporation;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Must be previously treated with or eligible for implantation with a deep brain&#x0D;&lt;br&gt;             stimulation system&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No Exclusion Criteria&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Essential Tremor;Dystonia
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Mean Change in Unified Parkinson's Disease Rating Scale (UPDRS III) at up to 5 years post implant compared to baseline
    </Primary_outcome>
    <Secondary_ID>A4170
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10306554
    </Internal_Number>
    <TrialID>NCT03630302
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Intraoperative Investigation of a Directional Lead and Local Field Potentials for the Optimization of Stimulation Efficacy
    </Public_title>
    <Scientific_title>Intraoperative Investigation of a Directional Lead and Local Field Potentials for the Optimization of Stimulation Efficacy
    </Scientific_title>
    <Acronym>INVENT
    </Acronym>
    <Primary_sponsor>Abbott Medical Devices
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180809
    </Date_registration3>
    <Date_registration>09/08/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03630302
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 12, 2018
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 18-70 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of idiopathic Parkinson's disease, and DBS consensus team review supporting&#x0D;&lt;br&gt;             the placement of STN DBS.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject is not a surgical candidate;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  In the Investigator's opinion the subject unable to tolerate multiple programming&#x0D;&lt;br&gt;             sessions within a single setting;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject unable to comply with the follow-up schedule&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson
    </Condition>
    <Intervention>Device: DBS
    </Intervention>
    <Primary_outcome>Concordance between LFP derived predictions and clinically optimized stimulation parameters
    </Primary_outcome>
    <Secondary_outcome>Characteristic of the LFP signals correlating to presence of side effects
    </Secondary_outcome>
    <Secondary_ID>CRD_931 INVENT
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Baylor College of Medicine;University of Houston
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10813364
    </Internal_Number>
    <TrialID>NCT03600740
    </TrialID>
    <Last_Refreshed_on>12 April 2021
    </Last_Refreshed_on>
    <Public_title>Advancing Pre-operative Targeting for Deep Brain Stimulation in the Globus Pallidus Internus
    </Public_title>
    <Scientific_title>Advancing Pre-operative Targeting for Deep Brain Stimulation in the Globus Pallidus Internus: Functional Segmentation Based on Probabilistic Tractography
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Mayo Clinic
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180717
    </Date_registration3>
    <Date_registration>17/07/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03600740
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 17, 2018
    </Date_enrollement>
    <Target_size>1
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Erik H Middlebrooks
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Mayo Clinic
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Patient with the diagnosis of Parkinson's Disease selected for placement of globus pallidus&#x0D;&lt;br&gt;        internus (GPi) deep brain stimulator (DBS)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: DBS Programming
    </Intervention>
    <Primary_outcome>Change in Unified Parkinson's Disease Rating Scale III (UPDRS-III)
    </Primary_outcome>
    <Secondary_ID>18-002176
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10301046
    </Internal_Number>
    <TrialID>NCT03558568
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>The Effect of Deep Brain Stimulation on Facial Expressions.
    </Public_title>
    <Scientific_title>The Effect of Subthalamic Nucleus Deep Brain Stimulation on Facial Expressions in Parkinson's Disease.
    </Scientific_title>
    <Acronym>STN-DBS
    </Acronym>
    <Primary_sponsor>Mustafa Kemal University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180528
    </Date_registration3>
    <Date_registration>28/05/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03558568
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 1, 2018
    </Date_enrollement>
    <Target_size>18
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Turkey
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Atilla YILMAZ;Atilla YILMAZ
    </Contact_Lastname>
    <Contact_Email>atillayilmaz@hotmail.com;atillayilmaz@hotmail.com
    </Contact_Email>
    <Contact_Tel>+905322253991;+905322253991
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic PD responsive to L-Dopa treatment,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Between 40-75 years of age,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having received bilateral STN DBS surgery at least one month prior to the&#x0D;&lt;br&gt;             investigation to ensure stable stimulation parameters,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mentally normal patients that could understand and respond to a questionnaire.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Above 75 years of age,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe dementia,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of an additional neurologic disease,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The presence of a disease, such as the facial paralysis, that could affect facial&#x0D;&lt;br&gt;             expressions,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having a wound on the face.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>The effect of Deep brain stimulation on facial expressions will be analyzed by volunteers via a web site then the results will evaluate by statistical analyses.
    </Primary_outcome>
    <Secondary_ID>1
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13310446
    </Internal_Number>
    <TrialID>NCT03800108
    </TrialID>
    <Last_Refreshed_on>4 September 2023
    </Last_Refreshed_on>
    <Public_title>Stimulation Parameters and Non-motor Symptoms in PD Treated With DBS
    </Public_title>
    <Scientific_title>Stimulation Parameters and Non-motor Symptoms in PD Treated With DBS
    </Scientific_title>
    <Acronym>FREQUENCY
    </Acronym>
    <Primary_sponsor>Darlene Floden
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180523
    </Date_registration3>
    <Date_registration>23/05/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT03800108
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 30, 2018
    </Date_enrollement>
    <Target_size>15
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Darlene Floden, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>The Cleveland Clinic
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Between 40 and 70 years of age,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Ability to provide informed consent,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Clinical diagnosis of idiopathic Parkinson disease (PD) by a movement disorders&#x0D;&lt;br&gt;             neurologist,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Disease duration of at least 4 years,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Treated with bilateral STN DBS for at least 3 months prior to study enrollment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. History of prior neurosurgical intervention for PD (e.g., DBS, thalamotomy,&#x0D;&lt;br&gt;             pallidotomy)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. History of other central nervous system disease (excluding migraine),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Presence of active psychiatric symptoms meeting Diagnostic and Statistical Manual of&#x0D;&lt;br&gt;             Mental Disorders-4th Edition (DSM-IV) criteria for Axis-I disorder on formal&#x0D;&lt;br&gt;             psychiatric evaluation, with the exception of mild depression (Beck Depression&#x0D;&lt;br&gt;             Inventory-2 score below 19),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Cognitive impairment meeting Diagnostic and Statistical Manual of Mental Disorders-4th&#x0D;&lt;br&gt;             Edition (DSM-IV) criteria for dementia on formal neuropsychological evaluation,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Current alcohol or substance abuse,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Lack of fluency in English which would invalidate cognitive testing,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Hearing or visual impairment precluding cognitive testing.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             Exclusion criteria for Day 2 procedures:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Inability to safely undergo MRI procedure (i.e., metal objects like prostheses,&#x0D;&lt;br&gt;             pacemakers)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Procedure: Personalized DBS adjustments
    </Intervention>
    <Primary_outcome>Reaction time;Verbal Fluency;Finger tapping speed
    </Primary_outcome>
    <Secondary_ID>17-1350
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10301341
    </Internal_Number>
    <TrialID>NCT03562403
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>DBS in the Treatment of Intractable Movement Disorders
    </Public_title>
    <Scientific_title>Deep Brain Stimulation in the Treatment of Intractable Movement Disorders ( Parkinson's Disease, Essential Tremors and Dystonia)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Assiut University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180522
    </Date_registration3>
    <Date_registration>22/05/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03562403
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>25 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 2018
    </Date_enrollement>
    <Target_size>16
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Amr Elnaggar, MD;Ahmed Nouby, masters degree
    </Contact_Lastname>
    <Contact_Email>;ahrano2015@gmail.com
    </Contact_Email>
    <Contact_Tel>;+201222336729
    </Contact_Tel>
    <Contact_Affiliation>University of Louisville;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Dopa responsiveness&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Minimum disease duration of 5 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Diagnosis of idiopathic Parkinsons disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patients with intractable Essential Tremors.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patients with intractable dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Significant medical health problems.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Significant cognitive impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Bleeding tendencies&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease, Essential Tremors and Dystonia
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Change in the unified parkinson's disease rating scale score
    </Primary_outcome>
    <Secondary_outcome>Change in antiparkinsonian medication use
    </Secondary_outcome>
    <Secondary_ID>DBS in movement disorders
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12648514
    </Internal_Number>
    <TrialID>NCT03593512
    </TrialID>
    <Last_Refreshed_on>14 November 2022
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation for Autonomic and Gait Symptoms in Multiple System Atrophy
    </Public_title>
    <Scientific_title>Deep Brain Stimulation for Autonomic and Gait Symptoms in Multiple System Atrophy
    </Scientific_title>
    <Acronym>STAG-MSA
    </Acronym>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180522
    </Date_registration3>
    <Date_registration>22/05/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03593512
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 9, 2018
    </Date_enrollement>
    <Target_size>5
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United Kingdom
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Alex L Green, FRCS(SN)
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Oxford
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Diagnosis of MSA with disabling autonomic symptoms (bladder dysfunction and&#x0D;&lt;br&gt;             orthostatic symptoms&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. UMSARS score of &gt;40&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. &gt;6/12 in the autonomic subsection (Q9-12) of the UMSAR scale&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient willing and able to give informed consent to involvement in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Male or female, aged 18 years or over.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Able to walk unaided (to perform gait analysis)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Have an anticipated prognosis &gt; 2 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. The patient is unwilling to participate or unable to give informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. The patient has been deemed unfit for stimulator insertion by their healthcare team&#x0D;&lt;br&gt;             i.e. surgical contraindications to DBS:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Bleeding or coagulation disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Not fit for general anaesthetic&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Unable to deal with implanted DBS system (turn on and off and recharging where&#x0D;&lt;br&gt;                  applicable, although it is acceptable if a carer can do this)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Untreated anxiety or depression&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Unable to undergo MRI (eg. metal implants)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Subject is currently participating in a clinical investigation that includes an active&#x0D;&lt;br&gt;             treatment arm.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Female who is pregnant - testing will be offered to female patients who are unsure.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Multiple System Atrophy;Autonomic Failure;Postural Hypotension;Bladder, Neurogenic;Gait Disorders, Neurologic
    </Condition>
    <Intervention>Procedure: Deep brain stimulation
    </Intervention>
    <Primary_outcome>EuroQol 5 Dimension (5 level) score before and after deep brain stimulation;Fluency of gait as measured by accelerometry before and after deep brain stimulation;Modified composite autonomic symptom scale before and after deep brains stimulation;Change in postural blood pressure change before and after PPN DBS
    </Primary_outcome>
    <Secondary_outcome>Number of Participants With Treatment-Related Adverse Events as Assessed by using approved UK reporting procedure;Muscle sympathetic nerve activity before and after deep brain stimulation;Cortical magentoencephalography profile with deep brain stimulation on and off;Physical anatomical white matter connections between the pedunculopontine nucleus and the rest of the central nervous system
    </Secondary_outcome>
    <Secondary_ID>13340
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Medical Research Council
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10325322
    </Internal_Number>
    <TrialID>NCT03874611
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Electrophysiology of Brain Activity During Electrode Implantation in Patients Treated With Deep Brain Stimulation
    </Public_title>
    <Scientific_title>Electrophysiology of Brain Activity During Electrode Implantation in Patients Treated With Deep Brain Stimulation
    </Scientific_title>
    <Acronym>LFP-DBS
    </Acronym>
    <Primary_sponsor>University Hospital, Grenoble
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180430
    </Date_registration3>
    <Date_registration>30/04/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03874611
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 13, 2011
    </Date_enrollement>
    <Target_size>125
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Olivier David, Dr;Stephan CHABARDES, Pr
    </Contact_Lastname>
    <Contact_Email>Olivier.David@inserm.fr;
    </Contact_Email>
    <Contact_Tel>04 56 52 05 86;04 76 76 75 59
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pathology requiring brain stimulation therapy (criteria of severity, therapeutic&#x0D;&lt;br&gt;             resistance and severity of disability): motor disorders (eg Parkinson's disease,&#x0D;&lt;br&gt;             dystonia) or psychiatric disorders (eg OCD, depression).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  These pathologies therefore include motor disorders (eg Parkinson's disease, dystonia)&#x0D;&lt;br&gt;             or psychiatric disorders that can be treated with brain stimulation therapy. Note that&#x0D;&lt;br&gt;             these are independent of motor disorders. The inclusion criteria obviously depend on&#x0D;&lt;br&gt;             the pathology.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        As an example for a motor pathology treated by stimulation, in Parkinson's disease the&#x0D;&lt;br&gt;        following inclusion criteria are used :&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients aged 18 to 75 and affiliated to a social security scheme&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic Parkinson's disease that meets the United Kingdom Parkinson's Disease Brain&#x0D;&lt;br&gt;             Bank (UKPDSBB) criteria or suffering from recessive autosomal juvenile parkinsonism&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  duration of evolution of the disease&gt; 5 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  stage of severe motor complications of levodopa despite optimal treatment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For dystonic patients, the following inclusion criteria are used :&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Disabling dystonia (severe focal, segmental or generalized).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient = 18 years of age and under age 65&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Duration of evolution of dystonia greater than one year.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For patients with obsessive-compulsive disorder (OCD), the following inclusion criteria are&#x0D;&lt;br&gt;        used :&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  OCD which has been diagnosed for at least 5 years according to the DSM-IV criteria as&#x0D;&lt;br&gt;             OCD with "good insight", confirmed using the Diagnostic Interview Genetic Study (DIGS)&#x0D;&lt;br&gt;             - OCD section ; score below the delusional idea threshold at the BABS (Brown&#x0D;&lt;br&gt;             Assessment of Beliefs Scale) insight scale (Eisen, Phillips et al., 1998)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  OCD of severe intensity (total YBOCS &gt; 25, or subscale Obsessions or Compulsions &gt; 15,&#x0D;&lt;br&gt;             EGF &lt; 40, CGI &gt; 4) with prognosis considered to be bad in the absence of intervention&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-responder OCD (an improvement of less than 25% on the Y-BOCS scale) to at least&#x0D;&lt;br&gt;             three IRS-type antidepressants, including clomipramine, used sequentially at the&#x0D;&lt;br&gt;             maximum tolerated dose for at least 12 weeks. Used alone and in combination for at&#x0D;&lt;br&gt;             least 1 month with risperidone or pimozide and any of the following products : lithium&#x0D;&lt;br&gt;             salts or clonazepam or buspirone or pindolol (Greist and Jefferson 1998) (McDougle,&#x0D;&lt;br&gt;             Epperson et al 2000) (Dannon , Sasson et al., 2000)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  OCD having benefited from Behavioral and Cognitive Therapy for at least 1 year&#x0D;&lt;br&gt;             (application of classical programs, including exposure techniques with prevention of&#x0D;&lt;br&gt;             ritualized response, with at least two sessions per month).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient between 18 and 60 years of age who has given his signature and informed&#x0D;&lt;br&gt;             consent after receiving written information on the proposed procedure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Sick with social security&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For patients with depressive illness, the following inclusion criteria were used :&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  male or female between the ages of 30 and 65&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  with a diagnosis of unipolar major depression (MINI) resistant to conventional&#x0D;&lt;br&gt;             treatments&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hamilton and Montgomery Depression Scale (HAMD) score&gt; 20&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Duration of the current depressive episode of more than 12 months, the patient being&#x0D;&lt;br&gt;             included in a care system has established the chronic and recurrent state of this&#x0D;&lt;br&gt;             depression,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ineffective treatment of the current episode with at least 4 therapeutic attempts&#x0D;&lt;br&gt;             including antidepressant drug monotherapy treatments (MAOIs, tricyclic&#x0D;&lt;br&gt;             antidepressants, selective serotonin reuptake inhibitors, mixed serotonin reuptake&#x0D;&lt;br&gt;             inhibitors, and norepinephrine), the potentiations of antidepressant treatments (by&#x0D;&lt;br&gt;             lithium salts, thyroid hormones or neuroleptics), the psychotherapies structured&#x0D;&lt;br&gt;             according to validated techniques, the ECT carried out under conditions in conformity&#x0D;&lt;br&gt;             with the recommendations (ANAES, 1998) (at least 6 sessions in technical bilateral&#x0D;&lt;br&gt;             with control of duration of seizure)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Women of childbearing age should follow a contraceptive method that is considered&#x0D;&lt;br&gt;                  sufficiently effective by the investigator. In this case a pregnancy test will be&#x0D;&lt;br&gt;                  performed on inclusion&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  outpatient or inpatient&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  fluent in the French language and able to understand the procedures of the study&#x0D;&lt;br&gt;                  and in particular complete the self-questionnaires used&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Patient likely to give informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Patient affiliated with Social Security&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Patient's written agreement to participate in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Intellectual abilities compatible with cognitive or motor tasks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Persons referred to in Articles L1121-5 to L1121-8 of the CSP.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Obsessive-Compulsive Disorder;Epilepsy;Depression
    </Condition>
    <Intervention>Other: electrophysiological data from DBS
    </Intervention>
    <Primary_outcome>Number of functional markers derived from electrophysiological signals recorded during cognitive tests.;Number of functional markers derived from electrophysiological signals recorded during cognitive tests.
    </Primary_outcome>
    <Secondary_outcome>cognitive and sensorimotor tasks;functional atlas of basal ganglia;number of electrophysiological responses
    </Secondary_outcome>
    <Secondary_ID>38RC11.242
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13640982
    </Internal_Number>
    <TrialID>DRKS00014614
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Influence of Implantation of directional leads on outcome in patients with Tremor after deep brain Stimulation?
    </Public_title>
    <Scientific_title>Influence of Implantation of directional leads on outcome in patients with Tremor after deep brain Stimulation? - directional lead tremor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Klinik für Neurochirurgie, UKSH Kiel
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180420
    </Date_registration3>
    <Date_registration>20/04/2018
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00014614
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>100 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>19/04/2018
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: treatment 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Ann-Kristin
    </Contact_Firstname>
    <Contact_Lastname>Helmers
    </Contact_Lastname>
    <Contact_Address>Arnold-Heller-Str. 3
    </Contact_Address>
    <Contact_Email>ann-kristin.helmers@uksh.de
    </Contact_Email>
    <Contact_Tel>0431-500-23840
    </Contact_Tel>
    <Contact_Affiliation>Klinik für Neurochirurgie, UKSH Kiel
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Tremor&lt;br&gt;Implantation of 2 directional leads&lt;br&gt;no higher cognitive deficits&lt;br&gt;Agreement to this study
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: no agreement to study&lt;br&gt;higher cognitive deficits
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G25.0;Essential tremor;G25.0
    </Condition>
    <Intervention>Group 1: Patients suffering from tremor, who underwent DBS (deep brain stimulation) using a directional lead should undergo testing of directional contacts versus ring mode. Therefor the therapeutic window (the difference between effect and adverse effect) should be measured, what takes 2 to 4 h. This has to be done once.&lt;br&gt;The controll Group are the same patients in an other Stimulation Setting. The testing is documented by Video tape. The rater is blinded.
    </Intervention>
    <Primary_outcome>therapeutic window in ring mode and in directional mode during a one-time testing
    </Primary_outcome>
    <Source_Support>UKSH Kiel Klinik für Neurochirurgie
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>30/01/2018
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ethikkomm@email.uni-kiel.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Medizinischen Fakultät der Christian-Albrechts-Universität zu Kiel
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-431-50014191
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ethikkomm@email.uni-kiel.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00014614#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>11462815
    </Internal_Number>
    <TrialID>NCT03548506
    </TrialID>
    <Last_Refreshed_on>11 October 2021
    </Last_Refreshed_on>
    <Public_title>Subthalamic Steering for Therapy Optimization in Parkinson's Disease
    </Public_title>
    <Scientific_title>Subthalamic Steering for Therapy Optimization in Parkinson's Disease
    </Scientific_title>
    <Acronym>SANTOP
    </Acronym>
    <Primary_sponsor>University Hospital Tuebingen
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180418
    </Date_registration3>
    <Date_registration>18/04/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03548506
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 19, 2018
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Alireza Gharabaghi, MD;Daniel Weiss, MD
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Division of Functional and Restorative Neurosurgery, Department of Neurosurgery, Tuebingen, Germany;Department for Neurodegenerative Diseases, Centre for Neurology, Tuebingen, Germany, and Hertie-Institute for Clinical Brain Research
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic Parkinson's disease (according to the "British Brain Bank criteria"&#x0D;&lt;br&gt;             (Hughes, 1992) including genetic forms&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment (Mini Mental State Exam &lt; 20)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Suicidality, Psychosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other severe pathological chronic condition that might confound treatment effects or&#x0D;&lt;br&gt;             interpretation of the data&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Omnidirectional Deep Brain Stimulation of STN;Device: Directional Deep Brain Stimulation of STN
    </Intervention>
    <Primary_outcome>Muscle Rigidity
    </Primary_outcome>
    <Secondary_outcome>Clinical motor and non-motor symptoms (1);Clinical motor and non-motor symptoms (2);Clinical motor and non-motor symptoms (3);Clinical motor and non-motor symptoms (4);Clinical motor and non-motor symptoms (5);Clinical motor and non-motor symptoms (6);Clinical motor and non-motor symptoms (7);Clinical motor and non-motor symptoms (8);Neurocognitive and non-motor symptoms (1);Neurocognitive and non-motor symptoms (2);Neurocognitive and non-motor symptoms (3);Neurocognitive and non-motor symptoms (4);Neurocognitive and non-motor symptoms (5);Neurocognitive and non-motor symptoms (6);Neurocognitive and non-motor symptoms (7);Neuropsychiatric symptoms (1);Neuropsychiatric symptoms (2);Freezing of gait (1);Freezing of gait (2);Quality of life
    </Secondary_outcome>
    <Secondary_ID>SANTOP
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Abbott
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10293644
    </Internal_Number>
    <TrialID>NCT03462082
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Asymmetric Subthalamic Deep Brain Stimulation for Axial Motor Dysfunction in Parkinson's Disease
    </Public_title>
    <Scientific_title>A Single-center, Randomized, Double-blinded, Double-crossover Trial of Asymmetric Subthalamic Deep Brain Stimulation for Axial Motor Dysfunction in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Toronto
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180305
    </Date_registration3>
    <Date_registration>05/03/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03462082
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 14, 2018
    </Date_enrollement>
    <Target_size>22
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Canada
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Alfonso Fasano, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Toronto
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with Parkinson's disease (PD) (previously diagnosed according to the UK brain&#x0D;&lt;br&gt;             bank criteria) who develop treatment-resistant postural instability gait dysfunction&#x0D;&lt;br&gt;             (PIGD) more than 6 months but less than 5 years after bilateral subthalamic nucleus&#x0D;&lt;br&gt;             deep brain stimulation (STN-DBS).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Treatment-resistant PIGD will be defined as freezing of gait and UPDRS or MDS-UPDRS&#x0D;&lt;br&gt;             PIGD subscales of more than 6 points despite optimization of medications and bilateral&#x0D;&lt;br&gt;             STN-DBS programming.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Treatment-resistant PIGD less than 6 months or more than 5 years after STN-DBS&#x0D;&lt;br&gt;             surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  PIGD responsive to optimization of medications and/or bilateral STN-DBS programming.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment or psychiatric comorbidities (including substance abuse) that&#x0D;&lt;br&gt;             would interfere with the informed consent process, study adherence or outcome&#x0D;&lt;br&gt;             assessments.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Advanced PD or any other neurological, cardiovascular or musculoskeletal&#x0D;&lt;br&gt;             co-morbidities that would preclude or require assistance to complete the 10-meter&#x0D;&lt;br&gt;             walking test.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients not able to comply with 4-week interval evaluations following their potential&#x0D;&lt;br&gt;             enrollment due to personal reasons.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Serious illness (requiring systemic treatment and/or hospitalization) until subject&#x0D;&lt;br&gt;             either completes therapy or is clinically-stable on therapy, in the opinion of the&#x0D;&lt;br&gt;             site investigator, for at least 30 days prior to study entry.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability or unwillingness of subject or legal guardian/representative to give written&#x0D;&lt;br&gt;             informed consent.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Asymmetric STN-DBS
    </Intervention>
    <Primary_outcome>Change in gait velocity
    </Primary_outcome>
    <Secondary_outcome>Change in postural instability gait dysfunction (1);Change in postural instability gait dysfunction (2);Change in postural instability gait dysfunction (3);Change in freezing of gait;Change in speech dysfunction;Change in the MDS-UPDRS;Change in cognitive tasks;Change in quality of life
    </Secondary_outcome>
    <Secondary_ID>17-5785
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13729061
    </Internal_Number>
    <TrialID>NL-OMON46346
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>Functional brain network changes as indicators of deep brain stimulation-induced cognitive and psychiatric side effects in Parkinson*s disease related to electrode contact points: a proof of concept study
    </Public_title>
    <Scientific_title>Functional brain network changes as indicators of deep brain stimulation-induced cognitive and psychiatric side effects in Parkinson*s disease related to electrode contact points: a proof of concept study - MEG in Parkinson*s disease patients with DBS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>Vrije Universiteit Medisch Centrum
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180207
    </Date_registration3>
    <Date_registration>2018-02-07
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/46346
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>64
    </Inclusion_agemax>
    <Inclusion_gender/>
    <Date_enrollement>2017-09-20
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Observational non invasive
    </Study_type>
    <Study_design>Open (masking not used), Uncontrolled, Treatment
    </Study_design>
    <Phase/>
    <Countries>The Netherlands
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address>De Boelelaan 1117
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Vrije Universiteit Medisch Centrum
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;p&gt;-Having undergone STN-DBS placement for PD six months or longer before MEG registrations; &lt;br&gt;-Age * 18 years; &lt;br&gt;-Written informed consent for the study; &lt;br&gt;-Monopolar stimulation (this restriction was chosen in order to improve inter-individual comparability); &lt;br&gt;-Pre-operative DTI data available and of sufficient quality. The patient*s nose should be included in at least one pre-operative MRI to allow optimal co-registration with the MEG data; &lt;br&gt;-Post-operative NPO is available and was performed in the same DBS settings as during the MEG recordings.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;p&gt;-Hoehn and Yahr stage (41) higher than 3, as determined in the DBS ON- (but medication OFF-)state during the visit to the outpatient clinic to establish the optimal DBS-settings, approximately ten days after surgery; &lt;br&gt;-Anatomical deformities that prevent the subject from undergoing an MEG registration in supine position (i.e. thoracic kyphosis); &lt;br&gt;-Continuous intrajejunal levodopa or subcutaneous apomorphine infusion in addition to DBS; &lt;br&gt;-Subjects who cannot read, speak or understand Dutch; &lt;br&gt;-Dementia according to the Movement Disorder Society criteria for PD with dementia (43). Mental competence is necessary in order to give informed consent for participation in the study and to follow instructions during MEG recordings. Minor cognitive decline post-DBS is not an exclusion criterion, since this is one of the outcome parameters of this study; &lt;br&gt;-Conditions that will cause excessive MEG artefacts (other than the DBS electrode and stimulator). A list of items that cause MEG signal perturbation is given in the participants information folder, on a poster at the entrance of the MEG system, and in this document (section 11); &lt;br&gt;-A history of stroke or major vascular lesions on brain MRI; &lt;br&gt;-A history of major traumatic brain injury; &lt;br&gt;-Peri-operative intracerebral complications (e.g. bleeding or infection) related to STN-DBS placement inflicting permanent changes;&lt;/p&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;idiopathic parkinsonism &lt;br&gt;paralysis agitans &lt;br&gt;Parkinsons disease;10028037;10009720;idiopathic parkinsonism;paralysis agitans;Parkinsons disease
    </Condition>
    <Intervention>&lt;p&gt;&lt;/p&gt;&lt;br&gt;;-Deep brain stimulation (DBS);-Magneto-encephalography (MEG);-Non-motor side effects;-Parkinsons disease
    </Intervention>
    <Primary_outcome>&lt;p&gt;The main study parameters are stimulation site-specific neurophysiological&lt;br /&gt;&lt;br&gt;measures, as obtained by MEG recordings, and individual differences in the&lt;br /&gt;&lt;br&gt;exact locations and structural connections of each stimulation site, as&lt;br /&gt;&lt;br&gt;obtained by pre- and post-DBS brain imaging. These network parameters will be&lt;br /&gt;&lt;br&gt;correlated with clinical measures of cognitive and psychiatric side effects.&lt;/p&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>&lt;p&gt;N.a.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>NL62093.029.17
    </Secondary_ID>
    <Source_Support>Ministerie van OC&amp;W
    </Source_Support>
    <Ethics_review_status>Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>02/08/2017;06/02/2018
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>;
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13640657
    </Internal_Number>
    <TrialID>DRKS00013789
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Concordance of MR-imaging based automatic segmentation of the Subthalamic Nucleus and intraoperatively recorded electrophysiology.
    </Public_title>
    <Scientific_title>Concordance of MR-imaging based automatic segmentation of the Subthalamic Nucleus and intraoperatively recorded electrophysiology. - CONCISE (CONCordance of Imaging Segmentation and Electrophysiology)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum Freiburg
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180122
    </Date_registration3>
    <Date_registration>22/01/2018
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00013789
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>10/01/2018
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: basic science  
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Peter
    </Contact_Firstname>
    <Contact_Lastname>Reinacher
    </Contact_Lastname>
    <Contact_Address>Breisacher Str. 64
    </Contact_Address>
    <Contact_Email>peter.reinacher@uniklinik-freiburg.de
    </Contact_Email>
    <Contact_Tel>+4976127050680
    </Contact_Tel>
    <Contact_Affiliation>Abteilung für Stereotaktische und Funktionelle Neurochirurgie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients with intraoperative electrophysiological testing and complete preoperative MR and CT images. 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: none
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: We retrospectively record the borders of the STN in 30 patients, who underwent an operation for deep brain stimulation in Parkinson´s disease, according to the automatic segmentation of MR images and according to the intraoperative electrophysiological measurement.
    </Intervention>
    <Primary_outcome>Distance of the electrophysiologically defined entry and exit points to the target region to the entry and exit points defined with automatic image segmentation.
    </Primary_outcome>
    <Secondary_outcome>Determining the average direction and difference between the electrophysiologiscally defined borders and the borders defined with automatic image segmentation. 
    </Secondary_outcome>
    <Secondary_ID>U1111-1207-7147
    </Secondary_ID>
    <Source_Support>Universitätsklinikum Freiburg
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>09/01/2018
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-761-27072600
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00013789#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>11290341
    </Internal_Number>
    <TrialID>NCT03409120
    </TrialID>
    <Last_Refreshed_on>30 August 2021
    </Last_Refreshed_on>
    <Public_title>Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology
    </Public_title>
    <Scientific_title>Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Alabama at Birmingham
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180113
    </Date_registration3>
    <Date_registration>13/01/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03409120
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2018
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Harrison C Walker, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Associate Professor of Neurology
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Enrollment in "Biomarkers to Guide Directional DBS for Parkinson's Disease"&#x0D;&lt;br&gt;             (ClinicalTrials.gov Identifier: NCT03353688)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of Parkinson's disease with and without dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Not enrolled in "Biomarkers to Guide Directional DBS for Parkinson's Disease"&#x0D;&lt;br&gt;             (ClinicalTrials.gov Identifier: NCT03353688)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Dystonia-Parkinsonism, Adult-Onset;Parkinson Disease
    </Condition>
    <Intervention>Device: Boston Scientific Vercise PC IPG with directional DBS lead
    </Intervention>
    <Primary_outcome>Burke-Fahn-Marsden Dystonia Rating Scale
    </Primary_outcome>
    <Secondary_ID>IRB-300001136
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Michael J. Fox Foundation for Parkinson's Research
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13552403
    </Internal_Number>
    <TrialID>JPRN-UMIN000030460
    </TrialID>
    <Last_Refreshed_on>20 November 2023
    </Last_Refreshed_on>
    <Public_title>A 3D gait analysis after deep brain stimulation in Parkinson&amp;#39;s disease
    </Public_title>
    <Scientific_title>A 3D gait analysis after deep brain stimulation in Parkinson&amp;#39;s disease - 3DGA-DBS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>Juntendo University Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20171219
    </Date_registration3>
    <Date_registration>19/12/2017
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034748
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>Not applicable
    </Inclusion_agemin>
    <Inclusion_agemax>Not applicable
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2017/12/19
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Cross-over Randomized
    </Study_design>
    <Phase>Not applicable
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname>Genko
    </Contact_Firstname>
    <Contact_Lastname>Oyama
    </Contact_Lastname>
    <Contact_Address>2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8431, JAPAN
    </Contact_Address>
    <Contact_Email>g_oyama@juntendo.ac.jp
    </Contact_Email>
    <Contact_Tel>+81-3-3813-3111
    </Contact_Tel>
    <Contact_Affiliation>Juntendo University Hospital Department of Neurology
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: -Any significant psychiatric problems including unrelated clinically significant depression  -Any current drug or alcohol abuse  -Any history of recurrent or unprovoked seizures.   -Any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints, including any terminal illness with survival less than 12 months.   -Subjects with &amp;quot;the 3rd grade: red patient&amp;quot; in &amp;quot;the grade of fall risk&amp;quot; of Juntendo University Hospital  -Subjects with large body frame expected not to be assisted by researchers in the case of their fall  -Subjects who was considered  inappropriate to participate in this study by the researchers
    </Exclusion_Criteria>
    <Condition>Parkinson&amp;#39;s disease
    </Condition>
    <Intervention>The setting of deep brain stimulation is set to 0 mA as a placebo control.&lt;br&gt;To change 31 patterns of deep brain stimulation settings
    </Intervention>
    <Primary_outcome>Number of steps and time on 6m walking and Time up and go test after the steering of deep brain stimulation
    </Primary_outcome>
    <Secondary_outcome>Gait parameters and side effect on 6m walking and Time up and go test using 3D gait analysis system after steering of deep brain stimulation and Unified Parkinson&amp;#39;s disease rating scale partIII
    </Secondary_outcome>
    <Source_Support>Kao Corporation;None
    </Source_Support>
    <Secondary_Sponsor>Kao Corporation
    </Secondary_Sponsor>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>12/10/2017
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>N/A
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Juntendo University Hospital Institutional Review Board
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>03-5802-1584
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>N/A
    </Ethics_review_contact_email>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>01/08/2023
    </results_date_posted>
    <results_date_completed>21/09/2018
    </results_date_completed>
    <results_url_link>https://authors.elsevier.com/sd/article/S1353-8020(23)00849-0
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10290627
    </Internal_Number>
    <TrialID>NCT03422757
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Safety and Efficacy of Adaptive DBS Vs Conventional DBS in Patients With Parkinson's Disease
    </Public_title>
    <Scientific_title>A Double Blind, Crossover Study to Evaluate Safety and Efficacy of an Adaptive Deep Brain Stimulation Closed-loop Method Compared With Conventional Deep Brain Stimulation in Patients With Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Newronika
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20171215
    </Date_registration3>
    <Date_registration>15/12/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03422757
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 1, 2017
    </Date_enrollement>
    <Target_size>6
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Italy
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of idiopathic PD;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  DBS implant since at least 3 years and in need of battery replacement, defined by&#x0D;&lt;br&gt;             battery level &lt;25%;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients must be able to sign the informed consent document to participate in the&#x0D;&lt;br&gt;             clinical trial;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with a suboptimal response to DBS treatment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with severe cognitive decline (MMSE &lt;25);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with major psychiatric issues;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with any medical condition potentially interfering with DBS battery&#x0D;&lt;br&gt;             replacement surgery;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients that cannot tolerate an interruption of DBS stimulation;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients taking only one levodopa dose per day;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with no LFPs recorded from any contacts pair, during intraoperatory IPG&#x0D;&lt;br&gt;             replacement procedure;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant or breastfeeding women.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: adaptive Deep Brain Stimulation;Device: conventional Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Total Electrical Energy Delivered (TEED) to the patient
    </Primary_outcome>
    <Secondary_outcome>Incidence of device related Adverse Events (safety and tolerability);Unified Parkinson's Disease Rating Scale (UPDRS) part III;Unified Dyskinesia Rating Scale (UDysRS)
    </Secondary_outcome>
    <Secondary_ID>NWK_aDBSext_01_2017
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12820166
    </Internal_Number>
    <TrialID>NCT03377569
    </TrialID>
    <Last_Refreshed_on>13 February 2023
    </Last_Refreshed_on>
    <Public_title>Subcortical Oscillations in Human Sleep Dysregulation
    </Public_title>
    <Scientific_title>Understanding the Role of Subcortical Oscillations in Human Sleep Dysregulation.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Colorado, Denver
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20171129
    </Date_registration3>
    <Date_registration>29/11/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03377569
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 27, 2018
    </Date_enrollement>
    <Target_size>15
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>John A Thompson, Ph.D.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Principal Investigator
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Subjects with Parkinson's Disease (PD) who are planning to have staged, bilateral deep&#x0D;&lt;br&gt;        brain stimulation surgery at the University of Colorado Hospital and willing and able to do&#x0D;&lt;br&gt;        the following:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Have a computer and be willing to use it as part of this study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Be able to learn to use and maintain a wristband-style sleep monitor.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Turn off their Implantable Pulse Generator (IPG, implanted battery).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Wear a wristband-style sleep monitor for 3 weeks, 6 weeks prior to surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Spend one overnight research stay in the UCH Sleep lab, 3 weeks prior to DBS surgery .&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Spend one overnight research stay in the UCH Sleep lab, immediately prior to IPG&#x0D;&lt;br&gt;             surgery, to record brain activity from the DBS electrode .&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Have a 15 minute surgery to externalize the DBS lead cable to allow overnight&#x0D;&lt;br&gt;             recordings to occur.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Be pseudo-randomized to one of 2 conditions: OFF stimulation or ON stimulation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Wear a wristband-style sleep monitor for 3 weeks, 3 months post-DBS surgery, in one of&#x0D;&lt;br&gt;             the 2 pseudo-randomized conditions.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Spend one overnight research stay in the UCH Sleep lab, 4 months post DBS surgery, in&#x0D;&lt;br&gt;             one of the pseudo-randomized conditions.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Subjects will have a sleep disorder documented in their medical history as determined by a&#x0D;&lt;br&gt;        single question screen for REM sleep behavior disorder.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subjects with Parkinson's Disease (PD) who are not planning to have staged, bilateral&#x0D;&lt;br&gt;             deep brain stimulation surgery at the University of Colorado Hospital.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subjects without a documented sleep disorder.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;REM Behavior Disorder
    </Condition>
    <Intervention>Other: Sleep, PD and DBS
    </Intervention>
    <Primary_outcome>Measuring brain physiological activity via local field potentials and correlation to sleep states (REM, non-REM, etc.);Chronic actigraphy to characterize sleep-wake behavior;Test the functional impact of STN-DBS on sleep-wake behavior through actigraphy
    </Primary_outcome>
    <Secondary_ID>17-0868
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13640378
    </Internal_Number>
    <TrialID>DRKS00013232
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Salivary secretion in Parkinson's Disease patients with and without deep brain stimulation
    </Public_title>
    <Scientific_title>Salivary secretion in Parkinson's Disease patients with and without deep brain stimulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>Uniklinik KölnAbteilung für Zahnerhaltung und Parodontologie
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20171113
    </Date_registration3>
    <Date_registration>13/11/2017
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00013232
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>15/12/2017
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: basic science  
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Greta
    </Contact_Firstname>
    <Contact_Lastname>Barbe
    </Contact_Lastname>
    <Contact_Address>Kerpener Str. 32
    </Contact_Address>
    <Contact_Email>anna.barbe@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>0221-478-96743
    </Contact_Tel>
    <Contact_Affiliation>Uniklinik KölnAbteilung für Zahnerhaltung und Parodontologie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: •  Patients with Parkinson's disease: after DBS (Deep Brain Stimulation) at least 3 months ago (Arm 1) or without DBS (Arm 2) &lt;br&gt;•  written informed consent &lt;br&gt;•  minimum 18 years old
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: •  actual or planned pregnancy during the study&lt;br&gt;•  actual or anamnestic radiation or chemotherapy in the head/neck region&lt;br&gt;•  actual or anamnestic parotid tumor&lt;br&gt;•  actual or anamnestic surgery in the head/neck region&lt;br&gt;•  Sjögren-Syndrome&lt;br&gt;•  daily intake of symptom-relieving products against xerostomia, besides frequent water intake
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20 &lt;br&gt;R68.2;Parkinson disease;Dry mouth, unspecified;R68.2
    </Condition>
    <Intervention>Group 1: PD (Parkinson's disease) patients with DBS (Deep Brain Stimulation) receive a salivation rate measurement and a masticatory function test via chewing gum in the  medication-OFF Status (no medication intake since the evening before) with DBS switched on and OFF.&lt;br&gt;Group 2: PD patients without DBS receive a salivation rate measurement and a masticatory function test via chewing gum in the  medication-OFF status (no medication intake since the evening before) and after standardized 200 mg Madopar intake.
    </Intervention>
    <Primary_outcome>Effect of Deep Brain Stimulation on salivation rates&lt;br&gt;&lt;br&gt;Therefore among Parkinson's disease patients with and without deep brain Stimulation in the Medication- OFF Status, there is Salivation amount measurement. Salivation rates is done by collecting all produced saliva for five minutes, afterwards saliva amount is measured. Finally the Stimulator is turned on again.
    </Primary_outcome>
    <Secondary_outcome>Effect of Dopamine on salivation rates, therefore, in the medication-OFF Status of Parkinson's disease patients without Deep Brain Stimulation, patients receive a standardized L-Dopa amount (200 mg), before and directly after salivation amounts are measured according to the primary endpoint. Masticatory function: participants chew 20 chewing cycles on two differently coloured chewing gums. Afterwards the degree of intermixing is documented by a specialized Software.
    </Secondary_outcome>
    <Source_Support>Uniklinik KölnAbteilung für Zahnerhaltung und Parodontologie
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>07/11/2017
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00013232#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>6696171
    </Internal_Number>
    <TrialID>NCT03347240
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Neuroablation Versus Neuromodulation Techniques for Treatment of Secondary Dystonia
    </Public_title>
    <Scientific_title>Comparative Study Between the Functional Outcomes of Neuromodulation and Neuroablation Techniques for Treatment of Secondary Dystonia
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Ain Shams University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20171112
    </Date_registration3>
    <Date_registration>12/11/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03347240
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>3 Years
    </Inclusion_agemin>
    <Inclusion_agemax>50 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 1, 2013
    </Date_enrollement>
    <Target_size>120
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Walid A Abdel Ghany, MD;Walid A Abdel Ghany, MD;Walid A Abdel Ghany, MD;Walid A Abdel Ghany, MD;Walid A Abdel Ghany, MD
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>Associate professor;Associate professor;Associate professor;Associate professor;Associate professor
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  secondary dystonia of previous etiologies&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients who are not candidate for anaesthesia&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  secondary dystonia of previous etiologies&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients who are not candidate for anaesthesia&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  secondary dystonia of previous etiologies&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients who are not candidate for anaesthesia&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  secondary dystonia of previous etiologies&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients who are not candidate for anaesthesia&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Secondary Dystonia;Secondary Dystonia;Secondary Dystonia;Secondary Dystonia
    </Condition>
    <Intervention>Procedure: Brain Lesioning;Procedure: Combined anterior and posterior lumbosacral rhizotomy;Device: Deep brain stimulation;Device: Intra-thecal baclofen infusion;Procedure: Brain Lesioning;Procedure: Combined anterior and posterior lumbosacral rhizotomy;Device: Deep brain stimulation;Device: Intra-thecal baclofen infusion;Procedure: Brain Lesioning;Procedure: Combined anterior and posterior lumbosacral rhizotomy;Device: Deep brain stimulation;Device: Intra-thecal baclofen infusion;Procedure: Brain Lesioning;Procedure: Combined anterior and posterior lumbosacral rhizotomy;Device: Deep brain stimulation;Device: Intra-thecal baclofen infusion
    </Intervention>
    <Primary_outcome>Burke-Fahn-Marsden dystonia rating scale;Burke-Fahn-Marsden dystonia rating scale;Burke-Fahn-Marsden dystonia rating scale
    </Primary_outcome>
    <Secondary_outcome>Modified Ashworth scale;Barthel index
    </Secondary_outcome>
    <Secondary_ID>4996
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13161208
    </Internal_Number>
    <TrialID>NCT03353688
    </TrialID>
    <Last_Refreshed_on>10 July 2023
    </Last_Refreshed_on>
    <Public_title>Biomarkers to Guide Directional DBS for Parkinson's Disease
    </Public_title>
    <Scientific_title>Noninvasive Biomarkers to Advance Emerging DBS Electrode Technologies in Parkinson's Disease (SUNDIAL, SUbthalamic Nucleus DIrectionAL vs Circular Stimulation Study)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Alabama at Birmingham
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170926
    </Date_registration3>
    <Date_registration>26/09/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03353688
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 3, 2017
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Harrison Walker, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Alabama at Birmingham
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Age =18 years and =70 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Clinically definite, advanced idiopathic PD based on at least 2 of 3 cardinal PD&#x0D;&lt;br&gt;             features (tremor, rigidity, or bradykinesia).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Disease duration of 4 years or more.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Participant has elected to undergo DBS surgery as part of routine care, and the&#x0D;&lt;br&gt;             subthalamic nucleus (STN) is recommended as the surgical target.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Participant agrees to not undergo contralateral DBS for the other side of the brain&#x0D;&lt;br&gt;             until = 12 months after initial DBS surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Participant is healthy enough to undergo surgery and the research protocol.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Normal, or essentially normal, preoperative brain MRI.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Willingness and ability to cooperate during awake DBS surgery, as well as during&#x0D;&lt;br&gt;             post-operative evaluations, adjustments of medications and stimulator settings.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Participant's health insurance and/or Medicare covers DBS surgery as part of routine&#x0D;&lt;br&gt;             care.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Refractory motor symptoms such as tremor, dyskinesias, wearing off, and/or motor&#x0D;&lt;br&gt;             fluctuations, causing significant disability or occupational dysfunction, despite&#x0D;&lt;br&gt;             reasonable attempts at medical management, as determined by our consensus DBS&#x0D;&lt;br&gt;             committee.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Stable doses of PD medications for at least 28 days prior to baseline assessments.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Improvement of motor signs =30% with dopaminergic medication as assessed with the use&#x0D;&lt;br&gt;             of the Movement Disorders - Unified Parkinson's Disease Rating Scale, part III&#x0D;&lt;br&gt;             (MDS-UPDRS III; scores range from 0 to 108, with higher scores indicating worse&#x0D;&lt;br&gt;             functioning).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Disease severity ratings above Hoehn and Yahr stage 1, defined as unilateral&#x0D;&lt;br&gt;             involvement only with minimal or no functional disability, with scores ranging from 0&#x0D;&lt;br&gt;             to 5 and higher scores indicating more severe disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. Score of more than 6 for activities of daily living in the worst "off" medication&#x0D;&lt;br&gt;             condition despite medical treatment, as assessed with the use of the MDS-UPDRS II&#x0D;&lt;br&gt;             (scores range from 0 to 52, with higher scores indicating worse functioning), or&#x0D;&lt;br&gt;             mild-to-moderate impairment in social and occupational functioning (score of 51 to 80%&#x0D;&lt;br&gt;             on the Social and Occupational Functioning Assessment Scale with scores ranging from 1&#x0D;&lt;br&gt;             to 100 and lower scores indicating worse functioning).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         15. Dementia Rating Scale-2 (DRS-2) score of =130 on medications.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         16. Beck Depression Inventory II (BDI-II) score of =25 on medications.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         17. Participant expresses understanding of the consent process, terms of the study&#x0D;&lt;br&gt;             protocol, is available for follow-up over the length of the study, and signs informed&#x0D;&lt;br&gt;             consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Age &lt;18 years or &gt;70 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Participant's insurance will not cover the costs of surgery with the investigational&#x0D;&lt;br&gt;             device.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Medical contraindications such as current uncontrolled hypertension, heart disease,&#x0D;&lt;br&gt;             coagulopathy, or other conditions contraindicating DBS surgery or stimulation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Duration of disease of &lt;4 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Participant or care team determine that contralateral DBS for the other side of the&#x0D;&lt;br&gt;             brain will likely be clinically indicated &lt;12 months after initial DBS surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Diagnosis or suspicion of atypical parkinsonism (progressive supranuclear palsy,&#x0D;&lt;br&gt;             multiple system atrophy, corticobasal syndrome) or drug-induced parkinsonism, or&#x0D;&lt;br&gt;             significant neurological disease other than Parkinson's disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Disease severity ratings of Hoehn and Yahr stage 1, defined as unilateral involvement&#x0D;&lt;br&gt;             only with minimal or no functional disability, with scores ranging from 0 to 5 and&#x0D;&lt;br&gt;             higher scores indicating more severe disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Diagnosis of psychogenic movement disorder based on consensus criteria.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Score of &gt;25 on the Beck Depression Inventory II, with scores ranging from 0 to 63 and&#x0D;&lt;br&gt;             higher scores indicating worse functioning), or history of suicide attempt.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Any current acute psychosis, alcohol abuse or drug abuse.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Clinical dementia (score of =130 on the Mattis Dementia Rating Scale with scores&#x0D;&lt;br&gt;             ranging from 0 to 144 and higher scores indicating better functioning).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Ongoing or pervasive impulse control disorder not resolved by reduction of&#x0D;&lt;br&gt;             dopaminergic medications.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Use of anticoagulant medications that cannot be discontinued during perioperative&#x0D;&lt;br&gt;             period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. History of hemorrhagic stroke.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         15. Current or future risk of immunocompromise that might significantly increase risk of&#x0D;&lt;br&gt;             infection.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         16. History of recurrent of unprovoked seizures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         17. Lack of clear levodopa responsiveness.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         18. Any medical condition requiring repeated MRI.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         19. The presence of an implanted device (e.g., cochlear implant, pacemaker,&#x0D;&lt;br&gt;             neurostimulators), whether turned on or off.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         20. Prior DBS surgery or ablation within the affected basal ganglion.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         21. A condition requiring or likely to require the use of diathermy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         22. Structural lesions such as basal ganglionic stroke, tumor or vascular malformation as&#x0D;&lt;br&gt;             etiology of the movement disorder.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         23. Any medical or psychological problem that would interfere with the conduction of the&#x0D;&lt;br&gt;             study protocol&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         24. A female who is breastfeeding or of child-bearing potential with a positive urine&#x0D;&lt;br&gt;             pregnancy test or not using adequate contraception.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Boston Scientific Vercise PC IPG with directional DBS lead
    </Intervention>
    <Primary_outcome>Change from preoperative baseline in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3 (MDS-UPDRS Part III) "off" medications;Change from preoperative baseline in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3 (MDS-UPDRS Part III) "off" medications;Change from preoperative baseline in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3 (MDS-UPDRS Part III) "off" medications;Change from preoperative baseline in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3 (MDS-UPDRS Part III) "off" medications;Treatment Preference Survey
    </Primary_outcome>
    <Secondary_outcome>Change from preoperative baseline in NIH Toolbox Cognition Battery;Change from preoperative baseline in NIH Toolbox Cognition Battery;Change from preoperative baseline in NIH Toolbox Cognition Battery;Change from preoperative baseline in the Beck Depression Inventory-2 (BDI-2);Change from preoperative baseline in the Beck Depression Inventory-2 (BDI-2);Change from preoperative baseline in the Beck Depression Inventory-2 (BDI-2);Change from preoperative baseline in the Beck Anxiety Inventory (BAI);Change from preoperative baseline in the Beck Anxiety Inventory (BAI);Change from preoperative baseline in the Beck Anxiety Inventory (BAI);Change from preoperative baseline in the Conners Continuous Performance Test Third Edition (Conners CPT-3);Change from preoperative baseline in the Conners Continuous Performance Test Third Edition (Conners CPT-3);Change from preoperative baseline in the Conners Continuous Performance Test Third Edition (Conners CPT-3);Change from preoperative baseline in the Auditory Verbal Learning Test (AVLT) (versions AB, CD, CR, GE);Change from preoperative baseline in the Auditory Verbal Learning Test (AVLT) (versions AB, CD, CR, GE);Change from preoperative baseline in the Auditory Verbal Learning Test (AVLT) (versions AB, CD, CR, GE);Change from preoperative baseline in the 10/36 Spatial Recall Test (forms 1, 2 ,3, 4);Change from preoperative baseline in the 10/36 Spatial Recall Test (forms 1, 2 ,3, 4);Change from preoperative baseline in the 10/36 Spatial Recall Test (forms 1, 2 ,3, 4);Change from preoperative baseline in the Letter Fluency Test (version: CFL, FAS);Change from preoperative baseline in the Letter Fluency Test (version: CFL, FAS);Change from preoperative baseline in the Letter Fluency Test (version: CFL, FAS);Change from preoperative baseline in the D-KEFS Color-Word Interference Test (CWIT);Change from preoperative baseline in the D-KEFS Color-Word Interference Test (CWIT);Change from preoperative baseline in the D-KEFS Color-Word Interference Test (CWIT);Change from preoperative baseline in the Neuropsychiatric Inventory;Change from preoperative baseline in the Neuropsychiatric Inventory;Change from preoperative baseline in the Neuropsychiatric Inventory;Change from preoperative baseline in the Rainbow Passage;Change from preoperative baseline in the Rainbow Passage;Change from preoperative baseline in the Rainbow Passage;Change from preoperative baseline in Spontaneous Speech Production;Change from preoperative baseline in Spontaneous Speech Production;Change from preoperative baseline in Spontaneous Speech Production;Change from preoperative baseline in Acoustic Measures;Change from preoperative baseline in Acoustic Measures;Change from preoperative baseline in Acoustic Measures;Change from preoperative baseline in the Voice Handicap Index;Change from preoperative baseline in the Voice Handicap Index;Change from preoperative baseline in the Voice Handicap Index;Change from preoperative baseline in the Communicative Participation Item Bank (CPIB);Change from preoperative baseline in the Communicative Participation Item Bank (CPIB);Change from preoperative baseline in the Communicative Participation Item Bank (CPIB);Change from preoperative baseline in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (UPDRS) Version 3 Part I;Change from preoperative baseline in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (UPDRS) Version 3 Part I;Change from preoperative baseline in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (UPDRS) Version 3 Part I;Change from preoperative baseline in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (UPDRS) Version 3 Part II;Change from preoperative baseline in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (UPDRS) Version 3 Part II;Change from preoperative baseline in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (UPDRS) Version 3 Part II;Change from preoperative baseline in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (UPDRS) Version 3 Part IV;Change from preoperative baseline in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (UPDRS) Version 3 Part IV;Change from preoperative baseline in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (UPDRS) Version 3 Part IV;Change from preoperative baseline in Activities-Specific Balance Confidence (ABC) Scale;Change from preoperative baseline in Activities-Specific Balance Confidence (ABC) Scale;Change from preoperative baseline in Activities-Specific Balance Confidence (ABC) Scale;Change from preoperative baseline in Activities-Specific Balance Confidence (ABC) Scale;Change from preoperative baseline in the Freezing of Gait Questionnaire (FOG-Q);Change from preoperative baseline in the Freezing of Gait Questionnaire (FOG-Q);Change from preoperative baseline in the Freezing of Gait Questionnaire (FOG-Q);Change from preoperative baseline in the Freezing of Gait Questionnaire (FOG-Q);Change from preoperative baseline in the 9-Hole Pegboard Test;Change from preoperative baseline in the 9-Hole Pegboard Test;Change from preoperative baseline in the 9-Hole Pegboard Test;Change from preoperative baseline in the 9-Hole Pegboard Test;Change from preoperative baseline in the Time to Walk Test;Change from preoperative baseline in the Time to Walk Test;Change from preoperative baseline in the Time to Walk Test;Change from preoperative baseline in the Time to Walk Test;Change from preoperative baseline in Gait Initiation Test;Change from preoperative baseline in Gait Initiation Test;Change from preoperative baseline in Gait Initiation Test;Change from preoperative baseline in Gait Initiation Test;Change from preoperative baseline in Stepping Thresholds Test;Change from preoperative baseline in Stepping Thresholds Test;Change from preoperative baseline in Stepping Thresholds Test;Change from preoperative baseline in Stepping Thresholds Test;Change from preoperative baseline in Quiet Stance Measure;Change from preoperative baseline in Quiet Stance Measure;Change from preoperative baseline in Quiet Stance Measure;Change from preoperative baseline in Quiet Stance Measure;Change from preoperative baseline in the Parkinson's Disease Quality of Life;Change from preoperative baseline in the Parkinson's Disease Quality of Life;Change from preoperative baseline in the Parkinson's Disease Quality of Life;Change from preoperative baseline in the Parkinson's Disease Quality of Life;Change from preoperative baseline in the the Neuro-QOL Item Bank v1.0 "Positive Affect and Well-Being" short form;Change from preoperative baseline in the the Neuro-QOL Item Bank v1.0 "Positive Affect and Well-Being" short form;Change from preoperative baseline in the the Neuro-QOL Item Bank v1.0 "Positive Affect and Well-Being" short form;Change from preoperative baseline in the the Neuro-QOL Item Bank v1.0 "Positive Affect and Well-Being" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.1 "Satisfaction with Social Roles and Activities" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.1 "Satisfaction with Social Roles and Activities" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.1 "Satisfaction with Social Roles and Activities" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.1 "Satisfaction with Social Roles and Activities" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v2.0 "Cognitive Function" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v2.0 "Cognitive Function" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v2.0 "Cognitive Function" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v2.0 "Cognitive Function" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Lower Extremity Function (Mobility)" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Lower Extremity Function (Mobility)" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Lower Extremity Function (Mobility)" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Lower Extremity Function (Mobility)" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Upper Extremity Function (Fine Motor, ADL)" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Upper Extremity Function (Fine Motor, ADL)" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Upper Extremity Function (Fine Motor, ADL)" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Upper Extremity Function (Fine Motor, ADL)" short form;Change from preoperative baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) Scale v1.2 "Global Health";Change from preoperative baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) Scale v1.2 "Global Health";Change from preoperative baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) Scale v1.2 "Global Health";Change from preoperative baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) Scale v1.2 "Global Health";Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Stigma" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Stigma" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Stigma" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Stigma" short form;Change from preoperative baseline in the Neuro-QOL Scale v1.0 "Communication" short form;Change from preoperative baseline in the Neuro-QOL Scale v1.0 "Communication" short form;Change from preoperative baseline in the Neuro-QOL Scale v1.0 "Communication" short form;Change from preoperative baseline in the Neuro-QOL Scale v1.0 "Communication" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Emotional and Behavioral Dyscontrol" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Emotional and Behavioral Dyscontrol" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Emotional and Behavioral Dyscontrol" short form;Change from preoperative baseline in the Neuro-QOL Item Bank v1.0 "Emotional and Behavioral Dyscontrol" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v2.0 "Ability to Participate in Social Roles and Activities" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v2.0 "Ability to Participate in Social Roles and Activities" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v2.0 "Ability to Participate in Social Roles and Activities" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v2.0 "Ability to Participate in Social Roles and Activities" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Emotional Distress - Anxiety" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Emotional Distress - Anxiety" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Emotional Distress - Anxiety" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Emotional Distress - Anxiety" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Emotional Distress - Depression" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Emotional Distress - Depression" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Emotional Distress - Depression" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Emotional Distress - Depression" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Fatigue" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Fatigue" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Fatigue" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Fatigue" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v2.0 "Physical Function" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v2.0 "Physical Function" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v2.0 "Physical Function" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v2.0 "Physical Function" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement;Change from preoperative baseline in Patient-Reported Outcomes Measurement;Change from preoperative baseline in Patient-Reported Outcomes Measurement;Change from preoperative baseline in Patient-Reported Outcomes Measurement;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Sleep Disturbance" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Sleep Disturbance" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Sleep Disturbance" short form;Change from preoperative baseline in Patient-Reported Outcomes Measurement Information System PROMIS v1.0 "Sleep Disturbance" short form
    </Secondary_outcome>
    <Secondary_ID>1UH3NS100553-01;IRB-161018001
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institutes of Health (NIH);National Institute of Neurological Disorders and Stroke (NINDS)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13640188
    </Internal_Number>
    <TrialID>DRKS00012931
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Hypogeusia In Vim/DRT-DBS
    </Public_title>
    <Scientific_title>Hypogeusia In Vim/DRT-DBS - HIDDen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum FreiburgKlinik für NeurochirurgieAbteilung für Stereotaktische und Funktionelle Neurochirurgie
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170908
    </Date_registration3>
    <Date_registration>08/09/2017
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00012931
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>18/10/2017
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: N/A: single arm study; Masking: Open (masking not used); Control: uncontrolled; Assignment: single; Study design purpose: diagnostic 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Bastian
    </Contact_Firstname>
    <Contact_Lastname>Sajonz
    </Contact_Lastname>
    <Contact_Address>Breisacher Str. 64
    </Contact_Address>
    <Contact_Email>bastian.sajonz@uniklinik-freiburg.de
    </Contact_Email>
    <Contact_Tel>+49 761 270 50010
    </Contact_Tel>
    <Contact_Affiliation>Universitätsklinikum FreibugKlinik für NeurochirurgieAbteilung für Funktionelle und Stereotaktische Neurochirurgie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Adult tremor patients who are being treated with DBS and where DTI imaging data is available. Decision for DBS therapy is made according to standard guidelines outside this study.&#x0D;&lt;br&gt;2. Written informed consent.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients suffering from multiple sclerosis.&#x0D;&lt;br&gt;2- Patients with allergies on citric acid or chinine.
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G25.0 &lt;br&gt;R43.8;Essential tremor;Other and unspecified disturbances of smell and taste;G25.0;R43.8
    </Condition>
    <Intervention>Group 1: Pre-operative gustometry, olfactometry and rhinomanometry prior to implantation of DBS (Deep Brain Stimulation) system. Post-operative gustometry, olfactometry and rhinomanometry 6-12 months after implantation. When post-operative results differ from pre-operative test results gustometry, olfactometry and rhinomanometry will be repeated with DBS stimulator turned OFF.
    </Intervention>
    <Primary_outcome>To compare gustatory and olfactory function by means of olfactometry and gustometry preoperatively as well as 6-12 months after Implantation of DBS (Deep Brain Stimulation)
    </Primary_outcome>
    <Secondary_outcome>Identification of risk factors for stimulation-induced hypogeusia (age, sex, pre-existing disturbance of olfaction or gustation).
    </Secondary_outcome>
    <Source_Support>Universitätsklinikum FreibugKlinik für NeurochirurgieAbteilung für Funktionelle und Stereotaktische Neurochirurgie
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>11/08/2017
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-761-27072600
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_email>
    <results_date_completed>28/03/2022
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00012931#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10281027
    </Internal_Number>
    <TrialID>NCT03267550
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>The Safety of Remote DBS Programming System
    </Public_title>
    <Scientific_title>A Pilot Study to Investigating Safety of A Remote and Wireless Deep Brain Stimulation Programming System for Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Ruijin Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170823
    </Date_registration3>
    <Date_registration>23/08/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03267550
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 8, 2017
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Device Feasibility. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Zhang Chencheng, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Ruijin Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Primary PD patients volunteered to receive DBS surgery with SceneRay wireless and&#x0D;&lt;br&gt;             remote DBS system,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 18-75 years,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Achieved optimal control of clinical symptoms after coventional programming for 3-12&#x0D;&lt;br&gt;             months,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Significant difference in motor function when DBS is switched on/off,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Good compliance and easy to follow-up,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No significant improvement or clinical efficacy in symptoms after surgery,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe cognitive impairment due to dementia (Mini-Mental State Examination score:&#x0D;&lt;br&gt;             illiteracy &lt;17, elementary school &lt;20, junior high school or above &lt;24) or inability&#x0D;&lt;br&gt;             to accurately record in a diary,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active psychosis or a history of psychosis,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Serious heart, liver, or kidney diseases,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe hypertension or orthostatic hypotension, severe diabetes, or diabetes&#x0D;&lt;br&gt;             accompanied by brain and cardiovascular diseases,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Malignant cancer, brain injuries, epilepsy, or other unstable medical conditions,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe alcohol dependence or drug abuse,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any situation that may jeopardize the patient's safety or lead to a failure to&#x0D;&lt;br&gt;             participate in the study (medical, psychological, social, or georational factors) at&#x0D;&lt;br&gt;             present or in the future,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participating in other clinical trials,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other factors that researchers think may not be suitable for research.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: SceneRay wireless and remote DBS system
    </Intervention>
    <Primary_outcome>The Unified Parkinson's Disease Rating Scale III&amp;IV;Deep Brain Stimulation Programming parameter;Deep Brain Stimulation Programming parameter;Deep Brain Stimulation Programming parameter;Deep Brain Stimulation Programming parameter;Serious Adverse Event
    </Primary_outcome>
    <Secondary_ID>DBS telemedicine
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12819973
    </Internal_Number>
    <TrialID>NCT03212885
    </TrialID>
    <Last_Refreshed_on>13 February 2023
    </Last_Refreshed_on>
    <Public_title>Stimulation of the Rostral Zona Incerta for Parkinson's Disease
    </Public_title>
    <Scientific_title>Deep Brain Stimulation (DBS) of the Rostral Zona Incerta (rZI) for Parkinson's Disease (PD): Clinical Efficacy and Evaluation of Adverse Effects
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Colorado, Denver
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170707
    </Date_registration3>
    <Date_registration>07/07/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03212885
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 3, 2017
    </Date_enrollement>
    <Target_size>14
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Drew S Kern, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Colorado, Denver
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parkinson's Disease,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No current deep brain stimulating electrodes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other movement disorders,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parkinson's Disease with already implanted electrode.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Motor testing
    </Primary_outcome>
    <Secondary_outcome>Dyskinesias;Cognition;Depression;Anxiety;Suicide;Non-motor features of Parkinson's disease;Motor aspects of daily living
    </Secondary_outcome>
    <Secondary_ID>16-1443
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10331771
    </Internal_Number>
    <TrialID>NCT03958617
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Thalamic Deep Brain Stimulation for Tourette Syndrome
    </Public_title>
    <Scientific_title>Thalamic Deep Brain Stimulation for Tourette's Syndrome: a Pragmatic Trial With Brief Randomized, Double-blinded Sham Controlled Sequences
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Cologne
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170626
    </Date_registration3>
    <Date_registration>26/06/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03958617
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 1, 2014
    </Date_enrollement>
    <Target_size>8
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Jens Kuhn, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University Hospital of Cologne
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Das Tourette-Syndrom (ICD-10: F 95.2; DSM IV: 307.23) als Hauptdiagnose. Bei dem&#x0D;&lt;br&gt;             Patienten ist aufgrund einer chronischen, schwergradigen und therapieresistenten&#x0D;&lt;br&gt;             Verlaufsform des TS eine Behandlung mittels THS thalamischer Strukturen im Sinne einer&#x0D;&lt;br&gt;             ultima ratio vorgesehen.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Alter des Patienten 18 bis 65 Jahre&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Sicher im Verstehen der deutschen Sprache&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unterzeichnete Einverständniserklärung&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Klinisch manifeste Psychose&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Schwangerschaft und Stillzeit&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unterbringung nach PsychKG&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Kontraindikationen einer MRT-Untersuchung wie z. B. implantierter Herzschrittmacher /&#x0D;&lt;br&gt;             Defibrillator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neoplastische neurologische Erkrankungen&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Kontraindikationen einer stereotaktischen Operation, wie z. B.: erhöhte&#x0D;&lt;br&gt;             Blutungsneigung, cerebrovaskuläre Erkrankungen (z. B. arteriovenöse Malformationen,&#x0D;&lt;br&gt;             Aneurysmata, systemische Gefäßerkrankungen, die auf das Cerebrum übergreifen).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Teilnahme an einer anderen klinischen Studie&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hirnassoziierte Kriterien, die eine OP ausschließen (Gefäßanomalien, große&#x0D;&lt;br&gt;             arteriovenöse Malformationen, Hirnmetastasen, Neoplasien des ZNS (Ausnahme&#x0D;&lt;br&gt;             asymptomatisches inzidentielles Meningeom))&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Antikoagulationtherapie, die in der perioperativen Phase nicht ausgesetzt werden kann&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  OP am Gehirn in der Anamnese, die mit der Platzierung/Funktion des MP interferieren&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Med. Gegebenheiten, die mit der Studienprozedur interferieren oder Evaluation der&#x0D;&lt;br&gt;             Studienparameter beeinträchtigen inkl. Erkrankungen im terminalen Stadium&#x0D;&lt;br&gt;             (Lebenserwartung &lt; 12 Monate)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Akute Suizidalität&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Abhängigkeit von Alkohol oder Drogen (exklusive Cannabis, da es von schwer betroffenen&#x0D;&lt;br&gt;             Patienten teilweise zur Ticreduktion im Sinne einer Selbstmedikation eingesetzt wird&#x0D;&lt;br&gt;             sowie exklusive Opioide und Benzodiazepine, wenn diese initial zur Ticreduktion im&#x0D;&lt;br&gt;             Sinne einer Selbstmedikation eingesetzt wurden)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Klinisch relevante internistische oder neurologische Erkrankungen&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intelligenzminderung&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Alle aktiv implantierten Medizinprodukte&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Schweres Schädel-Hirn-Trauma in der Anamnese&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Metallimplantate im Kopfbereich ( Bsp. Aneurysmaclips)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome
    </Condition>
    <Intervention>Device: Bilateral Deep brain stimulation of the thalamus, Medtronic Device
    </Intervention>
    <Primary_outcome>Yale Global Tic Severity Scale (YGTSS)
    </Primary_outcome>
    <Secondary_outcome>Modified Rush video rating scale (MRVRS)
    </Secondary_outcome>
    <Secondary_ID>1648
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>German Research Foundation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>6248363
    </Internal_Number>
    <TrialID>ChiCTR-OOC-17011684
    </TrialID>
    <Last_Refreshed_on>19 June 2017
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation of subthalamic nucleus to treat Meige Syndrome: registry study
    </Public_title>
    <Scientific_title>Deep Brain Stimulation of subthalamic nucleus to treat Meige Syndrome: registry study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>Aviation General Hospital of China Medical University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170617
    </Date_registration3>
    <Date_registration>2017-06-17
    </Date_registration>
    <Source_Register>ChiCTR
    </Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=19379
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>80
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2017-06-17
    </Date_enrollement>
    <Target_size>Case series:10;
    </Target_size>
    <Study_type>Observational study
    </Study_type>
    <Study_design>Case series
    </Study_design>
    <Phase>Other
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>Lin Wang
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>3 Beiyuan, Anwai, Chaoyang District, Beijing, China
    </Contact_Address>
    <Contact_Email>wanglin70321@126.com
    </Contact_Email>
    <Contact_Tel>+86 15810362938
    </Contact_Tel>
    <Contact_Affiliation>Aviation General Hospital of China Medical University
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. The diagnosis of idiopathic cranial facial focal or segmental dystonia, including simple blepharospasm or oromandibular dystonia patients, as well as other parts of the muscle of any of the above symptoms involving the craniofacial;&#x0D;&lt;br&gt;2. Patients who have failed to effectively control symptoms and / or have been treated with oral botulinum toxin for at least 6 months, and who have severe impact on their quality of life, are required to undergo surgical treatment;&#x0D;&lt;br&gt;3. Except for symptoms of dystonia, the body is in good health;&#x0D;&lt;br&gt;4. The MMSE showed normal screening results;&#x0D;&lt;br&gt;5. The subjects or their families can fully understand the treatment and sign informed consent;&#x0D;&lt;br&gt;6. The subjects with good compliance, can be required to complete the follow-up after operation.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Imaging findings of patients with abnormal basal ganglia;&#x0D;&lt;br&gt;2. Patients suffer from severe progressive neurological, cardiovascular, respiratory, or digestive diseases;&#x0D;&lt;br&gt;3. The patient's mental state is unstable;&#x0D;&lt;br&gt;4. Patients with contraindications to surgery or anesthesia, such as long-term use of anticoagulant, antiplatelet drugs;&#x0D;&lt;br&gt;5. Female patients who are planning to conceive or are pregnant and lactating women.&#x0D;&lt;br&gt;6. The patients have or need other implantable devices, such as pacemakers, defibrillators, cochlear and spinal nerve  stimulator;&#x0D;&lt;br&gt;7. The patients need do repeated MRI because of their own reasons during clinical trials in the future;&#x0D;&lt;br&gt;8. The patients have participated in other clinical trials.
    </Exclusion_Criteria>
    <Condition>Meige syndrome
    </Condition>
    <Intervention>Case series:STN DBS;
    </Intervention>
    <Primary_outcome>BFMDRS scale;
    </Primary_outcome>
    <Secondary_outcome>SF-36 scale;Score of HAMD;Score of YALE-BROWN;Cognitive Tests;
    </Secondary_outcome>
    <Source_Support>Self funding
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10274912
    </Internal_Number>
    <TrialID>NCT03156517
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>A Controlled Comparison of Two DBS Targets for Upper Extremity Action Tremor
    </Public_title>
    <Scientific_title>Deep Brain Stimulation in Disabling Action Tremor: A Randomized, Double-blind Study Comparing the Ventral Intermediate Nucleus (VIM) of the Thalamus and the Posterior Subthalamic Area (PSA) / Zona Incerta (The TREMORSTIM Study)
    </Scientific_title>
    <Acronym>Tremorstim
    </Acronym>
    <Primary_sponsor>Oslo University Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170515
    </Date_registration3>
    <Date_registration>15/05/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03156517
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 20, 2014
    </Date_enrollement>
    <Target_size>45
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Norway
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Inger Marie Skogseid, MDPhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Oslo University Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Min 5-yr duration chronic action tremor of upper limb(s), w/ or w/out tremor of&#x0D;&lt;br&gt;             head/neck, trunk, lower limbs, who have insufficient relief from adequate trials of&#x0D;&lt;br&gt;             recommended medications. The arm tremor must be so severe that it interferes with the&#x0D;&lt;br&gt;             patient's work performance or activities of daily living, such as drinking/eating,&#x0D;&lt;br&gt;             dressing/hygiene, and/or writing. Clinical diagnosis (according to criteria defined by&#x0D;&lt;br&gt;             the Consensus Statement of the Movement Disorders Society) include Essential Tremor,&#x0D;&lt;br&gt;             Dystonic Tremor, Cerebellar Tremor- idiopathic or secondary (to e.g.MS or SCA), or&#x0D;&lt;br&gt;             severe PD tremor (who are not eligible for DBS of the subthalamic nucleus).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Brain MRI showing so marked general atrophy, or supra-tentorial white matter changes,&#x0D;&lt;br&gt;             that the safety of the procedure is affected. Co-morbidity of dementia or other severe&#x0D;&lt;br&gt;             neuropsychiatric disorder (major depression or anxiety disorder, active/recent&#x0D;&lt;br&gt;             psychosis, drug or other substance abuse). Increased risk of bleeding, cancer at&#x0D;&lt;br&gt;             advanced/not stabilized stage, other severe co-morbidity (e.g. With chronic pain,&#x0D;&lt;br&gt;             short life expectancy,). Other surgical contraindications.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Action Tremor
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Upper extremity FTM-Tremor Rating Scale score change with VIM versus PSA-stimulation
    </Primary_outcome>
    <Secondary_outcome>FTM-Tremor rating Scale score changes from baseline to 1-yr (all body regions);Change of patient evaluated scores at 1 year of stimulation (QUEST and VAS Global Burden Disease Burden (Tremor-burden);Frequency of serious adverse events
    </Secondary_outcome>
    <Secondary_ID>2013/1013
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>South-Eastern Norway Regional Health Authority
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>6197521
    </Internal_Number>
    <TrialID>ChiCTR-ORC-17011398
    </TrialID>
    <Last_Refreshed_on>22 May 2017
    </Last_Refreshed_on>
    <Public_title>A Retrospective Study of Meige Patients After Bilateral STN DBS
    </Public_title>
    <Scientific_title>A Retrospective Study of Meige Patients After Bilateral STN DBS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Aviation General Hospital of China Medical University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170514
    </Date_registration3>
    <Date_registration>2017-05-14
    </Date_registration>
    <Source_Register>ChiCTR
    </Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=19378
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>75
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2017-05-13
    </Date_enrollement>
    <Target_size>Case series:15;
    </Target_size>
    <Study_type>Observational study
    </Study_type>
    <Study_design>Case series
    </Study_design>
    <Phase>Retrospective study
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>Lin Wang
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>3 North Anwai Yard, Chaoyang District, Beijing
    </Contact_Address>
    <Contact_Email>wanglin70321@126.com
    </Contact_Email>
    <Contact_Tel>+86 15810362938
    </Contact_Tel>
    <Contact_Affiliation>Aviation General Hospital of China Medical University
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Experience bilateral STN DBS surgery in the Aviation General Hospital of China Medical University, China.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Loss to follow-up
    </Exclusion_Criteria>
    <Condition>Meige syndrome
    </Condition>
    <Intervention>Case series:STN DBS;
    </Intervention>
    <Primary_outcome>BFMDRS scale;
    </Primary_outcome>
    <Secondary_outcome>SF-36 scale;
    </Secondary_outcome>
    <Source_Support>self-financing
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13639052
    </Internal_Number>
    <TrialID>DRKS00010876
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Social maladaptation after subthalamic deep brain stimulation for Parkinson's Disease
    </Public_title>
    <Scientific_title>Social maladaptation after subthalamic deep brain stimulation for Parkinson's Disease - SOMA-PD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Medizinische Psychologie: Neuropsychologie und Gender Studies, Uniklinik Köln
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170511
    </Date_registration3>
    <Date_registration>11/05/2017
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00010876
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>50 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>12/01/2017
    </Date_enrollement>
    <Target_size>96
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: basic science  
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Alexandra
    </Contact_Firstname>
    <Contact_Lastname>Zapf
    </Contact_Lastname>
    <Contact_Address>Kerpener Straße 62
    </Contact_Address>
    <Contact_Email>alexandra.zapf@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>022147887871
    </Contact_Tel>
    <Contact_Affiliation>Uniklinik KölnMedizinische Psychologie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Inclusion criteria patients with Parkinson's Disease with STN-DBS&lt;br&gt;• Clinical diagnosis of idiopathic PD (UK Brain Bank criteria, Hughes et al., 1992)&lt;br&gt;• Planned STN-DBS surgery&lt;br&gt;• Patients up to 80 years of age&lt;br&gt;• Minimum MMSE score = 25&lt;br&gt;• Able to give written informed consent&lt;br&gt;• German as native language&lt;br&gt;&lt;br&gt;Inclusion criteria patients with Parkinson's Disease without STN-DBS&lt;br&gt;• Clinical diagnosis of idiopathic PD (UK Brain Bank criteria, Hughes et al., 1992)&lt;br&gt;• Patients up to 80 years of age&lt;br&gt;• Minimum MMSE score = 25&lt;br&gt;• Able to give written informed consent&lt;br&gt;• German as native language&lt;br&gt;&lt;br&gt;Inclusion criteria healthy controls&lt;br&gt;• Individuals up to 80 years of age&lt;br&gt;• Minimum MMSE score = 25&lt;br&gt;• Able to give written informed consent&lt;br&gt;• German as native language&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Exclusion criteria patients:&lt;br&gt;• Any other neurological diseases besides PD (e.g., stroke, TBI, epilepsy)&lt;br&gt;• Psychiatric diseases (e.g. schizophrenia, bipolar disorder)&lt;br&gt;• Drug/medication addiction and/or alcohol addiction&lt;br&gt;• Patients at a late stage of the disease (stage 4 H &amp;Y)&lt;br&gt;• Signs of dementia (MMSE &lt; 25)&lt;br&gt;• Patients who are under medication for another disease indication with possible effects on the CNS&lt;br&gt;&lt;br&gt;Exclusion criteria healthy controls:&lt;br&gt;• Indviduals with a clinical diagnosis of idiopathic PD&lt;br&gt;• Any other neurological or psychiatric disease&lt;br&gt;• Individuals who are cognitively impaired (e.g., vascular incidents, dementia, etc.)&lt;br&gt;• 1 week before the testing: intake of substances that impact on the CNS&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: Patients with Parkinson's Disease with STN-DBS; conduct of neuropsychological and clinical assessments&lt;br&gt;Group 2: Patients with Parkinson's Disease without STN-DBS; conduct of neuropsychological and clinical assessments&lt;br&gt;Group 3: Healthy participants (control group); conduct of neuropsychological assessments
    </Intervention>
    <Primary_outcome>Social maladaption, measured by: self estimation and risk-seeking behavior in a social context, Reading the Mind in the Eyes Test, Ultimatum Game, Emotional competence questionnaire, NEO-FFI, DASS, Mild Behavioral Checklist; conduct of all tests and questionnaires at all time points of measurement (pre-surgery, 3-months post-surgery and 12-months post-surgery)
    </Primary_outcome>
    <Secondary_outcome>General cognitive state:&lt;br&gt;Mini Mental State Examination, PANDA, Dementia Rating Scale (Mattis)&lt;br&gt;executive functions:&lt;br&gt;Trail Making Test A/B, verbal fluency, modified Wisconsin Card Sortng Test, BADS (key search test), Stroop test, LPS-4&lt;br&gt;memory:&lt;br&gt;CERAD subtest (word list immediate &amp; delayed recall)&lt;br&gt;attention:&lt;br&gt;Brief Test of Attention&lt;br&gt;visuo-constructive abilities:&lt;br&gt;CERAD subtest (figure copying)&lt;br&gt;Psychiatric symptoms:&lt;br&gt;Beck-Depression Inventory, mania self-evaluation scale, apathy evaluation scale, QUIP-RS&lt;br&gt;quality of life:&lt;br&gt;PDQ-39&lt;br&gt;social desirability:&lt;br&gt;SES; conduct of all tests and questionnaires at all time points of measurement (pre-surgery, 3-months post-surgery and 12-months post-surgery)
    </Secondary_outcome>
    <Source_Support>Medizinische Psychologie, Uniklinik Köln
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>11/10/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_date_completed>15/08/2020
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00010876#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12637689
    </Internal_Number>
    <TrialID>NCT03088592
    </TrialID>
    <Last_Refreshed_on>7 November 2022
    </Last_Refreshed_on>
    <Public_title>Electrophysiological Recordings of Deep Brain Stimulation in the Basal Ganglia
    </Public_title>
    <Scientific_title>Electrophysiological Recordings of Deep Brain Stimulation in the Basal Ganglia
    </Scientific_title>
    <Acronym>DBSMER
    </Acronym>
    <Primary_sponsor>St. Joseph's Hospital and Medical Center, Phoenix
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170302
    </Date_registration3>
    <Date_registration>02/03/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03088592
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 1, 2016
    </Date_enrollement>
    <Target_size>34
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Francisco A Ponce, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Barrow Brain and Spine physician with SJHMC privileges
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parkinson's disease per Queens Square criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Appropriate DBS candidate for multi-disciplinary team consensus&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 18 - 85 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Motor skills allowing for capability to complete evaluations&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medically cleared for undergoing anesthesia and DBS surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia per DSM-V criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medical or other condition precluding MRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of supraspinal CNS disease other than PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Alcohol use of more than 4 drinks per day&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of suicide attempt&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently uncontrolled clinically significant depression (BDI&gt;20)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of schizophrenia, delusions, or currently uncontrolled visual hallucinations&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Neural Recordings
    </Primary_outcome>
    <Secondary_ID>PHX-16-0017-70-06
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Arizona State University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12637655
    </Internal_Number>
    <TrialID>NCT03051178
    </TrialID>
    <Last_Refreshed_on>7 November 2022
    </Last_Refreshed_on>
    <Public_title>Wearable Sensor for Responsive DBS for ET
    </Public_title>
    <Scientific_title>Wearable Sensor Driven Closed-loop Deep Brain Stimulation for Essential Tremor
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Florida
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170209
    </Date_registration3>
    <Date_registration>09/02/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03051178
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 18, 2018
    </Date_enrollement>
    <Target_size>17
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Aysegul Gunduz, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Florida
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is over 21 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has had a significant disabling, medication-refractory upper extremity tremor&#x0D;&lt;br&gt;             with no evidence of non-ET central nervous system disease or injury for at least three&#x0D;&lt;br&gt;             (3) months prior to implantation of Activa SC, PC, or RC device.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient receives Vim electrode and Activa SC, PC or RC device implants, and recovers&#x0D;&lt;br&gt;             fully after surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is available for study participation after their clinical programming&#x0D;&lt;br&gt;             appointments for six months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medication related movement disorders.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any suspicion of Parkinsonian tremor, including presence of Parkinsonian features such&#x0D;&lt;br&gt;             as bradykinesia, rigidity, or postural instability.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe medical co-morbidity including cardiovascular disorder, lung disorder, kidney&#x0D;&lt;br&gt;             disease, continuous neurological disease, hematological disease, or frailty that&#x0D;&lt;br&gt;             impact tolerability of the surgery as judged by the screening physicians.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is undergoing a lead revision surgery.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Device: Responsive deep brain stimulation
    </Intervention>
    <Primary_outcome>Clinical Rating Scale for Tremor (CRST)
    </Primary_outcome>
    <Secondary_ID>OCR17477;1F31NS115363-01A1;UH3NS095553;IRB201602458 -A
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Medtronic;De Luca Foundation;National Institute of Neurological Disorders and Stroke (NINDS)
    </Secondary_Sponsor>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>28/10/2022
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT03051178
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13639610
    </Internal_Number>
    <TrialID>DRKS00011748
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Characterization of performance monitoring in Tourette syndrome and its modulation through deep brain stimulation
    </Public_title>
    <Scientific_title>Characterization of performance monitoring in Tourette syndrome and its modulation through deep brain stimulation - TOSHI
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>Uniklinik KölnKlinik für Psychiatrie und Psychotherapie
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170209
    </Date_registration3>
    <Date_registration>09/02/2017
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00011748
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>60 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>19/07/2017
    </Date_enrollement>
    <Target_size>65
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Non-randomized controlled study; Masking: Open (masking not used); Control: active//No treatment / Standard of care; Assignment: parallel; Study design purpose: basic science  
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Canan
    </Contact_Firstname>
    <Contact_Lastname>Peisker
    </Contact_Lastname>
    <Contact_Address>Kerpenerstr.62
    </Contact_Address>
    <Contact_Email>canan.peisker@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>022147898843
    </Contact_Tel>
    <Contact_Affiliation>Uniklinik KölnKlinik für Psychiatrie und Psychotherapie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: • Age 18-60&lt;br&gt;• Patient approves to be evaluated&lt;br&gt;• Patients have to be capable to give consent&lt;br&gt;• Written informed consent
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: -clinical relevant psychiatric disorder&lt;br&gt;- severe and instable physical disorder and brain tumors&lt;br&gt;-clinical relevent internal or neurological disorder&lt;br&gt;- pregnancy or breat feeding&lt;br&gt;- suicidal tendencies or violent behavior in the last six months&lt;br&gt;- acute psychotic symptoms&lt;br&gt;- participation in a clinical study prior this study in the last thirty days&lt;br&gt;-withdrawal of informed consent
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;F95.2;Combined vocal and multiple motor tic disorder [de la Tourette];F95.2
    </Condition>
    <Intervention>Group 1: Patients with Tourette-Syndrom: follow-up after dbs &lt;br&gt;&lt;br&gt;Assesement of:&lt;br&gt;- psychopathological questionnaires (specific for disorder e.g. YGTSS)&lt;br&gt;- neuropsychological tests (TAP with subscales: working memory and alertness)&lt;br&gt;- behavioral paradigm (Delay Discounting Paradigm)&lt;br&gt;- EEG paradigms (effort discounting, task switching)&lt;br&gt;Patients perform all paradigms und test twice, once in the on-condition and once in the off-condition&lt;br&gt;&lt;br&gt;Deep brain stimulation: Frquency between 1,5 and 7 Volt, stength: 120 Hz, continous stimulation. Patients are operated (no relevant date for this study), then come to a 6 month follow-up (at this date our tests are assessed) and to a 12 month follow-up (no relevant date for this study). &lt;br&gt;Group 2: Patients with Tourette-Syndrom, recruited from our medical consultation for Tourette-Syndrom&lt;br&gt;&lt;br&gt;Assesement of:&lt;br&gt;- psychopathological questionnaires (specific for disorder e.g. YGTSS)&lt;br&gt;- neuropsychological tests (TAP with subscales: working memory and alertness)&lt;br&gt;- behavioral paradigm (Delay Discounting Paradigm)&lt;br&gt;- EEG paradigms (effort discounting, task switching)&lt;br&gt;&lt;br&gt;Patients with Tourette-Syndrom perform all paradigms und test twice.&lt;br&gt;Group 3: healthy controls&lt;br&gt;&lt;br&gt;Assesement of:&lt;br&gt;- psychopathological questionnaires (specific for disorder e.g. YGTSS)&lt;br&gt;- neuropsychological tests (TAP with subscales: working memory and alertness)&lt;br&gt;- behavioral paradigm (Delay Discounting Paradigm)&lt;br&gt;- EEG paradigms (effort discounting, task switching)&lt;br&gt;&lt;br&gt;&lt;br&gt;Healthy controls perform all paradigms und test twice.
    </Intervention>
    <Primary_outcome>Change of impulsivity will be assesed with a delay discounting paradigma which results in a k-parameter (a high k-paramater indicates high impulsivity and a low k-parameter indicates low impuslvity) and the the baseline k-parameter (assesment before operation) will be compared to the acute effects of the on/off condition. Additionally, a comparison between patients with Tourette's syndrom, DBS-patients with Tourette's syndrom and heathy control subjects will be made.
    </Primary_outcome>
    <Secondary_outcome>Parameter of effort discounting and task switching.&lt;br&gt;Effects of modulation shall be visualised by comparing the on and off condition.&lt;br&gt;Additionally, a comparison between patients with Tourette's syndrom, DBS-patients with Tourette's syndrom and heathy control subjects will be made.
    </Secondary_outcome>
    <Secondary_ID>U1111-1192-7646
    </Secondary_ID>
    <Source_Support>Marga und Walter Boll -Stiftung
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>02/02/2017
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_date_completed>29/11/2018
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00011748#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13692607
    </Internal_Number>
    <TrialID>NCT03037398
    </TrialID>
    <Last_Refreshed_on>19 February 2024
    </Last_Refreshed_on>
    <Public_title>Closed Loop Programming Evaluation Using External Responses for Deep Brain Stimulation
    </Public_title>
    <Scientific_title>Closed Loop Programming Evaluation Using External Responses for Deep Brain Stimulation
    </Scientific_title>
    <Acronym>CLOVER
    </Acronym>
    <Primary_sponsor>Boston Scientific Corporation
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170112
    </Date_registration3>
    <Date_registration>12/01/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT03037398
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 11, 2017
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany;United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Natalie Bloom Lyons;Heleen Scholtes
    </Contact_Lastname>
    <Contact_Email>;BSNClinicalTrials@bsci.com
    </Contact_Email>
    <Contact_Tel>;855-213-9890
    </Contact_Tel>
    <Contact_Affiliation>Boston Scientific Neuromodulation Corporation;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Key Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Implanted bilaterally in STN or GPi with a Vercise™ DBS system for Parkinson's&#x0D;&lt;br&gt;             disease, including directional leads, for at least four months and programming&#x0D;&lt;br&gt;             optimized according to standard of care with no changes to electrode configuration of&#x0D;&lt;br&gt;             primary settings for at least four weeks.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to understand the study requirements and the treatment procedures and provides&#x0D;&lt;br&gt;             written informed consent before any study-specific tests or procedures are performed.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be at least 18 years of age.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Device must have been implanted on label or must be on label by the time the subject&#x0D;&lt;br&gt;             gets enrolled.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Key Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any significant psychiatric problems, including unrelated clinically significant&#x0D;&lt;br&gt;             depression as determined by the investigator.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Vercise Deep Brain Stimulation System
    </Intervention>
    <Primary_outcome>Difference in time to program between the two arms at Programming Visit
    </Primary_outcome>
    <Secondary_ID>A4063
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10277517
    </Internal_Number>
    <TrialID>NCT03204526
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Low Frequency Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease
    </Public_title>
    <Scientific_title>Safety and Feasibility of Using Low Frequency Deep Brain Stimulation of the Subthalamic Nucleus to Improve Cognitive Performance in Patients With Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of California, Davis
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20161209
    </Date_registration3>
    <Date_registration>09/12/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03204526
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 2015
    </Date_enrollement>
    <Target_size>16
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parkinson's disease, undergoing deep brain stimulation implantation as part of their&#x0D;&lt;br&gt;             routine management of motor symptoms.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Cognitive Impairment
    </Condition>
    <Intervention>Device: deep brain stimulation
    </Intervention>
    <Primary_outcome>Beck's Depression Index;Mini Mental Status Exam;Anxiety Scores
    </Primary_outcome>
    <Secondary_outcome>N-back;Stroop
    </Secondary_outcome>
    <Secondary_ID>693382
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13725700
    </Internal_Number>
    <TrialID>NL-OMON42986
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>Optimizing patient selection for deep brain stimulation of the subthalamic nucleus in Parkinson*s disease: the OPTIMIST study
    </Public_title>
    <Scientific_title>Optimizing patient selection for deep brain stimulation of the subthalamic nucleus in Parkinson*s disease: the OPTIMIST study - OPTIMIST                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Leids Universitair Medisch Centrum
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20161130
    </Date_registration3>
    <Date_registration>2016-11-30
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/42986
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>64
    </Inclusion_agemax>
    <Inclusion_gender/>
    <Date_enrollement>2017-05-02
    </Date_enrollement>
    <Target_size>83
    </Target_size>
    <Study_type>Observational non invasive
    </Study_type>
    <Study_design>Open (masking not used), Uncontrolled, Treatment
    </Study_design>
    <Phase/>
    <Countries>The Netherlands
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address>Albinusdreef  2
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Leids Universitair Medisch Centrum
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;p&gt;- Age &gt;18 years. &lt;br&gt;- Diagnosis of idiopathic Parkinson's disease according to established criteria. &lt;br&gt;- Clinical indication for STN DBS at the participating centre. &lt;br&gt;- Ability to give informed consent. &lt;br&gt;- Ability to comply with the study assessments. &lt;br&gt;- Ability to read or understand Dutch.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;p&gt;There are no specific exclusion criteria for this study other than exclusion criteria that pertain to contra-indications for STN-DBS, which are the following: &lt;br&gt;- PD severity graded according to Hoehn &amp; Yahr stage 5. &lt;br&gt;- Score on Mattis Dementia Rating scale &lt;120. &lt;br&gt;- Psychiatric contraindications to STN DBS. &lt;br&gt;- General contraindications for stereotactic surgery and general anaesthesia &lt;/p&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Parkinson's disease &lt;br&gt;shaking palsy;10028037;10019190;Parkinson's disease;shaking palsy
    </Condition>
    <Intervention>&lt;p&gt;&lt;/p&gt;&lt;br&gt;;Deep brain stimulation;Parkinson's disease;Patient selection;Predictive factors
    </Intervention>
    <Primary_outcome>&lt;p&gt;The main endpoint in this study is the response to STN DBS as measured by an&lt;br /&gt;&lt;br&gt;acute stimulation challenge performed 12 months after surgery, defined as the&lt;br /&gt;&lt;br&gt;percentage change of MDS-UPDRS motor score after overnight medication&lt;br /&gt;&lt;br&gt;withdrawal between *off*-stimulation and *on*-stimulation. We will compare the&lt;br /&gt;&lt;br&gt;accuracy of the three models (described under Objectives) in predicting this&lt;br /&gt;&lt;br&gt;primary endpoint. In all models the effect of pertinent covariates and&lt;br /&gt;&lt;br&gt;variability between centres will be taken into account. &lt;/p&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>&lt;p&gt;- the occurrence of psychotic symptoms in the 72 hours following surgery, as&lt;br /&gt;&#x0D;&lt;br&gt;measured by a score &gt;=3 on the delirium observation scale (DOS).&lt;br /&gt;&#x0D;&lt;br&gt;- the change in quality of life after surgery, the *Global satisfaction with&lt;br /&gt;&#x0D;&lt;br&gt;surgery* scale and the number of contacts (outpatient visits, telephone calls,&lt;br /&gt;&#x0D;&lt;br&gt;emails) with the hospital team (neurologists, parkinson nurses) in the first&lt;br /&gt;&#x0D;&lt;br&gt;year.&lt;br /&gt;&#x0D;&lt;br&gt;- the SENS-PD score and MDS-UPDRS motor score.&lt;br /&gt;&#x0D;&lt;br&gt;- the cognitive decline 12 months after surgery, as defined by either a) the&lt;br /&gt;&#x0D;&lt;br&gt;transition to mild cognitive impairment or PD-related dementia diagnosed&lt;br /&gt;&#x0D;&lt;br&gt;according to criteria proposed by the Movement Disorders Society, or b) a&lt;br /&gt;&#x0D;&lt;br&gt;reduction in MoCA score &gt;3 points.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>NL58679.058.16
    </Secondary_ID>
    <Source_Support>Global Kinetics Corporation - Melbourne Victoria -  Australia;Stichting Parkinson Fonds;Stichting Alkemade-Keuls
    </Source_Support>
    <Ethics_review_status>Approved;Not available
    </Ethics_review_status>
    <Ethics_review_approval_date>30/11/2016;07/07/2022
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>&lt;p&gt;metc-ldd@lumc.nl&lt;/p&gt;&#x0D;
;&lt;p&gt;metc-ldd@lumc.nl&lt;/p&gt;&#x0D;

    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;
    </Ethics_review_contact_email>
    <results_date_completed>31/08/2020
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13638998
    </Internal_Number>
    <TrialID>DRKS00010783
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Directional Stimulation in Parkinson’s Disease
    </Public_title>
    <Scientific_title>Directional Stimulation in Parkinson’s Disease - DISPLAy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum FreiburgKlinik für NeurochirurgieAbteilung für Steroetaktische und Funktionelle Neurochirurgie
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20161122
    </Date_registration3>
    <Date_registration>22/11/2016
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00010783
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>35 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>23/05/2017
    </Date_enrollement>
    <Target_size>18
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Randomized controlled study; Masking: Open (masking not used); Control: active; Assignment: parallel; Study design purpose: treatment 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Peter
    </Contact_Firstname>
    <Contact_Lastname>Reinacher
    </Contact_Lastname>
    <Contact_Address>Breisacher Str. 64
    </Contact_Address>
    <Contact_Email>peter.reinacher@uniklinik-freiburg.de
    </Contact_Email>
    <Contact_Tel>+49 761 270-50680
    </Contact_Tel>
    <Contact_Affiliation>Universitätsklinikum FreiburgKlinik für NeurochirurgieAbteilung für Stereotaktische und Funktionelle Neurochirurgie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Male or female patients aged =35 and = 75 years&#x0D;&lt;br&gt;2. Patients with the diagnosis of Parkinson’s disease according to the criteria of the British PD Brain Bank. Parkinson patients are included with a prominent hypokinetic-rigid component of their disease and beginning or severe motor fluctuations&#x0D;&lt;br&gt;3. Disease duration = 4 years&#x0D;&lt;br&gt;4. Written informed consent&#x0D;&lt;br&gt;5. UPDRS part III (off) 30-50
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Major Depression with suicidal thoughts or suicidal thoughts in history&#x0D;&lt;br&gt;2. Signs of dementia in neuropsychological testing (part of clinical routine assessment)&#x0D;&lt;br&gt;3. Acute psychosis stated by a psychiatric physician&#x0D;&lt;br&gt;4. Nursing care at home&#x0D;&lt;br&gt;5. Unable to give written informed consent&#x0D;&lt;br&gt;6. Surgical contraindications&#x0D;&lt;br&gt;7. Medications that are likely to cause interactions in the opinion of the investigator&#x0D;&lt;br&gt;8. Known or persistent abuse of medication, drugs or alcohol&#x0D;&lt;br&gt;9. Current or planned pregnancy, nursing period
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: 12 patients will be randomized into group 1 and group 2 and will receive deep brain stimulation paradigms in the following order:&lt;br&gt;&lt;br&gt;Group 1:&lt;br&gt;Acute A (monopolar review)&lt;br&gt;Acute B (intraoperative testing)&lt;br&gt;Chronic A (monopolar review, DBS for 8 weeks)&lt;br&gt;Chronic B (intraoperative testing, DBS for 8 weeks)&lt;br&gt;Group 2: 12 patients will be randomized into group 1 and group 2 and will receive deep brain stimulation paradigms in the following order:&lt;br&gt;&lt;br&gt;Group 2:&lt;br&gt;Acute B (monopolar review)&lt;br&gt;Acute A (intraoperative testing)&lt;br&gt;Chronic B (monopolar review, DBS for 8 weeks)&lt;br&gt;Chronic A (intraoperative testing, DBS for 8 weeks)
    </Intervention>
    <Primary_outcome>Therapeutic width of a directed current paradigm compared to a conventional (“spherical”) stimulation
    </Primary_outcome>
    <Secondary_outcome>-	Therapeutic widths of directed current paradigms (conventional (“spherical”) mode stimulation, stimulation based on a computational model of an optimal electric field,  electrophysiology-based stimulation paradigm).&#x0D;&lt;br&gt;-	Unified Parkinson’s Disease rating scale (UPDRS) Part III (Stim On, Med Off) immediately after programming of the DBS-System. For this assessment, an amplitude will be selected that is just below the threshold of side effects (including On-state dyskinesia).&#x0D;&lt;br&gt;-	UPDRS Part III (Stim On, Med. On) after 4 weeks for each paradigm (spherical mode stimulation, modulation of the electric field based on a computational model, modulation of the electric field based on intraoperative electrophysiological measurements) &#x0D;&lt;br&gt;-	Description of side effects
    </Secondary_outcome>
    <Source_Support>Universitätsklinikum FreiburgKlinik für NeurochirurgieAbteilung für Stereotaktische und Funktionelle Neurochirurgie
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>14/11/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-761-27072600
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_email>
    <results_date_completed>08/08/2018
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00010783#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10265682
    </Internal_Number>
    <TrialID>NCT02982304
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Multi-Target Pallidal and Thalamic Deep Brain Stimulation for Hemi-Dystonia
    </Public_title>
    <Scientific_title>Multi-Target Pallidal and Thalamic Deep Brain Stimulation for Hemi-Dystonia
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of British Columbia
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20161114
    </Date_registration3>
    <Date_registration>14/11/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02982304
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 2015
    </Date_enrollement>
    <Target_size>4
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 1
    </Phase>
    <Countries>Canada
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Chris Honey, MD,DPhil,FRCSC;Chris Honey, MD,DPhil,FRCSC;Christopher R Honey, MD, DPhil
    </Contact_Lastname>
    <Contact_Email>;chris.honey@telus.net;chris.honey@telus.net
    </Contact_Email>
    <Contact_Tel>;604-875-5894;604.875.5894
    </Contact_Tel>
    <Contact_Affiliation>University of British Columbia;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Diagnosed with hemi-dystonia secondary to stroke&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Candidate for GPi DBS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Able to provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. History of intracranial pathology (such as multiple sclerosis, tumors, or aneurysms)&#x0D;&lt;br&gt;             that may account for dystonia or essential tremor.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. History or evidence of ongoing psychiatric or neurodegenerative disorders (such as&#x0D;&lt;br&gt;             Parkinson's disease, Alzheimer's disease).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Incompetent adults or those unable to communicate.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Dystonia;Dystonia, Secondary
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Burke Fahn Marsden Disability Rating Scale (BFMDRS);SF-36 Quality of Life Scale;Adverse effects of Vim or Vim + GPi Neuromodulation
    </Primary_outcome>
    <Secondary_ID>H14-03185
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10639853
    </Internal_Number>
    <TrialID>NCT02975193
    </TrialID>
    <Last_Refreshed_on>22 February 2021
    </Last_Refreshed_on>
    <Public_title>Neural Correlates of Cognition in Parkinson's Disease
    </Public_title>
    <Scientific_title>Neural Correlates of Cognition in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Florida
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20161110
    </Date_registration3>
    <Date_registration>10/11/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02975193
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 1, 2017
    </Date_enrollement>
    <Target_size>64
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Aysegul Gunduz, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Florida
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        PD-DBS Participants:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inclusion Criteria: Persons undergoing DBS surgery for the implantation of electrodes&#x0D;&lt;br&gt;             for the treatment of motor disorders&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Exclusion Criteria: Failure of the DBS surgical candidacy screening process&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Non-DBS PD Participants:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inclusion Criteria:Persons diagnosed with idiopathic Parkinson's disease and have not&#x0D;&lt;br&gt;             received and are not currently scheduled for DBS.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Exclusion Criteria: Individuals that :&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  that have been diagnosed with dementia or other serious brain diseases or&#x0D;&lt;br&gt;                  disorders such as strokes, traumatic brain injury, or brain tumor (the exception&#x0D;&lt;br&gt;                  is Parkinson's disease)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  who have had drug or alcohol abuse within the past 12 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  with severe sensory difficulties such as impaired vision or hearing&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  currently experiencing significant depression or sadness&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  with a history of schizophrenia or other serious mental health problems&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  using cognitive medications (e.g., Aricept) or stimulants (e.g., Adderall)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  who have undergone deep brain stimulation, fetal cell implants, or other brain&#x0D;&lt;br&gt;                  surgeries&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Behavioral: Computer task assessing cognition;Behavioral: Impulsive-Compulsive Disorders in Parkinson's Disease;Procedure: Deep Brain Stimulation Surgery
    </Intervention>
    <Primary_outcome>Change in behavioral performance
    </Primary_outcome>
    <Secondary_outcome>Change in Score on Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS);Local field potential brain signal
    </Secondary_outcome>
    <Secondary_ID>F30NS111841;IRB201601780
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institute of Neurological Disorders and Stroke (NINDS)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10743676
    </Internal_Number>
    <TrialID>NCT02963259
    </TrialID>
    <Last_Refreshed_on>22 March 2021
    </Last_Refreshed_on>
    <Public_title>IPG Replacement Study (PREFERENCE-H)
    </Public_title>
    <Scientific_title>Prospective Evaluation Comparing the Effects of Constant Current Versus Constant Voltage in Deep Brain Stimulation Using Hybrid Systems
    </Scientific_title>
    <Acronym>PREFERENCE-H
    </Acronym>
    <Primary_sponsor>Abbott Medical Devices
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20161110
    </Date_registration3>
    <Date_registration>10/11/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02963259
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>74 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 30, 2017
    </Date_enrollement>
    <Target_size>17
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States;Germany;Italy;Germany;Italy;United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Edward Karst
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Abbott
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject signed the approved Informed Consent;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject is =18 and = 74 years of age;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject is bilaterally treated with deep brain stimulation (DBS) in the subthalamic&#x0D;&lt;br&gt;             nucleus (STN) using a constant voltage device (i.e. Soletra™, Itrel™, Kinetra™,&#x0D;&lt;br&gt;             ActivaPC™ or ActivaRC™ IPG) and in the Investigator's opinion, is responding&#x0D;&lt;br&gt;             satisfactory to CV stimulation;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  In the physician's opinion the subject is a suitable candidate for an IPG replacement&#x0D;&lt;br&gt;             with different stimulation paradigm;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject needs and/or requests an IPG replacement within 12 months after consent and&#x0D;&lt;br&gt;             the current IPG has at least 2.6 V output left (i.e. approx. 30% of full battery&#x0D;&lt;br&gt;             capacity) at the time of subject enrollment;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  PD symptom onset is no longer than 20 years;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject has a Hoehn &amp; Yahr score &lt;IV (on stim);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject with a normal cognitive function (MMSE = 25);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject is fluent speaker (as judged by the investigator) of the language spoken in&#x0D;&lt;br&gt;             the country where the investigational site is located.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  IPG battery has less than 30% battery life at the time of consent;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Need to replace or reposition the leads or extensions during the IPG replacement&#x0D;&lt;br&gt;             procedure;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject had &gt;10 recurrent falls experienced in the 3 months prior to consent;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject is unwilling to change to either a St Jude Medical Infinity™ or a St Jude&#x0D;&lt;br&gt;             Medical Brio™ DBS system for the IPG replacement;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject is unable to attend the study visits.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: SJM Infinity™ DBS IPG or SJM Brio™ DBS IPG system
    </Intervention>
    <Primary_outcome>The proportion of subjects who indicate preference on constant current over constant voltage at the 3 Month follow-up visit.
    </Primary_outcome>
    <Secondary_outcome>Rate of safety events related to battery replacement procedures for hybrid systems
    </Secondary_outcome>
    <Secondary_ID>SJM-CIP-10135
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10920481
    </Internal_Number>
    <TrialID>NCT02960243
    </TrialID>
    <Last_Refreshed_on>10 May 2021
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation for Voice Tremor: Left, Right, or Both Hemispheres?
    </Public_title>
    <Scientific_title>Left, Right, or Bilateral Thalamic Deep Brain Stimulation for Voice Tremor: A Prospective, Randomized, Double-Blinded Trial
    </Scientific_title>
    <Acronym>EVT
    </Acronym>
    <Primary_sponsor>University of British Columbia
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20161105
    </Date_registration3>
    <Date_registration>05/11/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02960243
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 2016
    </Date_enrollement>
    <Target_size>6
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Canada
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has been implanted with the DBS for ET&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has significant voice tremor as determined by our&#x0D;&lt;br&gt;             laryngology/speech-language pathology team&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant does not have history of aphasia or other speech/language deficits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant does not have history of stroke or multiple sclerosis&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Voice Tremor;Deep Brain Stimulation;Essential Tremor;Laryngeal Diseases;Action Tremor;Tremor, Nerve
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>The Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)
    </Primary_outcome>
    <Secondary_outcome>Voice Tremor Severity
    </Secondary_outcome>
    <Secondary_ID>H16-01694
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12628446
    </Internal_Number>
    <TrialID>NCT02937688
    </TrialID>
    <Last_Refreshed_on>31 October 2022
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation (DBS) for Parkinson's Disease International Study
    </Public_title>
    <Scientific_title>Deep Brain Stimulation (DBS) for Parkinson's Disease International Study (REACH-PD)
    </Scientific_title>
    <Acronym>REACH-PD
    </Acronym>
    <Primary_sponsor>MedtronicNeuro
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20161017
    </Date_registration3>
    <Date_registration>17/10/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02937688
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>22 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 26, 2017
    </Date_enrollement>
    <Target_size>212
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Brazil;China;Brazil;China
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Indication of DBS for PD consistent with the country specific approved labeling.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Levodopa-responsive Parkinson's disease (UPDRS III = 30% improvement on Levodopa&#x0D;&lt;br&gt;             challenge test).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Symptoms treatable by medications but not adequately controlled with medications (with&#x0D;&lt;br&gt;             persistent disabling symptoms, such as motor fluctuations, dyskinesia).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. At least 22 years old.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Screening cranial MRI, performed within 12 months of entry into the study, that is&#x0D;&lt;br&gt;             normal or with a non-significant abnormality that does not present any incremental&#x0D;&lt;br&gt;             risks or concerns for the patient as a result of the DBS procedure.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Understand potential risk/benefit, consent to the study, study procedures, and agree&#x0D;&lt;br&gt;             to complete the study follow-up visits and comply with the study protocol&#x0D;&lt;br&gt;             requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Secondary Parkinson's disease, atypical syndromes.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Previous stereotactic functional neurosurgery or ablative therapy (e.g., pallidotomy,&#x0D;&lt;br&gt;             subthalamotomy), surgical contraindications related to DBS.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Dementia (Mattis Dementia Rating Scale = 130), major depression with suicidal thoughts&#x0D;&lt;br&gt;             (Beck Depression Inventory II &gt; 25), acute psychosis, active alcohol or drug abuse,&#x0D;&lt;br&gt;             terminal illness, and any major medical or psychological histories, diagnoses,&#x0D;&lt;br&gt;             conditions, or comorbidities that would interfere with participation in the study per&#x0D;&lt;br&gt;             the investigator's medical judgment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Electrical or electromagnetic implant (e.g., Cochlear prosthesis, cardiac pacemaker).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Surgical or medical contraindications to DBS surgery or therapy (e.g., uncontrolled&#x0D;&lt;br&gt;             hypertension, advanced coronary artery disease).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Participation in a drug, device, or biologics trial within the preceding 30 days that&#x0D;&lt;br&gt;             may confound the study results.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Pregnant female.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Medtronic DBS Therapy for Parkinson's disease
    </Intervention>
    <Primary_outcome>Change in Parkinson's disease-related quality of life, as measured by the Parkinson's Disease Questionnaire (PDQ-8).;Change in motor score, as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) III, off medication
    </Primary_outcome>
    <Secondary_ID>1678
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13702109
    </Internal_Number>
    <TrialID>NCT02911103
    </TrialID>
    <Last_Refreshed_on>27 February 2024
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation Surgery for Focal Hand Dystonia
    </Public_title>
    <Scientific_title>Deep Brain Stimulation Surgery for Treatment of Focal Hand Dystonia
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160921
    </Date_registration3>
    <Date_registration>21/09/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT02911103
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>22 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 17, 2018
    </Date_enrollement>
    <Target_size>3
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 1/Phase 2
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Debra J Ehrlich, M.D.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>National Institute of Neurological Disorders and Stroke (NINDS)
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        -  INCLUSION CRITERIA:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  FHD diagnosed by a neurologist&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  BFM upper extremity subscore of 3 or more (score range 0 to 4) or ADDS difficulty of&#x0D;&lt;br&gt;             performing score equal to or more than 3.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients must score 3 or below on the Tubiana and Chamagne scale or inability to&#x0D;&lt;br&gt;             perform at the concert level or patients must score a rating of "severe" on at least&#x0D;&lt;br&gt;             one item, impacting the patient s employment or essential activities on the Writer s&#x0D;&lt;br&gt;             Cramp Impairment scale.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Symptoms causing significant impairment in quality of life and work or daily&#x0D;&lt;br&gt;             activities by patient self-assessment and SF12 scale, as reported by subjects. The&#x0D;&lt;br&gt;             subjects should be severely impaired in at least one of the following domains:&#x0D;&lt;br&gt;             handwriting, typing or playing an instrument. The impairment needs to have affected&#x0D;&lt;br&gt;             employment, manifested by substantive change in, or loss of, employment or career of&#x0D;&lt;br&gt;             choice.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All patients must have failed or achieved inadequate benefit (continuing functional&#x0D;&lt;br&gt;             impairment) with at least two trials of botulinum toxin treatments.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women of childbearing age will have to agree to use contraception methods for the&#x0D;&lt;br&gt;             first 3 post operative months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        EXCLUSION CRITERIA:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects younger than 22 years old.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MRI findings that would make participation and surgery unsafe (such as tumor or other&#x0D;&lt;br&gt;             space occupying lesion, stroke, hemorrhage or hematoma, edema, hydrocephalus, abscess)&#x0D;&lt;br&gt;             and MRI findings that would confound study outcomes (such as iron deposits in the&#x0D;&lt;br&gt;             basal ganglia, demyelinating disease, traumatic brain injury, structural or&#x0D;&lt;br&gt;             developmental abnormality, moderate or severe white matter hyperintensities).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with prior brain surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant or nursing women as safety of DBS has not been established in this group.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of a more widespread neurologic syndrome with the dystonia being part of it,&#x0D;&lt;br&gt;             and/or dystonia caused by an ongoing etiology, such as tardive dystonia associated&#x0D;&lt;br&gt;             with ongoing psychotropic treatment or an inherited neurodegenerative syndrome&#x0D;&lt;br&gt;             associated with intractable dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intellectual disability as measured by the estimated General Ability Index (GAI) of&#x0D;&lt;br&gt;             the Wechsler Adult Intelligence Scale 4th Edition (WAIS-IV), which would render the&#x0D;&lt;br&gt;             participant not able to provide informed consent or to comply with the study&#x0D;&lt;br&gt;             procedures (estimated GAI less than 70)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia as evidenced by formal neuropsychological evaluation and Mattis Dementia&#x0D;&lt;br&gt;             Rating Scale-2 (DRS-2) score below 128.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Depressed subjects as determined by the neuropsychology or psychiatry screen,&#x0D;&lt;br&gt;             including Beck Depression Inventory (BDI) and psychiatric evaluation. Subjects scoring&#x0D;&lt;br&gt;             above 20 on the BDI or exhibiting moderate or severe active depression will be&#x0D;&lt;br&gt;             excluded&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with uncontrolled co-existing medical conditions: uncontrolled systemic&#x0D;&lt;br&gt;             hypertension with values above 170/100; active heart disease needing immediate&#x0D;&lt;br&gt;             intervention; active respiratory disease needing immediate intervention; uncorrected&#x0D;&lt;br&gt;             coagulation abnormalities; any condition that would render the patient unable to&#x0D;&lt;br&gt;             safely cooperate with the surgery and study tests as judged by the screening physician&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of a contraindication to undergo a brain MRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Metal in the body which would make having an MRI scan unsafe, such as pacemakers,&#x0D;&lt;br&gt;                  medication pumps, aneurysm clips, metallic prostheses (including metal pins and&#x0D;&lt;br&gt;                  rods, heart valves or cochlear implants), shrapnel fragments, permanent eye liner&#x0D;&lt;br&gt;                  or small metal fragments in the eye that welders and other metal workers may&#x0D;&lt;br&gt;                  have;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Uncomfortable in small closed spaces (have claustrophobia) such that the&#x0D;&lt;br&gt;                  participant will be uncomfortable in the MRI machine;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Unable to lay comfortably flat on their back for up to one hour in the MRI&#x0D;&lt;br&gt;                  scanner;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects who require diathermy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects who require post-op MRIs with full body coil&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             -- Subjects with an active systematic infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects who are immune-compromised&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects who are on anticoagulation therapy that would preclude their ability to&#x0D;&lt;br&gt;             undergo the implant procedure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects who are allergic or have shown hypersensitivity to any materials of the&#x0D;&lt;br&gt;             neurostimulation system which may come in contact with the body&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects that cannot appoint a Durable power of attorney (DPA)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Dystonia;Focal Dystonia;Musician's Dystonia
    </Condition>
    <Intervention>Procedure: DBS surgery
    </Intervention>
    <Primary_outcome>To confirm the safety of VOA/VOP thalamic DBS in FHD
    </Primary_outcome>
    <Secondary_outcome>Neuropsychological Evaluation;To determine if thalamic DBS targeting the VOA/VOP nuclear complex results in clinical improvement of severe intractable FHD;To determine if thalamic DBS targeting the VOA/VOP nuclear complex results in improved patient reported outcomes;To determine if thalamic DBS targeting the VOA/VOP nuclear complex results in improvement of severe intractable FHD in subjects with musician s dystonia;To determine if thalamic DBS targeting the VOA/VOP nuclear complex results in improvement of severe intractable FHD in subjects with Writer s cramp;To evaluate the botulinum toxin dose required for the treatment of FHD at baseline and 1 and 5 years after DBS therapy of the VOA/VOP complex
    </Secondary_outcome>
    <Secondary_ID>16-N-0166;160166
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>6665138
    </Internal_Number>
    <TrialID>NCT02894567
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Evaluation of Directional Recording and Stimulation Using spiderSTN
    </Public_title>
    <Scientific_title>Evaluation of Directional Recording and Stimulation Using the spiderSTN During the Implantation of DBS Leads
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Aleva Neurotherapeutics SA
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160824
    </Date_registration3>
    <Date_registration>24/08/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02894567
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 2016
    </Date_enrollement>
    <Target_size>6
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Switzerland;Switzerland;Switzerland;Switzerland;Switzerland
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Claudio Pollo, Professor;Claudio Pollo, Professor;Claudio Pollo, Professor;Claudio Pollo, Professor;Claudio Pollo, Professor
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>Inselspital, Bern University Hospital;Inselspital, Bern University Hospital;Inselspital, Bern University Hospital;Inselspital, Bern University Hospital;Inselspital, Bern University Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Patient foreseen to undergo DBS for Parkinson's disease or Essential Tremor according to&#x0D;&lt;br&gt;        routine criteria of the center.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For Parkinson Disease:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person is between 18 and 75 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Established diagnosis of idiopathic Parkinson's disease with progression of symptoms&#x0D;&lt;br&gt;             for a minimum of 2 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person has a history of at least 30% improvement on the UPDRS therapy in L-dopa&#x0D;&lt;br&gt;             (levodopa), except in the case of tremor dominant patient&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Weak control of symptoms by dopaminergic therapy (off phenomenon, fluctuations on /&#x0D;&lt;br&gt;             off, dyskinesia on)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For Essential Tremor:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person is between 18 and 80 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Established diagnosis of Essential Tremor for a minimum of 2 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Functional disability due to tremor was not adequately controlled by medication for at&#x0D;&lt;br&gt;             least 3 months prior to implant.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Person has given his/her written consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person suffering from an active major psychiatric disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mattis Dementia Rating Scale score &lt;130 or otherwise not capable of discernment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of major co-morbidity or medical condition that may affect participation to&#x0D;&lt;br&gt;             the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of an electrical or electromagnetic implant (e.g., cochlear implant,&#x0D;&lt;br&gt;             pacemaker)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person with a previous surgery for the treatment of Parkinson's disease or Essential&#x0D;&lt;br&gt;             Tremor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person with a previous brain ablation procedure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person who suffers from epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person who is pregnant: a pregnancy test will be performed in patients of childbearing&#x0D;&lt;br&gt;             age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person with coagulopathies&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Abuse of drugs or alcohol&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Patient foreseen to undergo DBS for Parkinson's disease or Essential Tremor according to&#x0D;&lt;br&gt;        routine criteria of the center.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For Parkinson Disease:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person is between 18 and 75 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Established diagnosis of idiopathic Parkinson's disease with progression of symptoms&#x0D;&lt;br&gt;             for a minimum of 2 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person has a history of at least 30% improvement on the UPDRS therapy in L-dopa&#x0D;&lt;br&gt;             (levodopa), except in the case of tremor dominant patient&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Weak control of symptoms by dopaminergic therapy (off phenomenon, fluctuations on /&#x0D;&lt;br&gt;             off, dyskinesia on)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For Essential Tremor:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person is between 18 and 80 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Established diagnosis of Essential Tremor for a minimum of 2 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Functional disability due to tremor was not adequately controlled by medication for at&#x0D;&lt;br&gt;             least 3 months prior to implant.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Person has given his/her written consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person suffering from an active major psychiatric disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mattis Dementia Rating Scale score &lt;130 or otherwise not capable of discernment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of major co-morbidity or medical condition that may affect participation to&#x0D;&lt;br&gt;             the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of an electrical or electromagnetic implant (e.g., cochlear implant,&#x0D;&lt;br&gt;             pacemaker)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person with a previous surgery for the treatment of Parkinson's disease or Essential&#x0D;&lt;br&gt;             Tremor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person with a previous brain ablation procedure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person who suffers from epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person who is pregnant: a pregnancy test will be performed in patients of childbearing&#x0D;&lt;br&gt;             age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person with coagulopathies&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Abuse of drugs or alcohol&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Patient foreseen to undergo DBS for Parkinson's disease or Essential Tremor according to&#x0D;&lt;br&gt;        routine criteria of the center.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For Parkinson Disease:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person is between 18 and 75 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Established diagnosis of idiopathic Parkinson's disease with progression of symptoms&#x0D;&lt;br&gt;             for a minimum of 2 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person has a history of at least 30% improvement on the UPDRS therapy in L-dopa&#x0D;&lt;br&gt;             (levodopa), except in the case of tremor dominant patient&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Weak control of symptoms by dopaminergic therapy (off phenomenon, fluctuations on /&#x0D;&lt;br&gt;             off, dyskinesia on)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For Essential Tremor:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person is between 18 and 80 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Established diagnosis of Essential Tremor for a minimum of 2 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Functional disability due to tremor was not adequately controlled by medication for at&#x0D;&lt;br&gt;             least 3 months prior to implant.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Person has given his/her written consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person suffering from an active major psychiatric disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mattis Dementia Rating Scale score &lt;130 or otherwise not capable of discernment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of major co-morbidity or medical condition that may affect participation to&#x0D;&lt;br&gt;             the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of an electrical or electromagnetic implant (e.g., cochlear implant,&#x0D;&lt;br&gt;             pacemaker)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person with a previous surgery for the treatment of Parkinson's disease or Essential&#x0D;&lt;br&gt;             Tremor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person with a previous brain ablation procedure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person who suffers from epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person who is pregnant: a pregnancy test will be performed in patients of childbearing&#x0D;&lt;br&gt;             age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person with coagulopathies&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Abuse of drugs or alcohol&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Patient foreseen to undergo DBS for Parkinson's disease or Essential Tremor according to&#x0D;&lt;br&gt;        routine criteria of the center.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For Parkinson Disease:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person is between 18 and 75 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Established diagnosis of idiopathic Parkinson's disease with progression of symptoms&#x0D;&lt;br&gt;             for a minimum of 2 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person has a history of at least 30% improvement on the UPDRS therapy in L-dopa&#x0D;&lt;br&gt;             (levodopa), except in the case of tremor dominant patient&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Weak control of symptoms by dopaminergic therapy (off phenomenon, fluctuations on /&#x0D;&lt;br&gt;             off, dyskinesia on)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For Essential Tremor:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person is between 18 and 80 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Established diagnosis of Essential Tremor for a minimum of 2 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Functional disability due to tremor was not adequately controlled by medication for at&#x0D;&lt;br&gt;             least 3 months prior to implant.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Person has given his/her written consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person suffering from an active major psychiatric disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mattis Dementia Rating Scale score &lt;130 or otherwise not capable of discernment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of major co-morbidity or medical condition that may affect participation to&#x0D;&lt;br&gt;             the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of an electrical or electromagnetic implant (e.g., cochlear implant,&#x0D;&lt;br&gt;             pacemaker)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person with a previous surgery for the treatment of Parkinson's disease or Essential&#x0D;&lt;br&gt;             Tremor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person with a previous brain ablation procedure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person who suffers from epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person who is pregnant: a pregnancy test will be performed in patients of childbearing&#x0D;&lt;br&gt;             age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person with coagulopathies&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Abuse of drugs or alcohol&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson's Disease;Essential Tremor;Parkinson's Disease;Essential Tremor;Parkinson's Disease;Essential Tremor;Parkinson's Disease;Essential Tremor
    </Condition>
    <Intervention>Device: Intraoperative test during a deep brain stimulation surgery;Device: Intraoperative test during a deep brain stimulation surgery;Device: Intraoperative test during a deep brain stimulation surgery;Device: Intraoperative test during a deep brain stimulation surgery
    </Intervention>
    <Primary_outcome>Measurement of the delivered electrical current at which a sustained side effect occurs, and compare the results from specific angular directions;Measurement of the delivered electrical current at which a sustained side effect occurs, and compare the results from specific angular directions;Measurement of the delivered electrical current at which a sustained side effect occurs, and compare the results from specific angular directions
    </Primary_outcome>
    <Secondary_outcome>Measurement of the electrical current created by the neuronal activity coming from specific directions, and compare the results.;Electrical functionality of the study device during the test phase
    </Secondary_outcome>
    <Secondary_ID>CIV-16-02-014704;KEK 272-15
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13456772
    </Internal_Number>
    <TrialID>JPRN-UMIN000022646
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Pathophysiology of speech and voice disorders in Parkinson&amp;#39;s disease patients treated with deep brain stimulation
    </Public_title>
    <Scientific_title>Pathophysiology of speech and voice disorders in Parkinson&amp;#39;s disease patients treated with deep brain stimulation - Speech and voice disorders after deep brain stimulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Nagoya university
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160728
    </Date_registration3>
    <Date_registration>28/07/2016
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026103
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20years-old
    </Inclusion_agemin>
    <Inclusion_agemax>80years-old
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2016/10/01
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single arm Non-randomized
    </Study_design>
    <Phase>Not applicable
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname>Takashi Tsuboi
    </Contact_Lastname>
    <Contact_Address>Showa-ku, Nagoya 466-8550, Japan
    </Contact_Address>
    <Contact_Email>takashi80@gmail.com
    </Contact_Email>
    <Contact_Tel>052-744-2391
    </Contact_Tel>
    <Contact_Affiliation>Nagoya University Graduate School of Medicine Department of Neurology
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients with further neurological disease, severe cognitive impairment or psychiatric disorders that may hinder the assessment.
    </Exclusion_Criteria>
    <Condition>Parkinson&amp;#39;s disease
    </Condition>
    <Intervention>One month after deep brain stimulation surgery, we perform the contact-screeing test. The correlation between speech and voice disorders and the electrode positions is analyzed.
    </Intervention>
    <Primary_outcome>The correlation between speech and voice disorders and the electrode positions
    </Primary_outcome>
    <Source_Support>Japan Science and Technology Agency
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10258669
    </Internal_Number>
    <TrialID>NCT02835274
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Study to Characterize Acute and Chronic Directional Aspects of Deep Brain Stimulation
    </Public_title>
    <Scientific_title>Directional Lead: Investigation of Rotational Current Steering, Ease of Use of Clinical Effects Map, and Therapeutic Outcomes of Deep Brain Stimulation
    </Scientific_title>
    <Acronym>DIRECT-DBS
    </Acronym>
    <Primary_sponsor>Boston Scientific Corporation
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160624
    </Date_registration3>
    <Date_registration>24/06/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02835274
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 19, 2016
    </Date_enrollement>
    <Target_size>12
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Other. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France;Germany;Netherlands;France;Germany;Netherlands;United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Roshini Jain
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Boston Scientific Neuromodulation Corporation
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Key Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of bilateral idiopathic PD with the presence of rigidity and at least one&#x0D;&lt;br&gt;             (1) of the following: resting tremor or bradykinesia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  UPDRS III score of &gt;25 in the meds OFF condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medication must improve PD symptoms by =30%, as measured by UPDRS subset III score&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Key Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any significant psychiatric problems, including unrelated clinically significant&#x0D;&lt;br&gt;             depression as determined by the investigator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any current drug or alcohol abuse as determined by the investigator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any history of recurrent or unprovoked seizures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any significant medical condition that is likely to interfere with study procedures or&#x0D;&lt;br&gt;             likely to confound evaluation of study endpoints, including any terminal illness with&#x0D;&lt;br&gt;             survival &lt;12 months&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: BSC Deep Brain Stimulation System with Directional Lead
    </Intervention>
    <Primary_outcome>Mean Change in Unified Parkinson's Disease Rating Scale (UPDRS) Scores - Motor Section (Part III) at End of Randomized Phase
    </Primary_outcome>
    <Secondary_ID>A4150
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>07/02/2020
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT02835274
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10270738
    </Internal_Number>
    <TrialID>NCT03078816
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Thalamic Deep Brain Stimulation for Secondary Dystonia in Children and Young Adults
    </Public_title>
    <Scientific_title>Thalamic Deep Brain Stimulation for Secondary Dystonia in Children and Young Adults
    </Scientific_title>
    <Acronym>DBSVop
    </Acronym>
    <Primary_sponsor>University of California, San Francisco
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160426
    </Date_registration3>
    <Date_registration>26/04/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03078816
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>7 Years
    </Inclusion_agemin>
    <Inclusion_agemax>25 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 3, 2017
    </Date_enrollement>
    <Target_size>5
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Marta San Luciano Palenzuela, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of California, San Francisco
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Ability to give informed consent or assent for the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Dystonia symptoms that are sufficiently severe, in spite of best medical therapy, to&#x0D;&lt;br&gt;             warrant surgical implantation of deep brain stimulators according to standard clinical&#x0D;&lt;br&gt;             criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Age 7-25&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Stable doses of anti-dystonia medications (such as levodopa, baclofen, or diazepam)&#x0D;&lt;br&gt;             for at least 30 days prior to baseline assessment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. If patient receives botulinum toxin injections, patient should be on a stable&#x0D;&lt;br&gt;             injection regimen&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Intact thalamic anatomy as determined by standard clinical MRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Pregnancy or breast feeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Major comorbidity increasing the risk of surgery (severe hypertension, severe&#x0D;&lt;br&gt;             diabetes, or need for chronic anticoagulation other than aspirin)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Inability to comply with study follow-up visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Any prior intracranial surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Uncontrolled epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Immunocompromised&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Has an active infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Requires diathermy, electroconvulsive therapy (ECT) or transcranial magnetic&#x0D;&lt;br&gt;             stimulation (TMS) to treat a chronic condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Has an existing implanted neurostimulator or cardiac pacemaker.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Dystonia caused by known genetic mutation in any DYT genes&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Dystonia
    </Condition>
    <Intervention>Device: Activa PC Primary Cell Neurostimulator - (Model 37601);Device: Activa RC Rechargeable Neurostimulator - (Model 37612);Device: Activa SC Single Cell Neurostimulator (Models 37602/37603);Device: DBS Lead - (Model 3387;Device: DBS Extension - (Models 37085/6);Device: Patient Programmer - (Model 37642);Device: Test Stimulator - (Model 3625);Device: N'Vision Clinician Programmer - (Model 8840);Device: N'Vision Software Application Card - (Model 8870)
    </Intervention>
    <Primary_outcome>Change From Baseline in Burke-Fahn-Marsden Dystonia Rating Scale;Percent Change in Pediatric Quality of Life Inventory (PedsQL);Change in Barry Albright Dystonia Rating Scale;Change in Blinded Burke-Fahn-Marsden Dystonia Rating Scale
    </Primary_outcome>
    <Secondary_outcome>Change in Modified Ashworth Scale - Upper Limbs;Change in Diadochokinetic Syllable Rates;Children's Memory Scale;Change in Behavioral Assessment System, 3rd Edition: Self Report of Personality;Change in Modified Ashworth Scale Spasticity Ratings - Lower Limbs;Change in Kaufman Brief Intelligence Test - Second Addition;Change in Burke-Fahn-Marsden Dystonia Disability Subscale;Change in Modified Unified Parkinson's Disease Rating Scale - Second Edition
    </Secondary_outcome>
    <Secondary_ID>123822A
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>08/10/2020
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT03078816
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13745715
    </Internal_Number>
    <TrialID>NL-OMON26420
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>GALAXY (General Anesthesia vs. Local Anesthesia in stereotaXY) study
    </Public_title>
    <Scientific_title>The GALAXY study: General Anesthesia versus Local Anesthesia in Stereotaxy for Deep Brain Stimulation in Parkinson’s disease: a randomized controlled trial&#x0D;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
    </Scientific_title>
    <Primary_sponsor>Academisch Medisch Centrum
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160423
    </Date_registration3>
    <Date_registration>2016-04-23
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/26420
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>2016-05-01
    </Date_enrollement>
    <Target_size>110
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized  controlled trial, Single blinded (masking used), Active, Parallel
    </Study_design>
    <Phase/>
    <Contact_Firstname>Rozemarije
    </Contact_Firstname>
    <Contact_Lastname>Holewijn
    </Contact_Lastname>
    <Contact_Address>Locatie AMC&#x0D;

    </Contact_Address>
    <Contact_Email>r.a.holewijn@amsterdamumc.nl
    </Contact_Email>
    <Contact_Tel>020 566 3542
    </Contact_Tel>
    <Contact_Affiliation>Amsterdam University Medical Centers, Department of Neurosurgery
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: •	Age &gt; 18 years; &lt;br /&gt;&lt;br&gt;•	Idiopathic PD with bradykinesia and at least two of the following signs; resting tremor, rigidity, and asymmetry;&lt;br /&gt;&lt;br&gt;•	Despite optimal pharmacological treatment, at least one of the following symptoms: severe response fluctuations, dyskinesias, painful dystonia or bradykinesia; &lt;br /&gt;&lt;br&gt;•	A life expectancy of at least two years. &lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: •	Legally incompetent adults;&lt;br /&gt;&lt;br&gt;•	Previous PD-neurosurgery (e.g., DBS, pallidotomy, thalamotomy); &lt;br /&gt;&lt;br&gt;•	Contraindications for DBS surgery, such as a physical disorder making surgery hazardous;&lt;br /&gt;&lt;br&gt;•	Hoehn and Yahr  stage 5 at the best moment during the day;&lt;br /&gt;&lt;br&gt;•	Psychosis;&lt;br /&gt;&lt;br&gt;•	Current depression;&lt;br /&gt;&lt;br&gt;•	No written informed consent.
    </Exclusion_Criteria>
    <Condition>Parkinson's Disease (PD)/ Ziekte van Parkinson&#x0D;
Deep Brain Stimulation (DBS)/ Diepe hersenstimulatie&#x0D;
Stereotaxy/ Stereotaxie&#x0D;
Subthalamic Nucleus (STN)/ Nucleus Subthalamicus
    </Condition>
    <Intervention>Patients will be randomized to DBS under general anesthesia or DBS under local anesthesia. For DBS, two electrodes will be implanted in the brain connected to an implanted pulse generator, which will be placed subcutaneously in the subclavian area.
    </Intervention>
    <Primary_outcome>The primary outcome measures is a composite score of the postoperative cognitive, mood and behavioral adverse effects. 
    </Primary_outcome>
    <Secondary_outcome>The secondary outcome measures consist of motor symptoms, adverse effects and complications, surgery time, functional health, quality of life, patient satisfaction on the outcome of treatment, patient evaluation of the burden of therapy, and medication 
    </Secondary_outcome>
    <Secondary_ID>NL5513;NTR5809;NL53375.018.15
    </Secondary_ID>
    <Source_Support>Dutch Brain Foundation
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>23/04/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10258136
    </Internal_Number>
    <TrialID>NCT02823158
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease-LATESTIM
    </Public_title>
    <Scientific_title>A Prospective Randomized Controlled Trial of Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease With Motor Complications and Relative or Absolute Contraindications for Subthalamic Stimulation
    </Scientific_title>
    <Acronym>LATESTIM
    </Acronym>
    <Primary_sponsor>University Hospital Inselspital, Berne
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160418
    </Date_registration3>
    <Date_registration>18/04/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02823158
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 2016
    </Date_enrollement>
    <Target_size>1
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Switzerland
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Michael Schüpbach, PD Dr. med;Ines Debove, Dr. med
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Inselspital University Hospital Bern;Inselspital University Hospital Bern
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parkinson's disease according to the UKBB criteria, with the exception that familial&#x0D;&lt;br&gt;             forms of otherwise typical parkinsonian syndromes may also be included&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  motor complications of dopaminergic medication (dyskinesia or motor fluctuations or&#x0D;&lt;br&gt;             both) that are at least moderately bothersome to the patient [on a scale of 5 possible&#x0D;&lt;br&gt;             levels: not at all / mildly / moderately / severely / extremely bothersome]&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of at least one of the following absolute exclusion criteria for STN&#x0D;&lt;br&gt;             stimulation:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Mattis dementia rating scale &lt;130 points&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  postural instability of &gt;1 in the item of MDS-UPDRS III [item #12] "on"&#x0D;&lt;br&gt;                  medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  less than 30% improvement of axial score in the acute levodopa challenge test&#x0D;&lt;br&gt;                  [axial score =sum of items 3.1, 3.9, 3.10, 3.12, 3.13 of the MDS UPDRS III]&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  or presence of at least two of the following relative exclusion criteria for STN&#x0D;&lt;br&gt;             stimulation:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  age &gt; 70 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Mattis dementia rating scale &lt;134 points&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  gait freezing "on" medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  dysarthria of &gt; 2 in the item of the MDS-UPDRS III [item #3.1]&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  less than 50% improvement of axial score in the acute levodopa challenge test&#x0D;&lt;br&gt;                  [axial score = sum of items 3.1, 3.9, 3.10, 3.12, 3.13 of the MDS UPDRS III]&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Starkstein apathy score of =14&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Complete baseline PDQ-39-SI and patient diary available&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &gt; 85 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  surgical or medical contraindications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  abnormalities on brain MRI that preclude the implantation of electrodes into the GPi&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  contraindication for 3T MRI (baseline imaging)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe medical illness that is likely to hamper the benefit of DBS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe personality disorder that may interfere with optimization of DBS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  dementia according to DSM-V and MMSE &lt; 20&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ongoing psychosis (except pseudohallucinations)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ongoing major depression (BDI-II &gt; 23) or depression of any severity with suicidal&#x0D;&lt;br&gt;             ideation&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Central Nervous System Disease;Basal Ganglia Disease;Movement Disorders;Neurodegenerative Disorders;Parkinson Disease
    </Condition>
    <Intervention>Procedure: Deep brain stimulation (DBS) of Globus Pallidus internus (GPi) and Best medical treatment (BMT);Procedure: Best medical treatment
    </Intervention>
    <Primary_outcome>Difference of change of the score of the Parkinson's disease questionnaire 39 (PDQ-39-SI) from baseline to follow-up between the two treatment groups.;Difference of change in number of hours per day spent in motor "on" without troublesome dyskinesia from baseline to follow-up between the two treatment groups.
    </Primary_outcome>
    <Secondary_outcome>Difference of change of the score of the MDS-UPDRS part III (Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale, part III) from baseline to follow up between the two trial groups.;Difference of change of the score of the MDS-UPDRS part IV (Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale, part IV) (MDS-UPDRS) from baseline to follow up between the two trial groups.;Difference of change in number of hours per day spent in motor "on" with troublesome dyskinesia from baseline to follow-up between the two treatment groups.
    </Secondary_outcome>
    <Secondary_ID>2016-000334
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Boston Scientific Corporation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13112771
    </Internal_Number>
    <TrialID>NCT02712515
    </TrialID>
    <Last_Refreshed_on>13 June 2023
    </Last_Refreshed_on>
    <Public_title>The Motor Network in Essential Tremor: Mechanisms of Therapy
    </Public_title>
    <Scientific_title>The Motor Network in Essential Tremor: Mechanisms of Therapy
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Florida
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20160315
    </Date_registration3>
    <Date_registration>15/03/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02712515
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 2016
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Aysegul Gunduz, PhD;Aysegul Gunduz, PhD;Aysegul Gunduz, PhD
    </Contact_Lastname>
    <Contact_Email>;agunduz@ufl.edu;agunduz@bme.ufl.edu
    </Contact_Email>
    <Contact_Tel>;3522736877;352-273-6877
    </Contact_Tel>
    <Contact_Affiliation>University of Florida;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neurosurgical patient populations with essential tremor (main cohort) and Parkinson's&#x0D;&lt;br&gt;             disease (control cohort)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non surgical candidates&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor;Parkinson's Disease
    </Condition>
    <Intervention>Procedure: Deep brain stimulation implantation surgery;Device: Ad-Tech Medical Instrumentation Corp. electrodes/subdural strips;Device: FHC Guideline 4000+ system and/or Medtronic RC+S
    </Intervention>
    <Primary_outcome>Brain signals between the groups
    </Primary_outcome>
    <Secondary_ID>03UH3NS095553;IRB201600172-N
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institute of Neurological Disorders and Stroke (NINDS);Medtronic
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13701992
    </Internal_Number>
    <TrialID>NCT02686125
    </TrialID>
    <Last_Refreshed_on>27 February 2024
    </Last_Refreshed_on>
    <Public_title>Registry of Deep Brain Stimulation With the VERCISE™ System for Treatment of Dystonia: Vercise DBS Dystonia Registry
    </Public_title>
    <Scientific_title>Registry of Deep Brain Stimulation With the VERCISE™ System for Treatment of Dystonia: Vercise DBS Dystonia Registry
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Boston Scientific Corporation
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160210
    </Date_registration3>
    <Date_registration>10/02/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT02686125
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>7 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 7, 2016
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Observational [Patient Registry]
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Belgium;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;United Kingdom;Belgium;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Natalie Bloom Lyons;Stephanie Delvaux
    </Contact_Lastname>
    <Contact_Email>;BSNClinicalTrials@bsci.com
    </Contact_Email>
    <Contact_Tel>;855-213-9890
    </Contact_Tel>
    <Contact_Affiliation>Boston Scientific Neuromodulation Corporation;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria (IC):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  IC1. Meets criteria established in the locally applicable Vercise System Directions&#x0D;&lt;br&gt;             for Use (DFU) for dystonia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  IC2. At least 7 years old. Parent or guardian consent is required in patients who are&#x0D;&lt;br&gt;             younger than 18 years at the time of consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria (EC):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  EC1. Meets any contraindication in the Vercise System locally applicable Directions&#x0D;&lt;br&gt;             for Use.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Dystonia
    </Condition>
    <Intervention>Device: Deep Brain Stimulation (DBS)
    </Intervention>
    <Primary_outcome>Proportion of subjects with reduction in dystonia symptoms as assessed by BFMDRS score;Proportion of cervical dystonia subjects with reduction in symptoms as assessed by TWSTRS score
    </Primary_outcome>
    <Secondary_ID>A4012
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12916438
    </Internal_Number>
    <TrialID>NCT02678429
    </TrialID>
    <Last_Refreshed_on>3 April 2023
    </Last_Refreshed_on>
    <Public_title>Atlas Predicted DBS Settings in Essential Tremor
    </Public_title>
    <Scientific_title>Atlas Predicted DBS Settings in Essential Tremor
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Vanderbilt University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160205
    </Date_registration3>
    <Date_registration>05/02/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02678429
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 2016
    </Date_enrollement>
    <Target_size>4
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Seleced for DBS of the VIM nucleus at Vanderbilt Medical center Diagnosis of essential&#x0D;&lt;br&gt;        tremor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Unable to use the patient handheld programmer&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Device: Change DBS programming
    </Intervention>
    <Primary_outcome>Fahn-Tolusa-Marsden Tremor Rating Scale
    </Primary_outcome>
    <Secondary_ID>160155
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>27/03/2023
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT02678429
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13682285
    </Internal_Number>
    <TrialID>NCT02649166
    </TrialID>
    <Last_Refreshed_on>12 February 2024
    </Last_Refreshed_on>
    <Public_title>Responsive Deep Brain Stimulator for Essential Tremor
    </Public_title>
    <Scientific_title>Closing the Loop on Tremor: A Responsive Deep Brain Stimulator for the Treatment of Essential Tremor
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Florida
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160106
    </Date_registration3>
    <Date_registration>06/01/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT02649166
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 1, 2017
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Aysegul Gunduz, Ph.D
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Florida
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. You provide informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. You are over 21 years of age.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. You are diagnosed with a postural-intention (essential) tremor for at least 3 years&#x0D;&lt;br&gt;             and meet strict diagnostic criteria and have been seen and examined by a movement&#x0D;&lt;br&gt;             disorders fellowship trained neurologist.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. You have had a significant disabling medical-refractory upper extremity tremor with no&#x0D;&lt;br&gt;             evidence of supraspinal central nervous system disease or injury (tremor not&#x0D;&lt;br&gt;             adequately controlled by medications for at least three (3) months before implant).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. You have had a postural or kinetic tremor severity score of at least 2 out of 4 in the&#x0D;&lt;br&gt;             extremity intended for treatment on the Fahn-Tolosa-Marin Clinical Rating Scale for&#x0D;&lt;br&gt;             Tremor (CRST).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. You have had a CRST score of 2 or above in any one of the items 16-23 from the&#x0D;&lt;br&gt;             Disability subsection of the CRST: speaking, feeding other than liquids, bringing&#x0D;&lt;br&gt;             liquids to mouth, hygiene, dressing, writing, working and social activities.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Your tremor is refractory adequate trials of at least two medications, one of which&#x0D;&lt;br&gt;             should be either propranolol or primidone. An adequate medication trial is defined as&#x0D;&lt;br&gt;             a therapeutic dose of each medication or the development of side effects as the&#x0D;&lt;br&gt;             medication dose is titrated.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. You are available for appropriate follow-up times for the length of the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Any previous neurosurgical intervention including deep brain stimulation or ablative&#x0D;&lt;br&gt;             brain lesions.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Medication related movement disorders.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Any suspicion of Parkinsonian tremor, including presence of Parkinsonian features such&#x0D;&lt;br&gt;             as bradykinesia, rigidity, or postural instability.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Any behaviors consistent with ethanol or substance abuse as defined by the criteria&#x0D;&lt;br&gt;             outlined in DSM-V.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Severe medical co-morbidity including cardiovascular disorder, lung disorder, kidney&#x0D;&lt;br&gt;             disease, continuous neurological disease, hematological disease, or frailty that&#x0D;&lt;br&gt;             impact tolerability of the surgery as judged by the screening physicians.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Abnormal brain MRI including hydrocephalus, stroke, structural lesions, demyelinating&#x0D;&lt;br&gt;             lesions, or infectious lesions. Also excluded will be subjects with severe atrophy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Any uncontrolled symptoms or signs of increased intracranial pressure (e.g., headache,&#x0D;&lt;br&gt;             nausea, vomiting, lethargy, papilledema).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. A history of seizures within the past year.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. A dementia rating scale score (DRS) &lt;130 signifying significant cognitive dysfunction&#x0D;&lt;br&gt;             and a potential for inability to cooperate with tasks involved in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Any attempt or intent of suicide in the last six months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Presence or history of psychosis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Significant or active mood disorders including depression. For the purpose of this&#x0D;&lt;br&gt;             study, we consider a significant mood disorder to include any subject who has:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Scores = 20 on the Patient Health Questionnaire - 9 (PHQ-9).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Currently under the care of a psychiatrist&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. Currently participating in cognitive-behavioral therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               4. Been hospitalized for the treatment of a psychiatric illness within 12 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               5. Ever received transcranial magnetic stimulation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               6. Ever received electroconvulsive therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        n. In addition, patients who are pregnant or plan to become pregnant will be excluded from&#x0D;&lt;br&gt;        this study.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Device: Deep brain stimulation;Device: Closed-loop deep brain stimulation
    </Intervention>
    <Primary_outcome>Clinical Rating Scale for Tremor (CRST) for continuous deep brain stimulation;Clinical Rating Scale for Tremor (CRST) for closed-loop deep brain stimulation;Clinical Rating Scale for Tremor (CRST) for continuous deep brain stimulation
    </Primary_outcome>
    <Secondary_ID>5UH3NS095553-04;IRB201501021 -N-A
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Medtronic;National Institute of Neurological Disorders and Stroke (NINDS)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12762797
    </Internal_Number>
    <TrialID>NCT02994719
    </TrialID>
    <Last_Refreshed_on>16 January 2023
    </Last_Refreshed_on>
    <Public_title>Gait Analysis in Neurological Disease
    </Public_title>
    <Scientific_title>Gait Pattern Analysis in Neurological Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Beth Israel Deaconess Medical Center
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20151221
    </Date_registration3>
    <Date_registration>21/12/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02994719
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 1, 2016
    </Date_enrollement>
    <Target_size>120
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 18-85 (for both healthy and affected subjects).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of at least 2 of the following: bradykinesia, rest tremor, rigidity, postural&#x0D;&lt;br&gt;             instability (UK PD Brain Bank Criteria) (Affected subjects only).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Montreal Cognitive Assessment will be employed to determine whether subjects will need&#x0D;&lt;br&gt;             the assent of a legally authorized representative. Subjects with MOCA = 21 will be&#x0D;&lt;br&gt;             consented only with the assent of the subject and informed consent of the authorized&#x0D;&lt;br&gt;             legal representative (Affected subjects only).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  These may include subjects who may have indeterminate parkinsonism, when it is not&#x0D;&lt;br&gt;             clear whether they have idiopathic Parkinson's Disease versus one of the Atypical&#x0D;&lt;br&gt;             Parkinsonisms, such as Vascular Parkinsonism, Multiple System Atrophy, Progressive&#x0D;&lt;br&gt;             Supranuclear Palsy, Normal Pressure Hydrocephalus or Corticobasal Degeneration&#x0D;&lt;br&gt;             (Affected subjects only).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with assistive devices will be eligible for the study and may use them during&#x0D;&lt;br&gt;             the study (Affected subjects only).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Absence of complaints regarding difficulty walking such as arthritic pain, fatigue&#x0D;&lt;br&gt;             during walking or slowness of walking (Healthy subjects only).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of alternative explanation for parkinsonism such as head trauma, drug-induced&#x0D;&lt;br&gt;             parkinsonism (affected subjects only).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently being treated for major medical illness requiring recent hospitalization&#x0D;&lt;br&gt;             (&lt;14 days) (for both healthy and affected subjects).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently participating in another clinical study with an intervention arm (for both&#x0D;&lt;br&gt;             healthy and affected subjects).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to consent due to cognitive impairment and absence of legally authorized&#x0D;&lt;br&gt;             representative (for both healthy and affected subjects).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with any cardiac, pulmonary conditions (congestive heart failure requiring&#x0D;&lt;br&gt;             hospitalization within the past 90 days, recent myocardial infarction &lt; 90 days,&#x0D;&lt;br&gt;             supplemental oxygen-requiring subjects due to cardiac or pulmonary conditions) that&#x0D;&lt;br&gt;             limit their ability to safely participate in a walking trial (for both healthy and&#x0D;&lt;br&gt;             affected subjects).&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson's Disease;Parkinsonian Disorders;Atypical Parkinson Disease;Progressive Supranuclear Palsy;Multiple System Atrophy;Corticobasal Degeneration;Gait, Frontal;Huntington Disease
    </Condition>
    <Intervention>Drug: Anti-Parkinson medication;Device: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Gait speed
    </Primary_outcome>
    <Secondary_outcome>Swing duration;Stance duration;Cadence;Stride length
    </Secondary_outcome>
    <Secondary_ID>2015P000310
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>6654492
    </Internal_Number>
    <TrialID>NCT02641366
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Electromagnetic Tracking to Measure Tremor
    </Public_title>
    <Scientific_title>Noninvasive Electromagnetic Tracking of Upper Extremity Motion Kinetics for Patients With Severe Tremor Disorders
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Florida
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20151214
    </Date_registration3>
    <Date_registration>14/12/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02641366
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 2016
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase>N/A
    </Phase>
    <Countries>United States;United States;United States;United States;United States
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Seth Oliveria, MD,PhD;Seth Oliveria, MD,PhD;Seth Oliveria, MD,PhD;Seth Oliveria, MD,PhD;Seth Oliveria, MD,PhD
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>University of Florida;University of Florida;University of Florida;University of Florida;University of Florida
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adults&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who have undergone or are scheduled to undergo Deep Brain Stimulation&#x0D;&lt;br&gt;             (DBS) placement&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who have not had or are not scheduled for Deep Brain Stimulation (DBS)&#x0D;&lt;br&gt;             placement&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adults&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who have undergone or are scheduled to undergo Deep Brain Stimulation&#x0D;&lt;br&gt;             (DBS) placement&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who have not had or are not scheduled for Deep Brain Stimulation (DBS)&#x0D;&lt;br&gt;             placement&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adults&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who have undergone or are scheduled to undergo Deep Brain Stimulation&#x0D;&lt;br&gt;             (DBS) placement&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who have not had or are not scheduled for Deep Brain Stimulation (DBS)&#x0D;&lt;br&gt;             placement&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adults&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who have undergone or are scheduled to undergo Deep Brain Stimulation&#x0D;&lt;br&gt;             (DBS) placement&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who have not had or are not scheduled for Deep Brain Stimulation (DBS)&#x0D;&lt;br&gt;             placement&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tremor;Tremor;Tremor;Tremor
    </Condition>
    <Intervention>Device: Electromagnetic tracking;Procedure: Tremor kinetics after DBS;Procedure: Tremor kinetics before and after DBS;Device: Electromagnetic tracking;Procedure: Tremor kinetics after DBS;Procedure: Tremor kinetics before and after DBS;Device: Electromagnetic tracking;Procedure: Tremor kinetics after DBS;Procedure: Tremor kinetics before and after DBS;Device: Electromagnetic tracking;Procedure: Tremor kinetics after DBS;Procedure: Tremor kinetics before and after DBS
    </Intervention>
    <Primary_outcome>Power spectrum peaks;Power spectrum peaks;Power spectrum peaks
    </Primary_outcome>
    <Secondary_ID>IRB201500964
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13454162
    </Internal_Number>
    <TrialID>JPRN-UMIN000020030
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Assessment of speech and voice disorders in Parkinson&amp;#39;s disease patients treated with subthalamic nucleus deep brain stimulation
    </Public_title>
    <Scientific_title>Assessment of speech and voice disorders in Parkinson&amp;#39;s disease patients treated with subthalamic nucleus deep brain stimulation - The effect of deep brain stimulation on speech and voice disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Nagoya university graduate school of medicine
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20151202
    </Date_registration3>
    <Date_registration>02/12/2015
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023132
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>30years-old
    </Inclusion_agemin>
    <Inclusion_agemax>80years-old
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2013/03/01
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel Non-randomized
    </Study_design>
    <Phase>Not applicable
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname>Takashi Tsuboi
    </Contact_Lastname>
    <Contact_Address>65, Tsurumaicho, Showa-ku, Nagoya city, Aichi
    </Contact_Address>
    <Contact_Email>takashi80@gmail.com
    </Contact_Email>
    <Contact_Tel>88-52-741-2111
    </Contact_Tel>
    <Contact_Affiliation>Nagoya University Graduate School of Medicine Department of Neurology
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients who had Cerebral vascular disorder or any other neurodegenerative diseases  Patients who had severe dementia  Patients who are pregnant
    </Exclusion_Criteria>
    <Condition>Parkinson&amp;#39;s disease
    </Condition>
    <Intervention>Patients with Parkinson&amp;#39;s disease who had undergone bilateral DBS in the Movement Disorders Clinic of the Nagoya University Hospital and had 6-month follow-up period after subthalamic implantation&lt;br&gt;Age, sex, disease duration and motor and cognitive function matched PD patients
    </Intervention>
    <Primary_outcome>Assessment of Motor Speech Dysarthria (AMSD)  Patients treated with DBS are assessed at least 6 months after subthalamic implantation. Patients treated without DBS are assessed when they are recruited in this study.
    </Primary_outcome>
    <Secondary_outcome>Stuttering Severity Instrument (SSI-3)  Multi Dimensional Voice Program (MDVP)  Voice Handicap Index (VHI)  GRBAS scale  Maximum phonation time (MPT)  UPDRS
    </Secondary_outcome>
    <Source_Support>Health and Labour Sciences Research  grants
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10920074
    </Internal_Number>
    <TrialID>NCT02585154
    </TrialID>
    <Last_Refreshed_on>10 May 2021
    </Last_Refreshed_on>
    <Public_title>Studying Movement Control in Parkinson's Disease Using Closed Loop Deep Brain Stimulation
    </Public_title>
    <Scientific_title>Studying Movement Control in Parkinson's Disease Using Closed Loop Deep Brain Stimulation
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20151008
    </Date_registration3>
    <Date_registration>08/10/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02585154
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>74 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 8, 2016
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Basic Science. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United Kingdom
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Study participants will be Parkinson's disease patients undergoing deep brain&#x0D;&lt;br&gt;             stimulation of the subthalamic nucleus (STN).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Whether or not a patient is selected for deep brain stimulation surgery is&#x0D;&lt;br&gt;                  determined by the patient's clinical team purely on independent clinical grounds.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Only those patients who have been accepted for deep brain stimulation treatment&#x0D;&lt;br&gt;                  by their clinical neurologist and functional neurosurgeon will be introduced to&#x0D;&lt;br&gt;                  the project and have their details passed on to the research team for further&#x0D;&lt;br&gt;                  information and formal consenting.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to give informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Lack of capacity to consent (judged by the clinician taking consent as not having&#x0D;&lt;br&gt;             sufficient mental capacity to understand the study and its requirements). This is&#x0D;&lt;br&gt;             including anyone who, in the opinion of the clinician taking consent, is unlikely to&#x0D;&lt;br&gt;             retain sufficient mental capacity for the duration of their involvement in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment/lack of capacity to perform experimental task.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Procedure: Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015);Procedure: closed-loop Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015);Procedure: Deep Brain Stimulation off;Device: local field potentials and electroencephalography recordings
    </Intervention>
    <Primary_outcome>Ability to suppress inappropriate movements as measured by motor tasks (accuracy measured in %);Ability to suppress inappropriate movements as measured by motor tasks (response time measured in s)
    </Primary_outcome>
    <Secondary_outcome>Local field potential spectra during open-loop deep brain stimulation, closed-loop deep brain stimulation and no deep brain stimulation;Connectivity between neural regions during open-loop deep brain stimulation, closed-loop deep brain stimulation and no deep brain stimulation
    </Secondary_outcome>
    <Secondary_ID>168287
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>5831680
    </Internal_Number>
    <TrialID>NCT02569021
    </TrialID>
    <Last_Refreshed_on>31 October 2016
    </Last_Refreshed_on>
    <Public_title>Battery-preserving Stimulation Patterns for Deep Brain Stimulation
    </Public_title>
    <Scientific_title>Battery-preserving Stimulation Patterns to Improve Symptoms in Parkinson's Disease and Essential Tremor
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Florida
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20151002
    </Date_registration3>
    <Date_registration>02/10/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02569021
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>May 2014
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational Model: Case-Only, Time Perspective: Prospective
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Micheal Okun, M.D.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Florida
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of Parkinson's disease or Essential Tremor by strict criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Deep brain stimulation (DBS) already implanted&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Optimized Deep brain stimulation (DBS) settings (or at least 4 months of DBS&#x0D;&lt;br&gt;             programming)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other neurological diagnoses (co-existent Alzheimer's or ALS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No Deep brain stimulation (DBS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  less than 4 Deep brain stimulation (DBS) programming&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinsons Disease;Essential Tremor
    </Condition>
    <Intervention>Device: Biphasic DBS stimulation;Other: Unified Parkinson's Disease Rating Scale;Other: Tremor Rating Scale;Device: Kinesia accelerometer;Device: Trigno wireless system;Other: GaitRite walking assessment.
    </Intervention>
    <Primary_outcome>Evaluate the efficacy of novel stimulation patterns by the Unified Parkinson's Disease Rating Scale;Evaluate the efficacy of novel stimulation patterns by the Tremor Rating Scale;Kinesia accelerometer to measure motor dysfunction;Trigno wireless system to measure motor dysfunction;GaitRite walking assessment.
    </Primary_outcome>
    <Secondary_outcome>Battery Consumption compared between pre and post settings
    </Secondary_outcome>
    <Secondary_ID>IRB201501030
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>5396245
    </Internal_Number>
    <TrialID>NCT02619084
    </TrialID>
    <Last_Refreshed_on>14 March 2016
    </Last_Refreshed_on>
    <Public_title>Subthalamic Stimulation in Tourette's Syndrome
    </Public_title>
    <Scientific_title>Subthalamic Nucleus Deep Brain Stimulation in Tourette's Syndrome
    </Scientific_title>
    <Acronym>STN-DBSinTS
    </Acronym>
    <Primary_sponsor>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20151002
    </Date_registration3>
    <Date_registration>02/10/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02619084
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>60 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>December 2011
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Italy
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Luigi M Romito, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age at least of 18 years (with potential exceptions)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of TS based on the diagnostic criteria of the Tourette Syndrome&#x0D;&lt;br&gt;             Classification Study Group&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A Yale Tic Global Severity Scale (YTGSS) &gt; 35/50 for at least 12 months, with tic&#x0D;&lt;br&gt;             severity documented by a standardized videotape assessment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inadequate response to standard drug treatment or botulinum toxin&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of secondary tic disorder, of heredodegenerative or neurometabolic diseases&#x0D;&lt;br&gt;             or history of toxic exposures or encephalitis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous surgery for TS (with potential exceptions)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette's Syndrome;Tourette Syndrome;Gilles de la Tourette Syndrome;Tourette Disorder
    </Condition>
    <Intervention>Procedure: STN DBS
    </Intervention>
    <Primary_outcome>Change in Yale Global Tic Severity Scale
    </Primary_outcome>
    <Secondary_outcome>Change in Milan Overall Dementia Assessment (MODA);Change in brain activity recorded by PET;STN DBS safety in treating medically-refractory Tourette syndrome;Change in Yale-Brown Obsessive Compulsive scale (Y-BOCS);Change in Global assessment scale (GAS).;Change in Global Clinical Impression Scale (GCI-S);Change in Gilles de la Tourette syndrome-quality of life scale (GTS-QOL);Change in Montgomery-Åsberg Depression Rating Scale (MADRS);Change in ADHD Rating Scale-IV (ADHD-RS);Change in Hamilton Anxiety Rating Scale (HAM-A)
    </Secondary_outcome>
    <Secondary_ID>GR-2009-1594645;RF-131
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Ministry of Health, Italy
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13724928
    </Internal_Number>
    <TrialID>NL-OMON42214
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>Coherence Analyses in Hyperkinetic Movement Disorders
    </Public_title>
    <Scientific_title>Coherence Analyses in Hyperkinetic Movement Disorders - Coherence Analyses HMD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Universitair Medisch Centrum Groningen
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20150930
    </Date_registration3>
    <Date_registration>2015-09-30
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/42214
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>64
    </Inclusion_agemax>
    <Inclusion_gender/>
    <Date_enrollement>2015-01-09
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Observational non invasive
    </Study_type>
    <Study_design>Open (masking not used), Uncontrolled, Basic science
    </Study_design>
    <Phase/>
    <Countries>The Netherlands
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address>Hanzeplein 1
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Universitair Medisch Centrum Groningen
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;p&gt;1. Patients with Dystonia (DYS) or Parkinson's Disease (PD) who will be treated with DBS, and Essential Tremor (ET) patients with DBS in which the stimulator will be replaced operatively. &lt;br&gt;2. 18 years and older. &lt;br&gt;3. life expectancy longer than one year &lt;/p&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;p&gt;Any condition with a life expectancy less then 1 year, which would result in incomplete follow-up.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;dystonia &lt;br&gt;essential tremor. &lt;br&gt;Hyperkinetic movement disorders; Parkinson;10028037;10009720;dystonia;essential tremor.;Hyperkinetic movement disorders; Parkinson
    </Condition>
    <Intervention>&lt;p&gt;&lt;/p&gt;&lt;br&gt;;Coherence analyses;Deep brain stimulation;Hyperkinetic movement disorders;Neurology / neurosurgery
    </Intervention>
    <Primary_outcome>&lt;p&gt;In all patients: Relation between LFP-EMG coherence and clinical effect of DBS&lt;br /&gt;&lt;br&gt;quantified by the difference pre- and post-surgery on the specific movement&lt;br /&gt;&lt;br&gt;disorder rating scales.&lt;/p&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>&lt;p&gt;In DYS: Cortico-muscular (EEG-EMG), intra-muscular (EMG-EMG) coherence, and&lt;br /&gt;&#x0D;&lt;br&gt;*Burke-Fahn-Marsden dystonia rating scale* (BFMDRS) values pre- and&lt;br /&gt;&#x0D;&lt;br&gt;post-DBS-surgery.&lt;br /&gt;&#x0D;&lt;br&gt;In PD: Cortico-muscular (EEG-EMG + accelerometer) coherence, intra-muscular&lt;br /&gt;&#x0D;&lt;br&gt;(EMG-EMG), and tremor severity assessed with tremor items of the motor (third)&lt;br /&gt;&#x0D;&lt;br&gt;part of the unified Parkinson's disease rating scale (UPDRS) values pre- and&lt;br /&gt;&#x0D;&lt;br&gt;post-DBS-surgery.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>NL50575.042.14
    </Secondary_ID>
    <Source_Support>Ministerie van OC&amp;W
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>18/12/2014;03/03/2015;24/09/2015
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>;;
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10247881
    </Internal_Number>
    <TrialID>NCT02589925
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Combined Subthalamic and Nucleus Basalis Meynert Deep Brain Stimulation for Parkinson's Disease With Dementia
    </Public_title>
    <Scientific_title>Kombinierte Tiefe Hirnstimulation Des Nucleus Subthalamicus Und Nucleus Basalis Meynert Zur Behandlung Der Parkinson-Krankheit Mit Demenz
    </Scientific_title>
    <Acronym>Dempark-DBS
    </Acronym>
    <Primary_sponsor>Wuerzburg University Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150928
    </Date_registration3>
    <Date_registration>28/09/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02589925
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>35 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2016
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Jens Volkmann, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Wuerzburg University Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Age at the time of enrollment: 35 - 75 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Diagnosis of idiopathic PD with probable Parkinson's disease dementia (PDD) as defined&#x0D;&lt;br&gt;             by the MDS consensus guidelines (Emre et al., 2007)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Mild to moderately severe dementia as defined by a Mini-Mental State Examination&#x0D;&lt;br&gt;             (MMSE) score of 10 to 24&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Duration of bilateral idiopathic PD: =5 years of motor symptoms.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Severity of bilateral idiopathic PD in the meds off state: modified Hoehn and Yahr&#x0D;&lt;br&gt;             stage =2.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. UPDRS subset III score of =30 in the meds off, stim off state.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Levodopa must improve PD symptoms by =30% in a levodopa challenge test, as measured by&#x0D;&lt;br&gt;             UPDRS subset III score.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. PDD with a symptom onset at least 2 years after first symptoms of PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Be willing and able to comply with all visits and study related procedures (e.g.,&#x0D;&lt;br&gt;             using the remote control, charging systems and completing the motor diary) if mentally&#x0D;&lt;br&gt;             competent or, if incompetent, their legally authorized representatives.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Able to understand the study requirements and the treatment procedures and to provide&#x0D;&lt;br&gt;             written informed consent before any study-specific tests or procedures are performed.&#x0D;&lt;br&gt;             If mentally incompetent, the legally authorized representative provides written&#x0D;&lt;br&gt;             informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Any significant psychiatric problems, including acute confusional state (delirium),&#x0D;&lt;br&gt;             ongoing psychosis, or clinically significant depression.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Any current drug or alcohol abuse.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Any history of recurrent or unprovoked seizures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Any prior movement disorder treatments that involved intracranial surgery or device&#x0D;&lt;br&gt;             implantation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. A history of neurostimulation intolerance in any area of the body.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Any significant medical condition that is likely to interfere with study procedures or&#x0D;&lt;br&gt;             likely to confound evaluation of study endpoints, including any terminal illness with&#x0D;&lt;br&gt;             survival &lt;12 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Participation in another drug, device, or biologics trial concurrently or within the&#x0D;&lt;br&gt;             preceding 30 days. Any other trial participation should be approved by the Principal&#x0D;&lt;br&gt;             Investigators.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Pregnancy, breast-feeding, or lack of reliable contraception&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Dementia
    </Condition>
    <Intervention>Device: Vercise deep brain stimulation;Procedure: subthalamic nucleus (STN) stimulation;Procedure: NBM stimulation;Procedure: sham stimulation
    </Intervention>
    <Primary_outcome>safety as determined by spontaneously reported adverse events
    </Primary_outcome>
    <Secondary_ID>DEMPARK-DBS V2.01
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>6651165
    </Internal_Number>
    <TrialID>NCT02558634
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial
    </Public_title>
    <Scientific_title>Thalamic Deep Brain Stimulation for Spasmodic Dysphonia: A Prospective, Randomized, Double-Blinded, Sham-Controlled Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of British Columbia
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150922
    </Date_registration3>
    <Date_registration>22/09/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02558634
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 2016
    </Date_enrollement>
    <Target_size>6
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 1
    </Phase>
    <Countries>Canada;Canada;Canada;Canada;Canada
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Christopher R Honey, MD, DPhil;Christopher R Honey, MD, DPhil;Christopher R Honey, MD, DPhil;Christopher R Honey, MD, DPhil;Christopher R Honey, MD, DPhil
    </Contact_Lastname>
    <Contact_Email>chris.honey@telus.net;chris.honey@telus.net;chris.honey@telus.net;chris.honey@telus.net;chris.honey@telus.net
    </Contact_Email>
    <Contact_Tel>604.875.5894;604.875.5894;604.875.5894;604.875.5894;604.875.5894
    </Contact_Tel>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically diagnosed isolated laryngeal dystonia (adductor spasmodic dysphonia)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to give informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who fall into the age range of 18-75 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with inadequate medical and BTX management of spasmodic dysphonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dystonia present in other body parts (i.e- eyes, neck, limbs) in addition to larynx&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of laryngeal denervation surgery for spasmodic dysphonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of intracranial pathology (such as multiple sclerosis, tumors, or aneurysms)&#x0D;&lt;br&gt;             that may account for dystonia or essential tremor.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History or evidence of ongoing psychiatric or neurodegenerative disorders (such as&#x0D;&lt;br&gt;             Parkinson's disease, Alzheimer's disease).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Incompetent adults or those unable to communicate.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically diagnosed isolated laryngeal dystonia (adductor spasmodic dysphonia)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to give informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who fall into the age range of 18-75 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with inadequate medical and BTX management of spasmodic dysphonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dystonia present in other body parts (i.e- eyes, neck, limbs) in addition to larynx&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of laryngeal denervation surgery for spasmodic dysphonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of intracranial pathology (such as multiple sclerosis, tumors, or aneurysms)&#x0D;&lt;br&gt;             that may account for dystonia or essential tremor.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History or evidence of ongoing psychiatric or neurodegenerative disorders (such as&#x0D;&lt;br&gt;             Parkinson's disease, Alzheimer's disease).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Incompetent adults or those unable to communicate.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically diagnosed isolated laryngeal dystonia (adductor spasmodic dysphonia)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to give informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who fall into the age range of 18-75 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with inadequate medical and BTX management of spasmodic dysphonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dystonia present in other body parts (i.e- eyes, neck, limbs) in addition to larynx&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of laryngeal denervation surgery for spasmodic dysphonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of intracranial pathology (such as multiple sclerosis, tumors, or aneurysms)&#x0D;&lt;br&gt;             that may account for dystonia or essential tremor.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History or evidence of ongoing psychiatric or neurodegenerative disorders (such as&#x0D;&lt;br&gt;             Parkinson's disease, Alzheimer's disease).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Incompetent adults or those unable to communicate.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically diagnosed isolated laryngeal dystonia (adductor spasmodic dysphonia)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to give informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who fall into the age range of 18-75 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with inadequate medical and BTX management of spasmodic dysphonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dystonia present in other body parts (i.e- eyes, neck, limbs) in addition to larynx&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of laryngeal denervation surgery for spasmodic dysphonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of intracranial pathology (such as multiple sclerosis, tumors, or aneurysms)&#x0D;&lt;br&gt;             that may account for dystonia or essential tremor.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History or evidence of ongoing psychiatric or neurodegenerative disorders (such as&#x0D;&lt;br&gt;             Parkinson's disease, Alzheimer's disease).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Incompetent adults or those unable to communicate.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Spasmodic Dysphonia;Laryngeal Dystonia;Deep Brain Stimulation;Spasmodic Dysphonia;Laryngeal Dystonia;Deep Brain Stimulation;Spasmodic Dysphonia;Laryngeal Dystonia;Deep Brain Stimulation;Spasmodic Dysphonia;Laryngeal Dystonia;Deep Brain Stimulation
    </Condition>
    <Intervention>Device: VIM Thalamic Deep Brain Stimulation ON;Device: VIM Thalamic Deep Brain Stimulation OFF;Device: VIM Thalamic Deep Brain Stimulation ON;Device: VIM Thalamic Deep Brain Stimulation OFF;Device: VIM Thalamic Deep Brain Stimulation ON;Device: VIM Thalamic Deep Brain Stimulation OFF;Device: VIM Thalamic Deep Brain Stimulation ON;Device: VIM Thalamic Deep Brain Stimulation OFF
    </Intervention>
    <Primary_outcome>Unified Spasmodic Dysphonia Rating Scale (USDRS);Voice-Related Quality of Life;Adverse/Safety of DBS Implantation and Stimulation in SD;Unified Spasmodic Dysphonia Rating Scale (USDRS);Voice-Related Quality of Life;Adverse/Safety of DBS Implantation and Stimulation in SD;Unified Spasmodic Dysphonia Rating Scale (USDRS);Voice-Related Quality of Life;Adverse/Safety of DBS Implantation and Stimulation in SD
    </Primary_outcome>
    <Secondary_outcome>Beck's Depression Inventory Scale;Montreal Cognitive Assessment Scale (MoCA);Voice-Handicap Index
    </Secondary_outcome>
    <Secondary_ID>H15-02535
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13725136
    </Internal_Number>
    <TrialID>NL-OMON42422
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>Adaptive neuromodulation for movement disorders.
    </Public_title>
    <Scientific_title>Adaptive neuromodulation for movement disorders. - adaptive DBS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Universitair Medisch Centrum Groningen
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150921
    </Date_registration3>
    <Date_registration>2015-09-21
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/42422
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>64
    </Inclusion_agemax>
    <Inclusion_gender/>
    <Date_enrollement>2016-06-06
    </Date_enrollement>
    <Target_size>24
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Open (masking not used), Uncontrolled, Treatment
    </Study_design>
    <Phase/>
    <Countries>The Netherlands
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address>Hanzeplein  1
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Universitair Medisch Centrum Groningen
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;p&gt;PD &lt;br&gt;- sound of mind &lt;br&gt;- eligible for battery replacement surgery &lt;br&gt;- ability to provide written informed consent &lt;br&gt;- ability to undergo testing in the OFF medication state - physical condition that enables 90 minutes of testing &lt;br&gt;Dystonia: &lt;br&gt;- sound of mind &lt;br&gt;- eligible for DBS surgery &lt;br&gt;- ability to provide written informed consent &lt;br&gt;- dystonia in at least one muscle that is suitable for prolonged EMG recording&lt;/p&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;p&gt;all contra-indications that apply to normal DBS surgery (eg pregnancy, life expectancy of less than one year) &lt;br&gt;&lt; 18 yo &lt;br&gt; other disorder that interferes with clinical assessment&lt;/p&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;dystonia &lt;br&gt;Parkinson's disease;10028037;dystonia;Parkinson's disease
    </Condition>
    <Intervention>&lt;p&gt; Application of adaptive DBS (aDBS) in patients who have already implanted DBS &lt;br&gt;electrodes. &lt;/p&gt;&lt;br&gt;;closed loop;deep brain stimulation;movement disorders;neurophysiology
    </Intervention>
    <Primary_outcome>&lt;p&gt;PD&lt;br /&gt;&lt;br&gt;clinical effect of aDBS compared placebo and cDBS based on blinded clinical&lt;br /&gt;&lt;br&gt;ratings&lt;br /&gt;&lt;br&gt;&lt;br /&gt;&lt;br&gt;dystonia:&lt;br /&gt;&lt;br&gt;feasibility and tolerability of aDBS based on LFP low-frequency power&lt;/p&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>&lt;p&gt;PD&lt;br /&gt;&#x0D;&lt;br&gt;side effect profile of aDBS compared to cDBS and placebo&lt;br /&gt;&#x0D;&lt;br&gt;energy consumption of aDBS compared to cDBS&lt;br /&gt;&#x0D;&lt;br&gt;&lt;br /&gt;&#x0D;&lt;br&gt;dystonia:&lt;br /&gt;&#x0D;&lt;br&gt;effect of aDBS on subcortico-muscular coherence and clinical ratings&lt;br /&gt;&#x0D;&lt;br&gt;energy consumption of aDBS compared to cDBS&lt;/p&gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>NL54475.042.15;NTR nummer volgt
    </Secondary_ID>
    <Source_Support>Ministerie van OC&amp;W
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>21/09/2015;10/05/2017;17/10/2017;07/03/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>;;;
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>6649924
    </Internal_Number>
    <TrialID>NCT02524886
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia
    </Public_title>
    <Scientific_title>Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia. Efficacy and Psychiatric and Cognitive Effects
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>GGZ Centraal
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20150727
    </Date_registration3>
    <Date_registration>27/07/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02524886
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 2015
    </Date_enrollement>
    <Target_size>1
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Netherlands;Netherlands;Netherlands;Netherlands;Netherlands
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Peter N van Harted, MD, PhD;Peter N van Harted, MD, PhD;Peter N van Harted, MD, PhD;Peter N van Harted, MD, PhD;Peter N van Harted, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>GGZ Centraal;GGZ Centraal;GGZ Centraal;GGZ Centraal;GGZ Centraal
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mental competence*&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A current or previous psychiatric illness that has been stable for at least the last&#x0D;&lt;br&gt;             six months, meaning no overt psychiatric symptoms or decompensation based on a written&#x0D;&lt;br&gt;             report of the clinician that is treating the patient&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of TDD, TDD symptoms developed whilst being treated with dopamine blocking&#x0D;&lt;br&gt;             agents or within three months (for oral) or within six months (for depot) after&#x0D;&lt;br&gt;             withdrawal (definition international review of neurobiology 98)(6)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  TDD must be present for at least 12 months and impede with physical and or social&#x0D;&lt;br&gt;             functioning. In this study that is defined as a score of at least 4 on the disability&#x0D;&lt;br&gt;             rating scale of the BFMDRS with at least two items scoring a minimum of two, or one&#x0D;&lt;br&gt;             item scoring a 3 or higher.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  BFMDRS &gt;12 at the moment of evaluation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient has proven treatment refractory for all other evidence based TDD&#x0D;&lt;br&gt;             treatments:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Withdrawal of the dopamine blocking agents or a switch to clozapine and/or&#x0D;&lt;br&gt;                  quetiapine for at least 3 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Adding tetrabenazine at the maximum tolerated dosage for at least 4 weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  In focal dystonia a trial with Botulinum toxin (at least three sessions)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient fully understands that DBS is not a treatment for the psychiatric disorder&#x0D;&lt;br&gt;             and agrees to take his or her psychiatric medication as prescribed by their&#x0D;&lt;br&gt;             psychiatrist.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient has unrealistic expectations of the possible benefit of DBS or does not&#x0D;&lt;br&gt;             fully understand the possible side effects and the likelihood of their occurring.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient is suicidal, a score of =4 on item 19 on the BPRS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mattis scale for dementia &lt;120&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A score of =6 on the Clinical Global Impression scale (CGI) psychiatric severity scale&#x0D;&lt;br&gt;             or a BPRS =68&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A neurological disease that is the cause of the dyskinesia and/or dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use of recreational drugs, such cocaine amphetamine or other drugs that affect TDD,&#x0D;&lt;br&gt;             within the last 3 months. Cannabis use within the last 3 months is not considered an&#x0D;&lt;br&gt;             exclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous DBS or ablative stereotactic brain surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  General contraindications for stereotactic surgery and general anaesthesia (e.g.&#x0D;&lt;br&gt;             severe hypertension, blood coagulation disorder)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A seizure disorder that is not sufficiently controlled&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  An implanted electronic device&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A language barrier that prevents the patients from understanding the investigators or&#x0D;&lt;br&gt;             vice versa&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mental competence*&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A current or previous psychiatric illness that has been stable for at least the last&#x0D;&lt;br&gt;             six months, meaning no overt psychiatric symptoms or decompensation based on a written&#x0D;&lt;br&gt;             report of the clinician that is treating the patient&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of TDD, TDD symptoms developed whilst being treated with dopamine blocking&#x0D;&lt;br&gt;             agents or within three months (for oral) or within six months (for depot) after&#x0D;&lt;br&gt;             withdrawal (definition international review of neurobiology 98)(6)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  TDD must be present for at least 12 months and impede with physical and or social&#x0D;&lt;br&gt;             functioning. In this study that is defined as a score of at least 4 on the disability&#x0D;&lt;br&gt;             rating scale of the BFMDRS with at least two items scoring a minimum of two, or one&#x0D;&lt;br&gt;             item scoring a 3 or higher.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  BFMDRS &gt;12 at the moment of evaluation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient has proven treatment refractory for all other evidence based TDD&#x0D;&lt;br&gt;             treatments:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Withdrawal of the dopamine blocking agents or a switch to clozapine and/or&#x0D;&lt;br&gt;                  quetiapine for at least 3 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Adding tetrabenazine at the maximum tolerated dosage for at least 4 weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  In focal dystonia a trial with Botulinum toxin (at least three sessions)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient fully understands that DBS is not a treatment for the psychiatric disorder&#x0D;&lt;br&gt;             and agrees to take his or her psychiatric medication as prescribed by their&#x0D;&lt;br&gt;             psychiatrist.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient has unrealistic expectations of the possible benefit of DBS or does not&#x0D;&lt;br&gt;             fully understand the possible side effects and the likelihood of their occurring.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient is suicidal, a score of =4 on item 19 on the BPRS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mattis scale for dementia &lt;120&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A score of =6 on the Clinical Global Impression scale (CGI) psychiatric severity scale&#x0D;&lt;br&gt;             or a BPRS =68&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A neurological disease that is the cause of the dyskinesia and/or dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use of recreational drugs, such cocaine amphetamine or other drugs that affect TDD,&#x0D;&lt;br&gt;             within the last 3 months. Cannabis use within the last 3 months is not considered an&#x0D;&lt;br&gt;             exclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous DBS or ablative stereotactic brain surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  General contraindications for stereotactic surgery and general anaesthesia (e.g.&#x0D;&lt;br&gt;             severe hypertension, blood coagulation disorder)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A seizure disorder that is not sufficiently controlled&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  An implanted electronic device&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A language barrier that prevents the patients from understanding the investigators or&#x0D;&lt;br&gt;             vice versa&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mental competence*&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A current or previous psychiatric illness that has been stable for at least the last&#x0D;&lt;br&gt;             six months, meaning no overt psychiatric symptoms or decompensation based on a written&#x0D;&lt;br&gt;             report of the clinician that is treating the patient&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of TDD, TDD symptoms developed whilst being treated with dopamine blocking&#x0D;&lt;br&gt;             agents or within three months (for oral) or within six months (for depot) after&#x0D;&lt;br&gt;             withdrawal (definition international review of neurobiology 98)(6)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  TDD must be present for at least 12 months and impede with physical and or social&#x0D;&lt;br&gt;             functioning. In this study that is defined as a score of at least 4 on the disability&#x0D;&lt;br&gt;             rating scale of the BFMDRS with at least two items scoring a minimum of two, or one&#x0D;&lt;br&gt;             item scoring a 3 or higher.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  BFMDRS &gt;12 at the moment of evaluation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient has proven treatment refractory for all other evidence based TDD&#x0D;&lt;br&gt;             treatments:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Withdrawal of the dopamine blocking agents or a switch to clozapine and/or&#x0D;&lt;br&gt;                  quetiapine for at least 3 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Adding tetrabenazine at the maximum tolerated dosage for at least 4 weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  In focal dystonia a trial with Botulinum toxin (at least three sessions)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient fully understands that DBS is not a treatment for the psychiatric disorder&#x0D;&lt;br&gt;             and agrees to take his or her psychiatric medication as prescribed by their&#x0D;&lt;br&gt;             psychiatrist.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient has unrealistic expectations of the possible benefit of DBS or does not&#x0D;&lt;br&gt;             fully understand the possible side effects and the likelihood of their occurring.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient is suicidal, a score of =4 on item 19 on the BPRS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mattis scale for dementia &lt;120&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A score of =6 on the Clinical Global Impression scale (CGI) psychiatric severity scale&#x0D;&lt;br&gt;             or a BPRS =68&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A neurological disease that is the cause of the dyskinesia and/or dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use of recreational drugs, such cocaine amphetamine or other drugs that affect TDD,&#x0D;&lt;br&gt;             within the last 3 months. Cannabis use within the last 3 months is not considered an&#x0D;&lt;br&gt;             exclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous DBS or ablative stereotactic brain surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  General contraindications for stereotactic surgery and general anaesthesia (e.g.&#x0D;&lt;br&gt;             severe hypertension, blood coagulation disorder)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A seizure disorder that is not sufficiently controlled&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  An implanted electronic device&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A language barrier that prevents the patients from understanding the investigators or&#x0D;&lt;br&gt;             vice versa&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mental competence*&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A current or previous psychiatric illness that has been stable for at least the last&#x0D;&lt;br&gt;             six months, meaning no overt psychiatric symptoms or decompensation based on a written&#x0D;&lt;br&gt;             report of the clinician that is treating the patient&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of TDD, TDD symptoms developed whilst being treated with dopamine blocking&#x0D;&lt;br&gt;             agents or within three months (for oral) or within six months (for depot) after&#x0D;&lt;br&gt;             withdrawal (definition international review of neurobiology 98)(6)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  TDD must be present for at least 12 months and impede with physical and or social&#x0D;&lt;br&gt;             functioning. In this study that is defined as a score of at least 4 on the disability&#x0D;&lt;br&gt;             rating scale of the BFMDRS with at least two items scoring a minimum of two, or one&#x0D;&lt;br&gt;             item scoring a 3 or higher.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  BFMDRS &gt;12 at the moment of evaluation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient has proven treatment refractory for all other evidence based TDD&#x0D;&lt;br&gt;             treatments:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Withdrawal of the dopamine blocking agents or a switch to clozapine and/or&#x0D;&lt;br&gt;                  quetiapine for at least 3 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Adding tetrabenazine at the maximum tolerated dosage for at least 4 weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  In focal dystonia a trial with Botulinum toxin (at least three sessions)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient fully understands that DBS is not a treatment for the psychiatric disorder&#x0D;&lt;br&gt;             and agrees to take his or her psychiatric medication as prescribed by their&#x0D;&lt;br&gt;             psychiatrist.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient has unrealistic expectations of the possible benefit of DBS or does not&#x0D;&lt;br&gt;             fully understand the possible side effects and the likelihood of their occurring.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient is suicidal, a score of =4 on item 19 on the BPRS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mattis scale for dementia &lt;120&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A score of =6 on the Clinical Global Impression scale (CGI) psychiatric severity scale&#x0D;&lt;br&gt;             or a BPRS =68&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A neurological disease that is the cause of the dyskinesia and/or dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use of recreational drugs, such cocaine amphetamine or other drugs that affect TDD,&#x0D;&lt;br&gt;             within the last 3 months. Cannabis use within the last 3 months is not considered an&#x0D;&lt;br&gt;             exclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous DBS or ablative stereotactic brain surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  General contraindications for stereotactic surgery and general anaesthesia (e.g.&#x0D;&lt;br&gt;             severe hypertension, blood coagulation disorder)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A seizure disorder that is not sufficiently controlled&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  An implanted electronic device&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A language barrier that prevents the patients from understanding the investigators or&#x0D;&lt;br&gt;             vice versa&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tardive Dyskinesia;Tardive Dystonia;Tardive Dyskinesia;Tardive Dystonia;Tardive Dyskinesia;Tardive Dystonia;Tardive Dyskinesia;Tardive Dystonia
    </Condition>
    <Intervention>Device: GPi DBS with Medtronic electorde and Activa PC pulsegenerator;Device: GPi DBS with Medtronic electorde and Activa PC pulsegenerator;Device: GPi DBS with Medtronic electorde and Activa PC pulsegenerator;Device: GPi DBS with Medtronic electorde and Activa PC pulsegenerator
    </Intervention>
    <Primary_outcome>DBS efficacy as measured as the change on the Burke Fahn Marsden Dystonia Rating Scale (BFMDRS);DBS efficacy as measured as the change on the Burke Fahn Marsden Dystonia Rating Scale (BFMDRS);DBS efficacy as measured as the change on the Burke Fahn Marsden Dystonia Rating Scale (BFMDRS)
    </Primary_outcome>
    <Secondary_outcome>Psychiatric safety as measured on the Brief Psychiatric Rating Scale (BPRS) and the Montgomery-Åsberg Depression Rating Scale (MADRS);Cognitive side effects as measured using neuropsychological test battery;Quality of life as measured on the Short Form 36 (SF-36) and the World Health Organiasation Brief Quality of Life Score (WHO-Bref)
    </Secondary_outcome>
    <Secondary_ID>DBS for TD
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University Medical Center Groningen;Maastricht University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10244615
    </Internal_Number>
    <TrialID>NCT02509338
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Validation of the Implantation of a New Electrode for the Treatment of Dystonia
    </Public_title>
    <Scientific_title>Validation of an Electrode Internal Globus Pallidum Deep Brain Stimulation Lead Implantation for Treatment of Dystonia
    </Scientific_title>
    <Acronym>MONOCONTACT
    </Acronym>
    <Primary_sponsor>University Hospital, Montpellier
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20150720
    </Date_registration3>
    <Date_registration>20/07/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02509338
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>64 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2013
    </Date_enrollement>
    <Target_size>7
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Laura A CIF, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>CHRU Montpellier
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age superior to 18 years and inferior to 65 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Generalized or segmental isolated dystonia or tardive dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis is based on history, clinical examination, check-up without abnormalities&#x0D;&lt;br&gt;             and normal brain MRI allowing exclusion of secondary and degenerative dystonias&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unsufficient response to pharmacological treatment (improvement &lt; 30/% on clinical&#x0D;&lt;br&gt;             dystonia scales)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No comorbidity interfering with general anesthesia, or representing contraindication&#x0D;&lt;br&gt;             for neurosurgical procedure or with the follow-up during the trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Consent of the patient&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Insurance affiliation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Follow-up possible for 12 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Available insurance for the operated patient&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No possibility for clinical follow-up&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acquired dystonia except for tardive dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MRI or generalized anesthesia contraindicated&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Anticoagulant treatment or antiaggregant treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ongoing participation to another clinical trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Guardianship or Trusteeship&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person deprived of liberty&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Generalized Dystonia;Segmental Dystonia;Tardive Dystonia
    </Condition>
    <Intervention>Device: Electrode deep brain stimulation (Monopolar DBS Lead Model 09064-40cm)
    </Intervention>
    <Primary_outcome>Technical feasibility of new electrode implantation;Safety of new electrode implantation (evaluated by the occurence of side effects)
    </Primary_outcome>
    <Secondary_outcome>clinical effect of deep brain stimulation using one contact-electrodes (Burke Fahn Marsden's dystonia rating scale and the Toronto Western Spasmodic Torticollis Rating Scale)
    </Secondary_outcome>
    <Secondary_ID>9053
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>11217096
    </Internal_Number>
    <TrialID>NCT02491554
    </TrialID>
    <Last_Refreshed_on>2 August 2021
    </Last_Refreshed_on>
    <Public_title>Deep braIn Stimulation for Tremor TractographIC Versus Traditional
    </Public_title>
    <Scientific_title>Deep braIn Stimulation for Tremor TractographIC Versus Traditional
    </Scientific_title>
    <Acronym>DISTINCT
    </Acronym>
    <Primary_sponsor>University Hospital Freiburg
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150630
    </Date_registration3>
    <Date_registration>30/06/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02491554
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>25 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 2015
    </Date_enrollement>
    <Target_size>24
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Volker A Coenen, MD;Volker A Coenen, MD;Volker Coenen, MD
    </Contact_Lastname>
    <Contact_Email>;stereotaxie@uniklinik-freiburg.de;volker.coenen@uniklinik-freiburg.de
    </Contact_Email>
    <Contact_Tel>;+49 761 270;+49 761 270
    </Contact_Tel>
    <Contact_Affiliation>University Hospital Freiburg;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Male or female patients aged = 25 and = 80 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patients with Essential Tremor according to the criteria of the consensus statement of&#x0D;&lt;br&gt;             the movement disorders society (Deuschl et al. 1998) are included with a medical&#x0D;&lt;br&gt;             treatment resistant and disabling postural and/or intentional tremor.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. FTMTRS to be completed within 42 days prior surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Stable tremor medication for at least 3 months prior inclusion&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Major Depression with suicidal thoughts or suicidal thoughts in history&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Dementia (Mattis Dementia Rating Score = 130)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Acute psychosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient incapability&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Nursing care at home&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Surgical contraindications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Medications that are likely to cause interactions in the opinion of the investigator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Known or persistent abuse of medication, drugs or alcohol&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Persons who are in a relationship of dependence/employment with the sponsor or the&#x0D;&lt;br&gt;             investigator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Fertile women not using adequate contraceptive methods: female condoms, diaphragm or&#x0D;&lt;br&gt;             coil, each used in combination with spermicides; intra-uterine device; hormonal&#x0D;&lt;br&gt;             contraception in combination with a mechanical method of contraception;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Current or planned pregnancy, nursing period&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Device: Conventional AC-PC based implantation of ACTIVA INS DBS system;Device: MR-tractography guided implantation of ACTIVA INS DBS system
    </Intervention>
    <Primary_outcome>Tremor reduction defined by the difference in FTMTRS at 6 months after intervention to baseline
    </Primary_outcome>
    <Secondary_outcome>Effective tremor reduction at 12 months after intervention;Tremor reduction measured by tremor analysis at baseline and 6 and 12 months after intervention;Tremor reduction measured by calculation of total power at baseline and 6 and 12 months after intervention;Quality of Life: QUEST, SF-36;Size of VAT;Effective contact position with respect to DRT and AC-PC coordinates;Duration of neurosurgery;Changes in BDI;Assessment of (Serious) Adverse Events related to intervention
    </Secondary_outcome>
    <Secondary_ID>DRKS00008913;P000847
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Medtronic Neuromodulation Europe
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>5839985
    </Internal_Number>
    <TrialID>NCT02468843
    </TrialID>
    <Last_Refreshed_on>7 November 2016
    </Last_Refreshed_on>
    <Public_title>Novel Stimulation Patterns for the Treatment of Dystonia
    </Public_title>
    <Scientific_title>Novel Stimulation Patterns and Personalized Deep Brain Stimulation for the Treatment of Dystonia
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Florida
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150603
    </Date_registration3>
    <Date_registration>03/06/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02468843
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>July 2015
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational Model: Case-Only, Time Perspective: Prospective
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Leonardo Almeida, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Florida Center for Movement Disorders and Neurorestoration
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of primary generalized dystonia or cervical dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Bilaterally implanted globus pallidus interus(GPi) DBS.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Minimum of 6 months of chronic stimulation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Greater than 60 days on stable DBS settings&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Does not have DBS for dystonia or cervical dystonia&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Dystonia;Cervical Dystonia
    </Condition>
    <Intervention>Device: Biphasic DBS stimulation;Other: Unified Dystonia Rating Scale;Other: Burke-Fahn- Marsden scale
    </Intervention>
    <Primary_outcome>Blinded Unified Dystonia Rating Scale (UDRS);Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS)
    </Primary_outcome>
    <Secondary_outcome>Tremor accelerometer to measure motor dysfunction;Kinesia accelerometer to measure motor dysfunction;Battery Consumption compared between pre and post settings;GaitRite walking assessment.
    </Secondary_outcome>
    <Secondary_ID>IRB201500366
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Medtronic
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13637868
    </Internal_Number>
    <TrialID>DRKS00007959
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Functional imaging of regional blood flow changes within the tremor network due to Deep Brain Stimulation in the ventrolateral thalamus with H2O-PET
    </Public_title>
    <Scientific_title>Functional imaging of regional blood flow changes within the tremor network due to Deep Brain Stimulation in the ventrolateral thalamus with H2O-PET - ColTrem II                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Department of Neurology, University Hospital of Cologne
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150407
    </Date_registration3>
    <Date_registration>07/04/2015
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00007959
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>50 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>01/08/2015
    </Date_enrollement>
    <Target_size>25
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Randomized controlled study; Masking: Blinded (masking used); Control: active//No treatment / Standard of care; Assignment: parallel; Study design purpose: diagnostic 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>David J.
    </Contact_Firstname>
    <Contact_Lastname>Pedrosa
    </Contact_Lastname>
    <Contact_Address>Kerpener Straße 62
    </Contact_Address>
    <Contact_Email>david.pedrosa@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>(+49) 221- 478 4014
    </Contact_Tel>
    <Contact_Affiliation>Universitätsklinik Köln
Klinik und Poliklinik für Neurologie
AG Bewegungsstörungen
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: ET-patients:&lt;br&gt;Male or female patients with the clinical diagnosis of essential tremor according to the Consensus statement of the Movement Disorder Society on Tremor; ET-Patients aged between 50-75 years; Disease duration of more than 5 years; Capacity for consent so that written informed consent can be achieved; ET-Patients with a formal indication to a treatment with Deep Brain Stimulation (DBS) due to a therapy-refractory manifestation on at least three different pharmaceutical options and with the indication to electrode placement in the ventrolateral thalamus (VLp/Vim); Tolerable tremor severity after switching off the stimulation (DBS-OFF)&lt;br&gt;&lt;br&gt;Control subjects:&lt;br&gt;Subjects aged between 50-75 years; Capacity for consent so that written informed consent can be achieved
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: ET-patients:&lt;br&gt;Persons without capacity for consent, minors as well as individuals who are accomodated in an institution due to official or legal regulations; ET-patients suffering from other conditions (e.g. Alzheimer's disease, dystonia, epilepsy) besides essential tremor; ET-pateints with presence of unambiguous unilateral symptoms or hypokinesia; Unilateral dopaminergic deficit in functional imaging (FP-CIT SPECT); ET-patients with a significant response of symptoms after oral administration of levodopa, Irregularities in previous MRI scans (such as e.g. cerebral ischaemia, cerebellar atrophy, head surgery, etc.); Excessive head tremor hampering lying on the back over 90 minutes; Presence of symptomatic tremor causes such as metabolic or psychogenic tremor or due to the intake of tremor facilitating substances/drugs respectively as a consequence of their withdrawal; Presence of life-threatening diseases; Severe psychiatric comorbidities; Pregnant or breastfeeding women; Visual or hearing impairment interfering in the testing; ET-patients taking part in other interventional studies;&lt;br&gt;&lt;br&gt;Control subjects:&lt;br&gt;Persons without capacity for consent, minors as well as individuals who are accomodated in an institution due to official or legal regulations; Subjects suffering from severe neurological disorders; Subjects with a regular intake of drugs interfering with the central nervous system which cannot be discontinued from the evening of the day before the testing until after testing is completed; Presence of life-threatening diseases; Severe psychiatric comorbidities; Pregnant or breastfeeding women; visual or hearing impairment interfering in the testing; Control subjects taking part in other interventional studies;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G25.0;Essential tremor;G25.0
    </Condition>
    <Intervention>Group 1: ET-patients before Deep Brain Stimulation electrode placement - pre-DBS&lt;br&gt;Group 2: Age- and gender-matched control subjects&lt;br&gt;Group 3: ET-patients receiving effective Deep Brain Stimulation (90-180Hz) - DBS-ON&lt;br&gt;Group 4: ET-patients with low-frequency stimulation (10Hz) and otherwise unaltered parameters (amplitude, pulsewidth) - LFS&lt;br&gt;Group 5: ET-patients without Deep Brain Stimulation - DBS-OFF
    </Intervention>
    <Primary_outcome>PET of the regional blood flow in the tremor network (consisting of distinct brain areas) immeaditely after injection of radioactive tracer
    </Primary_outcome>
    <Secondary_outcome>Tremor Rating Scale (TRS), standardised value for phonemic verbal fluency scores
    </Secondary_outcome>
    <Source_Support>Klinische Forschergruppe 219 (DFG)
Basalganglien-Kortex-Schleifen:
Mechanismen pathologischer Interaktionen und ihre therapeutische Modulation;Klinik und Poliklinik für Neurologie
Universitätsklinik zu Köln
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>15/05/2014
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00007959#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>5164885
    </Internal_Number>
    <TrialID>NCT02418858
    </TrialID>
    <Last_Refreshed_on>19 October 2015
    </Last_Refreshed_on>
    <Public_title>Functional Outcomes of Awake vs. Asleep Deep Brain Stimulation (DBS) for Essential Tremor
    </Public_title>
    <Scientific_title>Randomized Controlled Clinical Trial Comparing Functional Outcomes of Awake vs. Asleep Deep Brain Stimulation (DBS) for Essential Tremor
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>St. Joseph's Hospital and Medical Center, Phoenix
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20150324
    </Date_registration3>
    <Date_registration>24/03/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02418858
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>February 2015
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Francisco A Ponce, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Barrow Neurological Institute / St. Joseph's Hospital and Medical Center
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Essential Tremor diagnosed by criteria listed in the Consensus statement of the&#x0D;&lt;br&gt;             Movement Disorders Society on Tremor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 18 - 85 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Motor skills allowing for capability to complete evaluations&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medically cleared for undergoing anesthesia and DBS surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia per DSM-V criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medical or other condition precluding MRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of supraspinal CNS disease other than Essential Tremor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Alcohol use of more than 4 drinks per day&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of suicide attempt&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently uncontrolled clinically significant depression (BDI&gt;20)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of schizophrenia, delusions, or currently uncontrolled visual hallucinations&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Procedure: Deep Brain Stimulation surgery
    </Intervention>
    <Primary_outcome>Functional Outcomes;Quality of Life Assessment
    </Primary_outcome>
    <Secondary_outcome>Neurocognitive Function
    </Secondary_outcome>
    <Secondary_ID>IRB # 14BN146
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13724127
    </Internal_Number>
    <TrialID>NL-OMON41413
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation for patients with Tardive Dyskinesia and or Dystonia. Efficacy and Psychiatric and Cognitive Side-Effects
    </Public_title>
    <Scientific_title>Deep Brain Stimulation for patients with Tardive Dyskinesia and or Dystonia. Efficacy and Psychiatric and Cognitive Side-Effects - Deep Brain Stimulation for Tardive Dyskinesia and or Dystonia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Medisch Universitair Ziekenhuis Maastricht
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150311
    </Date_registration3>
    <Date_registration>2015-03-11
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/41413
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>64
    </Inclusion_agemax>
    <Inclusion_gender/>
    <Date_enrollement>2015-10-06
    </Date_enrollement>
    <Target_size>32
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized  controlled trial, Double blinded (masking used), Active, Parallel, Treatment
    </Study_design>
    <Phase/>
    <Countries>The Netherlands
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address>Universiteitssingel  40
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Medisch Universitair Ziekenhuis Maastricht
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;p&gt;- Mental competence &lt;br&gt;- Age between 18 and 65 years &lt;br&gt;- A current or previous psychiatric illness that has been stable for at least 6 months &lt;br&gt;- Diagnosis of TDD &lt;br&gt;- TDD must be present for at least 12 months and impede physical and or social functioning &lt;br&gt;- BFMDRS &gt;8 or AIMS &gt;16 &lt;br&gt;- Pharmacological treatments for TDD had insufficient effect or could not be tolerated &lt;br&gt;&lt;/p&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;p&gt;- The patient does not fully comprehend the effects and potential side effects of brain surgery &lt;br&gt;- The patient is suicidal &lt;br&gt;- The patient has cognitive impairments &lt;br&gt;- The patient is severely mentally ill &lt;br&gt;- A neurological disease that explains the dyskinesia or dystonia &lt;br&gt;- Use of recreational drugs within the last 3 months &lt;br&gt;- Previous DBS or ablative stereotactic brain surgery &lt;br&gt;- General contraindications for stereotactic surgery and general anaesthesia&lt;/p&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;movement disorder &lt;br&gt;secondary dystonia;10028037;10037176;movement disorder;secondary dystonia
    </Condition>
    <Intervention>&lt;p&gt;All patients will be treated with DBS in the posteroventrolateral GPi.&lt;/p&gt;&lt;br&gt;;Deep Brain Stimulation;Psychiatry;Side-effects;Tardive Dyskinesia and or Dystonia
    </Intervention>
    <Primary_outcome>&lt;p&gt;Primary objective, improvement on the movement disorder rating scales.&lt;/p&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>&lt;p&gt;Secondary objectives improvement on the quality of life measured on the SF36&lt;br /&gt;&#x0D;&lt;br&gt;and the WHO-QoL including a cost effectiveness analysis, psychiatric stability&lt;br /&gt;&#x0D;&lt;br&gt;as measured on the BPRS and the MADRS and cognitive effects as measured with&lt;br /&gt;&#x0D;&lt;br&gt;the test battery used in the Nstaps trial.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>NL43091.068.13
    </Secondary_ID>
    <Source_Support>Ministerie van OC&amp;W;GGz Centraal;subsidie leerstoel
    </Source_Support>
    <Ethics_review_status>Not available;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900;10/03/2015
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>;
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;
    </Ethics_review_contact_email>
    <results_date_completed>02/05/2017
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13637501
    </Internal_Number>
    <TrialID>DRKS00006778
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Deep brain stimulation before the age of 18 in patients with childhood-onset dyskinetic movement disorders - a German registry for quality assurance
    </Public_title>
    <Scientific_title>Deep brain stimulation before the age of 18 in patients with childhood-onset dyskinetic movement disorders - a German registry for quality assurance - GEPESTIM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>University of Cologne
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20141201
    </Date_registration3>
    <Date_registration>01/12/2014
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00006778
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>None
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>14/10/2013
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: treatment 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Anne
    </Contact_Firstname>
    <Contact_Lastname>Koy
    </Contact_Lastname>
    <Contact_Address>Kerpenerstr. 62
    </Contact_Address>
    <Contact_Email>anne.koy@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>022147887353
    </Contact_Tel>
    <Contact_Affiliation>Uniklinik Köln Neurologie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria:  - Diagnosis of childhood-onset dyskinetic movement disorders &lt;br&gt;- Deep brain stimulation before the age of 18 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria:  - No diagnosis of childhood-onset dyskinetic movement disorders &lt;br&gt;- Deep brain stimulation after the age of 18 
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G80.3 &lt;br&gt;G24.1 &lt;br&gt;G23.0 &lt;br&gt;E79.1 &lt;br&gt;G24.2;Dyskinetic cerebral palsy;Idiopathic familial dystonia;Hallervorden-Spatz disease;Lesch-Nyhan syndrome;Idiopathic nonfamilial dystonia;G80.3;G24.1;G23.0;E79.1;G24.2
    </Condition>
    <Intervention>Group 1: With the aid of the registry data of patients with a childhood-onset dyskinetic movement disorder who received DBS before the age of 18 years should be systematically collected encompassing information on medical history of the patients, disease etiology, evolution of symptoms, pharmacotherapy, supportive therapy, technical details of DBS implantation, stimulation parameters and complications.
    </Intervention>
    <Primary_outcome>Change of Burke-Fahn-Marsden Dystonia Rating Scale after Deep Brain Stimulation
    </Primary_outcome>
    <Secondary_outcome>Deep Brain Stimulation effect on - dystonia - dyskinesia - pain - memory - affect - quality of life - spasticity - motor function - cognition - attention - speech
    </Secondary_outcome>
    <Source_Support>Univerität zu Köln
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>07/10/2013
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00006778#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13740803
    </Internal_Number>
    <TrialID>NL-OMON21505
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>The INVEST study Treatment in advanced Parkinson’s disease: continuous intrajejunal levodopa INfusion VErsus deep brain STimulation.
    </Public_title>
    <Scientific_title>The INVEST study Treatment in advanced Parkinson’s disease: continuous intrajejunal levodopa INfusion VErsus deep brain STimulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
    </Scientific_title>
    <Primary_sponsor>ZonMw&#x0D;

    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20141103
    </Date_registration3>
    <Date_registration>2014-11-03
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/21505
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>64
    </Inclusion_agemax>
    <Inclusion_gender/>
    <Date_enrollement>2014-12-19
    </Date_enrollement>
    <Target_size>66
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized  controlled trial, Open (masking not used), Active, Other, Treatment
    </Study_design>
    <Phase>3
    </Phase>
    <Contact_Firstname>J.M.
    </Contact_Firstname>
    <Contact_Lastname>Dijk
    </Contact_Lastname>
    <Contact_Address/>
    <Contact_Email>j.m.dijk@amc.uva.nl
    </Contact_Email>
    <Contact_Tel>020-5669111
    </Contact_Tel>
    <Contact_Affiliation>Academisch Medisch Centrum &lt;br&gt;
Afdeling Neurologie &lt;br&gt;
Postbus 22660
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;p&gt;- Idiopathic Parkinson's Disease with bradykinesia and at least two of the following signs; resting tremor, rigidity, and asymmetry;&lt;br /&gt;&lt;br&gt;- Despite optimal pharmacological treatment, at least one of the following symptoms: severe response fluctuations, dyskinesias, painful dystonia or bradykinesia;&lt;br /&gt;&lt;br&gt;- A life expectancy of at least two years.&lt;/p&gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;p&gt;- Age below 18 years&lt;br /&gt;&lt;br&gt;- Previous PD-neurosurgery (e.g., DBS, pallidotomy, thalamotomy);&lt;br /&gt;&lt;br&gt;- Previous CLI (through a PEG-tube or Nasal Jejuna| tube);&lt;br /&gt;&lt;br&gt;- Hoehn and Yahr stage 5 at the best moment during the day;&lt;br /&gt;&lt;br&gt;- A Montreal Cognitive Assessment score of 25 or less (MOCA; http://www.mocatest.org);&lt;br /&gt;&lt;br&gt;- Psychosis;&lt;br /&gt;&lt;br&gt;- Current depression;&lt;br /&gt;&lt;br&gt;- Contraindications for DBS surgery, such as a physical disorder making surgery hazardous;&lt;br /&gt;&lt;br&gt;- Contraindications for PEG surgery such as interposed organs, ascites and oesophagogastric varices, or for Duodopa;&lt;br /&gt;&lt;br&gt;- Pregnancy, breastfeeding, and women of child bearing age not using a reliable method of contraception;&lt;br /&gt;&lt;br&gt;- No informed consent;&lt;br /&gt;&lt;br&gt;- Legally incompetent adults.&lt;/p&gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>&lt;p&gt;advanced Parkinson's disease, gevorderde ziekte van Parkinson&lt;/p&gt;
;10028037
    </Condition>
    <Intervention>&lt;p&gt;Continuous Intrajejunal Levodopa Infusion (CLI) and Deep Brain Stimulation (DBS).&lt;/p&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>&lt;p&gt;The costs per unit on the PDQ-39 and the costs per QALY for the cost-effectiveness and cost-utility analyses respectively. The EQ-5D will be applied as the utility measure.&lt;/p&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>&lt;p&gt;Secondary clinical outcomes are quality of life (PDQ-39 at baseline, 9 and 12 months), PD motor symptoms (MDS-UPDRS-score at baseline and 12 months), dyskinesias (CDRS at baseline and 12 months), 3-day motor symptom diary (at baseline and 12 months), non-motor symptoms such as autonomic functions and sleep (Non Motor Symptom Checklist, Rotterdam Symptom Checklist at baseline and 12 months), adverse effects and complications (at every visit), treatment failure (at every visit), stopping treatment, starting with the alternative than initially started treatment, PD-medication (at every visit), disability (Hoehn and Yahr stage at baseline and 12 months), functional health status (ALDS at baseline and 12 months), patient and physician preferences, patient satisfaction, caregiver burden, neuropsychological and psychiatric assessment at baseline and 12 months, and medical and non-medical care costs (iMCQ and iPCQ at every visit).&lt;/p&gt;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>NL4753;NTR4881;NL51240.018.14;2014-004501-32;NCT02480803
    </Secondary_ID>
    <Source_Support>ZonMw (Nederlandse organisatie voor gezondheidsonderzoek en zorginnovatie)&#x0D;
MedTronic
    </Source_Support>
    <Secondary_Sponsor>Medtronic Europe
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>28/11/2014
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>5823318
    </Internal_Number>
    <TrialID>NCT02253498
    </TrialID>
    <Last_Refreshed_on>24 October 2016
    </Last_Refreshed_on>
    <Public_title>The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Tourette Syndrome
    </Public_title>
    <Scientific_title>The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Tourette Syndrome
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Beijing Pins Medical Co., Ltd
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140929
    </Date_registration3>
    <Date_registration>29/09/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02253498
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>December 2016
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 0
    </Phase>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Li Luming, PhD;Jia Fumin, PhD;Li Luming, PhD;Jia Fumin, PhD
    </Contact_Lastname>
    <Contact_Email>;pins_medical@163.com;;pins_medical@163.com
    </Contact_Email>
    <Contact_Tel>;010-59361265;;010-59361265
    </Contact_Tel>
    <Contact_Affiliation>Tsinghua University;;Tsinghua University;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject is aged 18 or older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patient Group with Tourette's syndrome, Diagnosis of Tourette Syndrome by DSM-IV&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Major Depressive Episode within the previous 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Schizophrenia or other psychotic disorder.Participate in other clinical trial;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Has a life expectancy of &lt; 1 year.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. The investigator and/or enrollment review committee, would preclude participation in&#x0D;&lt;br&gt;             the study.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject is aged 18 or older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patient Group with Tourette's syndrome, Diagnosis of Tourette Syndrome by DSM-IV&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Major Depressive Episode within the previous 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Schizophrenia or other psychotic disorder.Participate in other clinical trial;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Has a life expectancy of &lt; 1 year.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. The investigator and/or enrollment review committee, would preclude participation in&#x0D;&lt;br&gt;             the study.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome;Tourette Syndrome
    </Condition>
    <Intervention>Device: deep brain stimulation (DBS);Device: deep brain stimulation (DBS)
    </Intervention>
    <Primary_outcome>Modified Rush Video Rating Scale (mRVRS);Modified Rush Video Rating Scale (mRVRS)
    </Primary_outcome>
    <Secondary_outcome>Tourette Syndrome Symptom List (TSSL);SF-36;Tourette Syndrome Symptom List (TSSL);SF-36
    </Secondary_outcome>
    <Secondary_ID>PINS-009;PINS-009
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors;Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Beijing Tiantan Hospital;Beijing Tiantan Hospital
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12883370
    </Internal_Number>
    <TrialID>NCT02263417
    </TrialID>
    <Last_Refreshed_on>13 March 2023
    </Last_Refreshed_on>
    <Public_title>A Randomized Controlled Trail Comparing Subthalamic and Pallidal Deep Brain Stimulation for Dystonia
    </Public_title>
    <Scientific_title>The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Dystonia
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Beijing Pins Medical Co., Ltd
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140927
    </Date_registration3>
    <Date_registration>27/09/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02263417
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 2015
    </Date_enrollement>
    <Target_size>70
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Li Luming, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Tsinghua University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject is aged 18 to 75 years old, male or female.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Diagnosed with cervical dystonia by a movement disorders neurologist.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Has cervical dystonia alone, not generalized or multifocal.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Has had adequate trials of medical therapy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Cognitive impairment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Abnormalities on pre-operative magnetic resonance imaging (MRI).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Medical conditions precluding general anaesthetic or surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Unstable psychiatric disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Previous brain lesions to treat cervical dystonia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Attended some other trials within three month.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Dystonia
    </Condition>
    <Intervention>Device: Deep Brain Stimulation (DBS) of Gpi;Device: Deep Brain Stimulation (DBS) of STN
    </Intervention>
    <Primary_outcome>Burke-Fahn-Marsden Scale (BFM)
    </Primary_outcome>
    <Secondary_outcome>Quality of life (SF-36);Psychiatric assessment (HADS-D and PANSS)
    </Secondary_outcome>
    <Secondary_ID>PINS-005
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Peking Union Medical College Hospital
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13637508
    </Internal_Number>
    <TrialID>DRKS00006785
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation (DBS) of the Globus pallidus (GP) in Huntington’s disease (HD): A prospective, randomised, controlled, international, multi-centre study
    </Public_title>
    <Scientific_title>Deep Brain Stimulation (DBS) of the Globus pallidus (GP) in Huntington’s disease (HD): A prospective, randomised, controlled, international, multi-centre study - HD-DBS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Universität Düsseldorf
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140924
    </Date_registration3>
    <Date_registration>24/09/2014
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00006785
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>18/03/2015
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Randomized controlled study; Masking: Blinded (masking used); Control: placebo; Assignment: parallel; Study design purpose: treatment 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Austria;Germany;France
    </Countries>
    <Contact_Firstname>Jan
    </Contact_Firstname>
    <Contact_Lastname>Vesper
    </Contact_Lastname>
    <Contact_Address>Moorenstr. 5
    </Contact_Address>
    <Contact_Email>jan.vesper@uniklinik-duesseldorf.de
    </Contact_Email>
    <Contact_Tel>+49 211 81 18408
    </Contact_Tel>
    <Contact_Affiliation>Funktionelle Neurochirurgie und StereotaxieNeurochirurgische Klinik,Universitätsklinikum DüsseldorfAmbulanz/Sekr.: +49 211 81 16058
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: •Clinically symptomatic and genetically confirmed HD (number of CAG repeats = 36)&lt;br&gt;•Age =18 years &lt;br&gt;•Moderate stage of the disease (UHDRS motor score = 30)&lt;br&gt;•Chorea despite best medical treatment (UHDRS chorea subscore  = 10) &lt;br&gt;•Mattis Dementia Rating Scale = 120  (or &gt; 80% of items testable independently from motor impairment) &lt;br&gt;•Patient has stable medication prior six weeks before inclusion&lt;br&gt;•Signed informed consent &lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: •Juvenile HD (Westphal variant) or predominant bradykinesia&lt;br&gt;•Postural instability with UHDRS retropulsion score &gt; 2&lt;br&gt;•Severe comorbidity compromising operability and/or life expectancy and/or quality of life during the trial duration (e.g. cancer with life expectancy &lt; 6 months, NYHA 3 and 4 rising the anaesthetic risk according to the anaesthesiologist)&lt;br&gt;•Acute suicidality&lt;br&gt;•Acute psychosis (symptoms within previous 6 months)&lt;br&gt;•Participation in any interventional clinical trial within 2 months before baseline&lt;br&gt;•Cortical atrophy grade 3&lt;br&gt;•Patients with risk of coagulopathies and/or increased risk of haemorrhage &lt;br&gt;•Patients with an implanted pacemaker or defibrillator&lt;br&gt;•Pregnancy&lt;br&gt;•lactation&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G10;Huntington disease
    </Condition>
    <Intervention>Group 1: Pallidal deep brain stimulation during the whole study (2x12weeks)&lt;br&gt;Group 2: No pallidal deep brain stimulation for 12 weeks following 12 weeks with stimulation.
    </Intervention>
    <Primary_outcome>Difference between the groups in the UHDRS (Unified Huntingon's Disease Rating Scale) total motor score (UHDRS-TMS) at 12 weeks postoperatively compared to baseline .
    </Primary_outcome>
    <Secondary_outcome>Motor function:&lt;br&gt;-Difference in the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore (items 14-20) &lt;br&gt;-Difference in the UHDRS  bradykinesia subscore (items 22-25 and 27-29)&lt;br&gt;-Difference in the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) motor score&lt;br&gt;-Difference in the Q-Motor "choreomotography” test (Reilmann Battery)&lt;br&gt;-Difference in the Q-Motor “digitomotography” test (Reilmann Battery) &lt;br&gt;i.Digitomotography – IOI-variability&lt;br&gt;ii.Dysdiadochomotography – IOI-variability&lt;br&gt;iii.Manumotography – GFV&lt;br&gt;iv.Choreomotography – Orientation-index&lt;br&gt;v.Pedomotography – IOI-variability&lt;br&gt;Cognition:&lt;br&gt;-Difference in the Mattis Dementia Rating Scale (MDRS) &lt;br&gt;-Difference in the Verbal Fluency Test (formal lexical, categorical, category change)&lt;br&gt;-Difference in the Symbol Digit Modalities Test (SDMT)&lt;br&gt;-Difference in STROOP word reading, colour naming and colour of the word naming&lt;br&gt;Psychiatry / Emotion:&lt;br&gt;-Difference in the Hospital Anxiety and Depression Scale combined with Snaith Irritability Scale (HADS-SIS)&lt;br&gt;-Difference in the Problem Behaviours Assessment Short Form (PBA-s)&lt;br&gt;Quality of Life:&lt;br&gt;-Difference in the Short Form (36) Health Survey (SF-36)&lt;br&gt;-Difference in the Clinical Global Impression Scale (CGI) &lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>NCT02535884;CIV-13-12-011770
    </Secondary_ID>
    <Source_Support>Bundesministerium für Bildung und Forschung Dienstsitz Berlin;CHDI Foundation
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>24/07/2014
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ethikkommission@med.uni-duesseldorf.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission an der Medizinischen Fakultät der Heinrich-Heine-Universität Düsseldorf
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-211-8119591
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ethikkommission@med.uni-duesseldorf.de
    </Ethics_review_contact_email>
    <results_date_completed>02/12/2021
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00006785#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13637379
    </Internal_Number>
    <TrialID>DRKS00006257
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Neuronal osciallations in basal-ganglia-loops and their therapeutic modulation in patients with idiopathic Parkinson syndrome.
    </Public_title>
    <Scientific_title>Neuronal osciallations in basal-ganglia-loops and their therapeutic modulation in patients with idiopathic Parkinson syndrome.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Uniklinik Köln, NeurologieArbeitsgruppe für Bewegungsstörungen und Tiefe Hirnstimulation
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140708
    </Date_registration3>
    <Date_registration>08/07/2014
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00006257
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>30 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>01/08/2014
    </Date_enrollement>
    <Target_size>48
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Non-randomized controlled study; Masking: Open (masking not used); Control: Other; Assignment: parallel; Study design purpose: basic science  
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Elfriede
    </Contact_Firstname>
    <Contact_Lastname>Stubbs
    </Contact_Lastname>
    <Contact_Address>Kerpener Str. 62
    </Contact_Address>
    <Contact_Email>elfriede.stubbs@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>0221-478-98842
    </Contact_Tel>
    <Contact_Affiliation>Klinik und Poliklinik für NeurologieArbeitsgruppe Bewegungsstörungen und Tiefe HirnstimulationStudienbüro
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Healthy subjects:&lt;br&gt;• Male and female participants between 30 and 80 years of age&lt;br&gt;• Right handed persons&lt;br&gt;• Capability of signing an informed consent&lt;br&gt;&lt;br&gt;Parkinson’s patients:&lt;br&gt;• Male and female patients with the diagnosis of an IPS according to the guidelines of the DGN&lt;br&gt;• Right handed patients&lt;br&gt;• Patients with the indication for receiving deep brain stimulation (target areas: STN, GPi, Vim) with uncontrollable motor symptomes due to strong dyskinesia and/ or ON/OFF fluctuations &lt;br&gt;• positive motor response to L-Dopa or Apomorphine;&lt;br&gt;• Patients between 30 and 80 (in order to exclude genetic variants of the disease);&lt;br&gt;• time period of the symptomes longer than 4 years (differential diagnosis);&lt;br&gt;•  patients have to be able to sign an informed consent;&lt;br&gt;• Ability to cooperate during the measurements&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Healthy subjects:&lt;br&gt;• non- "sui juris" patients, underaged persons as well as subjects which are judically sent to an institution&lt;br&gt;• diagnosis of an idiopathic parkinson syndrom or any other neurological disease&lt;br&gt;• participants that take drugs regularly which influence the nervous system and which can not be stopped the evening before the experiment&lt;br&gt;• severe internal comorbidities&lt;br&gt;• presence of psychiatric diseases&lt;br&gt;•impaired vision or hearing defect that may hinder the testing&lt;br&gt;• pregnant or breast feeding mothers&lt;br&gt;&lt;br&gt;Parkinson’s patients:&lt;br&gt;• non- "sui juris" patients, underaged persons as well as subjects which are judically sent to an institution&lt;br&gt;• patients that suffer from another neurological disease apart from Parkinsons like Epilepsy, Alzheimers or Dystonia&lt;br&gt;• patients with severe frontal executive disturbances&lt;br&gt;• presence of a Parkinson-Plus-Syndrom like corticobasal degeneration, progressive supranuclear palsy or multisystem atrophy&lt;br&gt;• other hypokinetic movement disorders like MPTP- or manganese intoxication, chorea Huntington, subcortical arteriosclerotic encephalopathy or psychogenic movement disorder&lt;br&gt;• clinically relevant abnormalities in preoperative MR-Images like ischemia, or cerebral athropy&lt;br&gt;• previous surgeries in the ZNS due to, for example, brain tumors, epilepsy or vascular reasons&lt;br&gt;• severe internal comorbidities&lt;br&gt;• presence of psychiatric diseases&lt;br&gt;• impaired vision or hearing defect that may hinder the testing&lt;br&gt;• pregnant or breast feeding mothers
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: healthy volunteers, age-matched&lt;br&gt;(EEG recording with a 128-channel-system from the head surface and synchronous measurment of the EMG from the right forearm during the conduction of simple movments)&lt;br&gt;Group 2: Parkinsons-Patients&lt;br&gt;(pre- and posteroperatively EEG-recording with a 128 channel system from the head surface, synchronous recording of the EMG from the right forearm during the conduction of simple movements; intraoperatively: the above mentioned electrophysiological measurements will be accompanied by the recording of local field potentials as well as single cell activity from the target structures of deep brain stimulation using microelectrodes; perioperatively, in addition to EEG and EMG, local field potentials will be recorded by the use of externalized electrodes)
    </Intervention>
    <Primary_outcome>Pathological, oscillatory coupling between EEG and EMG in the beta range (13-30 Hz) on different measurement days without treatment
    </Primary_outcome>
    <Secondary_outcome>Comparision of pathological, electrophysiological acitivity for two Parkinsons-Subtypes (tremor-dominant versus akinetic rigid)
    </Secondary_outcome>
    <Source_Support>Deutsche Forschungsgemeinschaft
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>19/05/2014
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00006257#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>11253457
    </Internal_Number>
    <TrialID>NCT02264925
    </TrialID>
    <Last_Refreshed_on>17 August 2021
    </Last_Refreshed_on>
    <Public_title>Thalamic LFPs and VIM DBS in Essential Tremor: Correlation, Evolution, and Therapeutic Perspectives
    </Public_title>
    <Scientific_title>Thalamic LFPs and VIM DBS in Essential Tremor: Correlation, Evolution, and Therapeutic Perspectives
    </Scientific_title>
    <Acronym>VIM-CLT
    </Acronym>
    <Primary_sponsor>University Hospital, Bordeaux
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140620
    </Date_registration3>
    <Date_registration>20/06/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02264925
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 2014
    </Date_enrollement>
    <Target_size>12
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>BURBAUD Pierre, MD-PhD;Nicolas LANGBOUR, PhD
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>University Hospital Bordeaux, France;IMN CNRS UMR 5293, Université Bordeaux 2 Segalen
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients suffering from severe and disabling ET with serious impact on their quality&#x0D;&lt;br&gt;             of life (QoL).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  18-70 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Free of evolutive and untreated psychiatric disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Tremor must be predominant in the upper limbs although it can affect the lower limbs,&#x0D;&lt;br&gt;             head and voice.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Affiliation to a social security system&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent signed by the participant and the investigator (prior to any&#x0D;&lt;br&gt;             examination required by research)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parkinsonian tremor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy or lactating women&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe co-morbidity (cardiac, renal or respiratory failures, evolutive cancer)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Impaired cognitive functions (score &lt;130 on Mattis scale).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with severe atrophy or lesions on MRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Depression (Beck &gt; 10)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participation in another clinical research for 18 months (after surgery)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Device: Deep Brain Stimulation with Medtronic Activa PC+S systems
    </Intervention>
    <Primary_outcome>LFPs records 3 month after implantation;LFPs records 12 month after implantation
    </Primary_outcome>
    <Secondary_ID>CHUBX 2013/15
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>APTES 100 rue boileau 69006 Lyon
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13637143
    </Internal_Number>
    <TrialID>DRKS00005797
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Effect of Deep Brain Stimulation in the Globus Pallidus internus on quality of life in young patients with dyston-dyskinetic Cerebral Palsy
    </Public_title>
    <Scientific_title>Effect of Deep Brain Stimulation in the Globus Pallidus internus on quality of life in young patients with dyston-dyskinetic Cerebral Palsy - STIM-CP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>University of Cologne
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20140404
    </Date_registration3>
    <Date_registration>04/04/2014
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00005797
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>7 Years
    </Inclusion_agemin>
    <Inclusion_agemax>18 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>28/02/2014
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: treatment 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Anne
    </Contact_Firstname>
    <Contact_Lastname>Koy
    </Contact_Lastname>
    <Contact_Address>Kerpenerstr. 62
    </Contact_Address>
    <Contact_Email>anne.koy@uk.koeln.de
    </Contact_Email>
    <Contact_Tel>0221 478 87353
    </Contact_Tel>
    <Contact_Affiliation>Uniklinik Köln Neurologie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: • The treating physician has chosen GPi-DBS for the treatment of the secondary dystonia caused by cere-bral palsy in this patient &lt;br&gt;• Patient and/or legal representative, if the patient is un-deraged or not capable to give consent himself, have chosen GPi-DBS as treatment&lt;br&gt;• The consent to participate in the trial of the underaged patient, if he is capable to understand the study re-quirements, is required&lt;br&gt;• Age at enrolment 7-18 years&lt;br&gt;• Diagnosis of secondary dystonia due to cerebral palsy caused by perinatal hypoxic injury&lt;br&gt;• Anti-dystonic pharmacotherapy insufficient (e.g. Jankovic J. Medical treatment of dystonia. Movement disorders, Vol. 28, No. 7, 2013) 67&lt;br&gt;• Stable anti-dystonic medication over the last 30 days&lt;br&gt;• Globus pallidus internus (pars posterior) and thalamus (motor part) intact on MRI (not older than 2 years - if possible)&lt;br&gt;• No fixed severe skeletal deformations with loss of function, which need immediate orthopaedic surgical intervention&lt;br&gt;• Sufficient compliance of the patient or the legal representative if the patient is underaged or not capable to give consent himself to take part in the study&lt;br&gt;• Informed consent to take part in the study from patient and/or legal representative if the patient is underaged or not capable to give consent himself&lt;br&gt;• Patient and/or legal representative if the patient is underaged or not capable to give consent himself, understands the study requirements and the treatment procedures and provides written informed consent before any study-specific tests or procedures are performed&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: • Patients with known primary (e.g. DYT1) or idiopathic dystonia&lt;br&gt;• Severe axial hypotonia with total loss of head control (e.g. absence of control at “upper thoracic level” in the SATCo score) (medication effect excluded)&lt;br&gt;• Fixed hemi-dystonia&lt;br&gt;• Severe spasticity in knee- and elbow-flexors and -extensors (Modified Ashworth Scale &gt;3)&lt;br&gt;• Fixed severe skeletal contractions with loss of function which require immediate orthopaedic surgical intervention&lt;br&gt;• Patients with other severe concurrent neurological disease (e. g. brain tumor, neurodegenerative diseases, trauma etc.)&lt;br&gt;• Condition likely to require use of MRI in the future&lt;br&gt;• Any intracranial abnormality or medical condition that would contraindicate DBS surgery&lt;br&gt;• Any findings in neuropsychological screening assessments that would contraindicate DBS surgery&lt;br&gt;• Any current drug and / or alcohol abuse&lt;br&gt;• Any history of frequent grand-mal seizures without response to anticonvulsive treatment&lt;br&gt;• Any other active implanted device (e.g. Cochlear implant, pacemaker), whether turned on or off, would be allowed provided that they do not interfere with functioning of the device.&lt;br&gt;• Any previous brain surgery that would interfere with the placement of the leads or the functioning of the device.&lt;br&gt;• A history of neurostimulation intolerance in any area of the body.&lt;br&gt;• Currently on any anticoagulant medications that cannot be discontinued during perioperative period.&lt;br&gt;• Any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints, including any terminal illness with survival &lt;12 months.&lt;br&gt;• Participation in another drug, device, or biologics trial concurrently or within the preceding 30 days; any other trial participation should be approved by the Principal Investigator.&lt;br&gt;• A female that is breastfeeding or of child bearing potential with a positive urine pregnancy test or - if a person is sexually active - not using sufficient contraception with a Pearl Index of less than 1% including all forms of hormonal contraception („antibaby-pill“, hormonal plaster, NuvaRing®, Implanon®, hormonal depot injections, contraceptive coil), the tubal ligature (female sterilization). Alternatively, the female of child bearing potential is sexually abstinent.
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G80.3;Dyskinetic cerebral palsy;G80.3
    </Condition>
    <Intervention>Group 1: In this single-arm, non-interventional trial qualitiy of life as well as motor skills, speech, pain perception, cognition, mood, memory and attention will be systematically assessed before and 6 and 12 months after Deep Brain Stimulation.
    </Intervention>
    <Primary_outcome>Difference in CPCHILD before and 12 months on DBS (response=improvement &gt; 10%)
    </Primary_outcome>
    <Secondary_outcome>Assensment of effect of bilateral GPi-DBS on&lt;br&gt;Dystonia&lt;br&gt;Spasticity&lt;br&gt;Dyskinesia&lt;br&gt;Motor function/disability&lt;br&gt;Pain&lt;br&gt;Cognition &lt;br&gt;Memory&lt;br&gt;Affection&lt;br&gt;Speech
    </Secondary_outcome>
    <Secondary_ID>NCT02097693
    </Secondary_ID>
    <Source_Support>Boston Scientific Corporation Neuromodulation
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>31/01/2014
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00005797#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12987035
    </Internal_Number>
    <TrialID>NCT02087046
    </TrialID>
    <Last_Refreshed_on>1 May 2023
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation (DBS) for the Suppression of Tremor
    </Public_title>
    <Scientific_title>A Clinical Evaluation of the Advanced Neuromodulation System (ANS) Totally Implantable Deep Brain Stimulation System for the Suppression of Tremor in the Upper Extremities of Patients With Essential Tremor.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Abbott Medical Devices
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20140312
    </Date_registration3>
    <Date_registration>12/03/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02087046
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2005
    </Date_enrollement>
    <Target_size>127
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Edward Karst
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Abbott
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patient or authorized representative has signed an informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patient is over 18 years of age.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patient is diagnosed with essential tremor for at least 3 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient has a disabling medical-refractory upper extremity tremor with no evidence of&#x0D;&lt;br&gt;             supraspinal central nervous system disease or injury (tremor not adequately controlled&#x0D;&lt;br&gt;             by medications for at least three (3) months before implant).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patient has a postural or kinetic tremor severity score of at least 3 out of 4 in the&#x0D;&lt;br&gt;             extremity intended for treatment on the Fahn-Tolosa-Marin Clinical Rating Scale for&#x0D;&lt;br&gt;             Tremor.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Patient will maintain a constant dose of anti-tremor medication indicated as best&#x0D;&lt;br&gt;             medical management for one (1) month prior to enrollment in study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Patient is available for appropriate follow-up times for the length of the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patient is not surgical candidate;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patient has other clinically or medically significant disease;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patient has any neurological injury or disease other than essential tremor;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient has any condition requiring repeated MRI scans;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patient has any condition requiring diathermy;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Patients on anticoagulant medications;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Patient has untreated clinically significant depression;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Patient has had an electrical or electromagnetic implant (cochlear prosthesis,&#x0D;&lt;br&gt;             pacemaker etc);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Patient has had a prior thalamotomy or surgical ablation procedure in either side of&#x0D;&lt;br&gt;             the brain;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Patient has dementia interfering with their ability to co-operate or comply with study&#x0D;&lt;br&gt;             requirements or comprehend the informed consent (mini-mental exam score &lt;24);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Patient abuses drugs or alcohol;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Patient has had botulinum toxin injections in the six (6) months prior to enrollment;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Patient has a history of cranial surgery;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. Patient has a history of seizures;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         15. Patient has any metallic implants that may interfere with the functioning of the&#x0D;&lt;br&gt;             device (e.g. aneurysm clips);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         16. Patient has a history of stimulation intolerance in any area of the body;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         17. Patient is a female of child bearing potential with a positive urine pregnancy test or&#x0D;&lt;br&gt;             not using adequate contraception.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tremor;Action Tremor;Essential Tremor;Tremor, Limb
    </Condition>
    <Intervention>Device: ANS Totally Implantable Deep Brain Stimulation System
    </Intervention>
    <Primary_outcome>Primary Efficacy Endpoint: Difference in the Postural Tremor Score of the Target Limb Between Stimulation On and Stimulation Off, As Assessed by the Blind Reviewer;Primary Safety Endpoint: Percentage of Participants With Device-related or Procedure Related Adverse Events
    </Primary_outcome>
    <Secondary_outcome>Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Target Limb Severity Score, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Target Limb Severity Score, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Target Limb Severity Score, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Target Limb Severity Score, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation- Target Limb Responder Analysis, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation- Target Limb Responder Analysis, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation- Target Limb Responder Analysis, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Handwriting for Target Side Severity Score, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Handwriting for Target Side Severity Score, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Handwriting for Target Side Severity Score, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Handwriting for Target Side Severity Score, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Handwriting for Target Side Severity Score, As Assessed by the Blind Reviewer;Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Pouring From Target Side Severity Scores, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation-Mean Pouring From Target Side Severity Scores, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Pouring From Target Side Severity Scores, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation-Mean Pouring From Target Side Severity Scores, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation- Pouring Ability From Target Side Severity Scores, As Assessed by the Blind Reviewer;Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Total Motor Score, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Total Motor Score, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Total Motor Score, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Total Motor Score, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation- Activity of Daily Living Score, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation- Activity of Daily Living Score, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation- Activity of Daily Living Score, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation- Activity of Daily Living Score, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation-Bilateral Stimulation, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation-Bilateral Stimulation, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation-Non-Target Limb Severity Scores, As Assessed by the Site Physician;Clinical Rating Scale for Tremor (CRST) Evaluation-Non-Target Limb Severity Scores, As Assessed by the Site Physician;Quality of Life in Essential Tremor (QUEST): Overall Summary Index;Change From Baseline for Quality of Life in Essential Tremor (QUEST): Overall Summary Index;Change From Baseline for Quality of Life in Essential Tremor (QUEST): Overall Summary Index;Change From Baseline for Quality of Life in Essential Tremor (QUEST): Overall Summary Index;SF36 Components and Individual Domains;SF36 Components and Individual Domains;SF36 Components and Individual Domains;SF36 Components and Individual Domains;Global Assessment Scores by Examiner;Global Assessment Scores by Examiner;Global Assessment Scores by Examiner;Global Assessment Scores by Examiner;Global Assessment by Caregiver;Global Assessment by Caregiver;Global Assessment by Caregiver;Global Assessment by Caregiver;Global Assessment by Patient;Global Assessment by Patient;Global Assessment by Patient;Global Assessment by Patient;Subjective Assessment by Patient Since Activation of System;Subjective Assessment by Patient Since Activation of System;Subjective Assessment by Patient Since Activation of System;Number of Participants With Satisfaction With the DBS System's Functioning and Ability to Control Symptoms;Number of Participants With Satisfaction With the DBS System's Functioning and Ability to Control Symptoms;Number of Participants With Satisfaction With the DBS System's Functioning and Ability to Control Symptoms;Number of Participants Who Would Choose to Receive the DBS System Again;Number of Participants Who Would Choose to Receive the DBS System Again;Number of Participants Who Would Choose to Receive the DBS System Again;Number of Participants Who Would Recommend the DBS System;Number of Participants Who Would Recommend the DBS System;Number of Participants Who Would Recommend the DBS System;Beck Depression Inventory II (BDI - II) Score for Depression Symptoms;Change From Baseline in Beck Depression Inventory II (BDI - II) Score for Depression Symptoms;Mini Mental State Exam (MMSE) for Examination of Mental Status;Change From Baseline in Mini Mental State Exam (MMSE) For Examination of Mental Status
    </Secondary_outcome>
    <Secondary_ID>C-04-02
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>26/02/2021
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT02087046
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13133043
    </Internal_Number>
    <TrialID>NCT02056873
    </TrialID>
    <Last_Refreshed_on>26 June 2023
    </Last_Refreshed_on>
    <Public_title>Tourette Syndrome Deep Brain Stimulation
    </Public_title>
    <Scientific_title>The Human Thalamocortical Network in Tourette Syndrome
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Florida
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140203
    </Date_registration3>
    <Date_registration>03/02/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02056873
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 2014
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Michael Okun, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Florida
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Must be 21+ years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of Tourette Syndrome (TS) in accordance to the Diagnostic and Statistical&#x0D;&lt;br&gt;             Manual of Mental DIsorders (DSM-V) criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Yale Global Tic Severity Scale (YGTSS) must be =35/50 for at least 12 months; Motor&#x0D;&lt;br&gt;             Tic subscore must be =15&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  TS must be causing incapacitation with severe distress, self-injurious behavior,&#x0D;&lt;br&gt;             and/or quality of life disruption&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  TS must be medication refractory. Criteria to determine if medication refractory is&#x0D;&lt;br&gt;             the exact criteria stated by Mink et. al TSA DBS Guidelines published in 2006:&#x0D;&lt;br&gt;             Subjects must have been treated by a psychiatrist or neurologist experienced in TS&#x0D;&lt;br&gt;             with therapeutic doses of either 1-4 mg/day of haloperidol or 2-8 mg/day of pimozide,&#x0D;&lt;br&gt;             risperidone (1-3 mg/day), and aripiprazole (2.5-5 mg/day). Must be at minimum a single&#x0D;&lt;br&gt;             trial with an alpha-2 adrenergic agonist (0.1-0.3 mg/day)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically relevant depression must be pharmacologically treated and deemed stable&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Must have been stabilized for 1 month on TS medication without a dose change prior to&#x0D;&lt;br&gt;             surgical intervention. If medication trials resulted in discontinuation of TS&#x0D;&lt;br&gt;             medications, the subject must be stabilized for 3 months off TS medicines&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Must be willing to keep TS related medications stable and unchanged throughout the&#x0D;&lt;br&gt;             trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Must have been offered habit reversal therapy/cognitive behavioral intervention&#x0D;&lt;br&gt;             therapy (HRT) if subject did not have it prior to enrollment. (Subjects not required&#x0D;&lt;br&gt;             to participate in HRT but it will be highly encouraged, and must be completed prior to&#x0D;&lt;br&gt;             start of this study's protocol. Those who improve significantly will be excluded from&#x0D;&lt;br&gt;             receiving DBS surgery)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If tic is focal or addressable by botulinum toxin treatment, the study neurologist&#x0D;&lt;br&gt;             will offer to administer a trial of botulinum toxin prior to consideration of surgical&#x0D;&lt;br&gt;             therapy. (If the subject chooses not to have the treatment, they cannot participate in&#x0D;&lt;br&gt;             the study. If the patient responds satisfactorily and their quality of life&#x0D;&lt;br&gt;             significantly improves, they will be excluded)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any previous neurological intervention including DBS or ablative brain lesions, any&#x0D;&lt;br&gt;             metal in the head, and any type of implanted stimulator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Untreated or unstable anxiety, depression, bipolar disorder, or other Axis I&#x0D;&lt;br&gt;             psychiatric disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of psychotic features&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Significant psychosocial factors that can cause increased risk&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The presence of only simple motor tics, a movement disorder other than TS, or&#x0D;&lt;br&gt;             medication related movement disorders from TS medications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe medical co-morbidity including cardiovascular disorder, lung disorder, kidney&#x0D;&lt;br&gt;             disease, chronic neurological disease, hematological disease, or frailty that impacts&#x0D;&lt;br&gt;             tolerability of the surgery as judged by the screening physicians&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Abnormal brain magnetic resonance imaging (MRI) scan, including severe atrophy,&#x0D;&lt;br&gt;             hydrocephalus, stroke, structural lesions, demyelinating lesions, or infectious&#x0D;&lt;br&gt;             lesions that would potentially confound the outcome or safety of the surgery as judged&#x0D;&lt;br&gt;             by the study neurosurgeon&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia or cognitive dysfunction that will place the subject at risk for worsening&#x0D;&lt;br&gt;             cognition, and/or may impact the ability to cooperate with tasks involved in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any attempt or intent of suicide in the last 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Significant substance abuse or dependence within the last 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Multiple failed medication treatments of inadequate dose or duration&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of noncompliance with previous medical and psychosocial treatment efforts&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe head banging tics&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women of child-bearing potential who are pregnant or planning pregnancy (urine&#x0D;&lt;br&gt;             pregnancy test required)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Positive urine drug screen for illicit substances (urine drug screen required)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of multiple surgical procedures with poor outcomes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unexplained gaps in medical history&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pending lawsuits or other legal action&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome
    </Condition>
    <Intervention>Device: DBS System;Device: DBS System (RBS Setting)
    </Intervention>
    <Primary_outcome>Reduction in total tics on the Yale Global Tic Severity Scale (YGTSS) after 6 months as an effect of centromedian (CM) continuous DBS stimulation;Correlation between increase in gamma oscillations and improvement in TS symptomatology;Responsive brain stimulation (RBS) as an effective alternative to continuous DBS stimulation;Reduction in total tics on the YGTSS after 24 months as an effect of centromedian (CM) continuous DBS stimulation
    </Primary_outcome>
    <Secondary_ID>KL2TR001429;1553482;OCR20343;IRB201300850 -A-N
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Medtronic;National Institutes of Health (NIH);National Science Foundation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13636570
    </Internal_Number>
    <TrialID>DRKS00004770
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Impairments of Parkinson's disease patients with deep brain stimulation: Development and validation of a self-report and proxy-rated questionnaire
    </Public_title>
    <Scientific_title>Impairments of Parkinson's disease patients with deep brain stimulation: Development and validation of a self-report and proxy-rated questionnaire - DBS-IS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>Deutsche Parkinson Vereinigung (dPV)
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20131126
    </Date_registration3>
    <Date_registration>26/11/2013
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00004770
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>None
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>01/10/2012
    </Date_enrollement>
    <Target_size>1500
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: other 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Catharine
    </Contact_Firstname>
    <Contact_Lastname>Lewis
    </Contact_Lastname>
    <Contact_Address>Kerpenerstr. 62
    </Contact_Address>
    <Contact_Email>catharine.lewis@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>0221 478 97435
    </Contact_Tel>
    <Contact_Affiliation>Klinik und Poliklinik für Neurologie, Uniklinik Köln
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients with Parkinson's disease and a respective caregiver
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients without Parkinson's disease and caregivers of patients without Parkinson's disease
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: Parkinson's disease patients (with and without DBS), survey with questionnaires&lt;br&gt;Group 2: caregivers of Parkinson's disease patients (with and without DBS), survey with questionnaires
    </Intervention>
    <Primary_outcome>Development and validation of a self-report and proxy-rated questionnaire
    </Primary_outcome>
    <Source_Support>Deutsche Parkinson Vereinigung (dPV)
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>20/06/2012
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00004770#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13636898
    </Internal_Number>
    <TrialID>DRKS00005316
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Neurocognitive Specification of Dysfunctions within Basal Ganglia-Cortex Loops and their Therapeutic Modulation by Deep Brain Stimulation in Patients with Obsessive Compulsive Disorders and Tourette Syndrome
    </Public_title>
    <Scientific_title>Neurocognitive Specification of Dysfunctions within Basal Ganglia-Cortex Loops and their Therapeutic Modulation by Deep Brain Stimulation in Patients with Obsessive Compulsive Disorders and Tourette Syndrome - KFO219 TP7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum Köln
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20131002
    </Date_registration3>
    <Date_registration>02/10/2013
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00005316
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>15/10/2009
    </Date_enrollement>
    <Target_size>35
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Non-randomized controlled study; Masking: Open (masking not used); Control: Other; Assignment: parallel; Study design purpose: basic science  
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Daniel
    </Contact_Firstname>
    <Contact_Lastname>Huys
    </Contact_Lastname>
    <Contact_Address>Kerpener Str. 62
    </Contact_Address>
    <Contact_Email>daniel.huys@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>0221 478 86211
    </Contact_Tel>
    <Contact_Affiliation>Uniklinik KölnKlinik für Psychiatrie und Psychotherapie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: For OCD and Tourette patients:&lt;br&gt;- chronic course&lt;br&gt;- serious expression with subjective distress and significant impairment of psychosocial functioning levels&lt;br&gt;- The patient agrees after detailed education about DBS and gives his written informed consent&lt;br&gt;- The patient agrees to a detailed evaluation&lt;br&gt;&lt;br&gt;For OCD patients:&lt;br&gt;-  OCD (ICD-10: F42) is the main psychiatric diagnosis&lt;br&gt;- strong symptom severity as measured by the YBOCS score&lt;br&gt;- At least one documented fully implemented cognitive-behavioral psychotherapy without sufficient success&lt;br&gt;- at least two unsuccessful drug therapies with SSRIs or clomipramine for 10 weeks in adequate doses&lt;br&gt;- At least one unsuccessful drug augmentation carried out for 10 weeks with one of the following medications: lithium, buspirone or neuroleptics&lt;br&gt;&lt;br&gt;For Tourette patients:&lt;br&gt;- Tourette Syndrome (ICD-10: F95.2) is the main psychiatric diagnosis&lt;br&gt;- strong symptom severity as measured by the score YGTSS&lt;br&gt;- Inadequate symptom relief through drug treatment strategies, as a minimum pre-treatment with preparations from all three pharmacological groups listed (neuroleptics, benzodiazepines, alpha-agonists). This should be documented with adequate doses of at least 3-month treatment periods.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: - Acute suicidality&lt;br&gt;- Simultaneously or previously existing schizophrenia according to DSM-IV criteria&lt;br&gt;- Abuse of or dependence on drugs or alcohol in the last six months&lt;br&gt;- Craniocerebral trauma in the anamnesis&lt;br&gt;- Clinically relevant internal or neurological diseases&lt;br&gt;- Pregnancy or breastfeeding&lt;br&gt;- Participation in a clinical trial within the last 30 days before the start of the study&lt;br&gt;- Intellectual deficit
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;F95.2 &lt;br&gt;F42;Combined vocal and multiple motor tic disorder [de la Tourette];Obsessive-compulsive disorder;F95.2
    </Condition>
    <Intervention>Group 1: Tourette patients treated with thalamic DBS are examined preoperative as well as 6 and 12 month after operation in regard to psychopathological, neuropsychological, electrophysiological aspekts and quality of life.&lt;br&gt;Group 2: Patients with obsessive compulsive disorder treated with DBS of the Nucleus accumbens are examined preoperative as well as 6 and 12 month after operation in regard to psychopathological, neuropsychological, electrophysiological aspekts and quality of life.&lt;br&gt;Group 3: 15 healthy controll subjects are examined in regard to psychopathological, neuropsychological, electrophysiological aspekts and quality of life.
    </Intervention>
    <Primary_outcome>Changes in Obsessive compulsive symptoms should be measured 12 month after Operation using the YBOCS (Yale-Brown Obsessive Compulsive Scale).&lt;br&gt;&lt;br&gt;Changes in Tic symptoms in Tourette patients should be measured 12 month after operation using the YGTSS (Yale Global Tic Severerity Scale).
    </Primary_outcome>
    <Secondary_outcome>Psychopathology: STAI, HZI, IKP, SKID, GAF, DAPP-BQ, BDI, GAF, SCL-90&lt;br&gt;Neuropsychology: ToL, CPT, FWIT, Stroop-Test, Go/NoGo-Test, Inhibiton of Return, PPI&lt;br&gt;All examinations are executed preoperative as well as 6 and 12 month after operation
    </Secondary_outcome>
    <Source_Support>Deutsche Forschungsgemeinschaft
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>08/10/2009
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00005316#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10962911
    </Internal_Number>
    <TrialID>NCT01945567
    </TrialID>
    <Last_Refreshed_on>24 May 2021
    </Last_Refreshed_on>
    <Public_title>Randomised Crossover Trial of DBS of Differential PSA Regions in Parkinson's Disease and Tremor
    </Public_title>
    <Scientific_title>Randomised Crossover Trial of Deep Brain Stimulation of Differential Posterior Subthalamic Area Regions in Parkinson's Disease and Tremor
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>The University of Western Australia
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20130914
    </Date_registration3>
    <Date_registration>14/09/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01945567
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 2012
    </Date_enrollement>
    <Target_size>39
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Australia
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Christopher Lind, MBChB, FRACS
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>The University of Western Australia
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medication-refractory tremor and/or Parkinson's disease as defined by UK Brain Bank&#x0D;&lt;br&gt;             criteria with either inadequate control of motor fluctuations or dyskinesia despite&#x0D;&lt;br&gt;             optimised medical therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Significant cognitive, psychiatric and medical co-morbidities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia with mini mental state examination score of less than 25/30&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Limited life expectancy due to a co-morbid condition&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson's Disease;Tremor
    </Condition>
    <Intervention>Device: Up to 3 mA, 60 us, 130 Hz deep brain stimulation;Device: Empirical unblinded deep brain stimulation programming
    </Intervention>
    <Primary_outcome>Change from baseline United Parkinsons Disease Rating Scale Part III at 3 months;Change from baseline United Parkinsons Disease Rating Scale Part III at 6 months;Change from baseline United Parkinsons Disease Rating Scale Part III at 12 months;Change from baseline Fahn Tolosa Marin tremor scale at 3 months;Change from baseline Fahn Tolosa Marin tremor scale at 6 months;Change from baseline Fahn Tolosa Marin tremor scale at 12 months
    </Primary_outcome>
    <Secondary_outcome>Change from baseline ON-OFF diary at 3 months;Change from baseline ON-OFF diary at 6 months;Change from baseline ON-OFF diary at 12 months;Adverse events;Change from baseline Short form 36 at 3 months;Change from baseline Short form 36 at 6 months;Change from baseline Short form 36 at 12 months;Change from baseline Parkinsons Disease Quality of Life 39 at 3 months;Change from baseline Parkinsons Disease Quality of Life 39 at 6 months;Change from baseline Parkinsons Disease Quality of Life 39 at 12 months;Change from baseline L-dopa equivalent dose at 3 months;Change from baseline L-dopa equivalent dose at 6 months;Change from baseline L-dopa equivalent dose at 12 months;Change from baseline neuropsychological battery at 3 months;Change from baseline neuropsychological battery at 6 months;Change from baseline neuropsychological battery at 12 months;Change from baseline verbal fluency at 3 months;Change from baseline verbal fluency at 6 months;Change from baseline verbal fluency at 12 months;Change from baseline Mini-International Neuropsychiatric Interview Plus at 3 months;Change from baseline Mini-International Neuropsychiatric Interview Plus at 6 months;Change from baseline Mini-International Neuropsychiatric Interview Plus at 12 months;Change from baseline United Parkinsons Disease Rating Scale parts I, II, IV, V at 3 months;Change from baseline United Parkinsons Disease Rating Scale parts I, II, IV, V at 6 months;Change from baseline United Parkinsons Disease Rating Scale parts I, II, IV, V at 12 months;Change from baseline Abnormal Involuntary Movement Scale at 3 months;Change from baseline Abnormal Involuntary Movement Scale at 6 months;Change from baseline Abnormal Involuntary Movement Scale at 12 months
    </Secondary_outcome>
    <Secondary_ID>2012-039
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13385653
    </Internal_Number>
    <TrialID>NCT01922388
    </TrialID>
    <Last_Refreshed_on>9 October 2023
    </Last_Refreshed_on>
    <Public_title>Early Versus Late Application of STN DBS to PD Patients With Motor Complications
    </Public_title>
    <Scientific_title>Early Versus Late Application of Subthalamic Deep Brain Stimulation to Parkinson's Disease Patients With Motor Complications: a Multicentre, Prospective and Observational Study
    </Scientific_title>
    <Acronym>ELASS
    </Acronym>
    <Primary_sponsor>Chen Ling
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20130808
    </Date_registration3>
    <Date_registration>08/08/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT01922388
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 2013
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>China
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Ling Chen, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>First Affiliated Hospital, Sun Yat-Sen University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic Parkinson's Disease with good response to levodopa(i.e. more than 30%&#x0D;&lt;br&gt;             improvement in the MDS-UPDRS Part III score after an acute levodopa challenge)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of fluctuations and/or dyskinesias&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age ranging from 18 to 75 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Normal brain MRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Absence of dementia (Mini Mental State Examination = 26)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Absence of severe psychiatric diseases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of severe metabolic diseases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe cardiac/respiratory/renal/hepatic diseases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Secondary parkinsonism or multiple system atrophy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Illiteracy or insufficient language skills to complete the questionnaires&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Poor compliance and unreasonable expectation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women who are pregnant or breast feeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Simultaneous participation in another clinical trial&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Bilateral deep brain stimulation of the subthalamic nucleus
    </Intervention>
    <Primary_outcome>Changes in 39-item Parkinson's disease questionnaire (PDQ-39) scores
    </Primary_outcome>
    <Secondary_outcome>Changes in Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III scores;Changes in time spent in the "on" state without troubling dyskinesia based on Parkinson's disease home diary;Changes in MDS-UPDRS patient questionnaire (Part I B and Part II) scores;Severe adverse effects
    </Secondary_outcome>
    <Secondary_ID>[2013]19
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Prince of Wales Hospital, Shatin, Hong Kong;Shenzhen Second People's Hospital
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13636230
    </Internal_Number>
    <TrialID>DRKS00004235
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Prospective, controlled study of deep brain stimulation (DBS) in the region of the posterior subthalamic area (PSA) with a randomized, double-blinded, cross-over comparison between PSA- and nucleus ventralis intermedius (VIM)-DBS for the treatment of essential tremor (ET).
    </Public_title>
    <Scientific_title>Prospective, controlled study of deep brain stimulation (DBS) in the region of the posterior subthalamic area (PSA) with a randomized, double-blinded, cross-over comparison between PSA- and nucleus ventralis intermedius (VIM)-DBS for the treatment of essential tremor (ET). - PSA-VIM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>Uniklinik Köln, Neurologie,
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20130709
    </Date_registration3>
    <Date_registration>09/07/2013
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00004235
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>10/01/2013
    </Date_enrollement>
    <Target_size>15
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Randomized controlled study; Masking: Blinded (masking used); Control: active; Assignment: crossover; Study design purpose: treatment 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Alin
    </Contact_Firstname>
    <Contact_Lastname>Milke
    </Contact_Lastname>
    <Contact_Address>Kerpener Str. 62
    </Contact_Address>
    <Contact_Email>kerstin.donner@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>0221-478-87353
    </Contact_Tel>
    <Contact_Affiliation>Universität zu Köln
Neurologie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: i.) confirmed diagnosis of ET according to the Movement Disorder Society (MDS) consensus diagnostic criteria for ET&lt;br&gt;ii.) &gt;18 years of age, &lt;br&gt;iii.) sufficient competence in the German language, &lt;br&gt;iv.) at least two medication attempts without satisfactory tremor control, and &lt;br&gt;v.) capability of informed consent.&lt;br&gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;i.) clinically relevant dementia that might interfere with the study,&lt;br&gt;	ii.) clinically relevant psychiatric disorder that might interfere with the study,&lt;br&gt;	iii.) surgical contraindication for bilateral DBS, &lt;br&gt;	iv.) participation in another interventional trial, &lt;br&gt;	v.) brain atrophy (i.e. width of 3rd ventricle &gt; 10mm), and &lt;br&gt;	vi.) pre- and perioperative intake of anticoagulative medication.&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G25.0;Essential tremor;G25.0
    </Condition>
    <Intervention>Group 1:  VIM stimulation (deep brain stimulation in nucleus ventralis intermedius )&lt;br&gt;Group 2:  PSA stimulation (deep brain stimulation in posterior subthalamic area)
    </Intervention>
    <Primary_outcome>Reduction of the Fahn Tremor Rating Scale (FTRS) at 3, 5 and 7 months after implantation and stimulation by PSA-DBS com-pared to baseline&lt;br&gt;&lt;br&gt;Please note: Amendment from 04.11.2014 regarding the timepoint of Assesment of primary Endpoint. Approved by the Ethics Commitee.
    </Primary_outcome>
    <Secondary_outcome>- Baseline vs. 3, 5 and 7 MFU&lt;br&gt;&lt;br&gt;Key secondary endpoint(s) PSA-DBS:&lt;br&gt;o	Improvement of Quality of Life (SF-36, QUEST)&lt;br&gt;o	Depression (BDI-II)&lt;br&gt;o	Ataxia rating Scale (ICARS)&lt;br&gt;o	Visual analogue scales – tremor/dysarthria/gait/general (physician)&lt;br&gt;o	Visual analogue scales – tremor/dysarthria/gait/general (patient)&lt;br&gt;&lt;br&gt;&lt;br&gt;Key secondary endpoint(s) VIM/PSA comparison (cross-over):&lt;br&gt;o	Fahn Tremor Rating Scale (FTRS)&lt;br&gt;o	Quality of Life (SF-36)&lt;br&gt;o	Depression (BDI-II)&lt;br&gt;o	Ataxia rating Scale (ICARS)&lt;br&gt;o	SOFAS&lt;br&gt;o	Visual analogue scales – tremor/dysarthria/gait/general (physician)&lt;br&gt;o	Visual analogue scales – tremor/dysarthria/gait/general (patient)&lt;br&gt;o	Effect and side effect thresholds&lt;br&gt;o	Amount of current applied to the tissue&lt;br&gt;o	Occurrence of AEs and SAEs&lt;br&gt;&lt;br&gt;Assessment of safety:&lt;br&gt;o	Regular clinical assessment&lt;br&gt;o	Evaluation of  adverse events and severe adverse events
    </Secondary_outcome>
    <Source_Support>Uniklinik Köln
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>31/05/2012
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_date_completed>11/01/2017
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00004235#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13636666
    </Internal_Number>
    <TrialID>DRKS00004928
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Temporal percpeption of patients suffering from Essential Tremor with and without Deep Brain Stimulation
    </Public_title>
    <Scientific_title>Temporal percpeption of patients suffering from Essential Tremor with and without Deep Brain Stimulation - ColTrem V.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>Klinik und Poliklinik für Neurologie
Universitätsklinik zu Köln
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20130603
    </Date_registration3>
    <Date_registration>03/06/2013
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00004928
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>01/06/2013
    </Date_enrollement>
    <Target_size>45
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Non-randomized controlled study; Masking: Blinded (masking used); Control: Other//No treatment / Standard of care; Assignment: parallel; Study design purpose: basic science  
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>David J.
    </Contact_Firstname>
    <Contact_Lastname>Pedrosa
    </Contact_Lastname>
    <Contact_Address>Kerpener Straße 62
    </Contact_Address>
    <Contact_Email>david.pedrosa@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>(+49) 221- 478 4014
    </Contact_Tel>
    <Contact_Affiliation>Universitätsklinik Köln
Klinik und Poliklinik für Neurologie
AG Bewegungsstörungen
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Age- and sex-matched control probands:&lt;br&gt;Age between 18-80 years&lt;br&gt;&lt;br&gt;ET-patients without Deep Brain Stimulation:&lt;br&gt;Patients with essential tremor (ET) fulfilling the criteria of the consensus statement of the Movement Disorder Society&lt;br&gt;Age between 18-80 years&lt;br&gt;Disease duration of at least 5 years&lt;br&gt;&lt;br&gt;ET-patienten with Deep Brain Stimulation:&lt;br&gt;Patients with essential tremor (ET) fulfilling the criteria of the consensus statement of the Movement Disorder Society and DBS for at least 3 months&lt;br&gt;Age between 18-80 years&lt;br&gt;Disease duration of at least 5 years&lt;br&gt;Electrode localisation in the ventrolateral thalamus or areas just below (posterior subthalamic area, PSA)&lt;br&gt;Tolerabel tremor after switching off the stimulation
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Age- and sex-matched controls:&lt;br&gt;Subjects with a severe neurologic disease (e.g. epilepsy, brain tumor, ischaemic stroke, dystonia)&lt;br&gt;Conspicuities in the MRI&lt;br&gt;Medication affecting cognition which cannot be withdrawn for at least 24 hours&lt;br&gt;Hypokinesia or resting tremor possibly indicating an underlying Parkinson's disease&lt;br&gt;DemTect &lt; 9&lt;br&gt;Severe depression&lt;br&gt;&lt;br&gt;ET-patients without Deep Brain Stimulation:&lt;br&gt;Patients with a severe neurologic disease other than essential tremor (e.g. epilepsy, brain tumor, ischaemic stroke, dystonia)&lt;br&gt;Conspicuities in the MRI&lt;br&gt;Medication affecting cognition which cannot be withdrawn for at least 24 hours&lt;br&gt;Hypokinesia or resting tremor possibly indicating an underlying Parkinson's disease&lt;br&gt;DemTect &lt; 9&lt;br&gt;Severe depression&lt;br&gt;&lt;br&gt;ET-patients with Deep Brain Stimulation:&lt;br&gt;Patients with a severe neurologic disease other than essential tremor (e.g. epilepsy, brain tumor, ischaemic stroke, dystonia)&lt;br&gt;Medication affecting cognition which cannot be withdrawn for at least 24 hours&lt;br&gt;Hypokinesia or resting tremor possibly indicating an underlying Parkinson's disease&lt;br&gt;DemTect &lt; 9&lt;br&gt;Severe depression
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G25.0;Essential tremor;G25.0
    </Condition>
    <Intervention>Group 1: Age- and gender-matched controls, whose time perception is measured once&lt;br&gt;Group 2: ET-patients without deep brain stimulation whose time perception is measured once&lt;br&gt;Group 3: ET-patients with deep brain stimulation, whose time perception is measured three times during different and randomly assigned stimulation settings
    </Intervention>
    <Primary_outcome>Time perception is measured with a self programmed software once in ET-patients and control subjects. Additionally, ET-patients with DBS are tested during three different stimulation regimes in a randomized order.
    </Primary_outcome>
    <Secondary_outcome>Fahn Tolosa Marin Tremor Rating Score (TRS) is measured objectively via Video ratings and ultrasound based measurements
    </Secondary_outcome>
    <Source_Support>Klinik und Poliklinik für Neurologie
Universitätsklinik zu Köln;Klinische Forschergruppe 219 (DFG)
Basalganglien-Kortex-Schleifen:
Mechanismen pathologischer Interaktionen und ihre therapeutische Modulation
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>15/04/2013
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_date_completed>01/03/2014
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00004928#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>5286893
    </Internal_Number>
    <TrialID>NCT01845883
    </TrialID>
    <Last_Refreshed_on>28 December 2015
    </Last_Refreshed_on>
    <Public_title>Perceptual Decision Making Under Conditions of Visual Uncertainty
    </Public_title>
    <Scientific_title>Perceptual Decision Making Under Conditions of Visual Uncertainty
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of California, Los Angeles
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20130423
    </Date_registration3>
    <Date_registration>23/04/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01845883
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>April 2013
    </Date_enrollement>
    <Target_size>120
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Michele Basso, PhD;Alessandra Perugini, PhD
    </Contact_Lastname>
    <Contact_Email>;APerugini@mednet.ucla.edu
    </Contact_Email>
    <Contact_Tel>;3108250278
    </Contact_Tel>
    <Contact_Affiliation>UCLA David Geffen School of Medicine;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Group 1 - Age and Sex matched healthy controls:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 18-80 Years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Group 2 - Patients with Parkinson's Disease - No DBS:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  "on meds" and "off meds" (tested in separate sessions) - total of 2 sessions&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 45-80 Years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unified PD rating scale (UPDRS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mini mental health Status (MMHS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Group 3 - Patients with Parkinson's Disease already consented for DBS (STN):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 45-80 Years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unified PD rating scale (UPDRS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mini mental health Status (MMHS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Group 4 - Patients with Parkinson's Disease already consented for DBS (GPi):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 45-80 Years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unified PD rating scale (UPDRS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mini mental health Status (MMHS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Group 5 - Patients with Cervical Dystonia - No DBS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 30-80 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fahn-Marsden dystonia rating scale (FMDRS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mini mental health Status (MMHS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Group 6 - Patients with Generalized Dystonia (Ach) - No DBS:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 30-80 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fahn-Marsden dystonia rating scale (FMDRS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mini mental health Status (MMHS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Group 7 - Patients with Dystonia already consented for DBS (GPi):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 30-80 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fahn-Marsden dystonia rating scale (FMDRS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mini mental health Status (MMHS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Group 8 - Patients Cerebellar Stroke&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 30-80 Years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Routine neuro exam&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mini mental health Status (MMHS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Group 9 - Patients Cerebellar Ataxia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 30-80 Years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Routine neuro exam&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mini mental health Status (MMHS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Visual impairment or ocular motility disorder Inability to sit for the 30 minute task&#x0D;&lt;br&gt;             plus 20-30 minute instruction time, setup, and wait time.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For Group 1 (Age Sex Matched Controls), there will additional exclusion criteria of other&#x0D;&lt;br&gt;        neurological disease and drug use&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson's Disease;Dystonia;Ataxia
    </Condition>
    <Intervention>Procedure: Deep Brain Stimulation (DBS)
    </Intervention>
    <Primary_outcome>Choice performance - % correct responses out of total number of trials
    </Primary_outcome>
    <Secondary_outcome>Reaction Time to make a choice - measured in milliseconds
    </Secondary_outcome>
    <Secondary_ID>12-001589
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>The Dana Foundation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13721798
    </Internal_Number>
    <TrialID>NL-OMON39084
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>Treatment in advanced Parkinson*s disease: continuous intrajejunal levodopa infusion versus deep brain stimulation; a feasibility study
    </Public_title>
    <Scientific_title>Treatment in advanced Parkinson*s disease: continuous intrajejunal levodopa infusion versus deep brain stimulation; a feasibility study - INVEST (INfusion VErsus STimulation) feasibility study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Academisch Medisch Centrum
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20130327
    </Date_registration3>
    <Date_registration>2013-03-27
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/39084
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>64
    </Inclusion_agemax>
    <Inclusion_gender/>
    <Date_enrollement>2014-03-24
    </Date_enrollement>
    <Target_size>59
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Open (masking not used), Uncontrolled, Other
    </Study_design>
    <Phase/>
    <Countries>Netherlands
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address>Meibergdreef 9
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Academisch Medisch Centrum
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;p&gt;-idiopathic PD with bradykinesia and at least two of the following signs; resting tremor, rigidity, and asymmetry; &lt;br&gt;-despite optimal pharmacological treatment at least one of the following symptoms: severe response fluctuations, dyskinesias, painful dystonias, or bradykinesia; &lt;br&gt;-a life expectancy of more than two years. &lt;br&gt;&lt;/p&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;p&gt;-age below 18 years; &lt;br&gt;-previous PD-neurosurgery (e.g. DBS, pallidotomy, thalamotomy); &lt;br&gt;-previous CLI (through a PEG-tube or Nasal Jejunal tube); &lt;br&gt;-Hoehn and Yahr stage 5 at the best moment during the day; &lt;br&gt;-a Montreal Cognitive Assessment score of 25 or less (MOCA; http://www.mocatest.org); &lt;br&gt;-psychosis; &lt;br&gt;-current depression despite optimal pharmacotherapy; &lt;br&gt;-contraindications for DBS surgery, such as a physical disorder making surgery hazardous; &lt;br&gt;-contraindications for PEG surgery and Duodopa; &lt;br&gt;-pregnancy, breastfeeding, and women of child bearing age not using a reliable method of contraception; &lt;br&gt;-inability to provide written informed consent; &lt;br&gt;-legally incompetent adults. &lt;br&gt;&lt;/p&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Parkinson's Disease; Parkinson;10028037;Parkinson's Disease; Parkinson
    </Condition>
    <Intervention>&lt;p&gt;For CLI treatment, a tube will be placed in the jejunum via a percutaneous &lt;br&gt;endoscopic gastrostomy (PEG). This tube is connected to an external pump that &lt;br&gt;delivers the levodopa-gel. For DBS treatment, 2 electrodes will be implanted in &lt;br&gt;the brain. The electrodes are connected to an implanted pulse generator, which &lt;br&gt;will be placed subcutaneously in the subclavian area.&lt;/p&gt;&lt;br&gt;;Continuous Levodopa Infusion;Deep Brain Stimulation;Parkinson Disease
    </Intervention>
    <Primary_outcome>&lt;p&gt;The main objective is the randomization rate, measured as the percentage of&lt;br /&gt;&lt;br&gt;patients that agrees to be randomized to CLI or DBS out of all eligible&lt;br /&gt;&lt;br&gt;patients.&lt;/p&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>&lt;p&gt;For the cross-sectional study, the secondary outcome measure is a structured&lt;br /&gt;&#x0D;&lt;br&gt;interview, qualitatively evaluating the reasons for declining randomization.&lt;br /&gt;&#x0D;&lt;br&gt;&lt;br /&gt;&#x0D;&lt;br&gt;n the pilot-trial, we will assess the implementation of the research protocol&lt;br /&gt;&#x0D;&lt;br&gt;including possible future outcome measures like the PDQ-39, UPDRS, ALDS, and&lt;br /&gt;&#x0D;&lt;br&gt;EQ-5D, neuropsychological and psychiatric measures and costs.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>2012-004643-69;NL41114.018.12
    </Secondary_ID>
    <Source_Support>Ministerie van OC&amp;W;Reserve De Bie AMC
    </Source_Support>
    <Ethics_review_status>Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>22/03/2013;11/03/2014
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>;
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13071483
    </Internal_Number>
    <TrialID>NCT01817517
    </TrialID>
    <Last_Refreshed_on>29 May 2023
    </Last_Refreshed_on>
    <Public_title>Thalamic Deep Brain Stimulation for the Treatment of Refractory Tourette Syndrome
    </Public_title>
    <Scientific_title>Phase 1 Study of Thalamic Deep Brain Stimulation for the Treatment of Refractory Tourette Syndrome
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Johns Hopkins University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20130318
    </Date_registration3>
    <Date_registration>18/03/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01817517
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 2014
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Shannon L Dean, MD, PhD;Shannon L Dean, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;sdean1@jh.edu
    </Contact_Email>
    <Contact_Tel>;4439234100
    </Contact_Tel>
    <Contact_Affiliation>The Johns Hopkins University School of Medicine, Kennedy Krieger Institute;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Males and females who are &gt;=15 years of age. There is no strict age cutoff at the&#x0D;&lt;br&gt;             upper limit of inclusion, however subjects may meet the exclusion criteria based on&#x0D;&lt;br&gt;             medical contraindications to deep brain stimulation surgery (Points 3. and 6. under&#x0D;&lt;br&gt;             the Exclusion Criteria). For subjects in the age range of 15-24 years, an additional&#x0D;&lt;br&gt;             Ethics Committee consultation will be obtained prior to offering the subject the&#x0D;&lt;br&gt;             required screening visit. This is based on the revised screening criteria now proposed&#x0D;&lt;br&gt;             by Shrock, Mink, et al. on studies investigating DBS in TS. Additionally, for subjects&#x0D;&lt;br&gt;             in the age range of 15-20, a caregiver will be required to be present for all study&#x0D;&lt;br&gt;             visits.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subject has a diagnosis of TS as determined by a review of medical records, discussion&#x0D;&lt;br&gt;             with referring psychiatrist as well as the DSM-IV criteria and videotaped assessment.&#x0D;&lt;br&gt;             This will include an assessment to determine the presence of psychogenic tics,&#x0D;&lt;br&gt;             embellishment, factitious symptoms, personality disorders and malingering.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Subject determined to be treatment-resistant for at least one year prior to the&#x0D;&lt;br&gt;             Screening Visit as demonstrated by clinical evidence (determined by review of medical&#x0D;&lt;br&gt;             records and discussion with referring psychiatrist or neurologist) of persistent&#x0D;&lt;br&gt;             functionally impairing tics that have not responded to treatment with a minimum of&#x0D;&lt;br&gt;             three adequate regimens of medication including two failed trials of at least one&#x0D;&lt;br&gt;             typical neuroleptic and one atypical neuroleptic medication, along with one failed&#x0D;&lt;br&gt;             trial of a first tier medication as defined as follows:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Adequate trials of one non-neuroleptic medication including drugs from the&#x0D;&lt;br&gt;                  following (first tier) list: clonidine, guanfacine, topiramate, baclofen,&#x0D;&lt;br&gt;                  levetiracetam, and clonazepam. Trial failure is defined as demonstrated lack of&#x0D;&lt;br&gt;                  efficacy or severe side effects.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Two adequate trials of at least one typical neuroleptic medication (pimozide,&#x0D;&lt;br&gt;                  fluphenazine, haloperidol) and at least one atypical neuroleptic (risperidone,&#x0D;&lt;br&gt;                  aripiprazole, ziprasidone, olanzapine, quetiapine). Trial failure is defined as&#x0D;&lt;br&gt;                  demonstrated lack of efficacy or severe side effects.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. A mandatory trial of behavioral interventions in an attempt to reduce the severity of&#x0D;&lt;br&gt;             the tics or comorbid symptoms must also be completed by the subject before offering&#x0D;&lt;br&gt;             participation in this trial. This may include habit reversal therapies, stress&#x0D;&lt;br&gt;             reduction therapies, or other behavioral therapies under investigation for tic&#x0D;&lt;br&gt;             suppression.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Subject has both significant vocal and motor tics with a tic subscale score of at&#x0D;&lt;br&gt;             least 35 on the YGTSS (Yale Global Tic Severity Scale) at all three Baseline Visits&#x0D;&lt;br&gt;             prior to undergoing surgery. For subjects with predominantly vocal tics (and minimal&#x0D;&lt;br&gt;             motor) causing significant problems this score requirement will be reduced to 18,&#x0D;&lt;br&gt;             similarly for subjects with predominantly motor tics (and minimal vocal) causing&#x0D;&lt;br&gt;             significant problems the required score will be 18. A portion of the study team,&#x0D;&lt;br&gt;             including the surgeon and two neurologists, will determine by consensus which category&#x0D;&lt;br&gt;             the subject falls into and whether the tics are a significant problem.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. All other aspects of the subject's care must be optimized during the preceding 6&#x0D;&lt;br&gt;             months before admission to the study. This includes treatment for comorbid medical,&#x0D;&lt;br&gt;             neurological, and psychiatric disorders. Additionally, it includes psychological&#x0D;&lt;br&gt;             interventions for any ongoing psychosocial problems the subject may have during the&#x0D;&lt;br&gt;             preceding 6 months before study admission.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Subject must be ambulatory.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Females who are postmenopausal, physically incapable of childbearing, or practicing an&#x0D;&lt;br&gt;             acceptable method of birth control. Acceptable methods of birth control include&#x0D;&lt;br&gt;             surgical sterilization, hormonal contraceptives, or double-barrier methods (condom or&#x0D;&lt;br&gt;             diaphragm with a spermicidal agent or intrauterine device [IUD]). If practicing an&#x0D;&lt;br&gt;             acceptable method of birth control, a negative urine pregnancy test result has been&#x0D;&lt;br&gt;             obtained at baseline Visits 1 and 3.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Subject is determined by an independent psychiatrist with expertise in capacity&#x0D;&lt;br&gt;             assessments to have decision-making capacity to provide informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Subject is able to read English, understand and cooperate with study procedures, and&#x0D;&lt;br&gt;             has signed a written informed consent form prior to any study procedures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subject has a positive urine drug screen at any of the three Baseline Visits.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subject had major surgery within three months prior to Baseline Visit 1 or has other&#x0D;&lt;br&gt;             surgery planned during the proposed study period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Subject is determined by medical consultant to have medical contraindications to&#x0D;&lt;br&gt;             undergoing surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Subject is pregnant or breast-feeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Subject has a history of alcohol or drug abuse within the past 6 months and/or&#x0D;&lt;br&gt;             dependence within the past year.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Subject has a medical illness/condition, and/or abnormal diagnostic finding that would&#x0D;&lt;br&gt;             interfere with the completion of the study, confound the results of the study, or pose&#x0D;&lt;br&gt;             risk to the patient.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Subject has an untreated or uncontrolled Axis I disorder or other major psychiatric&#x0D;&lt;br&gt;             disorder including major depression, bipolar disorder, or schizophrenia as determined&#x0D;&lt;br&gt;             by the screening psychiatrist.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Subject has either a current or past history of suicidal plan and/or intent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Subject has a tic disorder or other movement disorder attributable to another medical,&#x0D;&lt;br&gt;             neurological, or psychiatric disorder other than Tourette Syndrome.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Subject has a drug-induced tic disorder.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Subject has significant psychosocial factors that might increase the risk of the DBS&#x0D;&lt;br&gt;             procedure or complicate recovery and outcome assessments. (Examples include - history&#x0D;&lt;br&gt;             of noncompliance with previous medical and psychosocial treatments, multiple failed&#x0D;&lt;br&gt;             medication treatments of inadequate dose or duration, a history of multiple other&#x0D;&lt;br&gt;             surgical procedures with poor outcome, unexplained medical history gaps, or pending&#x0D;&lt;br&gt;             lawsuits or other legal action.)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Subject has metal in the head or any other type of implanted stimulator (i.e. cardiac&#x0D;&lt;br&gt;             pacemaker, deep brain stimulator for a different disease, spinal cord stimulator,&#x0D;&lt;br&gt;             cochlear implant, vagus nerve stimulator, etc.).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Subject has participated in another investigational drug trial or therapeutic trial&#x0D;&lt;br&gt;             within 30 days of Baseline Visit 1.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. Subject has a diagnosis of intellectual disability with documented IQ&lt;70.&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome
    </Condition>
    <Intervention>Device: Medtronic Activa Deep Brain Stimulation System
    </Intervention>
    <Primary_outcome>Change from baseline in the Yale Global Tic Severity Scale (YGTSS);Incidence of adverse device effects (ADEs).
    </Primary_outcome>
    <Secondary_outcome>Change from baseline in the Yale-Brown Obsessive Compulsive Scale;Change from baseline in the WHO Adult ADHD Self-Report Scale (ASRS)
    </Secondary_outcome>
    <Secondary_ID>NA_00073086
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13443389
    </Internal_Number>
    <TrialID>JPRN-UMIN000009229
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Juntendo Early Deep Brain Stimulation Trial (JuST)
    </Public_title>
    <Scientific_title>Juntendo Early Deep Brain Stimulation Trial (JuST) - JuST trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Department of Research and Therapeutics for Movement Disorders, Juntendo University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20121101
    </Date_registration3>
    <Date_registration>01/11/2012
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010634
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20years-old
    </Inclusion_agemin>
    <Inclusion_agemax>75years-old
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2012/10/22
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel Non-randomized
    </Study_design>
    <Phase>Not applicable
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname>Atsushi
    </Contact_Firstname>
    <Contact_Lastname>Umemura
    </Contact_Lastname>
    <Contact_Address>2-1-1 Hongo, Bunkyo, Tokyo
    </Contact_Address>
    <Contact_Email>g_oyama@juntendo.ac.jp
    </Contact_Email>
    <Contact_Tel>+81-3-3813-3111
    </Contact_Tel>
    <Contact_Affiliation>Juntendo University Department of Research and Therapeutics for Movement Disorders
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pregnancy  2. Patients who cannot understand informed consent.  3. Patients who are participating other clinical trial.  4. Patients who are considered not appropriate for the study by investigator.
    </Exclusion_Criteria>
    <Condition>Parkinson&amp;#39;s disease
    </Condition>
    <Intervention>Combination of deep brain stimulation and best medical treatment&lt;br&gt;Best medical treatment
    </Intervention>
    <Primary_outcome>The Parkinson&amp;#39;s Disease Questionnaire (PDQ-39)
    </Primary_outcome>
    <Secondary_outcome>Unified Parkinoson&amp;#39;s Disease Rating Scale (UPDRS) part I-IV, Modified Hoehn &amp;amp; Yahr stage, Beck Depression Inventory (BDI), Hamilton Rating Scale for Depression (HAMD), Montgomery-Asberg Depression Scale (MADRS), Zung Self-rating Depression Scale (SDS), Apathy scale (AS), Mini-Mental State Examination (MMSE), Frontal Assessment Battery (FAB), Japanese version of Montreal Cognitive Assessment (MoCA-J), Keio version Wisconsin card sorting test (KWCST), other adverse events (impulse control disorder, dopamine disregulation syndrome, dopamine agonist withdrawal syndrome, e.t.c.)
    </Secondary_outcome>
    <Source_Support>Department of Research and Therapeutics for Movement Disorders, Juntendo University
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>22/10/2012
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>g_oyama@juntendo.ac.jp
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Juntendo University Faculty of Medicine
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>0338133111
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>g_oyama@juntendo.ac.jp
    </Ethics_review_contact_email>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>06/11/2019
    </results_date_posted>
    <results_date_completed>31/03/2016
    </results_date_completed>
    <results_url_link>NA
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13739998
    </Internal_Number>
    <TrialID>NL-OMON20700
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>Intra-operative evaluation of efficacy and safety of a new lead for steering Deep Brain Stimulation.
    </Public_title>
    <Scientific_title>Intra-operative evaluation of efficacy and safety of a new lead for steering Deep Brain Stimulation.&#x0D;
 First Acute-in-Man Evaluation of Steering Brain Stimulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Sapiens Steering Brain Stimulation B.V.&#x0D;
H.C.F. Martens, PhD&#x0D;
Director of Clinical Science&#x0D;
High Tech Campus 48&#x0D;
5656 AE Eindhoven&#x0D;
The Netherlands&#x0D;
Tel: +31 40 800 2104&#x0D;

    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20121008
    </Date_registration3>
    <Date_registration>2012-10-08
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/20700
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>2012-10-22
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Observational non invasive
    </Study_type>
    <Study_design>N/A: single arm study, Open (masking not used), N/A , unknown, Parallel
    </Study_design>
    <Phase/>
    <Contact_Firstname>P.R.
    </Contact_Firstname>
    <Contact_Lastname>Schuurman
    </Contact_Lastname>
    <Contact_Address>Meibergdreef 9
    </Contact_Address>
    <Contact_Email>p.r.schuurman@amc.nl
    </Contact_Email>
    <Contact_Tel>+31 (0)20 5669111
    </Contact_Tel>
    <Contact_Affiliation>Academic Medical Center (AMC), department of Neurosurgery,&#x0D;
P.O. Box 22660
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Diagnosis of idiopathic Parkinson's disease;&lt;br /&gt;&lt;br&gt;2. Clinical indication for STN DBS with MER;&lt;br /&gt;&lt;br&gt;3. Age &gt; 18 years;&lt;br /&gt;&lt;br&gt;4. Subject is a male or non-pregnant female;&lt;br /&gt;&lt;br&gt;5. Ability to comply with the study assignments;&lt;br /&gt;&lt;br&gt;6. Ability to give informed consent.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Parkinson's disease graded according to Hoehn and Yahr stage 5;&lt;br /&gt;&lt;br&gt;2. Score on MATTIS dementia rating scale &lt;120;&lt;br /&gt;&lt;br&gt;3. Psychiatric contraindications to STN DBS;&lt;br /&gt;&lt;br&gt;4. General contraindications for stereotactic surgery and general anaesthesia (e.g.  severe hypertension, blood coagulation disorder);&lt;br /&gt;&lt;br&gt;5. Subject has factors that would put the subject at an additional risk for intra-operative or postoperative bleeding. This includes underlying disorders of the coagulation cascade (eg, hemophilia), disorders that affect platelet count or function (eg, Von Willebrand's disease), as well as administration of any anti-platelet or anti-coagulant medication in the 7 days prior to surgery, or any history of anticoagulant or aspirin use or history of hemorrhagic stroke, that in the view of the neurosurgeon or neurologist would place the subject at an increased risk for intra-operative or postoperative bleeding;&lt;br /&gt;&lt;br&gt;6. Subject has a diagnosis of acute myocardial infarction or cardiac arrest less than or equal to 6 months prior to the screening testing;&lt;br /&gt;&lt;br&gt;7. Subject has a history of a seizure disorder;&lt;br /&gt;&lt;br&gt;8. Subject requires short surgery time due to general health issues, as determined by the investigator;&lt;br /&gt;&lt;br&gt;9. Subject is a woman who is pregnant or planning to become pregnant, or a woman of child-bearing potential, who is not using a medically-acceptable method of birth control. Women of child-bearing potential must undergo a pregnancy test, with a clear negative result, no more than 7 days prior to the investigational procedure visit.
    </Exclusion_Criteria>
    <Condition>Parkinson's disease, Deep Brain Stimulation&#x0D;
Ziekte van Parkinson, Diepe Hersenstimulatie
    </Condition>
    <Intervention>Sapiens Deep brain stimulation lead.
    </Intervention>
    <Primary_outcome>1. Description of and threshold for effects obtained by stimulation through Sapiens lead in standard mode;&lt;br /&gt;&lt;br&gt;2. Analysis of safety of stimulation with the Sapiens lead compared to control data.
    </Primary_outcome>
    <Secondary_outcome>1. Description of and threshold for effects obtained by stimulation through Sapiens lead in different modes;&lt;br /&gt;&lt;br&gt;2. Determination and comparison of "therapeutic window", obtained by stimulation through Sapiens lead in different modes.
    </Secondary_outcome>
    <Secondary_ID>NL3475;NTR3655;CCMO : S-12-0076 / NL40206.018.12;;ISRCTN wordt niet meer aangevraagd.
    </Secondary_ID>
    <Source_Support>Sapiens Steering Brain Stimulation B.V.
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>08/10/2012
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13636213
    </Internal_Number>
    <TrialID>DRKS00004210
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Effects of DBS on cognition of ppatients with essential tremor
    </Public_title>
    <Scientific_title>Effects of DBS on cognition of ppatients with essential tremor - ColTrem V                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum Köln
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20120627
    </Date_registration3>
    <Date_registration>27/06/2012
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00004210
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>28/06/2012
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Randomized controlled study; Masking: Blinded (masking used); Control: active//placebo; Assignment: parallel; Study design purpose: basic science  
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>David J.
    </Contact_Firstname>
    <Contact_Lastname>Pedrosa
    </Contact_Lastname>
    <Contact_Address>Kerpener Straße 62
    </Contact_Address>
    <Contact_Email>david.pedrosa@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>(+49) 221- 478 4014
    </Contact_Tel>
    <Contact_Affiliation>Universitätsklinik Köln
Klinik und Poliklinik für Neurologie
AG Bewegungsstörungen
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Subjects with essential tremor treated by DBS at least 3 months ago&lt;br&gt;Localization of electrodes in the Vim/Vlp or the posterior subthalamic Area (PSA)&lt;br&gt;Tolerable Tremor after switching off stimulation&lt;br&gt;Age between 18 and 80 years&lt;br&gt;Disease duration longer than 5 years&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Subjects with other severe neurological disease&lt;br&gt;Irregularities in cranial imaging&lt;br&gt;Subjects suffering from rest tremor or bradykinesia on one side&lt;br&gt;DemTect &lt; 9&lt;br&gt;Subjects suffering from depression 
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G25.0;Essential tremor;G25.0
    </Condition>
    <Intervention>Group 1: Patient with optimal settings of DBS under which motor symptoms are best under control&lt;br&gt;Group 2: Patients without DBS&lt;br&gt;Group 3: Patients with ineffective DBS
    </Intervention>
    <Primary_outcome>Cognitive assessment through questionnaires: 1. Stroop-Test, 2. Hamilton anxiety rating scale (HARS), 3. Verbal fluency. 1+3 are tested in every condition and 2 is tested only once
    </Primary_outcome>
    <Secondary_outcome>Tremor improvement by DBS, measured by TRG Essential Tremor Rating Assessment Scale
    </Secondary_outcome>
    <Source_Support>Universitätsklinikum Köln
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>16/01/2012
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_date_completed>01/10/2012
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00004210#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13701626
    </Internal_Number>
    <TrialID>NCT01581580
    </TrialID>
    <Last_Refreshed_on>27 February 2024
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation Surgery for Movement Disorders
    </Public_title>
    <Scientific_title>Deep Brain Stimulation Surgery for Movement Disorders
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20120419
    </Date_registration3>
    <Date_registration>19/04/2012
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT01581580
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 17, 2011
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Kareem A Zaghloul, M.D.;Gretchen C Scott, R.N.;For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
    </Contact_Lastname>
    <Contact_Email>;SNBrecruiting@nih.gov;ccopr@nih.gov
    </Contact_Email>
    <Contact_Tel>;Not Listed;800-411-1222
    </Contact_Tel>
    <Contact_Affiliation>National Institute of Neurological Disorders and Stroke (NINDS);
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        -  INCLUSION CRITERIA:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        To be eligible for entry into the study, candidates must meet all the following criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Be 18 years of age or older.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Able to provide informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Have a clinical diagnosis of one of the following as confirmed by the NIH movement&#x0D;&lt;br&gt;        disorders clinic team and the multi-disciplinary DBS surgical conference, and deemed as&#x0D;&lt;br&gt;        appropriate for the use of Deep Brain Stimulation therapy:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  idiopathic PD not adequately controlled with medication or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  primary dystonia that is medically refractory, or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ET that is not adequately controlled by medications or constitutes a significant&#x0D;&lt;br&gt;             functional disability.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        EXCLUSION CRITERIA:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Candidates will be excluded if they:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Are unable or unwilling to give informed consent to the research procedures.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson's Disease;Essential Tremor;Dystonia
    </Condition>
    <Intervention>Procedure: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>physiology and efficacy of DBS surgery for movement disorders
    </Primary_outcome>
    <Secondary_ID>11-N-0211;110211
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13636015
    </Internal_Number>
    <TrialID>DRKS00003530
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>The impact of deep brain stimulation on intrinsic frontal lobe organization
    </Public_title>
    <Scientific_title>The impact of deep brain stimulation on intrinsic frontal lobe organization                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>Neurologische Universitätsklinik Freiburg
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20120210
    </Date_registration3>
    <Date_registration>10/02/2012
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00003530
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>04/06/2013
    </Date_enrollement>
    <Target_size>48
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: basic science  
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Lena
    </Contact_Firstname>
    <Contact_Lastname>Köstering
    </Contact_Lastname>
    <Contact_Address>Breisacher Strasse 64
    </Contact_Address>
    <Contact_Email>lena.koestering@uniklinik-freiburg.de
    </Contact_Email>
    <Contact_Tel>0761 270 54795
    </Contact_Tel>
    <Contact_Affiliation>Neurologische Universitätsklinik Freiburg
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: healthy test persons;  Parkinson's Disease patients with implanted deep brain stimulation system
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: brain trauma with brain damage (contusion)
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: The deep brain stimulation system will be deactivated after the information of the patient and the signing of the consent, followed by the application of the optodes above the frontal cortex. After a defined period of 2 h, necessary for reaching a steady state, we will measure the metabolism in the frontal cortex, using near-infrared spectroscopy (NIRS) for 8 minutes. Afterwards the stimulator will be turned on, while measuring for another 24 minutes. So the overall recording will take 32 minutes. &lt;br&gt;Group 2: Healthy control subjects: The metabolism of the frontal cortex will be recorded for 32 minutes, using near-infrared spectroscopy (NIRS).
    </Intervention>
    <Primary_outcome>The comparison of the frontal organization in  Parkinson's Disease patients with that of a control collective, using fNIRS (near-infrared spectroscopy).
    </Primary_outcome>
    <Secondary_outcome>The comparison of the frontal organization in PD patients with activated vs. deactivated DBS, using fNIRS.
    </Secondary_outcome>
    <Secondary_ID>U1111-1127-6717
    </Secondary_ID>
    <Source_Support>Neurologische Universitätsklinik Freiburg
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>19/01/2012
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-761-27072600
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ekfr.mpg@uniklinik-freiburg.de
    </Ethics_review_contact_email>
    <results_date_completed>24/11/2015
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00003530#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10216355
    </Internal_Number>
    <TrialID>NCT01485276
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Combined Deep Brain Stimulation for Parkinson's Disease
    </Public_title>
    <Scientific_title>Pilot Study of Bilateral Pedunculo-Pontine Nucleus (PPN) Deep Brain Stimulation for Patients With Parkinson Disease (PD) Who Have Persistent Gait Disturbance, Despite Bilateral Subthalamic Nucleus (STN) Deep Brain Stimulation
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20111202
    </Date_registration3>
    <Date_registration>02/12/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01485276
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>22 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 8, 2011
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 1/Phase 2
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Mark Hallett, M.D.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>National Institute of Neurological Disorders and Stroke (NINDS)
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        -INCLUSION CRITERIA:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        i. Greater than 22 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        ii. Successful bilateral STN DBS implants for at least 1 year&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        iii. At least 30% improvement in the motor UPDRS following STN therapy, by history and&#x0D;&lt;br&gt;        record review&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        iv. Improved UPDRS and self assessment questionnaire following STN DBS by at least 20%, by&#x0D;&lt;br&gt;        history and record review.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        v. Good STN DBS placement assessed with imaging (CT scan, MRI or fused CT-MRI imaging)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        vii. Persistent gait disturbance as ascertained by abnormal performance on the&#x0D;&lt;br&gt;        time-up-and-go test compared to age-matched controls as well as preoperative evaluation&#x0D;&lt;br&gt;        with posturography and quantitative gait assessment (values compared to normal age-matched&#x0D;&lt;br&gt;        controls) at least 30% difference from age-matched controls on either measure.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        vii. Persistent speech and swallowing problems as measured by a minimum score of I in items&#x0D;&lt;br&gt;        5 and 7 of the UPDRS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        viii. Evaluation by an independent movement disorders specialist who will confirm gait&#x0D;&lt;br&gt;        disturbance in the presence of STN stimulation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        EXCLUSION CRITERIA:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        i. Pregnant or nursing women&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        ii. Cognitively impaired subjects as determined by pre-operative neuropsychology&#x0D;&lt;br&gt;        evaluation, including Mattis Dementia Rating Scale (DRS). Patients scoring below 70 on the&#x0D;&lt;br&gt;        Mattis DRS will be excluded.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        iii. Depressed subjects as determined by the neuropsychology screen, including Beck&#x0D;&lt;br&gt;        Depression Inventory. Patients scoring above 20 on the Beck inventory will be excluded.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        iv. Patients with uncontrolled co-existing medical conditions: uncontrolled systemic&#x0D;&lt;br&gt;        hypertension with values above 170/100; heart disease needing intervention; respiratory&#x0D;&lt;br&gt;        disease needing intervention; uncorrected coagulation abnormalities or need for therapeutic&#x0D;&lt;br&gt;        anticoagulation which cannot be interrupted; any condition that would render the patient&#x0D;&lt;br&gt;        unable to safely cooperate with the study tests as judged by the screening physician.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        v. Patients with metal objects in their body that are not MRI compatible, excluding the&#x0D;&lt;br&gt;        previous STN DBS hardware&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        vi. Patients who have a history of seizures, require repeated magnetic resonance imaging&#x0D;&lt;br&gt;        (MRI) scans or have had a cranial neurosurgical procedure since receiving an STN implant.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Procedure: DBS Surgery
    </Intervention>
    <Primary_outcome>Change in the amount of time needed to complete a standardized timed up and go (TUG) study at 6 months post-surgery on stimulation
    </Primary_outcome>
    <Secondary_outcome>TUG study at 1, 3 and 12 months post-surgery.;UPDRS III score and UPDRS III points 27-30 at 1, 3, 6 and 12 months;PDQ 31 questionnaire at 6 months;Swallowing function at 6 moths;Static and dynamic posturography parameters at 1, 3, 6 and 12 months on stimulation.
    </Secondary_outcome>
    <Secondary_ID>12-N-0012;120012
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13635766
    </Internal_Number>
    <TrialID>DRKS00003137
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Networkmodulation in Dystonia patients with Globus pallidus deep brain stimulation with H2O-PET
    </Public_title>
    <Scientific_title>Networkmodulation in Dystonia patients with Globus pallidus deep brain stimulation with H2O-PET - DYSTO-PET                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>Uniklinik Köln
Klinik für Neurologie
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20111018
    </Date_registration3>
    <Date_registration>18/10/2011
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00003137
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>01/06/2010
    </Date_enrollement>
    <Target_size>36
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: basic science  
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Lars
    </Contact_Firstname>
    <Contact_Lastname>Timmermann
    </Contact_Lastname>
    <Contact_Address>Kerpener Str. 62
    </Contact_Address>
    <Contact_Email>lars.timmermann@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>0221/4787494
    </Contact_Tel>
    <Contact_Affiliation>Uniklinik Köln
Klinik für Neurologie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: - male or female patients with cervical or segmental dystonia with or without deep brain stimulation in the globus pallidus internus&lt;br&gt;- diagnosis has to be confirmed with the clinical course and a neurological examination&lt;br&gt;- dystonia has to be bearable after switching the deep brain stimulation
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: - no preoperative coregistered cranial magnetresonancetomography in case of patients with deep brain stimulation&lt;br&gt;- patients with other neurological disorders (e.g. epilepsia, stroke, Alzheimer's dementia)&lt;br&gt;- life-threatening diseases&lt;br&gt;- severe psychiatric disorders&lt;br&gt;- obvious premorbid mental deficits&lt;br&gt;- pregnant women
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G24;Dystonia
    </Condition>
    <Intervention>Group 1: Patients with dystonia without deep brain stimulation&lt;br&gt;&lt;br&gt;Examination:&lt;br&gt;H2O-positron emission tomography (PET) with active and passive finger movement and simultaneous EMG-recording at one timepoint&lt;br&gt;Group 2: Patients with dystonia with deep brain stimulation&lt;br&gt;&lt;br&gt;Examination:&lt;br&gt;H2O-positron emission tomography (PET) with active and passive finger movementand simultaneous EMG-recording at one timepoint&lt;br&gt;Group 3: Healthy controls&lt;br&gt;&lt;br&gt;Examination:&lt;br&gt;H2O-positron emission tomography (PET) with active and passive finger movement and simultaneous EMG-recording at one timepoint
    </Intervention>
    <Primary_outcome>changes in the blood flow in H2O-PET between the following conditions/groups:&lt;br&gt;1. patients in the rest-condition with and without deep brain stimulation&lt;br&gt;2. patients in the rest-condition with and without dystonia&lt;br&gt;3. patients with dystonia and deep brain stimulation in the active and passive movement condition&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>Changes in the muscular oscillations in the EMG in the following conditions/groups:&lt;br&gt;1. patients in the rest-condition with and without deep brain stimulation&lt;br&gt;2. patients in the rest-condition with and without dystonia&lt;br&gt;3. patients with dystonia and deep brain stimulation in the active and passive movement condition&lt;br&gt;
    </Secondary_outcome>
    <Source_Support>Uniklinik Köln
Klinik für Neurologie
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>04/05/2009
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_date_completed>31/05/2015
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00003137#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13440108
    </Internal_Number>
    <TrialID>JPRN-UMIN000005941
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>usefulness of neuro mate for stereotactic functional surgery for Parkinson disease
    </Public_title>
    <Scientific_title>usefulness of neuro mate for stereotactic functional surgery for Parkinson disease - usefulness of neuro mate for stereotactic functional surgery                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Nagoya University hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20110901
    </Date_registration3>
    <Date_registration>01/09/2011
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007022
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20years-old
    </Inclusion_agemin>
    <Inclusion_agemax>80years-old
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2011/09/01
    </Date_enrollement>
    <Target_size>8
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single arm Non-randomized
    </Study_design>
    <Phase>Not applicable
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname>Shimizu Shinobu
    </Contact_Lastname>
    <Contact_Address>65 Tsurumai Shouwa Nagoya
    </Contact_Address>
    <Contact_Email>s-shimizu@med.nagoya-u.ac.jp
    </Contact_Email>
    <Contact_Tel>052-744-2942
    </Contact_Tel>
    <Contact_Affiliation>Nagoya University hospital center for clinical study and
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: patients with severe physical and mental disorder
    </Exclusion_Criteria>
    <Condition>Parkinson disease
    </Condition>
    <Intervention>deep brain stimulation
    </Intervention>
    <Primary_outcome>Accuracy of electrode implantation  Unified Parkinson disease rating scale
    </Primary_outcome>
    <Secondary_outcome>Yahr grade, Mini Mental Scale Examination
    </Secondary_outcome>
    <Source_Support>Nagoya University hospital
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/10/2014
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13635741
    </Internal_Number>
    <TrialID>DRKS00003105
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Deep brain stimulation in idiopathic dystonia: clinical characterisation of a cohort of patients with therapeutic failure of GPi-DBS
    </Public_title>
    <Scientific_title>Deep brain stimulation in idiopathic dystonia: clinical characterisation of a cohort of patients with therapeutic failure of GPi-DBS - GPi-DBS-failure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>Klinik und Poliklinik fuer Neurologie
Uniklinik Köln
Medizinische Fakultaet der Universitaet zu Koeln
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20110711
    </Date_registration3>
    <Date_registration>11/07/2011
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00003105
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>31/10/2010
    </Date_enrollement>
    <Target_size>26
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: treatment 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Amande
    </Contact_Firstname>
    <Contact_Lastname>Pauls
    </Contact_Lastname>
    <Contact_Address>Kerpener Str. 62
    </Contact_Address>
    <Contact_Email>amande.pauls@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>0221-47897818
    </Contact_Tel>
    <Contact_Affiliation>Neurologie, Uniklinik Köln
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: - age between 18-85 years&lt;br&gt;- diagnosis of idiopathic dystonia at time of surgery&lt;br&gt;- bilateral GPI-DBS&lt;br&gt;- poor response to GPI-DBS (less than 30 % improvement on the BFMDRS-M compared to preoperative state)&lt;br&gt;- stable clinical status after GPi-DBS for a minimum of 3 months&lt;br&gt;- written informed consent given by patient&lt;br&gt;- no other severe neurological or other clinical problem
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: - other severe neurological disease (dementia, epilepsy)&lt;br&gt;- persons who are not legally competent, minors and indivduals who have been under custody due to a court ruling or by decision of public authorities
    </Exclusion_Criteria>
    <Condition>insufficient response to deep brain stimulation of the internal part of the globus pallidus &lt;br&gt;G24.1;Idiopathic familial dystonia;G24.1
    </Condition>
    <Intervention>Group 1: cross-sectional study in a cohort of 26 patients with GPi-DBS and insufficient therapeutic response to GPi-DBS&lt;br&gt;clinical examination and characterisation of cohort
    </Intervention>
    <Primary_outcome>cross-sectional study: examination of patients with poor therapeutic response to GPi-DBS (Globus Pallidus internus- deep brain stimulation), clinical characterisation of this patient cohort with re-evaluation of initial diagnosis at time of surgery, classification into groups with putative causes of therapeutic failure, evaluation of frequencies of symptoms and findings in this cohort
    </Primary_outcome>
    <Source_Support>Klinik und Poliklinik fuer Neurologie, Uniklinik Koeln
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>26/10/2010
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_date_completed>20/07/2015
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00003105#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13439777
    </Internal_Number>
    <TrialID>JPRN-UMIN000005610
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Clinical study for efficacy of the deep brain stimulation for the Tourette Syndrome with severe involuntary movement
    </Public_title>
    <Scientific_title>Clinical study for efficacy of the deep brain stimulation for the Tourette Syndrome with severe involuntary movement - The deep brain stimulation for the Tourette Syndrome with severe involuntary movement                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    </Scientific_title>
    <Primary_sponsor>Nagoya University, Postgraduate School of Medicine
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20110520
    </Date_registration3>
    <Date_registration>20/05/2011
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006608
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18years-old
    </Inclusion_agemin>
    <Inclusion_agemax>Not applicable
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2011/07/01
    </Date_enrollement>
    <Target_size>4
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Cross-over Randomized
    </Study_design>
    <Phase>Not applicable
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname>Yasukazu Kajita
    </Contact_Lastname>
    <Contact_Address>65 Tsurumai Syouwa, Nagoya
    </Contact_Address>
    <Contact_Email>ykajita@med.nagoya-u.ac.jp
    </Contact_Email>
    <Contact_Tel>052-744-2353
    </Contact_Tel>
    <Contact_Affiliation>Nagoya University, Postgraduate School of Medicine Neurosurgery
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: The patients with severe cardiac disease, Respiratory failure, epilepsy, severe head injury, cerebral vascular accident, autism, schizophrenia, manic-deprresive psychosis, gravida
    </Exclusion_Criteria>
    <Condition>Tourette Syndrome
    </Condition>
    <Intervention>Deep Brain Stimulation group&lt;br&gt;Sham Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Yale Global Tic Severity Scale
    </Primary_outcome>
    <Secondary_outcome>modified Rush video-based protocol and rating scale (mRVRS), Short-Form 36-Item Health Survey (SF-36), WAIS-III, WMS-R, BDI-II, MMPI
    </Secondary_outcome>
    <Source_Support>Nagoya University, Postgraduate School of Medicine
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>5389763
    </Internal_Number>
    <TrialID>NCT01495897
    </TrialID>
    <Last_Refreshed_on>14 March 2016
    </Last_Refreshed_on>
    <Public_title>Abnormal Movements, Cerebellum and Sensorimotor : Oculomotor Study
    </Public_title>
    <Scientific_title>Adaptation Sensorimotrice, Cervelet et Mouvements Anormaux: Projet d'étude Oculomotrice
    </Scientific_title>
    <Acronym>MOUVADOC
    </Acronym>
    <Primary_sponsor>Institut National de la Santé Et de la Recherche Médicale, France
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20110518
    </Date_registration3>
    <Date_registration>18/05/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01495897
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>March 2011
    </Date_enrollement>
    <Target_size>14
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Emmanuel Flamand-Roze, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Institut National de la Santé Et de la Recherche Médicale, France
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age =18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  -normal cognitive functions (&gt;24y)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Normal clinical examination of ocular mobility, visualization of the target&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No drug potentially able to modify and to influence the data: anti-depressants,&#x0D;&lt;br&gt;             neuroleptics, anti-emetics, amphetamines, anti myoclonic/dystonic drugs, alcohol,&#x0D;&lt;br&gt;             dopaminergic drug, antiepileptic.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dystonia or essential tremor or Parkinson: diagnostic made by a neurologist&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For DYT11: mutation in SGCE gene.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For dystonia: No secondary dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For Parkinson : UPDRS&lt;28&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No other neurological disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For the patient having deep brain stimulation:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Duration of stimulation&gt; 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cerebral imagery post operation made&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Stimulation parameter stable since 3 months at least.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Usual stop of the stimulation during the night&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uncontrollable medical problems not related to M-D&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current active psychiatric disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intake during the last 3 days of drugs potentially able to modify and to influence&#x0D;&lt;br&gt;             the data: anti-depressants, neuroleptics, anti-emetics, amphetamines, anti&#x0D;&lt;br&gt;             myoclonic/dystonic drugs, alcohol, dopaminergic drug&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects legally protected.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects who are not enrolled at social security.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Healthy;Dystonia;Parkinson Disease
    </Condition>
    <Intervention>Device: Tracking eye movement;Device: Tracking eye movement under deep brain stimulation
    </Intervention>
    <Primary_outcome>Saccadic adaptation;Characteristics of the saccade
    </Primary_outcome>
    <Secondary_ID>2010-A00740-39;C10-18
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10211288
    </Internal_Number>
    <TrialID>NCT01169324
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Effect of Deep Brain Stimulation (DBS) on Sleep Architecture in Patients With Movement Disorders
    </Public_title>
    <Scientific_title>Effect of DBS on Sleep Architecture in Patients With Movement Disorders.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Alabama at Birmingham
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20100702
    </Date_registration3>
    <Date_registration>02/07/2010
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01169324
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>19 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 15, 2010
    </Date_enrollement>
    <Target_size>17
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Other. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Amy W Amara, MD, phD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>UAB Neurology
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Prior DBS surgery for treatment of movement disorders such as PD, tremor, or dystonia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Stable DBS stimulator settings and medication regimen for at least 6 weeks prior to&#x0D;&lt;br&gt;             the sleep studies.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Sleep dysfunction as measured by the Pittsburgh Sleep Quality Index (PSQI) (score &gt;5)&#x0D;&lt;br&gt;             at the subject's baseline pre-surgical evaluation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known narcolepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other previous surgical treatment of Parkinson's disease, tremor, or dystonia (with&#x0D;&lt;br&gt;             the exception of DBS) including pallidotomy, thalamotomy, or gene therapy procedures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Untreated obstructive sleep apnea. If obstructive sleep apnea is discovered during the&#x0D;&lt;br&gt;             first sleep study, the subject will be removed from the study. After they have been&#x0D;&lt;br&gt;             treated for at least 6 weeks with CPAP, they can re-start the study.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson's Disease;Tremor;Dystonia
    </Condition>
    <Intervention>Other: Alteration of DBS stimulator settings
    </Intervention>
    <Primary_outcome>Sleep Efficiency
    </Primary_outcome>
    <Secondary_outcome>Wake after sleep onset (WASO);Total Sleep Time;Two timed motor tasks
    </Secondary_outcome>
    <Secondary_ID>F100528004
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>5810272
    </Internal_Number>
    <TrialID>ISRCTN16511360
    </TrialID>
    <Last_Refreshed_on>17 October 2016
    </Last_Refreshed_on>
    <Public_title>Deep brain stimulation of the pedunculopontine nucleus for Parkinson's Disease
    </Public_title>
    <Scientific_title>Deep brain stimulation of the pedunculopontine nucleus for Parkinson's Disease: a single centre randomised interventional treatment trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>North Bristol NHS Trust (UK)
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20100528
    </Date_registration3>
    <Date_registration>28/05/2010
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN16511360
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>22/10/2007
    </Date_enrollement>
    <Target_size>8
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single centre randomised interventional treatment trial (Treatment)
    </Study_design>
    <Phase>Phase II
    </Phase>
    <Countries>United Kingdom
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: 1. Diagnosis of advanced idiopathic Parkinson's disease poorly controlled on optimum medication with significant functional disability and predominant symptoms of postural instability and gait dysfunction in both the on and off medication states&lt;br&gt;2. They will have a Unified Parkinson's Disease Rating Scale (UPDRS) motor score of 30 or greater in their practically defined off condition at an initial evaluation. They will each show at least a 30% improvement in the UPDRS motor score from that of the practically defined off condition following a morning levodopa challenge.&lt;br&gt;3. At two preoperative evaluations the practically defined off UPDRS motor score should differ no more than +/- 15%&lt;br&gt;4. Subjects will be under the age of 70 years, either sex&lt;br&gt;5. Appropriate surgical candidate with no medical conditions that would interfere with long-term implantation of device and follow up&lt;br&gt;6. Patient must give signed informed consent
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Known current or past diabetes&lt;br&gt;2. Evidence of dementia, head trauma or medical conditions that may alter cerebral functioning&lt;br&gt;3. Past or present history of alcohol or substance abuse&lt;br&gt;4. Mini-mental state examination (MMSE) scores below 27 or above 30&lt;br&gt;5. Evidence of past or current serious psychopathology likely to affect the patients ability to benefit from surgery
    </Exclusion_Criteria>
    <Condition>Topic: Dementias and Neurodegenerative Diseases Research Network; Subtopic: Parkinson?s Disease; Disease: Parkinson's disease &lt;br&gt;Nervous System Diseases &lt;br&gt;Parkinson's Disease
    </Condition>
    <Intervention>Following fully informed consent and surgical implantation of DBS electrodes to both the PPN and subthalamic region bilaterally, patients will enter into an initial 6 week period over which the Subthalamic region and PPN electrodes will be programmed individually and in combination in order to define the optimal settings for symptom control. At the end of the first 6 week period patients will be randomised into receiving deep brain stimulation at the predetermined optimal setting at either the Subthalamic region or the both the PPN and Subthalamic region simultaneously. This will occur for a further 6 - 12 week period at the end of which the primary and secondary outcome measures will be assessed. Following assessment of the outcome measures, patients will crossover to the other stimulator setting for a further 6 - 12 weeks. With two possible combinations of stimulator settings and an initial period used to define optimal stimulator settings the total duration of the trial will be 18 - 30 weeks.
    </Intervention>
    <Primary_outcome>Change in frequency of gait freezing, measured for 3 days in each condition and averaged.
    </Primary_outcome>
    <Secondary_outcome>1. Quality of life questionnaires (39-item Parkinson's Disease Questionnaire [PDQ-39] and 36-item Short Form Health Survey [SF-36])&lt;br&gt;2. The Unified Parkinson's Disease Rating Scale (UPDRS)&lt;br&gt;3. Change in concomitant antiparkinsonian medications&lt;br&gt;4. Neuropsychological assessment&lt;br&gt;5. Parkinson's Disease Non-Motor Symptoms Questionnaire&lt;br&gt;6. Timed walk, upper and lower limb movements and Purdue Pegboard&lt;br&gt;7. Tinetti balance and gait assessment tool&lt;br&gt;&lt;br&gt;Measured pre-operatively and after each of the two randomisation settings (which could be at 12 - 18 weeks, or 18 - 30 weeks depending on how long the patient needs to be on each &lt;br&gt;stimulation setting in order to reach a stable clinical state on each of the stimulation settings.
    </Secondary_outcome>
    <Secondary_ID>4455
    </Secondary_ID>
    <Source_Support>Medtronic PLC
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>8756063
    </Internal_Number>
    <TrialID>ACTRN12610000385044
    </TrialID>
    <Last_Refreshed_on>13 January 2020
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation for Cerebral Palsy
    </Public_title>
    <Scientific_title>A randomized, placebo controlled, double blinded trial of pallidal Deep Brain Stimulation for dystonic or dyskinetic Cerebral Palsy to improve Quality of Life                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Martin Krause
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20100513
    </Date_registration3>
    <Date_registration>13/05/2010
    </Date_registration>
    <Source_Register>ANZCTR
    </Source_Register>
    <web_address>https://anzctr.org.au/ACTRN12610000385044.aspx
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>10 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both males and females
    </Inclusion_gender>
    <Date_enrollement>01/04/2010
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Purpose: Treatment; Allocation: Randomised controlled trial;
    </Study_design>
    <Phase/>
    <Countries>Australia
    </Countries>
    <Inclusion_Criteria>Inclusion criteria: Dystonic or dyskinetic Cerebral Palsy
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Dementia&#x0D;&lt;br&gt;Predominant Spasticity
    </Exclusion_Criteria>
    <Condition>Cerebral Palsy; &lt;br&gt;Cerebral Palsy;Neurological - Other neurological disorders
    </Condition>
    <Intervention>All patients will have deep brain stimulator implanted in the globus pallidus internus, which is part of the basal ganglia network in the brain. The implantation of deep brain stimulators takes approximately 3 to 6 hours. Deep brain stimulators are similar to cardiac pacemakers and the battery is placed - like in pacemakers - under the collar bone. However the electrodes are not in the heart but end in the brain where they stimulate certain areas of the brain - in our study the pallidum or globus pallidus internus. This part of the brain is involved in involuntary movements. We believe that continuous high frequency stimulation of this part of the brain can block involuntary movements and improve dystonia. The treatment group will receive effective continuous stimulation through their implanted deep brain stimulators for three months; The standard setting of the stimulator are pulse width of 90µs, 130 Hz and the highest possible amplitude , that does not cause side effects. The sham group will receive ineffective stimulation through their implanted deep brain stimulators which will mean the stimulator is switched on with the same settings but amplitude of 0 Volt.
    </Intervention>
    <Primary_outcome>Quality of life will be assessed by the Quality of Life Instrument for People with Developmental Disabilities (Rosenbaum, P.L., et al., Quality of life and health-related quality of life of adolescents with cerebral palsy. Dev Med Child Neurol, 2007. 49(7): p. 516-21.) with the domains of Being, Belonging, and Becoming. This scale is validated in Cerebral Palsy (CP).  The health-related quality of life will be assessed with the Short Form General-Health-Survey (SF-36), which evaluates both physical and mental components of functioning (Ware, J.E., Jr. and C.D. Sherbourne, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care, 1992. 30(6): p. 473-83).[The primary outcome parameter will be measured within 2 months before the intervention. Within 48 hours after implantation of the deep brain stimulator patients will be randomised and either allocated to sham or active treatment. Three months after the randomisation and therefore three months after having had continuous effective deep brain stimulation or sham stimulation the primary endpoint will be assed again. Than all deep brain stimulators will be activated and the third assessment of the primary endpoint will be 6 months after the initial randomisation.]
    </Primary_outcome>
    <Secondary_outcome>Movement and disability will be assessed by the Burke-Fahn-Marsden-Dystonia Rating Scale (BFMDRS) (Burke, R.E., et al., Validity and reliability of a rating scale for the primary torsion dystonias. Neurology, 1985. 35(1): p. 73-7.), which comprises of a disability score ranging from 0 to 30 and motor score ranging from 0 to 120. Further more the motor function will be video taped according to the previous applied video protocol. &#x0D;&lt;br&gt;The Gross Motor Function Classification System for children with Cerebral Palsy (GMFCS) [Palisano, R., et al., Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol, 1997. 39(4): p. 214-23.] will be applied as a standard classification tool for children with CP, which rates the severity of the disease in 5 levels with regard to their motor function.[The secondary outcome parameter will be measured within 2 months before the intervention. Within 48 hours after implantation of the deep brain stimulator patients will be randomised and either allocated to sham or active treatment. Three months after the randomisation and therefore three months after having had continuous effective deep brain stimulation or sham stimulation the secondary endpoint will be assed again. Than all deep brain stimulators will be activated and the third assessment of the secondary endpoint will be 6 months after the initial randomisation.]
    </Secondary_outcome>
    <Secondary_ID>None
    </Secondary_ID>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>4691338
    </Internal_Number>
    <TrialID>NCT01334814
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Chronic Versus Intermittent Deep Brain Stimulation for Essential Tremor
    </Public_title>
    <Scientific_title>Chronic Versus Intermittent Deep Brain Stimulation for Essential Tremor
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Mayo Clinic
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20100309
    </Date_registration3>
    <Date_registration>09/03/2010
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01334814
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>50 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>January 2002
    </Date_enrollement>
    <Target_size>8
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Ryan Uitti, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Mayo Clinic
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  individuals with essential tremor who are at least 6 months status-post thalamic&#x0D;&lt;br&gt;             stimulator placement&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  maintained a consistent chronic or intermittent stimulation schedule for at least 4&#x0D;&lt;br&gt;             consecutive weeks prior to study enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  no changes in stimulation parameters for at least 2 consecutive months prior to study&#x0D;&lt;br&gt;             enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients with clinically significant dementia (i.e., a score less than 24 out of 30&#x0D;&lt;br&gt;             on the Mini Mental Status Exam14)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  women who are not post-menopausal&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients with other significant neurological or psychiatric disease other than&#x0D;&lt;br&gt;             essential tremor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients treated with  pallidotomy or thalamotomy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients with significant psychiatric disturbance as determined by Diagnostic and&#x0D;&lt;br&gt;             Statistical Manual-IV criteria which would make informed consent/cooperation&#x0D;&lt;br&gt;             problematic&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Device: Deep Brain Stimulation (Model 7438 Therapy Controller)
    </Intervention>
    <Primary_outcome>sleep quality
    </Primary_outcome>
    <Secondary_outcome>measures of tremor,voltage threshold for optimal tremor control;Side effects
    </Secondary_outcome>
    <Secondary_ID>1324-02
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13437016
    </Internal_Number>
    <TrialID>JPRN-UMIN000002849
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Multicentric double-blinded crossover randomized clinical trial of deep brain stimulation for intractable Tourette syndrome
    </Public_title>
    <Scientific_title>Multicentric double-blinded crossover randomized clinical trial of deep brain stimulation for intractable Tourette syndrome - Crossover and randomization design of intractable Tourette syndrome after surgery (CARITAS) trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Department of Neurosurgery, National Center Hospital of Neurology and Psychiatry
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20091205
    </Date_registration3>
    <Date_registration>05/12/2009
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003478
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18years-old
    </Inclusion_agemin>
    <Inclusion_agemax>Not applicable
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2010/12/01
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Cross-over Randomized
    </Study_design>
    <Phase>Phase III
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname>Takanobu Kaido
    </Contact_Lastname>
    <Contact_Address>Ogawahigashicho 4-1-1, Kodaira, Tokyo, 187-8551, Japan
    </Contact_Address>
    <Contact_Email>kaido@ncnp.go.jp
    </Contact_Email>
    <Contact_Tel>+81-42-341-2711
    </Contact_Tel>
    <Contact_Affiliation>National Center Hospital of Neurology and Psychiatry Department of Neurosurgery
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Exclusion criteria are a significant untreated structural brain lesion, a tic disorder due to other medical causes, no severe medical, neurological, psychiatric, or cognitive disorders that inordinately increase the risk (e.g., severe cardiovascular, pulmonary, or hematological disorders, epilepsy, a history of head injury, stroke, neurodegenerative disease, autism, schizophrenia, bipolar disorder, recent substance dependence, current pregnancy, and a recent history of suicide attempts).
    </Exclusion_Criteria>
    <Condition>Intractable Tourette syndrome
    </Condition>
    <Intervention>A stereotactic operation is performed aided by functional software and computed tomography (CT) or magnetic resonance imaging (MRI). Two permanent quadripolar leads (model 3387, Medtronic) are implanted bilaterally under general anesthesia.  The pulse generators (Soletra, Medtronic) are also implanted bilaterally and attached to lead extensions at the same time.  The pulse generator is activated and neuroelectrical parameters were changed by an investigator.  Patients are randomized 1 month after DBS, and stimulation &amp;#39;on&amp;#39; or &amp;#39;off&amp;#39; is started in a double-blinded fashion 1 month more later.    Group A: &amp;#39;On&amp;#39; for 3 months and &amp;#39;off&amp;#39; for 3 months, then open-labeled &amp;#39;on&amp;#39; for 6 months.&lt;br&gt;Group B: &amp;#39;Off&amp;#39; for 3 months and &amp;#39;on&amp;#39; for 3 months, then open-labeled &amp;#39;on&amp;#39; for 6 months.
    </Intervention>
    <Primary_outcome>Yale Global Tic Severity Scale (YGTSS) tic score
    </Primary_outcome>
    <Secondary_outcome>modified Rush Video-Based Rating Scale (mRVRS)  YGTSS social impairment score  Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score  Short Form-36 (SF-36)  Gilles de la Tourette syndrome-specific health-related -QOL scale (GTS-QOL)
    </Secondary_outcome>
    <Source_Support>Ministry of Health, Labour and Welfare, Japan
    </Source_Support>
    <Secondary_Sponsor>Kyoto Univ.  Kinki Univ.  Natl Ctr of Neurol and Psychiat  Univ. of Tokyo  Tokyo Metropolitan Neurological Hosp.  Tohoku Univ.  Nagoya Univ.  Nara Med. Univ.  Nihon Univ.  Hamamatsu Univ. School of Med.  Yamaguchi Univ.
    </Secondary_Sponsor>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/03/2012
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13716390
    </Internal_Number>
    <TrialID>NL-OMON33676
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>Select Stim: Selective stimulation of the subthalamic nucleus in Parkinsons disease
"A feasability study"
    </Public_title>
    <Scientific_title>Select Stim: Selective stimulation of the subthalamic nucleus in Parkinsons disease
"A feasability study" - Select Stim                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Neurochirurgie
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20090717
    </Date_registration3>
    <Date_registration>2009-07-17
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/33676
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>64
    </Inclusion_agemax>
    <Inclusion_gender/>
    <Date_enrollement>2008-09-10
    </Date_enrollement>
    <Target_size>5
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Open (masking not used), Uncontrolled, Treatment
    </Study_design>
    <Phase/>
    <Countries>The Netherlands
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Selecteer
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;p&gt;Patients with the clinical findings consistent with idiopathic Parkinson Disease (PD) and who suffer from severe response fluctuations and/or dyskinesias, despite optimal drug treatment, who are candidates for DBS.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;p&gt;Those PD patients suffering from severe psychiatric co-morbidities and cognitive decline, e.g. dementia and psychosis, are excluded from this study. The mini mental state exam (MMSE) score is not allowed to be &lt;24. Other exclusion criteria are the same as for the classical STN DBS operation: significant cerebral atrophy, causative factors of PD, multiple white matter lesions or focal brain anomalies and a Hoehn and Yahr stage of 5 at the best moment of the day. &lt;/p&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Parkinson disease &lt;br&gt;Parkinsonism;10028037;10009720;Parkinson disease;Parkinsonism
    </Condition>
    <Intervention>&lt;p&gt;The intervention is an expansion of the classical STN DBS procedure. The &lt;br&gt;targeting using the multichannel registration system by stimulation of the &lt;br&gt;motor cortex and registration of the subthalamic nucleus will be added to the &lt;br&gt;procedure. For this procedure, it is necessary to place a subdural strip under &lt;br&gt;the skull.&lt;/p&gt;&lt;br&gt;;deep brain stimulation (DBS);Parkinson;subthalamic nucleus (STN)
    </Intervention>
    <Primary_outcome>&lt;p&gt;There are two main endpoints to measure the feasibility. First, the patients&lt;br /&gt;&lt;br&gt;burden and outcome. We will interview the patient and ask him to fill in a&lt;br /&gt;&lt;br&gt;standardized questionnaire. Only if the burden is acceptable, we will start&lt;br /&gt;&lt;br&gt;with the main study (average marks for each testing must be above 5 to continue&lt;br /&gt;&lt;br&gt;with a RCT). Thereby the motor symptoms must be significantly less pronounced&lt;br /&gt;&lt;br&gt;with stimulation than pre-operatively.&lt;br /&gt;&lt;br&gt;Secondly, the technical feasibility depends on the possibility to register the&lt;br /&gt;&lt;br&gt;potentials, evoked by motor cortex stimulation in the STN (so-called evoked&lt;br /&gt;&lt;br&gt;potentials). These potentials have to be clearly identifiable in order to&lt;br /&gt;&lt;br&gt;recognize the motor part of the STN. This is necessary as in the final study we&lt;br /&gt;&lt;br&gt;want to compare the results of selective stimulation of the motor part of the&lt;br /&gt;&lt;br&gt;STN with results of the classical procedure.&lt;/p&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>&lt;p&gt;Cognition, and in particular impulsivity, and affect, will be assessed by&lt;br /&gt;&#x0D;&lt;br&gt;neuropsychological testing and a self-report questionnaire, the Positive and&lt;br /&gt;&#x0D;&lt;br&gt;Negative Affect Scale (Watson et al 1988). Neuropsychological testing covers&lt;br /&gt;&#x0D;&lt;br&gt;the main cognitive domains but the study parameters are related to the&lt;br /&gt;&#x0D;&lt;br&gt;performance on tasks in the relevant domain of executive functioning, including&lt;br /&gt;&#x0D;&lt;br&gt;word fluency, the Stroop (Lezak, 2004), a finger precuing task (Adam et al,&lt;br /&gt;&#x0D;&lt;br&gt;2002) and the Iowa Gambling Task (Bechera et al., 1994). (These are not&lt;br /&gt;&#x0D;&lt;br&gt;endpoints of the feasibility trial.)&lt;br /&gt;&#x0D;&lt;br&gt;&lt;br /&gt;&#x0D;&lt;br&gt;Advantage of fMRI above TMS or double contrast MRI in the planning of the OR.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>NL21387.068.08
    </Secondary_ID>
    <Source_Support>NWO;Smartmix
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>09/06/2008;15/12/2008;17/07/2009
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>;;
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>4652329
    </Internal_Number>
    <TrialID>NCT00821743
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Pedunculo-Pontin Nucleus (PPN) - Deep Brain Stimulation (DBS) in Gait and Balance Disturbance in Parkinson's Disease (PPN-GAB-PARK Study)
    </Public_title>
    <Scientific_title>Study of Deep Brain Stimulation of the Pedunculo-pontin Nucleus (PPN) for the Treatment of Gait and Balance Disturbances in Patients With Parkinson's Disease (PPN-GAB-PARK Study)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Centre Hospitalier Universitaire de Nice
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20090112
    </Date_registration3>
    <Date_registration>12/01/2009
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00821743
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>March 2010
    </Date_enrollement>
    <Target_size>5
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 1/Phase 2
    </Phase>
    <Countries>France
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Denys FONTAINE, PhD;Denys FONTAINE, PhD;Denys Fontaine, PhD
    </Contact_Lastname>
    <Contact_Email>;fontaine.d@chu-nice.fr;fontaine.d@chu-nice.fr
    </Contact_Email>
    <Contact_Tel>;04 92 03 84 50;04 92 03 84 50
    </Contact_Tel>
    <Contact_Affiliation>Department of neurosurgery, CHU de Nice;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe idiopathic Parkinson's disease (stage of Hoehn and Yahr = 3).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Disease duration = 5 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Predominant axial motor signs (gait and balance disturbance as freezing of gait,&#x0D;&lt;br&gt;             postural instability, falls) with disability in daily life, defined by a score UPDRS&#x0D;&lt;br&gt;             II  2 of item  13 or  3 of item 14 or 15.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Axial motor signs resistant to optimal drug and non-drug treatment, including&#x0D;&lt;br&gt;             physical therapy and eventually STN-DBS (if STN-DBS is ongoing for at least 1 year&#x0D;&lt;br&gt;             and has shown no efficacy on axial motor signs).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No significant abnormality on brain MRI.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Non-inclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient with non-axial, dopa-responsive motor signs and indication of first line&#x0D;&lt;br&gt;             STN-DBS. In case of absence of efficacy of STN-DBS on axial motor signs after one&#x0D;&lt;br&gt;             year of stimulation, PPN-DBS may be proposed to these patients.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient with major cognitive disturbances defined by a score Mattis DRS 130 (of 144).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant or breast-feeding woman.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient with contraindication for general anaesthesia, a contraindication for surgery&#x0D;&lt;br&gt;             (including disorders of haemostasis, or necessity of anticoagulant and antiaggregant&#x0D;&lt;br&gt;             drug), or a contraindication for MRI.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient presenting major depression, psychosis or addiction in six months preceding&#x0D;&lt;br&gt;             inclusion.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Deep brain stimulation electrode
    </Intervention>
    <Primary_outcome>Primary endpoint will be the optimal parameters of PPN-DBS, defined as those leading to the best improvement of posture, balance and gait disturbance
    </Primary_outcome>
    <Secondary_outcome>Efficacy of PPN-DBS on disturbance of posture, balance and gait;Long term tolerance will be assessed by general and neurological examination, neuro-psychological tests (MMS, Mattis-DRS, Score fontal, BREF, MADRS) and by assessment of adverse events;;the components of gait that are most improved by PPN-DBS will be determined using computer-based systems (GAITRite and VICON);;evaluation of unilateral versus bilateral stimulation will be done during the double-blind assessment of all efficacy criteria;;effects of PPN-DBS on other PD symptom will be assessed using UPDRS and Hoehn and Yahr's staging;;the impact of PPN-DBS on quality of life and activities of daily living will be assessed by UPDRS II, SF36 and PDQ39 questionnaires and by a global satisfaction scale.
    </Secondary_outcome>
    <Secondary_ID>PPN-GAB-PARK study
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10206434
    </Internal_Number>
    <TrialID>NCT00792532
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Use of Interventional MRI for Implantation of Deep Brain Stimulator Electrodes
    </Public_title>
    <Scientific_title>Use of Interventional MRI for Implantation of Deep Brain Stimulator Electrodes
    </Scientific_title>
    <Acronym>iMRI
    </Acronym>
    <Primary_sponsor>University of California, San Francisco
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20081114
    </Date_registration3>
    <Date_registration>14/11/2008
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00792532
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 2003
    </Date_enrollement>
    <Target_size>8
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Philip Starr, M.D., Ph.D.;Paul Larson, M.D.;Jill L Ostrem, MD;Alastair J Martin, PhD
    </Contact_Lastname>
    <Contact_Email>;;;
    </Contact_Email>
    <Contact_Tel>;;;
    </Contact_Tel>
    <Contact_Affiliation>University of California, San Francisco; SFVAMC;University of California, San Francisco; SFVAMC;University of California San Francisco, SFVAMC;University of California, San Francisco
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Parkinson's Disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Diagnosis of idiopathic PD with clinically significant motor fluctuations despite&#x0D;&lt;br&gt;             maximized anti-Parkinsonian therapy. This will be based on medical history, neurologic&#x0D;&lt;br&gt;             examination (the presence of at least 2 of the following: resting tremor, rigidity, or&#x0D;&lt;br&gt;             bradykinesia), and response to anti-Parkinsonian therapy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Approximately 5 years' duration, relative to the date of surgery, since diagnosis of&#x0D;&lt;br&gt;             PD.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Age &gt;20 inclusive, on date of surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. The subject is ambulatory in their best on time (not wheelchair bound).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. The subject is medically able to undergo the surgery as determined by clinical and&#x0D;&lt;br&gt;             laboratory evaluations and any other evaluations that are part of the standard&#x0D;&lt;br&gt;             practice at the institution in which the subject is to undergo surgery (e.g., subjects&#x0D;&lt;br&gt;             will have normal coagulation tests and normal platelet levels).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. The subject is expected to be able to comply with and understand the required visit&#x0D;&lt;br&gt;             schedule and all required tests and procedures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Signed IRB-approved informed consent is obtained before any study-specific procedure,&#x0D;&lt;br&gt;             including assessments required during the eligibility evaluation period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. In the judgment of the investigator, a history of any clinically significant medical,&#x0D;&lt;br&gt;             psychiatric, or laboratory abnormality for which participation in the study would pose&#x0D;&lt;br&gt;             a safety risk to the subject.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. History of treatment of PD by any procedure involving intracranial surgery or&#x0D;&lt;br&gt;             implantation of a device.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. MRI of the brain within 12 months before the surgery which demonstrates an&#x0D;&lt;br&gt;             intracranial abnormality that would contraindicate surgery (e.g. stroke, tumor,&#x0D;&lt;br&gt;             vascular abnormality affecting the DBS target area).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Any disorder that precludes a surgical procedure (e.g., signs of sepsis or&#x0D;&lt;br&gt;             inadequately treated infection) or alters wound healing.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Receipt of antiplatelet agents for at least 10 days prior surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Significant cognitive impairment based on investigator assessment during the&#x0D;&lt;br&gt;             eligibility evaluation period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. History of significant psychiatric illness, epilepsy, or Alzheimer's disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Active drug or alcohol abuse.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Pregnancy or lack of effective contraception in women of childbearing potential&#x0D;&lt;br&gt;             defined as one year post-menopausal or surgically sterile.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Treatment with non anti-Parkinsonian agents (e.g., atypical neuroleptics) that may&#x0D;&lt;br&gt;             affect symptoms of PD within 60 days before entering the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Any medical disability (e.g., severe degenerative arthritis, compromised nutritional&#x0D;&lt;br&gt;             state, severe peripheral neuropathy) that would interfere with the assessment of&#x0D;&lt;br&gt;             safety and efficacy in this trial.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Inability to follow-up with post-operative study visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Inability to speak or read English&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Dystonia Inclusion Criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Dystonia diagnosed by a movement disorders neurologist&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Significant functional impairment despite optimal medical management, including failed&#x0D;&lt;br&gt;             botulinum toxin therapy if appropriate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Age &gt;20 years inclusive, on date of surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. The subject is medically able to undergo the surgery as determined by clinical and&#x0D;&lt;br&gt;             laboratory evaluations and any other evaluations that are part of the standard&#x0D;&lt;br&gt;             practice at the institution in which the subject is to undergo surgery (e.g., subjects&#x0D;&lt;br&gt;             will have normal coagulation tests and normal platelet levels).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. The subject is able to comply with and understand the required visit schedule and all&#x0D;&lt;br&gt;             required tests and procedures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Signed IRB-approved informed consent is obtained before any study-specific procedure,&#x0D;&lt;br&gt;             including assessments required during the eligibility evaluation period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Any disorder that precludes a surgical procedure (e.g., signs of sepsis or&#x0D;&lt;br&gt;             inadequately treated infection) or alters wound healing.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Receipt of antiplatelet agents for at least 10 days prior surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Significant cognitive impairment based on investigator assessment during the&#x0D;&lt;br&gt;             eligibility evaluation period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. History of significant psychiatric illness, epilepsy, or Alzheimer's disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Active drug or alcohol abuse.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Pregnancy or lack of effective contraception in women of childbearing potential&#x0D;&lt;br&gt;             defined as one year post-menopausal or surgically sterile.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Any medical disability (e.g., severe degenerative arthritis, compromised nutritional&#x0D;&lt;br&gt;             state, severe peripheral neuropathy) that would interfere with the assessment of&#x0D;&lt;br&gt;             safety and efficacy in this trial.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Inability to follow-up with post-operative study visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Inability to speak or read English&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson's Disease;Dystonia
    </Condition>
    <Intervention>Procedure: interventional MRI for implantation of DBS electrodes;Device: DBS electrodes
    </Intervention>
    <Primary_outcome>Parkinson's disease: The degree of benefit from baseline off medication UPDRS(part III) motor score to postoperative off medication scores at 12 months with stimulation on.;Dystonia: The percent change from baseline in the Burk-Fahn-Marsden Dystonia rating scale movement subscore to the 12 month postoperative subscore
    </Primary_outcome>
    <Secondary_ID>iMRI
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>MRI Interventions, Inc.
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>13714558
    </Internal_Number>
    <TrialID>NL-OMON31844
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>Effects of bilateral subthalamic nucleus deep brain stimulation on plasma triglycerides and glucose metabolism in patients with advanced Parkinsons disease.
    </Public_title>
    <Scientific_title>Effects of bilateral subthalamic nucleus deep brain stimulation on plasma triglycerides and glucose metabolism in patients with advanced Parkinsons disease. - Effects of subthalamic nucleus stimulation on metabolism                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Academisch Medisch Centrum
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20081112
    </Date_registration3>
    <Date_registration>2008-11-12
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/31844
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>64
    </Inclusion_agemax>
    <Inclusion_gender/>
    <Date_enrollement>2008-11-01
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Observational invasive
    </Study_type>
    <Study_design>Randomized  controlled trial, Single blinded (masking used), Active, Parallel, Basic science
    </Study_design>
    <Phase/>
    <Countries>The Netherlands
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Academisch Medisch Centrum
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;p&gt;Patients with idiopathic Parkinson's disease, bilateral subthalamic nucleus deep brain stimulation, and a documented effect of bilateral subthalamic nucleus deep brain stimulation on parkinsonism *measured with the Unified Parkinson*s disease Rating Scale (UPDRS) motor section*equal or more than 75% of the difference between the preoperative provoked OFF and ON phases.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;p&gt;Age less than 18 years, other functional stereotactic neurosurgical interventions (e.g. pallidotomy), psychosis, depression, alcoholism, dyslipidemia (primary or secondary form), use of lipid lowering drugs, unstable weight, presence of type II diabetes mellitus, former history of diabetes gravidarum, first line familial preponderance of type II diabetes mellitus, active smoking, renal insufficiency (creatinine &gt; 150 umol/L, creatinine clearance &lt;60 ml/min) or elevated liver enzymes (2x upper limit).&lt;/p&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Lipids and glucose metabolism in patients with Parkinson disease;10021112;10018424;10028037;Lipids and glucose metabolism in patients with Parkinson disease
    </Condition>
    <Intervention>&lt;p&gt;&lt;/p&gt;&lt;br&gt;;Deep brain stimulation;Glucose metabolism;Parkinson's disease;Triglycerides
    </Intervention>
    <Primary_outcome>&lt;p&gt;Evaluation of the effect of stimulation on the subthalamic nucleus on plasma&lt;br /&gt;&lt;br&gt;triglycerides and glucose metabolism. &lt;/p&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>&lt;p&gt;NA&lt;/p&gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>NL22171.018.08
    </Secondary_ID>
    <Source_Support>Ministerie van OC&amp;W
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10206205
    </Internal_Number>
    <TrialID>NCT00773604
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation in Patients With Dystonia
    </Public_title>
    <Scientific_title>Subthalamic Nucleus (STN) Deep Brain Stimulation (DBS) in Patients With Dystonia
    </Scientific_title>
    <Acronym>STN DBS
    </Acronym>
    <Primary_sponsor>University of California, San Francisco
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20081007
    </Date_registration3>
    <Date_registration>07/10/2008
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00773604
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>7 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 2008
    </Date_enrollement>
    <Target_size>9
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Jill Ostrem, M.D.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of California, San Francisco
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Refractory primary dystonia diagnosed by a movement disorders neurologist&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe functional impairment despite optimal medical management, including failed&#x0D;&lt;br&gt;             botulinum toxin therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 7-80 years (UCSF patients) and 18-80 (VA patients)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients considered at high risk for elective neurosurgery because of co-morbid&#x0D;&lt;br&gt;             conditions&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Brain MRI showing extensive brain atrophy or small vessel ischemic disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to tolerate awake microelectrode-guided neurosurgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to follow up with post-operative study visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to speak or read English&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with a score of 4.5 or lower on the BFMDRS movement scale&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with Secondary dystonia&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Dystonia
    </Condition>
    <Intervention>Device: Medtronic implantable deep brain stimulation (DBS) system
    </Intervention>
    <Primary_outcome>The Toronto Western Spasmodic Rating Scale (TWSTRS) Movement Scores Measured Before DBS Surgery (Baseline) and at 12 Months
    </Primary_outcome>
    <Secondary_ID>Private donor
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>19/02/2019
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT00773604
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10204642
    </Internal_Number>
    <TrialID>NCT00634478
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Pre-lemniscal Radiation Deep Brain Stimulation for ET
    </Public_title>
    <Scientific_title>Pre-lemniscal Radiation Deep Brain Stimulation for ET
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Medical College of Wisconsin
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20080109
    </Date_registration3>
    <Date_registration>09/01/2008
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00634478
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2008
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Serena W Hung, M.D.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Medical College of Wisconsin
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. diagnosis of essential tremor based on clinical criteria established by the Essential&#x0D;&lt;br&gt;             Tremor Consortium&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Moderate or severe axial-dominant (head/neck/voice) tremor (Tremor Rating Scale [TRS]&#x0D;&lt;br&gt;             face, tongue, voice, head or trunk tremor score of 2 or above)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. May have bilateral appendicular tremor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Tremor refractory to at least two medications, including primidone and propranolol&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Age between 21 and 75&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Male or Female&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Significant disability due to essential tremor despite medical treatment (TRS score of&#x0D;&lt;br&gt;             2 or above in any one of the items 16-23 [speaking, feeding other than liquids,&#x0D;&lt;br&gt;             bringing liquids to mouth, hygiene, dressing, writing, working, and social&#x0D;&lt;br&gt;             activities])&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Tremor due to other etiologies&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Presence of any other neurodegenerative disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Presence of significant cognitive impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Presence of any medical condition that precludes neurological surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Patients with another implanted stimulator or metallic implant, e.g. cochlear implant,&#x0D;&lt;br&gt;             cardiac pacemaker, spinal cord stimulator, aneurysm clips&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Patients who have a known need for future MRIs using a full body radio-frequency (RF)&#x0D;&lt;br&gt;             coil or a head transmit coil that extends over the chest area or that do not comply&#x0D;&lt;br&gt;             with Medtronic's "MRI Guidelines for Medtronic Deep Brain Simulation Systems"&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Patients with a history of seizures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Patients with psychiatric illness that are not well controlled&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Patients with risk factors for intraoperative or postoperative bleeding (platelet&#x0D;&lt;br&gt;             count less than 125,000 per cubic millimeter, PT and PTT not within normal limits)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Patients with brain tumors&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Radiation: Pre-lemniscal Radiation Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Tremor rating scale axial score and total score
    </Primary_outcome>
    <Secondary_outcome>quality of life (SF 36 and clinical global impression of change)
    </Secondary_outcome>
    <Secondary_ID>PRO00008047
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10203600
    </Internal_Number>
    <TrialID>NCT00552474
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation to Treat Symptoms of Parkinson's Disease
    </Public_title>
    <Scientific_title>A Clinical Evaluation of Bilateral Stimulation of the Subthalamic Nucleus (STN) Using the ANS Totally Implantable Deep Brain Stimulation System as an Adjunctive Treatment for Reducing Some of the Symptoms of Advanced, Levodopa-responsive Parkinson's Disease That Are Not Adequately Controlled With Medication.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Abbott Medical Devices
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20071031
    </Date_registration3>
    <Date_registration>31/10/2007
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00552474
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2005
    </Date_enrollement>
    <Target_size>136
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>DeLea Peichel
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>ANS/St Jude Medical
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person is 18 to 80 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person has been diagnosed with Parkinson's disease for at lease five (5) years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person experiences at least six (6) hours or more daily "off-time" or moderate to&#x0D;&lt;br&gt;             severe dyskinesias during waking hours&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person has a history of improvement of Parkinson's symptoms with l-dopa (levodopa)&#x0D;&lt;br&gt;             therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person must be willing to maintain a constant dose of anti-Parkinson's disease&#x0D;&lt;br&gt;             medication for at least one month prior to study enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person must be available for appropriate follow-up times for the length of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person has any major illness or medical condition that would interfere with&#x0D;&lt;br&gt;             participation in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person currently suffers from untreated, major depression&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person has an electrical or electromagnetic implant (e.g. cochlear prosthesis or&#x0D;&lt;br&gt;             pacemaker)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person has had a prior surgery for the treatment of PD symptoms, including previous&#x0D;&lt;br&gt;             DBS surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person has dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person has a history of seizures&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Movement Disorders
    </Condition>
    <Intervention>Device: Libra Deep Brain Stimulation System;Device: Libra Deep Brain Stimulation System
    </Intervention>
    <Primary_outcome>Increase the duration of "on time" without dyskinesias or with non-bothersome dyskinesias
    </Primary_outcome>
    <Secondary_outcome>Changes in the following over time: Incidence of AEs; UPDRS motor scores; Activities of Daily Living; Quality of Life, Quality Sleep Index, Hoehn and Yahr Staging, Global Outcome evaluation and Patient Satisfaction
    </Secondary_outcome>
    <Secondary_ID>C-04-01
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>5810383
    </Internal_Number>
    <TrialID>ISRCTN45455499
    </TrialID>
    <Last_Refreshed_on>17 October 2016
    </Last_Refreshed_on>
    <Public_title>Pilot randomised controlled trial of deep brain stimulation in Tourette syndrome
    </Public_title>
    <Scientific_title>Pilot randomised controlled trial of deep brain stimulation in Tourette syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>University Hospital Birmingham NHS Foundation Trust (UK)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20070706
    </Date_registration3>
    <Date_registration>06/07/2007
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN45455499
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/04/2008
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomised placebo-controlled crossover study (Treatment)
    </Study_design>
    <Phase/>
    <Countries>United Kingdom
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: Adults with medically intractable Tourette syndrome for whom surgery and post-operative care is not contraindicated.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Tics for other neurological reasons&lt;br&gt;2. High risk for surgery or post-op care
    </Exclusion_Criteria>
    <Condition>Tourette syndrome &lt;br&gt;Mental and Behavioural Disorders &lt;br&gt;Somatoform disorders
    </Condition>
    <Intervention>Current interventions as of 05/12/2007:&lt;br&gt;Group 1:&lt;br&gt;Group 1 will have deep brain stimulation electrodes placed in the globus palludus internum. After 6 weeks, the electrodes will be switched on and adjusted maximally. After 3 months, electrodes will be switched off and the patient followed up after a further 3 months. &lt;br&gt; &lt;br&gt;Group 2:&lt;br&gt;Group 2 will have deep brain stimulation electrodes placed in the globus pallidus internum. After 6 weeks, the participant will have a "sham" switching on of electrodes. After 3 months, the electrodes will be switched on and adjusted maximally. The patient will be followed up and assessed after a further 3 months.&lt;br&gt;&lt;br&gt;Previous interventions:&lt;br&gt;Intervention group:&lt;br&gt;Intervention group will have deep brain stimulation electrodes placed in globus pallidus externum. After 6 weeks, the electrodes will be switched on and further adjusted at 12 and 18 weeks. Follow-up assessments will then happen at 6 months, 9 months and 12 months. &lt;br&gt;&lt;br&gt;Control group:&lt;br&gt;Control group will also have severe Tourette syndrome. They will also have electrodes implanted in the same way as the patients. After 6 weeks they will have a "sham switch on" proceedure. Follow-ups will be done in the same way as the intervention group.&lt;br&gt; &lt;br&gt;After one year of treatment, the code will be broken and data analysed. Participants in the intervention and control group will then be invited to participate in a further year of open-label extension study with all stimulators switched on. Data will then be gathered at 18 and 24 months.
    </Intervention>
    <Primary_outcome>Yale Global Tic severity scale.
    </Primary_outcome>
    <Secondary_outcome>1. Yale-Brown Obsessive Compulsive Scale&lt;br&gt;2. Hospital Anxiety and Depression Scale&lt;br&gt;3. Total Subjective Quality Of Life (TS-QOL)
    </Secondary_outcome>
    <Secondary_ID>NCT01647269;V 1.0
    </Secondary_ID>
    <Source_Support>Tourette Syndrome Association (UK) - applied for funding
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>6609239
    </Internal_Number>
    <TrialID>NCT00478842
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Pallidal Stimulation and Gilles de la Tourette Syndrome
    </Public_title>
    <Scientific_title>Treatment of Gilles de la Tourette Syndrome by Bilateral Stimulation of the Internal Part of the Globus PALLIDUS
    </Scientific_title>
    <Acronym>STIC
    </Acronym>
    <Primary_sponsor>Assistance Publique - Hôpitaux de Paris
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20070524
    </Date_registration3>
    <Date_registration>24/05/2007
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00478842
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>60 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 2007
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>France;France;France;France;France
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Marie-Laure WELTER, MD,PhD;Marie-Laure WELTER, MD,PhD;Marie-Laure WELTER, MD,PhD;Marie-Laure WELTER, MD,PhD;Marie-Laure WELTER, MD,PhD
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>Assistance Publique - Hôpitaux de Paris;Assistance Publique - Hôpitaux de Paris;Assistance Publique - Hôpitaux de Paris;Assistance Publique - Hôpitaux de Paris;Assistance Publique - Hôpitaux de Paris
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe form of GTS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age 18 to 60 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  failure of medical treatment (including neuroleptics)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Major depression&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe personality disorder&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe form of GTS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age 18 to 60 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  failure of medical treatment (including neuroleptics)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Major depression&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe personality disorder&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe form of GTS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age 18 to 60 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  failure of medical treatment (including neuroleptics)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Major depression&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe personality disorder&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe form of GTS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age 18 to 60 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  failure of medical treatment (including neuroleptics)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Major depression&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe personality disorder&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Gilles de la Tourette Syndrome;Gilles de la Tourette Syndrome;Gilles de la Tourette Syndrome;Gilles de la Tourette Syndrome
    </Condition>
    <Intervention>Device: Deep brain stimulation;Device: Deep brain stimulation;Device: Deep brain stimulation;Device: Deep brain stimulation
    </Intervention>
    <Primary_outcome>To evaluate the therapeutic effect of the high frequency bilateral stimulation of GPI in severe forms and invalidating MGT, in a protocol randomized as a double blind man in parallel groups.;The assumption tested is that of the frank improvement (&gt; 60% on scale YGTSS) of the symptoms of the MGT by the bilateral stimulation of GPI in its former part.;To evaluate the therapeutic effect of the high frequency bilateral stimulation of GPI in severe forms and invalidating MGT, in a protocol randomized as a double blind man in parallel groups.;The assumption tested is that of the frank improvement (&gt; 60% on scale YGTSS) of the symptoms of the MGT by the bilateral stimulation of GPI in its former part.;To evaluate the therapeutic effect of the high frequency bilateral stimulation of GPI in severe forms and invalidating MGT, in a protocol randomized as a double blind man in parallel groups.;The assumption tested is that of the frank improvement (&gt; 60% on scale YGTSS) of the symptoms of the MGT by the bilateral stimulation of GPI in its former part.
    </Primary_outcome>
    <Secondary_outcome>To evaluate time necessary to obtaining the maximum effect and its evolution after this one (maintenance or not of the effect in the course of time);To study the effects of the stimulation of GPI in its former part, on the driving tics simple and complex, vocal, the self-mutilations, and the psychopathology of which time, emotions and impulsiveness;To evaluate the repercussion of this technique on the sociological-professional handicap, operation and the adaptation;To seek determinants before intervention of the effectiveness of stimulation (determining neurological, psychiatric, neuropsychological, functional);To establish correlations between the localization of the studs of stimulation (retiming atlas/IRM) and the symptoms;To determine the modifications of cerebral activation induced by the bilateral stimulation of GPI at the time of the improvement of the neurological symptoms (study in Mtoe).
    </Secondary_outcome>
    <Secondary_ID>P051050
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>6484735
    </Internal_Number>
    <TrialID>NCT00360009
    </TrialID>
    <Last_Refreshed_on>19 October 2017
    </Last_Refreshed_on>
    <Public_title>Effects of Deep Brain Stimulation on Motor, Mood, and Cognitive Symptoms in Parkinson's Disease
    </Public_title>
    <Scientific_title>Cognition and Mood in Parkinson's Disease (PD) in Subthalamic Nucleus (STN) Versus Globus Pallidus Interna (GPi) Deep Brain Stimulation (DBS)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Florida
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20060802
    </Date_registration3>
    <Date_registration>02/08/2006
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00360009
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>30 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 2004
    </Date_enrollement>
    <Target_size>62
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design/>
    <Phase>N/A
    </Phase>
    <Countries>United States;United States;United States;United States
    </Countries>
    <Contact_Firstname> ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Michael Okun, MD;Kelly Foote, MD;Hubert Fernandez, MD;Ramon Rodriguez, MD;Michael Okun, MD;Kelly Foote, MD;Hubert Fernandez, MD;Ramon Rodriguez, MD;Michael Okun, MD;Kelly Foote, MD;Hubert Fernandez, MD;Ramon Rodriguez, MD;Michael Okun, MD;Kelly Foote, MD;Hubert Fernandez, MD;Ramon Rodriguez, MD
    </Contact_Lastname>
    <Contact_Email>;;;;;;;;;;;;;;;
    </Contact_Email>
    <Contact_Tel>;;;;;;;;;;;;;;;
    </Contact_Tel>
    <Contact_Affiliation>University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida;University of Florida
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intractable, disabling PD with motor fluctuations, dyskinesias, or freezing episodes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age between 30-75 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unsatisfactory clinical response to maximal medical management (with trials of both&#x0D;&lt;br&gt;             higher and lower doses of anti-Parkinsonian drugs)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A stable and optimal medical regimen of anti-Parkinsonian drug therapy for at least&#x0D;&lt;br&gt;             three months prior to surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients must be right-handed to be included in the study since mood and cognition are&#x0D;&lt;br&gt;             being analyzed and right hemisphere dominant patients could confound the results.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical disease that would increase risk of developing pre- or&#x0D;&lt;br&gt;             postoperative complications (e.g., significant cardiac or pulmonary disease,&#x0D;&lt;br&gt;             uncontrolled hypertension)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of secondary or atypical parkinsonism as suggested by the presence of any of&#x0D;&lt;br&gt;             the following: 1) history of stroke(s), 2) exposure to toxins or neuroleptics, 3)&#x0D;&lt;br&gt;             history of encephalitis, 4) neurological signs of upper motor neuron disease,&#x0D;&lt;br&gt;             cerebellar involvement, supranuclear gaze palsy, or significant orthostatic&#x0D;&lt;br&gt;             hypotension&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MRI scan with significant evidence of brain atrophy or other abnormalities (e.g.,&#x0D;&lt;br&gt;             lacunar infarcts or iron deposits in the putamen)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The Mattis Dementia Rating Scale will be used to assess the level of intellectual&#x0D;&lt;br&gt;             function and patients will be excluded with scores reflecting clinical dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A major psychiatric disorder on the Structured Clinical Interview for DSM-IV&#x0D;&lt;br&gt;             (SCID-IV).&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intractable, disabling PD with motor fluctuations, dyskinesias, or freezing episodes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age between 30-75 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unsatisfactory clinical response to maximal medical management (with trials of both&#x0D;&lt;br&gt;             higher and lower doses of anti-Parkinsonian drugs)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A stable and optimal medical regimen of anti-Parkinsonian drug therapy for at least&#x0D;&lt;br&gt;             three months prior to surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients must be right-handed to be included in the study since mood and cognition are&#x0D;&lt;br&gt;             being analyzed and right hemisphere dominant patients could confound the results.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical disease that would increase risk of developing pre- or&#x0D;&lt;br&gt;             postoperative complications (e.g., significant cardiac or pulmonary disease,&#x0D;&lt;br&gt;             uncontrolled hypertension)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of secondary or atypical parkinsonism as suggested by the presence of any of&#x0D;&lt;br&gt;             the following: 1) history of stroke(s), 2) exposure to toxins or neuroleptics, 3)&#x0D;&lt;br&gt;             history of encephalitis, 4) neurological signs of upper motor neuron disease,&#x0D;&lt;br&gt;             cerebellar involvement, supranuclear gaze palsy, or significant orthostatic&#x0D;&lt;br&gt;             hypotension&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MRI scan with significant evidence of brain atrophy or other abnormalities (e.g.,&#x0D;&lt;br&gt;             lacunar infarcts or iron deposits in the putamen)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The Mattis Dementia Rating Scale will be used to assess the level of intellectual&#x0D;&lt;br&gt;             function and patients will be excluded with scores reflecting clinical dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A major psychiatric disorder on the Structured Clinical Interview for DSM-IV&#x0D;&lt;br&gt;             (SCID-IV).&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intractable, disabling PD with motor fluctuations, dyskinesias, or freezing episodes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age between 30-75 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unsatisfactory clinical response to maximal medical management (with trials of both&#x0D;&lt;br&gt;             higher and lower doses of anti-Parkinsonian drugs)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A stable and optimal medical regimen of anti-Parkinsonian drug therapy for at least&#x0D;&lt;br&gt;             three months prior to surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients must be right-handed to be included in the study since mood and cognition are&#x0D;&lt;br&gt;             being analyzed and right hemisphere dominant patients could confound the results.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical disease that would increase risk of developing pre- or&#x0D;&lt;br&gt;             postoperative complications (e.g., significant cardiac or pulmonary disease,&#x0D;&lt;br&gt;             uncontrolled hypertension)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of secondary or atypical parkinsonism as suggested by the presence of any of&#x0D;&lt;br&gt;             the following: 1) history of stroke(s), 2) exposure to toxins or neuroleptics, 3)&#x0D;&lt;br&gt;             history of encephalitis, 4) neurological signs of upper motor neuron disease,&#x0D;&lt;br&gt;             cerebellar involvement, supranuclear gaze palsy, or significant orthostatic&#x0D;&lt;br&gt;             hypotension&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MRI scan with significant evidence of brain atrophy or other abnormalities (e.g.,&#x0D;&lt;br&gt;             lacunar infarcts or iron deposits in the putamen)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The Mattis Dementia Rating Scale will be used to assess the level of intellectual&#x0D;&lt;br&gt;             function and patients will be excluded with scores reflecting clinical dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A major psychiatric disorder on the Structured Clinical Interview for DSM-IV&#x0D;&lt;br&gt;             (SCID-IV).&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intractable, disabling PD with motor fluctuations, dyskinesias, or freezing episodes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age between 30-75 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unsatisfactory clinical response to maximal medical management (with trials of both&#x0D;&lt;br&gt;             higher and lower doses of anti-Parkinsonian drugs)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A stable and optimal medical regimen of anti-Parkinsonian drug therapy for at least&#x0D;&lt;br&gt;             three months prior to surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients must be right-handed to be included in the study since mood and cognition are&#x0D;&lt;br&gt;             being analyzed and right hemisphere dominant patients could confound the results.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical disease that would increase risk of developing pre- or&#x0D;&lt;br&gt;             postoperative complications (e.g., significant cardiac or pulmonary disease,&#x0D;&lt;br&gt;             uncontrolled hypertension)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of secondary or atypical parkinsonism as suggested by the presence of any of&#x0D;&lt;br&gt;             the following: 1) history of stroke(s), 2) exposure to toxins or neuroleptics, 3)&#x0D;&lt;br&gt;             history of encephalitis, 4) neurological signs of upper motor neuron disease,&#x0D;&lt;br&gt;             cerebellar involvement, supranuclear gaze palsy, or significant orthostatic&#x0D;&lt;br&gt;             hypotension&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MRI scan with significant evidence of brain atrophy or other abnormalities (e.g.,&#x0D;&lt;br&gt;             lacunar infarcts or iron deposits in the putamen)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The Mattis Dementia Rating Scale will be used to assess the level of intellectual&#x0D;&lt;br&gt;             function and patients will be excluded with scores reflecting clinical dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A major psychiatric disorder on the Structured Clinical Interview for DSM-IV&#x0D;&lt;br&gt;             (SCID-IV).&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Parkinson Disease;Parkinson Disease;Parkinson Disease
    </Condition>
    <Intervention>Procedure: DBS of the STN;Procedure: DBS of the GPI;Procedure: DBS of the STN;Procedure: DBS of the GPI;Procedure: DBS of the STN;Procedure: DBS of the GPI;Procedure: DBS of the STN;Procedure: DBS of the GPI
    </Intervention>
    <Primary_outcome>Change in Mean T-score of Visual Analogue Mood Scales (VAMS) Angry State;Change in Visual Analogue Mood Scales (VAMS) Afraid State;Change in Visual Analogue Mood Scales (VAMS) Confused State;Change in Visual Analogue Mood Scales (VAMS) Energetic State;Change in Visual Analogue Mood Scales (VAMS) Happy State;Change in Visual Analogue Mood Scales (VAMS) Sad State;Change in Visual Analogue Mood Scales (VAMS) Tense State;Change in Visual Analogue Mood Scales (VAMS) Tired State;Change in Mean T-score of Visual Analogue Mood Scales (VAMS) Angry State;Change in Visual Analogue Mood Scales (VAMS) Afraid State;Change in Visual Analogue Mood Scales (VAMS) Confused State;Change in Visual Analogue Mood Scales (VAMS) Energetic State;Change in Visual Analogue Mood Scales (VAMS) Happy State;Change in Visual Analogue Mood Scales (VAMS) Sad State;Change in Visual Analogue Mood Scales (VAMS) Tense State;Change in Visual Analogue Mood Scales (VAMS) Tired State
    </Primary_outcome>
    <Secondary_outcome>Change in Spielberger State-Trait Anxiety Inventory (STAI);Change in Beck Depression Inventory (BDI);Change in Letter Fluency Tasks (LFT)
    </Secondary_outcome>
    <Secondary_ID>K23NS044997;303-2002
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institute of Neurological Disorders and Stroke (NINDS)
    </Secondary_Sponsor>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>02/02/2010
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT00360009
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>4617321
    </Internal_Number>
    <TrialID>NCT00358189
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Effects of Deep Brain Stimulation for the Treatment of Parkinson's Disease
    </Public_title>
    <Scientific_title>Deep Brain Stimulation and Motor Function in Parkinson's Patients
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Department of Veterans Affairs
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20060728
    </Date_registration3>
    <Date_registration>28/07/2006
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00358189
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>30 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>October 2006
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Time Perspective: Prospective
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Jay L Alberts, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Investigator
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  a) Patients must have had the Deep Brain Stimulator implanted for at least six months&#x0D;&lt;br&gt;             prior to enrollment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hoehn and Yahr stage III or worse when off stimulation and medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intractable, disabling motor fluctuations, dyskinesias or freezing episodes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age between 30-75 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Normal cognition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Demonstrated good response to levodopa.  In order to exclude patients with&#x0D;&lt;br&gt;             Parkinson's plus (i.e. progressive supranuclear palsy, multiple system atrophy,&#x0D;&lt;br&gt;             striato-nigral degeneration, etc) all patients included in this study must have&#x0D;&lt;br&gt;             demonstrated a good response to levodopa, defined as demonstrating at least 30%&#x0D;&lt;br&gt;             improvement in parkinsonian motor signs, based on UPDRS motor examination subscore&#x0D;&lt;br&gt;             following the administration of levodopa during their screening neurological exam.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unsatisfactory clinical response to maximal medical management A stable and optimal&#x0D;&lt;br&gt;             medical regimen of antiparkinsonian drug therapy for at least three months prior to&#x0D;&lt;br&gt;             or after surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical disease that would increase risk of developing pre- or&#x0D;&lt;br&gt;             postoperative complications (e.g. significant cardiac or pulmonary disease,&#x0D;&lt;br&gt;             uncontrolled hypertension).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of secondary or atypical parkinsonism as suggested by:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of CVA's, exposure to toxins, neuroleptics or encephalitis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neurologic signs of upper motor neuron or cerebellar involvement, supranuclear gaze&#x0D;&lt;br&gt;             palsy or significant orthostatic hypertension&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia as evidenced by impairment in two neuropsychological domains and impaired or&#x0D;&lt;br&gt;             borderline neuropsychological function in one additional domain&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use of DBS for psychiatric disorder (obsessive compulsive or depression)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson
    </Condition>
    <Intervention>Device: Deep Brain Stimulation
    </Intervention>
    <Secondary_ID>B4061I
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>4615355
    </Internal_Number>
    <TrialID>NCT00331669
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia
    </Public_title>
    <Scientific_title>Multicenter, Randomized Trial on the Effects of Pallidal Deep Brain Stimulation for Tardive Dystonia
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Charite University, Berlin, Germany
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20060526
    </Date_registration3>
    <Date_registration>26/05/2006
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00331669
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>May 2006
    </Date_enrollement>
    <Target_size>24
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Andreas R Kupsch, MD;Andreas R Kupsch, MD, PhD;Andreas R Kupsch, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;andreas.kupsch@charite.de;andreas.kupsch@charite.de
    </Contact_Email>
    <Contact_Tel>;xx49-30-450-50;xx49-30-450-50
    </Contact_Tel>
    <Contact_Affiliation>Dpt. of Neurology, Augustenburger Platz 1, 13353 Berlin, Charite, Campus Virchow, Germany;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Operational criteria for tardive dystonia for &gt; 18 months after cessation of&#x0D;&lt;br&gt;             neuroleptic exposure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  18-75 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Relevant functional impairment in daily living activities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  BFMDRS &gt; 8 or AIMS &gt; 16&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Informed written consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  PANNS &gt;60 (Schizophrenia)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hamilton-Score &gt; 18 (Depression)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MATTIS-Score &lt;120 (Dementia)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Preceding stereotactic neurosurgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pronounced brain atrophy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Increased bleeding risk&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Decreased immune status&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Botulinum Toxin treatment within the last 3 months&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Dystonia;Movement Disorder
    </Condition>
    <Intervention>Procedure: deep brain stimulation
    </Intervention>
    <Primary_outcome>Improvement of the motor scale of Burke-Fahn-Marsden-Dystonia Rating Scale via blinded video assessment 3 months after starting DBS in comparison to sham-stimulated patients
    </Primary_outcome>
    <Secondary_outcome>AIMS;Non-motor subscores of BMFDRS;Visual analogue scales for both patients and treating physicians;Quality of life (SF-36);Psychiatric assessment (HADS-D and PANSS)
    </Secondary_outcome>
    <Secondary_ID>DBS and tardive dystonia
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Humboldt-Universität zu Berlin;Ruhr University of Bochum;Medical University of Cologne;Heinrich-Heine University, Duesseldorf;University Hospital Freiburg;Medical University of Hannover;Medical University Innsbruck;University of Kiel;Philipps University Marburg Medical Center;Ludwig-Maximilians - University of Munich;University of Rostock;University of Regensburg;University Hospital Tuebingen;Medical University of Vienna;Medtronic
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>12267331
    </Internal_Number>
    <TrialID>NCT00311909
    </TrialID>
    <Last_Refreshed_on>16 May 2022
    </Last_Refreshed_on>
    <Public_title>Thalamic Deep Brain Stimulation for Tourette Syndrome
    </Public_title>
    <Scientific_title>Thalamic Deep Brain Stimulation for Tourette Syndrome: A Prospective Clinical Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University Hospitals Cleveland Medical Center
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20060405
    </Date_registration3>
    <Date_registration>05/04/2006
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00311909
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 2005
    </Date_enrollement>
    <Target_size>5
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double. 
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Robert J Maciunas, MD MPH FACS
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University Hospitals Cleveland Medical Center
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age 18 or older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of Tourette Syndrome by DSM-IV&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Tic frequency at least one per minute at screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  prior failure of at least two dopamine receptor or presynaptic blockers&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  negative impact on quality of life&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  significant structural brain lesion (on imaging studies)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  significant dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe head trauma preceding onset of tics&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  use of dopamine receptor blockers prior to recognition of tics&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  prior implanted electrical device&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  electroconvulsive therapy (ECT) within 24 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  suicide attempt within 12 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  significant sociopathic personality&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  current or planned pregnancy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome
    </Condition>
    <Intervention>Device: Thalamic deep brain stimulation
    </Intervention>
    <Primary_outcome>modified Rush Video Rating Scale (mRVRS)
    </Primary_outcome>
    <Secondary_outcome>tic counts (on video recording);Yale Global Tourette Severity Scale (YGTSS);Tourette Syndrome Symptom List (TSSL);Quality of Life Visual Analog Scale (VAS);SF-36;Neuropsychological battery
    </Secondary_outcome>
    <Secondary_ID>UHC DBS TS
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Medtronic
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>4610904
    </Internal_Number>
    <TrialID>NCT00272246
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Bilateral Internal Pallidum Stimulation in Primary Generalized Dystonia
    </Public_title>
    <Scientific_title/>
    <Acronym/>
    <Primary_sponsor>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20060104
    </Date_registration3>
    <Date_registration>04/01/2006
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00272246
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>12 Years
    </Inclusion_agemin>
    <Inclusion_agemax>60 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>February 2005
    </Date_enrollement>
    <Target_size>24
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Netherlands
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Hans Speelman, PhD;Elisabeth MJ Foncke, MD;Elisabeth MJ Foncke, MD
    </Contact_Lastname>
    <Contact_Email>;e.m.foncke@amc.uva.nl;e.m.foncke@amc.uva.nl
    </Contact_Email>
    <Contact_Tel>;0031205669111;0031205669111
    </Contact_Tel>
    <Contact_Affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Invalidating primary generalized dystonia (BFMDRS-motor part &gt;= 35)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Disease duration  &gt;= 5 yrs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Age at surgery between 12 and 60&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Insufficient improvement with pharmacological and physical therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Signed informed consent, for patients &lt; 19 yrs of age a written consent  of the&#x0D;&lt;br&gt;             parent(s) or caretaker(s) is needed.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Mental retardation or dementia (MMSE &lt;24)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Depressive state (HADS&gt;21)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. History of former stereotactic brain surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Severe brain atrophy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. General surgical contraindications, such as uncontrolled hypertension or diabetes&#x0D;&lt;br&gt;             mellitus, cardiovascular or pulmonary risks, disturbances of bloodclotting.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Dystonia;Primary Generalized Dystonia
    </Condition>
    <Intervention>Procedure: deep brain stimulation of the internal globus pallidus
    </Intervention>
    <Primary_outcome>change in BFMDRS-motor score from baseline to six months after stimulation equipment implantation
    </Primary_outcome>
    <Secondary_outcome>BFMDRS-disability score;MOS-SF-36 (Medical Outcome Scale);GOS (Global Outcome Scale);Neuropsychological and neuropsychiatric validated scales;Questionnaire designed for the registration of the number and extent of morbidity due to the surgical;procedure, stimulation equipment and active stimulation
    </Secondary_outcome>
    <Secondary_ID>DYSPAS
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Princess Beatrix Fund, The Netherlands
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>4607130
    </Internal_Number>
    <TrialID>NCT00221793
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Weight Changes in Parkinsonian Patients, Treated With Deep Brain Stimulation
    </Public_title>
    <Scientific_title>Study of Ponderal Load in Parkinsonian Patients After Deep Brain Stimulation of the Subthalamic Nucleus
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University Hospital, Bordeaux
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20050913
    </Date_registration3>
    <Date_registration>13/09/2005
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00221793
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>35 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>December 2002
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>François TISON, Pr;Jacques DEMOTES-MAINARD, Pr
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Service de neurologie Hôpital Haut-Lévêque Pessac;CIC Inserm-CHU de Bordeaux Pessac
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age between 35 and 70; male or female; parkinson disease, with levo dopa response (at&#x0D;&lt;br&gt;             least 30%); severe but stable incapacity; no dementia, no psychosis, no depression;&#x0D;&lt;br&gt;             normal brain scanner done during the last 2 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diabetes thyroid disease pacemaker coagulation troubles previous drug abuse&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Procedure: Deep brain stimulation
    </Intervention>
    <Primary_outcome>Measurement of energy expenditure with indirect calorimetry in open chamber: at rest in the morning, without 24h-dopaminergic treatment, and after dopaminergic treatment intake; and post prandial thermogenesis after a test meal.
    </Primary_outcome>
    <Secondary_outcome>Weight gain;increase of energy intake;leptin, glucose, insulin blood levels;cognitive and psychological assessments;UDPRS scale
    </Secondary_outcome>
    <Secondary_ID>9212-02
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>5125281
    </Internal_Number>
    <TrialID>NCT00169338
    </TrialID>
    <Last_Refreshed_on>28 September 2015
    </Last_Refreshed_on>
    <Public_title>Pallidal Stimulation in Patients With Post-anoxic and Idiopathic Dystonia
    </Public_title>
    <Scientific_title/>
    <Acronym/>
    <Primary_sponsor>Marie-laure Welter
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20050912
    </Date_registration3>
    <Date_registration>12/09/2005
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00169338
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>September 2005
    </Date_enrollement>
    <Target_size>13
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>France
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Marie Vidailhet, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Hôpital Saint-Antoine
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Post-anoxic generalised dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic non-generalised dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Disease duration &gt; 1 year&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Contraindication to magnetic resonance imaging (MRI)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mini-mental status (MMS) &lt; 24&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe psychiatric disorder&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Dystonia
    </Condition>
    <Intervention>Procedure: Deep brain stimulation
    </Intervention>
    <Secondary_ID>P020918
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>4603199
    </Internal_Number>
    <TrialID>NCT00169403
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Pallidal Stimulation in Patients With Idiopathic Generalised Dystonia
    </Public_title>
    <Scientific_title/>
    <Acronym/>
    <Primary_sponsor>Groupe Hospitalier Pitie-Salpetriere
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20050912
    </Date_registration3>
    <Date_registration>12/09/2005
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00169403
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>March 2004
    </Date_enrollement>
    <Target_size/>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>France
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Marie Vidailhet, MD, PhD;Marie Vidailhet, MD, PhD;Marie-Laure Welter, MD
    </Contact_Lastname>
    <Contact_Email>;marie.vidailhet@sat.ap-hop-paris.fr;marie-laure.welter@psl.aphp.fr
    </Contact_Email>
    <Contact_Tel>;33-142161950;33-142161950
    </Contact_Tel>
    <Contact_Affiliation>Hôpital Saint-Antoine;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic generalised dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pallidal stimulation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mini-mental status (MMS) &lt; 24&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe psychiatric disorder&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Dystonia
    </Condition>
    <Intervention>Procedure: Deep brain stimulation
    </Intervention>
    <Secondary_ID>P000201
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Délégation Régionale à la Recherche Clinique
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10199793
    </Internal_Number>
    <TrialID>NCT00148889
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Double-blind, Multicenter Study to Assess the Efficacy of Bilateral Pallidal Stimulation in Patients With Medically Refractory Primary Cervical Dystonia
    </Public_title>
    <Scientific_title>Prospective,Randomised, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Bilateral Globus Pallidus Internus - in Patients With Medically Refractory Primary Cervical Dystonia
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>German Parkinson Study Group (GPS)
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20050907
    </Date_registration3>
    <Date_registration>07/09/2005
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00148889
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 2005
    </Date_enrollement>
    <Target_size>63
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Austria;Germany;Austria;Germany
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Joerg Mueller, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Department of Neurology, Medical University Innsbruck, Anichstr. 35, A-6020 Innsbruck, Austria
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Primary cervical dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Disease duration 3 years or longer&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adult patient (18 years or older)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  TWSTRS severity score 15 or more&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-response to Botulinum Toxin&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-response to oral antidystonic medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia (Mattis Dementia Rating Scale below 120)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe depression (Beck Depression Inventory &gt;25)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous functional stereotactic surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hemidystonia or generalized dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe brain atrophy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Contraindication against surgery&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cervical Dystonia
    </Condition>
    <Intervention>Device: Deep brain stimulation (DBS)
    </Intervention>
    <Primary_outcome>Toronto Western Spasmodic Torticollis Scale (TWSTRS) at 3 months following surgery (comparison between placebo and control group)
    </Primary_outcome>
    <Secondary_outcome>side-effects, quality of life, depression, pain, long-term efficacy
    </Secondary_outcome>
    <Secondary_ID>CD-DBS-2005-JM
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Medtronic;Competence Network on Parkinson's Disease
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>4601149
    </Internal_Number>
    <TrialID>NCT00142259
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Efficacy and Safety of DBS of the GPi in Patients With Primary Generalized and Segmental Dystonia
    </Public_title>
    <Scientific_title>Randomisierte, Doppelblinde Langzeitstudie Zur Klinischen Wirksamkeit Der Bilateralen Globus Pallidus Internus-Stimulation Bei Idiopathischer Generalisierter Oder Segmentaler Dystonie
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>German Parkinson Study Group (GPS)
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20050901
    </Date_registration3>
    <Date_registration>01/09/2005
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00142259
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>14 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>October 2002
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Austria;Germany;Austria;Germany
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Jens Volkmann, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Dept. Neurology, UKSH Campus Kiel, Germany
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosis of idiopathic multifocal, segmental or generalised dystonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  duration of disease &gt; 5 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age between 14 and 75 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  relevant disability in activities of daily living despite optimal drug treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  informed consent signed by the patient&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For adolescents between 14 and 18 years: an additional informed consent signed by a&#x0D;&lt;br&gt;             legal guardian is necessary&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mattis-Score &lt; 120&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  BDI &gt; 25&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  previous stereotactic brain surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe brain atrophy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  increased bleeding risk&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  immunosuppression and increased risk of infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  relevant cerebrovascular disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  psychiatric disorders, which might interfere with the cooperation in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  other contraindications for surgery&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Dystonia
    </Condition>
    <Intervention>Device: Deep brain stimulation of the internal globus pallidus
    </Intervention>
    <Primary_outcome>relative change of the individual Burk-Fahn-Marsden-Dystonia motor score 3 months after treatment compared to baseline
    </Primary_outcome>
    <Secondary_outcome>relative change of the individual Burk-Fahn-Marsden-Dystonia ADL score 3 months after treatment compared to baseline
    </Secondary_outcome>
    <Secondary_ID>Grant: 01 GI 0201 / 01 GI 0401;15
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Medtronic;Competence Network on Parkinson's Disease
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>10199692
    </Internal_Number>
    <TrialID>NCT00132990
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>A Multicenter Pilot Study of Pallidal Deep Brain Stimulation for Cervical Dystonia
    </Public_title>
    <Scientific_title>A Multicenter Pilot Study of Pallidal Deep Brain Stimulation of Cervical Dystonia
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Calgary
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20050818
    </Date_registration3>
    <Date_registration>18/08/2005
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00132990
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 2003
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: Single. 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Canada
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Zelma Kiss, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Calgary
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adult patients, male or female&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosed with cervical dystonia by a movement disorders neurologist&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has cervical dystonia alone, not generalized or multifocal&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has had adequate trials of medical therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Abnormalities on pre-operative magnetic resonance imaging (MRI)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medical conditions precluding general anaesthetic or surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unstable psychiatric disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous brain lesions to treat cervical dystonia&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cervical Dystonia
    </Condition>
    <Intervention>Device: Deep brain stimulation
    </Intervention>
    <Primary_outcome>Improvement in neck postures/movements;Improvement in quality of life
    </Primary_outcome>
    <Secondary_outcome>Document adverse effects of surgery
    </Secondary_outcome>
    <Secondary_ID>16760
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Canadian Institutes of Health Research (CIHR);Calgary Health Region;Medtronic
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:16:07</Export_date>
    <Internal_Number>4598388
    </Internal_Number>
    <TrialID>NCT00105430
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Deep Brain Stimulation for Cervical Dystonia
    </Public_title>
    <Scientific_title>Deep Brain Stimulation of the Globus Pallidus Interna or the Subthalamic Nucleus for Treatment of Generalized Primary Dystonia
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20050311
    </Date_registration3>
    <Date_registration>11/03/2005
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00105430
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>7 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>March 2005
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>United States
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        -  INCLUSION CRITERIA:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        To be eligible for entry into the study, candidates must meet all the following criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patients greater than 7 years of age with generalized primary dystonia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patients who are refractory to medical treatment  (including levodopa,&#x0D;&lt;br&gt;             anticholinergics, benzodiazepines, Baclofen) who are considered surgical candidates.&#x0D;&lt;br&gt;             Patients will be determined to have medical refractory dystonia after having been&#x0D;&lt;br&gt;             treated by at least two medications of two different groups at the maximum&#x0D;&lt;br&gt;             recommended dose for a duration of at least two months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. In case of treatment by intrathecal Baclofen delivered by a pump, a change to oral&#x0D;&lt;br&gt;             Baclofen must be performed, so that the pump can be taken out.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patients must have a minimum BFM score of 20 on optimal medical therapy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Adults must be mentally competent to consent for entrance into the protocol at the&#x0D;&lt;br&gt;             time of admission.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Patients must have a signed DPA for research purposes.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        EXCLUSION CRITERIA:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Candidates will be excluded if:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. The patient has had previous lesioning surgery including radiofrequency lesioning of&#x0D;&lt;br&gt;             deep nuclei (thalamus, pallidum, STN).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. The patient currently has a functioning and effective stimulator in deep brain nuclei&#x0D;&lt;br&gt;             (thalamus, pallidum, STN).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. The patient is not able to tolerate surgery, as determined by the preoperative&#x0D;&lt;br&gt;             evaluation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. The patient has a coagulopathy demonstrated by an abnormal prothrombin time,&#x0D;&lt;br&gt;             activated partial thromboplastin time, or thrombocytopenia (platelet count less than&#x0D;&lt;br&gt;             150,000 platelets/mm(3)).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. The patient has an acute or untreated infection (viral, bacterial or fungal).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. The patient has a contraindication to MR-imaging such as previous surgery that&#x0D;&lt;br&gt;             involved placement of metal objects that could cause tissue damage or produce image&#x0D;&lt;br&gt;             artifacts.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. The patient has another chronic neurologic disorder.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. The patient is pregnant at the time of surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. The patient has epilepsy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. The patient does not have access to proper follow-up care at home and may not be&#x0D;&lt;br&gt;             eligible for the study.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Dystonia;Generalized Primary Dystonia
    </Condition>
    <Intervention>Procedure: Deep Brain Stimulation
    </Intervention>
    <Primary_outcome>Clinical effectiveness of DBS of the Gpi or STN will be measured by the Burke-Fahn-Marsden Scale (BFM) and monitored over time to determine the effectiveness DBS and if there is an ideal anatomic stimulation site.@@@@@@@@@
    </Primary_outcome>
    <Secondary_outcome>Determine the underlying pathophysiology of dystonia, and the mechanism of action of DBS.
    </Secondary_outcome>
    <Secondary_ID>05-N-0111;050111
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>
</Trials_downloaded_from_ICTRP>